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Restenosis, a pathological condition characterised by neointima formation and lumen 
narrowing, can occur in some patients submitted to percutaneous coronary intervention. 
Reducing its incidence remains an important medical issue.  
 
Circulating endothelial precursor cells (EPCs) home to the vascular injury site and contribute to 
re-endothelialisation and neointima attenuation. However, the engraftment and repair capacity 
of EPCs from patients with cardiovascular disease are typically impaired.  
 
Priming strategies to increase EPCs’ engraftment may improve post-injury outcomes. Anti-
angiogenic miR-92a is upregulated in EPCs of cardiovascular patients, contributing to their 
reduced regenerative capacity. It was hypothesized that miR-92a antagonism in EPCs could 
result in a more favourable angiogenesis profile, with the rationale of developing a future 
functional priming strategy before cell transplantation which could lead to increased 
engrafting/thriving and accelerated re-endothelialisation on injured segments, hence, 
contributing towards post-PCI restenosis prevention.  
 
The aims of the work were: 1) to differentiate and characterise CD34+-derived late-outgrowth 
EPCs from an enriched progenitor human source; 2) to characterise target gene expression and 
demonstrate in vitro the functional priming following the treatment of EPCs with miR-92a 
inhibitor and relate it to the ensueing integrin α5 subunit (ITGA5) derepression. 
 
A human EPC culture was obtained following differentiation of cord blood CD34+ cells. miR-92a 
inhibitor treatment using oligofectamine in CD34+-derived late-outgrowth EPCs revealed pro-
angiogenic,-migratory,-proliferative, and -adhesive effects in vitro, which was accompanied by 
the derepression of integrin α5 (ITGA5). Remarkably, siRNA ITGA5 abrogated the enhanced 
matrix adhesion in primed EPCs, highlighting the role of the miR-92a downstream target in EPC 
engraftment. Preliminary intraluminal transplantation results suggested enhanced engraftment 
capacity of primed EPCs in the rat carotid balloon angioplasty model. 
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Introduction 
Chapter 1: Endothelial progenitor 




Coronary artery disease (CAD) is the principal cause of death in industrialised nations 
and expected to become so in emerging countries by 2020 (Bassand et al., 2007). 
Atherosclerotic plaque stenosis or rupture, with differing degrees of superimposed 
thrombosis and distal embolization, is the substrate for the acute or chronic ischemia 
seen in these patients. For both, the advent percutaneous coronary intervention (PCI) 
inaugurated a new era of clinical management. PCI is considered a minimally invasive, 
endovascular procedure to widen stenotic or (partially) occluded arteries, usually 
subsequent to arterial atherosclerosis. A deflated balloon attached to a catheter is 
passed over a guide-wire into the narrowed vessel and then inflated to a fixed size. The 
balloon forces expansion of the blood vessel and the surrounding muscular wall, 
allowing an improved blood flow (angioplasty). A stent may be inserted at the time of 
ballooning to ensure the vessel remains open, and the balloon is then deflated and 
withdrawn. Still, PCI can often fail because of restenosis, thrombosis, and vasospasm 
(Bennett & O'Sullivan, 2001). In this introductory chapter, I will review some of the 
principles behind (1.1) post-PCI restenosis, the (1.2) contribution of Endothelial 
precursor cells (EPCs) for vascular repair and (1.3) the role of miR-92a for priming EPCs.  
 
  





Post-injury arterial restenosis is a prevalent condition among 
certain risk groups 
 
PCI has become widely accepted as an efficient and safe treatment modality for CAD, 
leading to improved perfusion, quality of life and survival (Kolh & Wijns, 2011). However, 
being an invasive technique, there is a risk of complications. As the balloon is inflated to 
high atmospheric pressures to restore normal coronary blood flow and compress the 
atheroma plaque, it also eccentrically distends the vessel. Mechanical injury is 
necessarily a feature of PCI, resulting from the barotrauma and vigorous opposition of 
stent struts against the vessel wall if a stent is also deployed. Consequently, a 
comprehensive inflammatory and proliferative reaction, involving several different 
cellular players, is set in motion. Although this response is physiological, it can be 
exaggerated in some patients, resulting in lumen re-narrowing or restenosis. PCI success 
can be limited by restenosis of the target vessel in 30–60% of patients, particularly if 
multi-vessel disease or diabetes is present (Rajagopal & Rockson, 2003), while the 
incidence of in-stent restenosis has been reported to be as high as 29% in high-risk 
populations using bare metal stents (Mauri et al., 2008). This complication is defined by 
angiographic or clinical criteria and prompts revascularization (Cutlip et al., 2007). To 
date, many predictive clinical, biological, (epi)genetic, lesion-related and procedural risk 
factors (RFs) have been recognized (Jukema, Verschuren, Ahmed, & Quax, 2012). 
Defining risk markers is not only helpful for risk stratification and prognosis, helping in 
the identification of those that could benefit from additional treatment modalities, but 
also provides valuable information on the underlying molecular and cellular mechanism 
of restenosis, with implications for new therapies.  
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Restenosis pathophysiology involves a complex interplay of 
endothelial cells, platelets, leukocytes, vascular smooth muscle 
cells, mesenchymal and endothelial precursor cells  
 
The reason why restenosis remains largely unsolved clinically is likely attributed to its 
complex mechanisms. The vascular endothelium is a dynamic border between 
circulating blood elements and the surrounding tissue. The entire endothelial cell (EC) 
monolayer comprises 1013 ECs and covers approximately 7m2 in an average adult (Cines 
et al., 1998). It regulates nutrient and blood component traffic and participates in many 
other complex physiologic events such as angiogenesis and inflammation (Y. Lin, 
Weisdorf, Solovey, & Hebbel, 2000). Moreover, it has pivotal roles in coagulation, 
inflammation, vasodilatation and vasoconstriction through a variety of important 
regulatory substances, including prostaglandins and nitric oxide (NO) (Cines et al., 1998). 
In healthy subjects, a low level of endothelial turnover occurs basally (Hristov & Weber, 
2008). However, in acute vascular injury (as in PCI), there is a significant (potentially 
reversible) impairment of the endothelial monolayer.  Under normal circumstances, the 
cellular and molecular processes that control vascular injury responses result in vascular 
healing. In pathological conditions, dysregulation of vascular repair results in persistent 
vascular inflammation. These cases may cause irreversible structural damage, i.e. a 
restenotic obstruction of the lumen, which can constitute a medical condition on its 
own. The cascade of complex biological events leading to restenosis comprises two 
major processes: neointimal hyperplasia and constrictive remodelling (Figure 1). Its 
putative causal mechanisms have not yet been fully identified, but are thought to 
include inflammation,  vascular smooth muscle cell (VSMC) proliferation, and matrix 
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Figure 1 | Restenosis 
Intravascular ultrasound images of the various stages of coronary artery disease. Indicated are the outer 
border of the vessel (green), the lumen (red), and the coronary stent (pink). Schematic representations 
are shown to the right of these images. The processes occurring in the vessel immediately after PCI (with 
stent placement) are highlighted in detail. Adapted from (Jukema, Verschuren, et al., 2012). ECM, 
extracellular matrix; PCI - Percutaneous coronary intervention. 
 
 
A functionally intact endothelium is a pre-requisite for the inhibition of intimal 
hyperplasia (Kipshidze et al., 2004), which is attributed to the potent inhibitory effects 
of endothelium-derived NO (von der Leyen et al., 1995). The endovascular laceration 
due to rigid stent struts and high-pressure balloon inflations is considered the initiating 
event of neointimal hyperplasia after balloon angioplasty (Behrendt & Ganz, 2002), since 
it determines the loss of a significant anti-thrombogenic cap, triggering an intense local 
inflammatory response. Then, there is dysfunction of neighbouring ECs, which undergo 
apoptosis. The resulting endothelial denudation and fragmentation of the internal 
elastic lamina result in a rapid influx of leukocytes and in the exposure of circulating 
platelets to the sub-endothelial matrix (Inoue et al., 2011). The exposed deeper matrix 
contains many platelet-activating factors (Fager, 1995), which give rise to 
microthrombus formation. Activated platelets, dysfunctional ECs, and macrophages 
within thrombi are a primary source of reactive oxygen species, chemotactic and 
mitogenic factors which can induce a VSMC phenotypic transition (Durham, Speer, 
Scatena, Giachelli, & Shanahan, 2018; Pakala, Willerson, & Benedict, 1997). Mature, 
differentiated VSMCs express a unique repertoire of contractile proteins (Owens, 1995), 
enabling them to perform their contractile functions. VSMCs are highly plastic cells and 
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can undergo de-differentiation upon environmental modulation, a change that is 
reversible. Within one week after endothelial denudation, the shortage of 
arterioprotective factors, such as NO, and the increased production of growth factors, 
such as platelet-derived growth factor (PDGF-BB), drive the VSMCs in the innermost part 
of the media to switch back to a more synthetic phenotype (N. M. Liu, Siu, Youn, & Cai, 
2016). Synthetic VSMCs are characterised by a reduced contractile protein content, an 
increased rate of proliferation, and increased secretion of extracellular matrix (ECM) 
proteins and cytokines (Doran, Meller, & McNamara, 2008).  The disassembly of stress 
fibres and the rearrangement of actin filaments, drive the transformed VSMCs to acquire 
a polarised asymmetric shape, facilitating the migratory activity towards the tunica 
intima, the source of chemoattractants (cytokines, growth factors, ECM components). 
Later on, the neointima is developed by excessive matrix deposition and the 
accumulation of migrated VSMCs, circulating progenitor cells (Psaltis, Harbuzariu, 
Delacroix, Holroyd, & Simari, 2011; Sata et al., 2002) and myofibroblasts (Y. Shi et al., 
1996; D. Wang, Li, Dai, Wang, & Li, 2018).  
Neointima formation is followed by inward remodelling of the vessel, a process called 
constrictive remodelling.  The proposed underlying mechanisms for this process include 
media matrix remodelling (Riessen, Wight, Pastore, Henley, & Isner, 1996), migration of 
myofibroblasts towards the intima (Zargham, 2008), and restoration of the VSMC 
contractile phenotype within the neointima (Shanahan & Weissberg, 1998). Whereas 
PDGF signalling promotes the synthetic phenotype, activation of TGF-β pathways 
favours their differentiation back into contractile VSMCs (Nazari-Jahantigh, Wei, & 
Schober, 2012). It seems likely that there is a disturbed blood flow after neointima 
outgrowth that may lead to chronic TGF-β mediated deposition of collagen and FN 
(Zargham, 2008). This matrix composition will activate specific integrin receptors in 
VSMC, such as α1β1 and α8β1 (Zargham, Pepin, & Thibault, 2007), eliciting re-expression 
of differentiated contractile markers (Shanahan & Weissberg, 1998), resulting in scar 
contraction and late luminal loss. The latter suggests that the pathophysiology of 
restenosis may be different in the early and late phases after vascular injury.  
 
Given its complexity, the development of innovative therapeutic approaches to 
restenosis lies in a detailed understanding of the events and timings causing both 
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neointimal thickening and vascular remodelling, including all cellular sources. The 
restenosis process was formerly ascribed to vascular SMCs and ECs only, however 
diverse vascular wall progenitor cells with specific mural distribution (Figure 2)  are also 
implicated in vascular disease and repair (Vono, Spinetti, Gubernator, & Madeddu, 2012; 
D. Wang et al., 2018) through their intrinsic endothelial, smooth muscle, hematopoietic 
or mesenchymal differentiation potential (Psaltis & Simari, 2015). 
 
Figure 2 | Mural distribution of postnatal vascular wall and bone marrow derived progenitor cells 
implicated in vascular repair. 
Different types of progenitor cells have been identified within all mural layers of arteries and veins, as 
well as derived from the circulation. AMPC – adventitial macrophage progenitor cell; BM - bone marrow; 
EPC – endothelial precursor cell; CVC - calcifying vascular cells; HPC/HSC – hematopoietic progenitor/stem 
cell; MVSC – multipotent vascular stem cell; SVP - saphenous vein-derived progenitor cells; SPC – smooth 
muscle progenitor cell; VW-MSC – vascular wall mesenchymal stem cell. 
 
 
Vascular wall progenitors 
The adventitia, the outermost layer of the blood vessel, is composed of a collagen-rich 
extracellular matrix embedded with a mixture of cells. It provides an interface to the 
highly cellular and cytokine-rich perivascular connective/adipose tissue and with vasa 
vasorum (Stenmark et al., 2013). Evidence for vascular stem/progenitor cell enrichment 
in the adventitia, specifically along its border with the media (vasculogenic zone), is 
robust (Halper, 2018). Namely, the presence of cells with endothelial potential 
(CD34+CD31-) in the so-called vasculogenic zone of the inner adventitia has been 
inferred from arterial ring sprouting assays (Zengin et al., 2006). 
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Also, adventitial macrophage progenitor cells (AMPCs) proliferate and differentiate in 
response to growth factors to generate macrophages and dendritic cells locally in the 
adventitia (Halper, 2018).  
In addition, a specific population of Sox10+ multipotent vascular stem cell (MVSCs) is 
activated upon vascular injury, becomes proliferative, and can migrate from both medial 
and adventitial layers to contribute to neointima formation and microvessel formation 
during tissue repair and regeneration (D. Wang et al., 2017). 
Highly proliferative progenitors have also been isolated from human veins, and termed 
“saphenous vein-derived progenitor cells” (SVPs). These cells are localized around 
adventitial vasa vasorum and co-express CD34, pericyte/mesenchymal antigens and  
stem cell marker Sox2 (D. Wang et al., 2018). SVPs improve neovascularization and blood 
flow recovery (Campagnolo et al., 2010). 
Vascular wall multipotent stem cells (VW-MPSCs), which co-express certain MSC 
markers (CD44, CD73,  CD105, CD90, Stro1 and CD29) and stemness markers Oct4 and 
Sox2 (D. Klein et al., 2011), when transplanted with human umbilical vein endothelial 
cells (HUVECs) into matrigel plugs in immunodeficient mice, lead to new vessel 
formation covered with MPSC-derived pericyte- and smooth muscle-like cells (D. Klein 
et al., 2011). MPSCs include two cell types:  (1) Perycites are contractile cells that 
surround and appose microvascular ECs, with which they share a basement membrane 
that separates much of the pericyte–endothelial interface, except at discrete 
intercellular contact points. Perycites serve to pattern vascular networks and facilitate 
EC growth and differentation, while regulating vessel tone, caliber, permeability and 
providing mechanical stability in established vessels (Psaltis & Simari, 2015), therefore, 
facilitating neovascularization and angiogenesis (Katare et al., 2011). However, pericytes 
can also differentiate into myofibroblasts and are another important cellular source of 
vascular/organ fibrosis (Katare et al., 2011).  (2) VW-MSCs also occupy the perivascular 
niche supporting angiogenesis, and they have multilineage differentiation potential into 
mature pericytes, SMCs, and perhaps even ECs, help mediate vascular tissue 
homeostasis and repair (Psaltis & Simari, 2015). This is achieved by trophic support of 
other vascular cells, vasa vasorum expansion, differentiation into SMCs, pericytes and 
adventitial fibroblasts, and production of mineral and fat deposits, collagen and 
extracellular matrix in both adventitia and atheroma.  
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The media also harbors MVSCs and side population (SP) progenitors, both of which have 
smooth muscle cell-forming potential.  This small population of Sca-1+, c-kit (-/low), Lin-
, CD34-/low cells from the media layer, can give rise to ECs and SMCs cultured with 
vascular endothelial growth factor (VEGF) and transforming growth factor β1 (TGF-
β1)/platelet-derived growth factor BB (PDGF-BB) respectively. A population of calcifying 
vascular cells (CVCs) which can be found in human atherosclerotic lesions in the arterial 
media is also known to to differentiate into SMC, osteogenic, and chondrogenic lineages 
(Tintut et al., 2003). 
 
In the intima progenitor cells with endothelial potential have been described (cKit+ SP), 
and subendothelial pericytes also identified in the intima in human arteries of all sizes 
(Psaltis & Simari, 2015).   
 
Bone marrow progenitors 
While the before mentioned progenitor populations are locally derived or maintained in 
the vessel wall itself, the vascular repair process seems to be partially governed by cells 
derived from the bone marrow (BM) too (Bianconi et al., 2018; Sata et al., 2002). It is 
understood that the participation of the BM in arterial remodelling after injury is not 
only limited to the inflammatory stage of the vascular remodelling process driven by 
mononuclear cells (MNCs) and macrophages. A minor population of BM-derived VSMCs 
within the neointima has also been identified (Rodriguez-Menocal et al., 2009), as well 
as, circulating BM-derived endothelial progenitor cells (EPCs) recruited to sites of 
vascular injury, where they encourage healing by resident ECs, thereby significantly 
contributing to re-endothelialisation and limiting neointimal formation (Haider, Aziz, & 
Al-Reshidi, 2017; Szmitko, Kutryk, Stewart, Strauss, & Verma, 2006). Only EPCs will merit 
our focus for the PhD work. 
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1.2 The role of EPCs in restenosis 
 
There is widespread consensus that there are circulating blood cells termed EPCs that 
are involved in the process of forming new blood vessels and repairing injured ones. 
Since Asahara first identified them in 1997 (Asahara et al., 1997), mounting evidence 
suggests that this cell population functionally contributes to pathological changes in 
cardiovascular disease (CVD) models of peripheral vascular disease (Vaughan et al., 
2012), stroke (Y. Fan et al., 2010; Takizawa, Nagata, Nakayama, Masuda, & Asahara, 
2016), retinopathy (X. Liu et al., 2010), myocardial and limb ischemia (Bonauer et al., 
2009), atherosclerosis (Torsney, Mandal, Halliday, Jahangiri, & Xu, 2007; Q. Xu, 2008) 
and tumour vascular associated-growth (Lyden et al., 2001; Patenaude, Parker, & 
Karsan, 2010), which makes them therapeutically promising for vascular repair (Balaji, 
King, Crombleholme, & Keswani, 2013). These precursor cells are mobilised mainly from 
the BM, and are then recruited to sites of ischemic (Zampetaki, Kirton, & Xu, 2008), 
atherosclerotic (Pelliccia et al., 2010) or endothelial (Werner et al., 2002) distress, and 
there contribute to angiogenesis (Takahashi et al., 1999) and re-endothelialisation 
(Pelliccia et al., 2010). Their regeneration potential is associated with an inherent ability 
to incorporate within the vessel and secrete pro-angiogenic factors (Zampetaki et al., 
2008) and to terminally differentiate into proliferative mature ECs (Lev et al., 2010). 
Consequently, autologous EPC transplantation to improve neovascularization and 
vascular repair has been sought, as well as epigenetic and genetic techniques aimed at 
enhancing their ex vivo expansion and therapeutic potential (Balaji et al., 2013). 
However, so far, there is still substantial ambiguity regarding the origin, definition, and 








Adult stem cells are unspecialized cells capable of replicating or self-renewing 
themselves, and are able to give rise to mature cell types that have characteristic 
morphologies and specialised functions (Figure 3) (Bautch, 2011). A precursor or 
progenitor cell is an intermediately undifferentiated cell type but lacks self-renewing 
ability (Bautch, 2011). Such cells are usually regarded as "committed" to differentiating 
along a specific cellular development pathway. EPCs are a putative kind of adult 
progenitor cells committed to differentiate into mature ECs when triggered (Bai & 
Wang, 2008), but they do not have baseline characteristics of mature ECs. According to 
various in vitro and in vivo studies (Gunsilius et al., 2000), EPCs and hematopoietic 
progenitor cells (HPCs) are believed to derive from a common stem cell called  
hemangioblast (A. M. Muller, Medvinsky, Strouboulis, Grosveld, & Dzierzak, 1994), since 
both lineages share similar cell-surface antigens, including Kinase insert domain 
receptor (KDR), Tie-2, and CD34 (Flamme & Risau, 1992).   Specifically, CD34+KDR+ cells 
have been shown to give rise to both HPC and EPCs with long-term proliferative 
potential (Pelosi et al., 2002). CD34 antigen expression is then gradually reduced as 
hematoendothelial lineages maturate (Sidney, Branch, Dunphy, Dua, & Hopkinson, 
2014).  CD45 expression seems to be a distinctive feature since CD34+ cells are known 
not to express CD45 during hematoendothelial development, rather acquiring it during 
differentiation into HPC, except if they are destined to differentiate into ECs 
(Timmermans et al., 2009). To make things more complex, the potential of BM-derived 
HPCs to transdifferentiate in vivo and in vitro into EPCs has also been documented by 
some research groups (Gehling et al., 2000; Grant et al., 2002). Understanding the 
endothelial-to-hematopoietic transition will have significant implications for the 
interpretation of the EPC phenotype and vascular biology in general since there is 
considerable overlap between these cellular players.  
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Figure 3 | Hemangioblast model.  
Development of ECs from EPC (precursor cell) and angioblast (stem cell). HPC – hematopoietic progenitor 
cell; HSC – hematopoietic stem cell; EPC – endothelial precursor cell; SMC – smooth muscle cell. Adapted 





Controversy still exists whether cells with numerous hematopoietic features that also 
participate in the process of new blood vessel formation and vascular repair ought to be 
called EPCs or not. Should the term EPC be reserved for a progenitor for the endothelial 
lineage alone? The answer is yes, and to date, some defining properties have been 
proposed for EPCs (Patel, Donovan, & Khosrotehrani, 2016; Simard et al., 2017; Yoder, 
2012). It must be a circulating cell that gives rise to progeny exhibiting clonal 
proliferation and differentiation restricted to the endothelial lineage. Moreover, it can 
generate capillary-like structures with a lumen in vitro (cytoplasmic vacuolation). It 
should have the capability to form stable blood vessels (cells must secrete a basement 
membrane) when implanted into tissues, to become an integrated part of the host 
circulatory system and to present the potential to undergo remodelling to form the 
intima of the vessel. Most circulating BM-derived cells identified so far fail to do so 
(Hirschi, Ingram, & Yoder, 2008). Thus their EPC designation should be revisited. Finding 
a unique cell surface marker that would allow prospective isolation and enrichment of 
cells displaying the above activities would certainly help clarify the EPC identity and must 
remain a focus for the field. 
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EPC identification  
 
To date, putative EPCs have been identified using two general approaches: surface and 
functional phenotyping. Nevertheless, the precise identification of EPCs remains 
tentative (Hristov et al., 2003; Patel et al., 2016; Simard et al., 2017), since many of the 
(nonspecific) markers used in phenotyping these cells are shared by both HPCs and 
mature ECs. Their multiple roles in vascular homoeostasis, redundant sources (Urbich & 
Dimmeler, 2004), broad plasticity (Asahara et al., 1997) and general uncertainty about 
tissue culture modulation on phenotype add to the uncertainty around the identification 
so far. All the afore-mentioned factors have resulted in various proangiogenic subsets 
being used in basic research and clinical trials (Chong, Ng, & Chan, 2016; Rafii & Lyden, 
2003; Sekiguchi, Ii, & Losordo, 2009) with inconsistent therapeutic outcomes (Beeres, 
Atsma, van Ramshorst, Schalij, & Bax, 2008; Chong et al., 2016).  
 
 
Cell surface phenotype 
 
EPC antigen characterization has been evolving thanks to the contribution of modern 
flow cytometry, which now uses multiple simultaneous fluorochromes properly 
compensated, linear scale analysis of low-intensity staining regions, gate exclusion of 
false signals by erythrocyte or monocyte specific staining as well as by positive nDNA 
staining, a feature lacking in microparticles (Pober, 2012). 
 
Historically, EPCs have been thought to be derived from CD34+ cells, which subsequently 
differentiated into cells expressing definitive endothelial markers (Asahara et al., 1997) 
and which play a role in regenerative angiogenesis (Fadini et al., 2008). This was further 
supported by the findings by Kawamoto and colleagues, who demonstrated that CD34- 
cells lacked proangiogenic potential (Kawamoto et al., 2006). The transmembrane 
phosphoglycoprotein CD34 belongs to the CD34-superfamily, which also comprises 
podocalyxin and endoglycan (Nielsen & McNagny, 2008). CD34 has a molecular weight 
of 115 kDa and possesses an extracellular domain that is heavily sialylated, O-linked 
glycosylated and contains several N-linked glycosylation sites (Sidney et al., 2014). l-
Selectin (CD62L), E-selectin and CrkL are the most commonly described ligands for CD34 
 Introduction - 29 
 
(Baumheter et al., 1993; Felschow, McVeigh, Hoehn, Civin, & Fackler, 2001). The CD34 
antigen was first identified on hematopoietic stem cells (HSCs) (and then on 
mesenchymal stem cells or MSCs), but it is not restricted to these cell types. Several 
other non-hematopoietic cell types coexpress tissue-specific markers alongside CD34, 
suggesting that the presence of CD34 may indicate a specific progenitor for that tissue. 
Evidence for this is certainly apparent in muscle satellite cells, epithelial progenitors, 
corneal keratocytes, and interstitial cells (Sidney et al., 2014). It has been hypothesised 
that CD34 plays a role in trafficking of HSCs to niches within the BM (Nielsen & McNagny, 
2008, 2009). Additionally, CD34 is involved in cytoadhesion, regulation of cell 
differentiation and proliferation processes (Healy et al., 1995; Nielsen & McNagny, 2008, 
2009). Its role in enhancing cell proliferation and/or blocking differentiation is 
corroborated by its progressive decline in surface density from multipotent 
hematopoietic progenitors to more mature cells, suggesting a role in the maintenance 
of the undifferentiated progenitor phenotype (Krause, Fackler, Civin, & May, 1996). 
Moreover, there are fewer HPCs in embryonic and adult tissues in CD34-knockout mice 
compared with wild-type animals, while adult-derived progenitors seem to harbour a 
proliferation defect (J. Cheng et al., 1996). Despite the hematopoietic changes, the 
CD34 knockout mice are viable and show a typical hematopoietic profile of adult blood 
(Salati et al., 2008). Nevertheless, their vascular phenotype is abnormal, given that CD34 
is also expressed on all vascular ECs of both adults and embryos (Baumhueter, Dybdal, 
Kyle, & Lasky, 1994; Young, Baumhueter, & Lasky, 1995). Gene deletion studies have 
demonstrated the pivotal role of CD34 in the development and integrity of blood 
vessels. CD34-/- mice are prone to autoimmune arthritis because of increased vascular 
permeability (Blanchet et al., 2010). Loss of CD34 results in altered vessel structure and 
vascular integrity within developing tumors (Maltby et al., 2011). Moreover, during early 
embryogenesis, the loss of CD34 was sufficient to delay the opening of the nascent 
lumen of the aorta (Strilic et al., 2009). 
 
Exactly, because CD34 expression has also been reported in microvasculature mature 
ECs (Timmermans et al., 2009), other groups have suggested the use of a more immature 
marker for putative EPCs (Gehling et al., 2000). CD133 was considered a good candidate 
since it is expressed on HSCs but, unlike CD34, not on mature ECs (Handgretinger et al., 
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2003). In fact, virtually all mature hematopoietic cells, including megakaryocytes, 
mature myeloid, lymphoid and erythroid cells fail to express CD133 (Miraglia et al., 
1997). Since the discovery of CD133, also called Prominin-1, as a transmembrane 
glycoprotein in human HSCs and mouse neuroepithelial cells (Z. Li, 2013), many studies 
have demonstrated that its expression is associated with progenitor/stem activity, 
tumorigenesis, regeneration, differentiation, and metabolism (Z. Li, 2013). Among other 
processes, CD133 is particularly involved in glucose and transferrin uptake, autophagy, 
membrane-membrane interaction, and as a matrix metalloproteinase (Z. Li, 2013). 
CD133+ cells are kept at relatively constant numbers in BM, blood, different tissues and 
even tumours, due to a dynamic and reversible expression in response to the changes 
of cell microenvironment. Typically, when cellular damage occurs via chemical, physical 
or mutational insults, CD133+ progenitor or stem cells are activated, differentiate and 
start proliferating to promote neuronal, bone, muscle or vascular regeneration (Cao et 
al., 2013; Kijima et al., 2009; M. Shi et al., 2009). In the hematopoietic system, its 
expression seems to be more restricted to a subset of CD34 bright progenitor cells in 
human fetal liver, BM, umbilical cord blood (UCB) and peripheral blood (PB) (Buhring et 
al., 1999). CD133+ cells isolated from UCB have been reported to undergo in vitro pre-
angiogenic process, form pseudo-vessel structures and present angiogenesis under 
hypoxic conditions (Paprocka et al., 2011), but there are contradictory reports 
concerning their EC differentiation (Case et al., 2007; Peichev et al., 2000). In vivo, 
CD133+ cells seem to support neovascularization of ischemic tissues in animal models 
(Bartunek et al., 2005; Y. X. Cui, Kafienah, Suleiman, & Ascione, 2013; Perin & Silva, 
2009), but generally speaking, total CD133+ cells should not be regarded as EPCs because 
they lack endothelial markers and mostly represent HPCs (Gehling et al., 2000). In 
summary, the relative non-specificity of this marker, the rarity of these cells in human 
BM and UCB (Y. X. Cui et al., 2013), and different differentiation results have been 
limiting factors for its use.  
 
Unfortunately, no single specific surface marker has been found to distinguish EPCs. 
Currently, investigators characterise EPCs by including hematopoietic stemness markers 
in combination with markers demonstrating endothelial commitment, but this has 
resulted in an extensive list of putative EPCs immunophenotypes (Timmermans et al., 
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2009). The most studied one reflects the co-expression of CD34 and Kinase insert 
domain receptor (KDR), considered to be immature cells with endothelial priming (Balaji 
et al., 2013) able to generate ECs in vitro (Asahara et al., 1997; Bompais et al., 2004). 
KDR is also known as vascular endothelial growth factor receptor 2 (VEGFR-2), CD309 or 
Flk1 (Fetal Liver Kinase 1). KDR, the human gene that encodes the type III 
transmembrane kinase receptor, is located in chromosome 4q11–q12 (Holmes, Roberts, 
Thomas, & Cross, 2007). VEGFR-2 is the principal receptor transmitting VEGF signals in 
the vascular endothelium (and aslo lymphatic endothelium). Therefore it has a critical 
role in vascular development, which is highlighted by the fact that VEGFR-2 knockout 
mice die at E8.5-9.5 due to defective development of blood islands, endothelial cells and 
haematopoietic cells (Shalaby et al., 1995). VEGFR-2 binds all VEGF-A isoforms, VEGF-C, 
-D and -E.  Ligand binding induces receptor dimerisation and autophosphorylation. 
Downstream effects of VEGFR-2 activation in the vascular endothelium include cell 
proliferation, migration, permeability and survival, resulting in vasculogenesis and 
angiogenesis, through a number of genes with known roles in angiogenesis, such as Cox-
2, Down syndrome critical region-1 (DSCR-1), Endocan, Decay-accelerating factor (DAF), 
Egr3, Ets-1, MMP-1 or Flt-1 (Sato et al., 2000). 
One major problem is that CD34+KDR+ cells are so rare in the steady-state PB that they 
can usually be sorted only from CB or mobilised PB (Fadini et al., 2008). Moreover, there 
is also substantial debate concerning this definition, because none of the markers is 
specific (Peichev et al., 2000) and CD34+KDR+ phenotype may represent mature ECs in 
microvascular endothelia or circulating mature ECs (CECs) sloughed from vasculature as 
well (Kachamakova-Trojanowska, Bukowska-Strakova, Zukowska, Dulak, & Jozkowicz, 
2015; Timmermans et al., 2009).  
 
As some mature ECs may detach from the vessel wall and enter the circulation of healthy 
and diseased human subjects (Blann et al., 2005), Peichev et al. attempted to devise a 
separation protocol to distinguish circulating EPCs from CECs (Peichev et al., 2000). Since 
mature ECs do not express CD133 (Gehling et al., 2000), the authors, in addition to CD34 
and KDR positivity, included CD133 expression as a discriminating marker. According to 
their results, only a small subset of CD34+ cells derived from hematopoietic sources 
expressed CD133 and KDR (2% percentage of total circulating CD34+ cells). The 
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restrictive triple expression pattern was also observed in some cells coating the luminal 
surface of implanted left ventricular assist devices in human subjects, suggesting that 
one could use CD34, CD133, KDR as markers for circulating EPC in human subjects. 
Therefore, they extrapolated that CD34+KDR+ cells that coexpress the more immature 
CD133 might represent the true EPC population. Remarkably, CD34+CD133+KDR+ cells 
have been shown to facilitate tumour microvasculature growth (Bertolini, Mancuso, & 
Kerbel, 2005; D. Gao et al., 2008), yet there is no evidence that these cells differentiate 
into ECs and directly incorporate into the vessels. In fact, CD34+CD133+KDR+ cells do not 
contribute to the formation of ECs in vitro (Case et al., 2007), nor do they spontaneously 
form capillary-like structures in vitro or in vivo (Case et al., 2007; Timmermans et al., 
2007). Interestingly, Peichev and colleagues back in 2000 (Peichev et al., 2000) did not 
test the triple positive cells for expression of CD45, a common leukocyte antigen. Case 
and colleagues subsequently reported that CD34+CD133+KDR+ cells represent an 
enriched population of CD45+ cells using in vitro hematopoiesis assays.  It is clearer now 
that the proangiogenic CD34+CD133+KDR+ cells are of haematopoietic origin and may 
not be true EPCs (Case et al., 2007; Simard et al., 2017) since they do not possess the 
postnatal vasculogenic profile that is proposed for a cell with endothelial progenitor 
properties (Estes et al., 2010; Medina et al., 2017). While these proangiogenic HPCs may 
be recruited to denuded vessels early in the process of vascular repair, it is more 
probable that they promote angiogenesis via paracrine mechanisms (Estes et al., 2010; 
Medina et al., 2017; Medina et al., 2010; Richardson & Yoder, 2011). Since the evidence 
does not support the use of CD133, another marker is needed to discriminate circulating 
CD34+KDR+ precursors from mature CECs, which also express CD34 and KDR.  
 
Lately, the combined analysis of CD45 expression has also been proposed to identify 
EPCs. Most CD34+ cells express CD45 at low intensity (CD45dim) (Fadini, Losordo, & 
Dimmeler, 2012). Timmermans and colleagues (Timmermans et al., 2007) used 
Magnetic activated cell sorting (MACS) preenriched UCB CD34+ cells (mean purity 94,3%) 
and sorted them into CD34+CD45+ HPCs (mean purity 99.5%) and a small (2% of total 
CD34+ cells) CD34+CD45- cell fraction (mean purity 99.2%) from the same blood unit, 
using stringent flow cytometry gates. The cell fractions were then cultured separately in 
M199 or EBM2 media. Their experiences revealed that in vitro EC-like cells derived only 
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from the CD34+CD45- cells, whereas CD34+CD45+ HPCs did not generate cells with 
endothelial phenotype in culture (Timmermans et al., 2007).  They also showed that the 
CD34+CD45- cell fraction expressed KDR, unlike CD34+CD45+ HPC cells.  Intriguingly, Case 
(Case et al., 2007) and Timmermans’s (Timmermans et al., 2007) findings seem to clash, 
since Case advocated by Fluorescence-activated cell sorting (FACS) that MACS CD34+-
enriched CD133+KDR+-FACS sorted are universally positive for CD45, while Timmermans 
could not find KDR expression by real time polymerase chain reaction (RT-PCR) in 
CD34+CD45+ cells. It may be that Timmermans’ group while sorting for MACS CD34+-
enriched CD45+-FACS sorted cells did not manage to gate in the limited 
CD34+CD133+KDR+ cell subset, or that the KDR cDNA numbers were too low to start PCR 
amplification. Both hypotheses could explain a negative KDR expression in RT-PCR. More 
recently, Lanuti et al. using rigorous polychromatic flow cytometry settings, came to the 
same observation, that CD45+CD34+CD133+KDR+ could not be found in any PB or CB 
sample since KDR expression could not be detected on the surface of 
CD45+CD34+CD133+ cells (Lanuti et al., 2016). Irrespective of the contribution of the 
small triple positive population, the data presented by Timmermans et al. are consistent 
with the previous observation that CD34+KDR+, but not CD34+KDR- cells, are endothelial 
precursors (Pelosi et al., 2002). Because analysis of the hematopoietic marker CD45 was 
not performed in the initial description of CD34+KDR+ precursors (Asahara et al., 1997; 
Peichev et al., 2000; Pelosi et al., 2002; Q. Shi et al., 1998) it is likely that CD34+KDR+ cells 
in these studies were confined to the CD34+CD45- cell fraction, which probably 
comprises the true origin of EPCs (Medina et al., 2017; Simard et al., 2017; Timmermans 
et al., 2007).  In fact, CD34+KDR+ cells show improved association with CAD and response 
to statin therapy if restricted to the CD45dim gate (Schmidt-Lucke et al., 2010). 
 
Looking for a more accurate EPC phenotype, CD146, a transmembrane glycoprotein 
described as a component of the endothelial junction involved in cell adhesion, 
permeability and transmigration (Kebir et al., 2010), has also gathered recent interest. 
CD146 was initially implicated in melanoma growth and metastasis (L. Mills et al., 2002), 
yet it has shown links to angiogenesis as well (Y. Kang et al., 2006). In their article, Tura 
et al. (Tura et al., 2013) confirmed that endothelial colony-generating EPCs were present 
only in the CD34+CD133- MNC fraction. Following further enrichment using CD146 they 
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found that only the CD34+CD133-CD146+ subset gave rise to colonies with true 
endothelial characteristics, unlike CD146 negative. These findings are in line with a 
recent study by Mund et al. who also reported that EPC colonies express CD146 (Mund, 
Estes, Yoder, Ingram, & Case, 2012). Unfortunately, Tura et al. did not assay for KDR 
expression in their subsets. Moreover, another critical issue remains unresolved: the cell 
marker CD146 used to identify putative EPC is not able to distinguish them from 
circulating mature cells, since CD146 is constitutively expressed on mature ECs too 
(Boos, Lip, & Blann, 2006). 
 
In summary, our best attempt to identify a putative EPC surface phenotype is presented 
in Figure 4. 
 
Figure 4 | Simplified Venn diagram depicting subgrouping of different progenitor cell phenotypes 
HPC-comprehending subsets: CD34+CD133+KDR+(Case et al., 2007); CD34-CD133+KDR+ (Reyes et al., 2002); 
CD34+CD45+(CD133+) (Timmermans et al., 2007), (Case et al., 2007); EPC-comprehending subsets: 
CD34+CD45-(KDR+CD133-) (Timmermans et al., 2007)); CD34+KDR+ (Pelosi et al., 2002), (Tura et al., 2013). 
The question mark represents the putative region with EPC potential. Alternatively, EPCs could arise from 
two distinct subsets, CD34+CD146+ and CD34+KDR+. No single marker is known to date to distinguish EPCs 
from ECs. CD – cluster of differentiation; HPC – hematopoietic progenitor cell; EC – endothelial cell; EPC – 
endothelial precursor cell; KDR – kinase insert domain receptor. 
 
 
Altogether, it seems that the CD34+KDR+ phenotype represents the best compromise 
regarding detection accuracy, biological meaning and clinical usefulness. It is possible 
that a distinctive marker or marker combination is still to be found. Until then, the use 
of heterogeneous marker combinations to define EPCs (and even gating strategies which 
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are not standardised), makes the significance of flow cytometric studies difficult to 
interpret, creates obstacles to the direct comparison of data between researchers, and 
may result in discrepancies in the interpretations of study results among different 
groups. It is now clear that hematopoietic and vascular endothelial progenitors display 
the same set of antigens and can only be discriminated by extensive testing. Therefore, 
one should strongly consider that any putative EPC, whatever its surface phenotype, be 
carefully assessed by gene expression and validating its endothelial potential in vitro and 




Inferring the presence of endothelial precursors within a given cell population by the 
identification of cells bearing mature endothelial characteristics after a period of culture 
under pro-angiogenic conditions is another approach to identifying (and isolating) EPCs. 
This was first attempted by Asahara et al. (Asahara et al., 1997) in 1997 by isolating 
human PB CD34+ cells (15.7% enrichment) and culturing them in fibronectin (FN)-coated 
dishes. They reported that CD34-enriched cells had a spindle-shaped morphology and 
clustered together similarly to blood island-like clusters found in the embryonic yolk sac. 
The putative EPCs expressed numerous cell surface proteins typically present in human 
umbilical vein endothelial cells (HUVECs). They interpreted this endothelial-like 
outgrowth as constituting evidence for the presence of circulating post-natal angioblasts 
which could generate EPCs. Further studies revealed that KDR expressing putative EPCs 
(enriched to 20%) improved microvascular density after infusion into nude mice with 
induced hindlimb ischemia. Although the results were ground-breaking, potential 
limitations of this study have been discussed. These included the lack of sufficient 
cellular pre-enrichment to constitute a purified cell population, failure to perform clonal 
analytical studies and lack of high cellular resolution evidence that the infused putative 
EPCs directly formed the new blood vessels in the ischemic tissues of the mice with 
induced vascular injury.  
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Three optimised culture methods inspired by the original Asahara assay (Asahara et al., 
1997) have been proposed as an alternative to FACS antigen analysis (Fadini et al., 2012; 
Williamson, Stringer, & Alexander, 2012) (Figure 5). 
 
The first one developed by Kalka et al. (Kalka, Masuda, Takahashi, Kalka-Moll, et al., 
2000) involves plating MNCs on FN-coated dishes and incubating them with medium 
containing endothelial growth factors and serum. After three days in culture, the non-
attached cells were removed and the adherent cells kept in culture for 14 days. Two 
types of cell populations were generated sequentially by the EPC culture assay. The cells 
initially seeded were round, and after 3 to 5 days started grouping in clusters. These 
were comprised of elongated cells which had a spindle shape like that of the EPC first 
reported by Asahara (Asahara et al., 1997). These cells were termed early EPC, given 
their short culture time. They showed peak growth at 2 to 3 weeks and after that, they 
did not replicate in vitro and gradually disappeared after four weeks in culture.  
 
Figure 5 | An overview of the most common methods to isolate EPCs. 
Adapted from (Fadini et al., 2012). CD – cluster of differentiation; EC – endothelial cell; EC-CFU - 
endothelial cell colony-forming unit; ECFC - endothelial colony-forming cell; eNOS – endothelial nitric 
oxide synthase; EPC – endothelial precursor cell; KDR – kinase domain insert receptor; LDL – low-density 
lipoprotein; MNC – mononuclear cell; vWF – von Willebrand factor.  
 
 
Another population of cells with different morphology and growth pattern appeared in 
2 to 3 weeks after plating and were defined as late-outgrowth EPCs. These were firmly 
attached to the plate and rapidly replicated from several cells to colonies with 
 Introduction - 37 
 
cobblestone appearance like ECs. They exhibited multiple population doublings without 
senescence resulting in exponential growth at 4 to 8 weeks and lived up to 12 weeks. 
Remarkably, both cell types internalised acetylated-low density lipoproteins (ac-LDL). 
Despite its simplicity, this isolating method seems flawed by the lack of specificity of the 
cells obtained.  Several blood cells (stem, progenitor, or mature lineages) also possess 
integrin receptors for FN which promote their attachment to the culture matrix. 
Remarkably, adherent monocytes when cultured in media containing endothelial 
growth factors are known to express a variety of proteins typically associated with ECs 
(von Willebrand factor - vWF, endothelial nitric oxide synthase - eNOS, CD31 and KDR) 
(Schmeisser et al., 2001; Schmeisser, Graffy, Daniel, & Strasser, 2003). Hence, this very 
straightforward assay of adherent MNCs growth did not promote the exclusive 
emergence of EPCs. 
 
Hill and colleagues  optimised the previous assay by attempting to deplete the early-
adherent MNCs, macrophages and circulating mature ECs from the putative EPC system 
(Hill et al., 2003). To do this, they allowed a 48h incubation before replating the non-
adherent cells on fresh FN-coated dishes. In 5-7 days, central clusters of round cells 
surrounded by multiple spindle-shaped cells emerged and were scored as endothelial 
cells colony-forming units (EC-CFUs). Subsequent transcriptome, proteomic, and 
functional analysis have revealed that cells generated by the CFU assay are more closely 
related to hematopoietic cells than to ECs (Yoder, 2012). Although worthy in intent, the 
failure to show that all hematopoietic cells were depleted by the preplating step 
diminished the interest on this method to isolate putative EPCs. 
 
Later, a different type of colony derived from an ECFC assay developed by Ingram et al. 
(Ingram et al., 2004) and further improved by Yoder et al. (Yoder et al., 2007) was 
described. In contrast to EC-CFUs, the ECFC colonies emerged from the adherent 
fraction on type I collagen following the removal of the non-attached population within 
the first 24h, after 14–21 days in culture (Ingram et al., 2004; Y. Lin et al., 2000).  
According to Lin and colleagues (Y. Lin et al., 2000), who have subsequently replicated 
the assay, the discarding of non-adherent cells leaves 19 ± 9 attached cells with 
endothelial-like morphology and positive for anti-endothelial monoclonal antibody 
P1H12 staining, plus 100–200 other MNCs which die out within the first two weeks of 
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culture. The outgrowth colonies are composed of CD34+ ECFCs (Timmermans et al., 
2007) which are morphologically indistinguishable from mature ECs, but present a 
delayed robust proliferative potential, with some colonies growing to more than 10,000 
progeny from a single cell plated 14 days earlier (Ingram, Caplice, & Yoder, 2005; Ingram 
et al., 2004). 
Although both short and long-term cultured cells arising from EC-CFU and ECFC assays 
share mutual properties, such as expression of CD31, CD34, lectin binding, and 
acetylated low-density lipoprotein (acLDL) uptake, they possess distinctive phenotypes 
regarding morphology, proliferative and functional potential (Medina et al., 2017; 
Timmermans et al., 2007) (Table 1). 
 
Table 1 | Progeny characteristics following EC-CFU and ECFC assays. 
EC-CFUs or “early EPCs” are generated from a non-adherent population of MNCs cultured on fibronectin 
and appear some 5 to 7 days in culture. EC-CFUs exhibit endothelium-like surface characteristics, 
however, they are composed of monocytes and angiogenic lymphocytes and have little capacity to form 
perfusing vessels or incorporate directly into vascular structures. EC-CFUs exhibit phagocytic activity and 
avidly secrete angiogenic growth factors. Contrastingly, ECFCs or late-outgrowth EPCs are generated from 
adherent MNCs grown on type I collagen and appear after 2 to 3 weeks of cell culture. ECFCs are 
morphologically indistinguishable from mature ECs and are derived from non-hematopoietic (CD45-) cells 
expressing CD34. ECFCs have robust proliferative potential and the capacity to form perfusing blood 
vessels in vitro. Adapted from (Timmermans et al., 2009), (Fadini et al., 2012), (Tura et al., 2013), (Balaji 
et al., 2013; Medina et al., 2017). CD – cluster of differentiation; EC – endothelial cell; EC-CFU - endothelial 
cell colony-forming unit; ECFC - endothelial colony-forming cell; MACs- myeloid angiogenic cells;  MNC – 
mononuclear cell; PAC – proangiogenic cells. 
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Short-term cultured EC-CFUs, historically termed “early EPCs”, are forced within a few 
days in culture to express endothelial markers, such as eNOS, CD31, CD105, CD141, 
CD144, CD146, vWF, Tie-2, KDR, and E-selectin, while preserving CD34 positivity 
(Padfield, Newby, & Mills, 2010; Yoder et al., 2007; Zampetaki et al., 2008). Therefore, 
they were thought to be cells with EC fate derived from circulating HPCs (Hirschi et al., 
2008). However, the coexpression of endothelial markers by EC-CFUs has been a topic 
of controversy. There is evidence that the detection of endothelial markers might result 
from contamination with microparticles deriving from platelets which fuse with MNCs 
leading to false-positive events in FACS analysis (Prokopi et al., 2009), which would mean 
that isolated HPCs do not differentiate at all into an endothelial lineage as some groups 
have hinted (Yoder et al., 2007). The lack of an endothelial predetermination is further 
supported by the discovery that the endothelial genes in EC-CFUs are epigenetically 
repressed (Ohtani et al., 2011). Silencing of promoters of specific endothelial 
commitment genes (eNOS, KDR, vWF, and VE-cadherin) seems to occur at the level of 
histones and DNA methylation (Ohtani et al., 2011). In fact, it is well established now 
that the colonies arising from the CFU-Hill assay are, in fact, composed of a heterogenic 
population that mainly originates from myeloid hematopoietic cells, and shares 
common features with monocyte/macrophages, such as spindle morphology (Yoder et 
al., 2007), bacteria phagocytic ability (Hur et al., 2007), and colony stimulating factor-1 
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receptor and expression of nonspecific esterase that is inhibited by sodium fluoride 
(Yoder et al., 2007). These colonies are in fact a combination of core CD3+CD31+CXCR4+ 
angiogenic T-cell lymphocytes and monocytes at the periphery (Hur et al., 2007; Rohde 
et al., 2007). EC-CFUs are generated from CD14+ cells (Urbich et al., 2003) since depletion 
of CD14+ cells prevents their formation (Rohde et al., 2006). Their numbers are high after 
isolation, but they have a low proliferative potential (Zampetaki et al., 2008), and thus 
cannot be further expanded. Despite being able to incorporate into the endothelial 
monolayer, they fail to form perfused vessels in vivo (Yoder et al., 2007; Zampetaki et 
al., 2008). It is thought that “early EPCs” support neovascularization in vivo in an indirect 
fashion, by producing specific growth factors and chemokines, since they do not seem 
to adopt a typical endothelial phenotype in vitro (Timmermans et al., 2007). 
Hypothetically, “early EPCs” are recruited to damaged sites and secrete regulatory 
cytokines that help vessel repair by local neighbour (Ingram, Mead, et al., 2005) or 
circulating (Timmermans et al., 2009) cells with endothelial progenitor potential. The 
paracrine secretion of pro-angiogenic substances like VEGF, stromal derived factor 1 
(SDF-1), interleukin 8 (IL-8), matrix metalloproteinase 9 (MMP-9), granulocyte and 
granulocyte-monocyte colony stimulating factors (G-CSF and GM-CSF) by these cells has 
been extensively demonstrated, all of which are implicated in the mobilisation of BM 
progenitors (Hur et al., 2007; Inoue et al., 2011; Rehman, Li, Orschell, & March, 2003) 
and in support of tissue-residing cells contributing indirectly to angiogenesis and 
vascular repair (Simard et al., 2017; Urbich & Dimmeler, 2004; Ziegelhoeffer et al., 2004). 
Based on their ability to support angiogenesis, not necessarily associated with any 
definitive endothelial commitment (Rehman et al., 2004), early EPCs should be 
redefined (Fadini et al., 2012) as proangiogenic cells (PACs) or myeloid angiogenic cells 
(MACs) instead, as some researchers have already suggested (Medina et al., 2017; Yoder 
et al., 2007). 
 
In contrast, ECFCs or late-outgrowth EPCs display similar endothelial features in vitro 
and were reported to contribute to neovascularization by incorporating as newly 
matured ECs into vessels in vivo (Yoder et al., 2007), and therefore probably act more as 
true EPCs (Ingram et al., 2004; Y. Lin et al., 2000; Medina et al., 2017; Yoder et al., 2007). 
The number of late-outgrowth EPCs is extremely low after isolation, with approximately 
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1 colony arising per 108 mononuclear cells plated (Fadini et al., 2012). However, while 
short-term cultured PACs can only support vascular network formation, long-term 
outgrowing EPCs can form vascular structures in vitro in the absence of co-culture 
(Sieveking, Buckle, Celermajer, & Ng, 2008). Unlike PACs which have a spindle-shaped 
morphology, these clusters appear as tightly adherent colonies with cobblestone 
appearance, which begin to proliferate only 2–3 weeks after seeding at a high 
proliferation rate (Ingram et al., 2004; Zampetaki et al., 2008), and can be maintained in 
culture extensively (Zampetaki et al., 2008). In fact, in compliance with the notion that 
the hallmark of progenitor cells is their ability to proliferate and to give rise to progeny, 
Ingram and colleagues demonstrated that the late EPCs could achieve ≥100 population 
doublings (Ingram et al., 2004). These cells do not exhibit the pan-leukocyte marker 
CD45 (Timmermans et al., 2007), the myeloid/macrophage markers CD14 (Padfield et 
al., 2010), CD11 (Padfield et al., 2010) and CD133 (Timmermans et al., 2007), nor do they 
have phagocytic behaviour (Padfield et al., 2010). In fact, there is no ECFC growth 
starting from CD45+ or CD14+ enriched populations (Gulati et al., 2003; Timmermans et 
al., 2007), clearly indicating the need for a CD45-CD14-CD34+ origin. Remarkably, late-
outgrowth EPCs, unlike PACs, do not produce an enormous amount of angiogenic 
growth factors (Hur et al., 2004). Medina and colleagues compared PACs and late EPCs 
by genome-wide transcriptional profiling and 2D protein electrophoresis and discovered 
they displayed strikingly different gene expression signatures (Medina et al., 2010). PACs 
highly expressed haematopoietic specific transcripts (WAS, RUNX1, LYN) with links to 
immunity and inflammation (TLRs, HLAs), whereas late-outgrowth EPCs expressed many 
transcripts involved in angiogenesis-related signalling pathways (Tie2, eNOS, Ephrins). 
Proteomic comparison between PACs and MNCs indicated that 77% of the proteins 
isolated by 2-D gels are also expressed by monocytes, while 90% of spots identified are 
common between late-outgrowth EPCs and ECs (Medina et al., 2010). Therefore, PACS 
are haematopoietic cells with a monocytic-like molecular profile, while late-outgrowth 
EPCs have a molecular fingerprint which suggests a close association to the endothelial 
lineage. In concordance with the latter, while short-term cultured PACs can only support 
vascular network formation, long-term outgrowing EPCs can form vascular structures in 
vitro (Sieveking et al., 2008). The ability of the ECFCs to display spontaneous 
vasculogenic properties distinguishes this EPC from all other types of cells that have 
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been given this term.  They are mobilised upon injury insults (Massa et al., 2009), have 
proliferative capacity (Ingram et al., 2004), adopt an EC phenotype, and are capable of 
forming perfusing vessels in vivo (Yoder et al., 2007).  
 
Altogether, late-outgrowth EPCs most accurately fulfil the criteria of an EPC suitable for 
endogenous vascular repair. However, and even though the cells obtained by the 
protocols differ in their capacity to differentiate in ECs and to physically form new blood 
vessels, most of the published short-term or long-term culture methods yielded cells 
with the ability to improve neovascularization in preclinical models (Hur et al., 2004; 
Urbich & Dimmeler, 2004; Yoder et al., 2007; Yoon et al., 2005). Consequently, it could 
be suggested that both phenotypes have a complementary role in vascular repair (Chong 
et al., 2016; Urbich, Aicher, et al., 2005), where the low proliferative potential PACs act 
to secrete angiogenic factors stimulating the proliferative capability of the late 
outgrowth EPCs (Zampetaki et al., 2008). In fact, the simultaneous injection of both cells 
types has been shown to significantly promote greater tissue repair (Yoon et al., 2005), 
highlighting their synergistic role in improving physiological angiogenesis.  
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EPC sources and mobilisation 
 
Despite the advance in EPC research, the primary sources of these cells and 
differentiation pathways of late-outgrowth EPCs are still under debate (Simard et al., 
2017)  (Figure 6). 
 
Figure 6 | Origin and differentation of EPCs. 
Scheme depicts the possible origin and differentiation of EPCs from hematopoietic and non-
hematopoietic cells. EPCs give rise to endothelial cell lineage, including late-outgrowth EPCs and ECs. HPCs 
give rise to blood cells, such as monocytes and PACs. Whether monocytes can act as PACs and vice versa 
is still controversial. CECs can arise from the detachment of mature ECs and repair other areas of 
endothelium damage or can stem from the differentiation of PACs. Adapted from (Urbich & Dimmeler, 
2004), (Timmermans et al., 2009), (Balaji et al., 2013), (Marcola & Rodrigues, 2015), (Cappellari, D'Anna, 
Avogaro, & Fadini, 2016). CD – cluster of differentiation; CEC – circulating endothelial cell; EC - endothelial 
cells; EPC – endothelial precursor cell; HPC – hematopoietic progenitor cell; KDR – kinase insert domain 




Initially, late EPCs were ascribed to BM-derived circulating angioblasts (Y. Lin et al., 
2000). At the BM, EPCs reside in a special osteoblastic niche characterised by low oxygen 
tension and high SDF-1α level and from there are repeatedly mobilised in response to 
peripheral stimuli (Hristov et al., 2003) for supporting re-endothelialisation and 
angiogenesis (Figure 7). The interaction between stem cells and stromal cells 
(osteoblasts, ECs, fibroblasts) are amplified by membrane-anchored cytokines which 
transduce proliferation and or differentiation signals, or by the maintenance of 
progenitors in a quiescent state under the constraints of limited growth factor 
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concentrations. Rapid availability of cytokines is essential for the recruitment of 
quiescent EPCs to a permissive vascular niche where they can proliferate, differentiate, 
and be released into circulation. EPC recruitment has been demonstrated to be impaired 
in eNOS−/− mice (Aicher, Heeschen, et al., 2003).  Therefore, the mobilization is believed 
to be chiefly dependent on the activation of eNOS (Heissig et al., 2002) produced by 
osteoblasts and ECs in the presence of several mobilizing factors. These include insulin, 
G-CSF, HIF1-α, VEGF, erythropoietin, SDF-1, placental growth factor, estrogen and SDF-
1α (also known as CXCL12), which get upregulated upon tissue hypoxia, or wound-
healing conditions to a concentration greater than that in the BM (Aicher, Heeschen, et 
al., 2003; Balaji et al., 2013; De Falco et al., 2004; B. Li et al., 2006; Shim, Nam, Hyuk, 
Yoon, & Song, 2015). All these factors act via the phosphoinositide 3-kinase/protein 
kinase B (Akt) pathway resulting in eNOS activation (Dimmeler et al., 1999). In turn, the 
increased bioavailability of NO upregulates the enzymatic activity of elastase, cathepsin 
G and MMPs, which then cleave the intercellular bonds between the stem and stromal 
cells (Dimmeler et al., 1999; Urbich & Dimmeler, 2004). Particularly, MMP-9 activation 
results in the release of a soluble kit ligand in the BM niche, which cleaves adhesive 
bonds on stromal cells, leading to EPC migration into the vascular zone, and subsequent 
proliferation and PB mobilisation via transendothelial migration (Heissig et al., 2002). 
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Figure 7 | EPC mobilisation from BM. 
The BM-derived EPCs reside in an osteoblastic microenvironment where they can readily sense and 
respond to the stress-induced demands for supporting re-endothelialisation and angiogenesis. The NO-
induced activation of MMP-9, which cleaves adhesion/survival-promoting membrane-bound Kit ligand 
(mKitL) into a survival/motogenic soluble Kit ligand (sKitL), constitutes an early step in this process. 
Subsequently, cKit-positive stem and progenitor cells, including the common hemangioblast, move to the 
vascular zone of the BM microenvironment, where they switch from a quiescent to a proliferative state 
and are released into circulation. Adapted from (Heissig et al., 2002) and (Balaji et al., 2013). BM – bone 
marrow; CD – cluster of differentiation; EC - endothelial cells; eNOS – endothelial nitric oxide synthase; 
EPC – endothelial precursor cell; EPO – erythropoietin; G-CSF – granulocyte colony stimulating factor; GM-
CSF – granulocyte-monocyte colony stimulating factor; HPC – hematopoietic progenitor cell; KDR – kinase 
insert domain receptor; MMP9 – matrix metalloproteinase-9; PAC – proangiogenic cell; SDF-1- stromal 
derived factor 1; VEGF – vascular endothelial growth factor. 
 
 
Irrespective of the BM contribution to an EPC circulatory pool, the possible existence of 
specific niche(s) of vascular wall EPCs locally derived or maintained should also be 
considered. Indeed, during the past decade evidence of an array of progenitor cells 
resident within the mural layers which could contribute towards the endothelial 
homoeostasis (Figure 8) has emerged (Psaltis & Simari, 2015).  
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Figure 8 | Hypothetical scheme of vascular wall EPC zones. 
This scheme illustrates the concept of vascular mural zones containing EPCs and HPCs capable of 
differentiating into endothelial cells and form capillary-like sprouts from the vascular wall, and immune 
cells, respectively. Additionally, lineage-committed MSCs, SPCs, MVSCs and AMPCs have also been 
described to reside within the mural layers of vessels. Dashed lines correspond to internal and external 
elastic laminas.  Adapted from (Ingram, Mead, et al., 2005), (Zengin et al., 2006), (Naito, Kidoya, Sakimoto, 
Wakabayashi, & Takakura, 2012), (S. Fang, Wei, Pentinmikko, Leinonen, & Salven, 2012) and (Psaltis & 
Simari, 2015). ABC - ATP-binding cassette; AMPC -  adventitial macrophage progenitor cells; CD – cluster 
of differentiation; EPC – endothelial precursor cell; HPC – hematopoietic precursor cell; HP-ECFC – high 
potential endothelial colony forming cell; KDR – kinase domain receptor; MSC – mesenchymal stem cell; 
MVSC -  multipotent vascular stem cell; SP – side population; SPC - smooth muscle progenitor cell; VE-cad 
– vascular endothelial cadherin. 
 
 
In support of this theory, Zengin and colleagues identified an enriched area of CD34+ and 
KDR+ cells (aside from the expected positive staining for CD34 in the endothelial layer), 
located between the smooth muscle and adventitial layers of the vascular wall, in close 
vicinity to the external elastic membrane (Zengin et al., 2006). Interestingly, this zone 
did not stain for CD31 and VE-cadherin like in the intima, nor SMA-like in the media. By 
marking the cells of the vasculogenic zone ex vivo with an AdV5-GFP-system, Zengin 
demonstrated that this vascular wall zone contains a niche of cells capable of forming 
outward capillary sprouts during an arterial ring assay. During the Matrigel assay, there 
was a significant accumulation of CD34+ cells not only in the vasculogenic zone but also 
in the whole adventitia of the vascular wall. During this process, the GFP-CD34+ cells 
became positive for markers typical of activated (CEACAM1) and tightly-junctional 
endothelium (occluding, VE-cadherin), but remained negative for CD31. Another 
minority population that was detected in the vasculogenic zone were cells positive for 
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CD45. Their number within the wall did not change significantly after the ring assay, nor 
did they apparently participate in capillary formation, although a few of them migrated 
into the collagen gel outside the rings. Therefore, it was hypothesised that the 
vasculogenic zone seemingly contains cells of different subpopulations and CD45+ cells, 
postulated to be cells of HPC origin, which may act as inflammatory cells relevant for a 
local immune response or angiogenesis support. Although the observations were 
compelling towards the existence of a niche of cells within the vessel wall with 
angiogenic outgrowth potential, this work did not unequivocally identify a putative EPC 
nor a definitive EPC source. No distinctive antigenic or clonogenic characterization was 
pursued to differentiate this cells from CECs bearing low proliferative potential, for 
instance. Moreover, peri-adventitial AdGFP tagging is not sufficient to validate that the 
outgrowth ECs came from the “vasculogenic zone”. Moreover, matrigel-based sprouting 
assays are not specific for cells of endothelial lineage, and outgrowths from vascular 
explants contain a mixture of fibroblasts, macrophages, ECs, and pericytes (Zengin et al., 
2006; Zorzi, Aplin, Smith, & Nicosia, 2010) making it difficult to differentiate bona fide 
EPCs from other PACs that coexist in the adventitia and possess hematopoietic features 
(Zengin et al., 2006).  
 
In contrast to the previous study by Zengin, others used rigorous clonal assays to try to 
identify vascular wall EPCs. Ingram and colleagues described an entire hierarchy of cells 
that could be isolated from vessel wall-derived cultures (Ingram, Mead, et al., 2005) and 
which displayed a high proliferative potential similar to that of late-outgrowth EPCs. In 
endopoiesis, the most proliferative progenitor that can be cultured in the absence of a 
stromal cell monolayer is designated a high proliferative potential–ECFC (Ingram et al., 
2004). Single high proliferative potential-ECFCs are capable of generating colonies that 
go on to form secondary and tertiary colonies upon replating (Ingram et al., 2004). To 
compare the clonogenic capacity of single cells derived from UCB or vessel walls, Ingram 
grew monolayers of UCB-derived late-outgrowth EPCs, HUVECs, and Human aortic 
endothelial cell (HAECs) and demonstrated that, surprisingly, they could all be passaged 
for at least 40 population doublings. Then, they performed single cell culture which 
revealed that both high proliferative potential-ECFCs and low proliferative potential-
ECFCs exist among HUVEC and HAEC populations. These intima-derived progenitor cells 
expressed EC surface markers (CD31, CD141, CD105, CD146, CD144, vWF) and displayed 
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the similar clonogenic potential to UCB EPCs. The presence of high proliferative 
potential-ECFCs among HUVECs and HAECs derived from vessel walls could explain the 
high passage number achieved by otherwise terminally differentiated mature ECs with 
low proliferative potential (Bompais et al., 2004).  
 
Subsequent data have supported this notion that EC turnover is not a stochastic 
property of mature ECs, but rather the result of a hierarchical organisation of different 
endothelial subpopulations categorised by their clonogenic potential (Psaltis & Simari, 
2015). Naito and colleagues identified a side population (SP) of CD31+CD45− 
stem/progenitor-like ECs at the intima of pre-existing blood vessels, based on their 
ability to efflux lipophilic fluorescent Hoechst 33342 dye via the ATP-binding cassette 
(ABC) family of cell membrane transporter proteins (Naito et al., 2012). The SP assay is 
a FACS based method that relies on the fact that while uptake of the DNA binding dye 
occurs uniformly in all cells through passive diffusion, efflux is an active energy-driven 
process, and only certain cells expressing a sufficient number of ABC transporters are 
able to actively efflux the dye out of the cell, which in turn is captured on FACS. 
Combining the SP assay with cell surface phenotyping lead to the observation that this 
sub-population of stem/progenitor-like ECs were found to constitute nearly 1% of all 
CD31+CD45− ECs present in samples of hindlimb muscle, liver, lung and heart, but could 
not be detected in BM, blood or ECs in culture. Since the SP assay is performed on viable 
cell populations, this enabled subsequent functional characterization of the cells in vitro 
and in vivo. Although quiescent in steady state, the sorting of the SP-ECs revealed within 
them a colony forming nature, high replication potential compared to other colony-
forming ECs, and ability to regenerate mature blood vessels in vivo ischemic milieus, as 
well as a distinct gene expression pattern compared with conventional ECs. Moreover, 
a high nucleus/cytoplasm ratio and high expression of surface marker CD133 strongly 
suggest that the SP ECs possessed essential characteristics of stem/progenitor cells. 
Nevertheless, although ABC transporters are enriched in stem/progenitor cells, several 
reports document that the SP phenomenon is not restricted to this phenotype 
(Golebiewska, Brons, Bjerkvig, & Niclou, 2011). Such transporters have also been 
described in specific differentiated cells where they are thought to play a role in 
protection against the cytotoxic effects of toxins and xenobiotics (multiple drug 
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resistance) by limiting toxin/drug entry into certain tissues and promoting their 
elimination into bile and urine (Fromm, 2000). 
 
Fang and colleagues later identified an intimal population of Lin−CD31+CD105+Sca-1+c-
kit+ ECs from mouse pulmonary vasculature that contained a rare (0.4%) subset of ECFCs. 
This c-kit+ clonal subset was shown by transgenic reporter tracing to be of probably 
endothelial and non-hematopoietic origin (S. Fang et al., 2012). These cells were 
recognised by in situ immunostaining in the capillaries, arteries, and veins of a range of 
organs (lung, liver, kidney and subcutaneous tissues), as well as in neovessels in 
subcutaneous Matrigel plugs, and in murine and human melanoma cells and breast 
cancer samples. Then, the authors demonstrated that the clonal progeny of single c-kit+ 
ECFCs could generate host-perfused blood vessels in vivo within Matrigel plugs, and 
confirmed their capacity for long-term self-renewal. Phenotyping of c-kit-deficient mice 
exposed a reduction in ECFC recovery, along with reduced angiogenesis and tumour 
growth, that notably were not restored by reconstitution of the hematopoietic system 
with wild-type BM (S. Fang et al., 2012). 
 
These vascular wall EPCs are not to be confused with the reduced outgrowth potential 
mature intima-derived CECs which get dislodged from the vessel wall.  Some so-called 
circulating EPCs are these injured, or senescent ECs sloughed from the vessel wall into 
the blood stream (Figure 6). CECs which are CD146+CD34brightCD45- (Cappellari et al., 
2016), are described as mature ECs that detach from the endothelial layer into the 
circulation at angiogenic sites, during increased shear stress (Rowand et al., 2007), 
veinpuncture (Boos, Lane, et al., 2006) and several clinical disorders that have in 
common the presence of vascular injury (Blann et al., 2005), such as diabetes (Lombardo 
et al., 2012). It is estimated that normal adults have 2.6 ± 1.6 CEC/mm of PB. The majority 
of these CECs are quiescent, and at least half are microvascular as defined by CD36 
positivity (A. Solovey et al., 1997). CECs bear no or low proliferative potential in culture 
(Blann et al., 2005), unlike late EPCs (CD34+KDR+). In fact, CECs are currently practically 
indistinguishable by flow cytometry alone from late-outgrowth EPCs, except for CD34 
brightness (Cappellari et al., 2016). Therefore one needs to differentiate them according 
to their proliferative capacity. Lin et al. studying sex-mismatched BM transplant patients 
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claimed that the majority of the so-called circulating EPCs (95%) were in fact derived 
from the vessel wall and displayed restricted growth capability (Y. Lin et al., 2000). 
Briefly, the authors, following the analysis of fluorescence in situ hybridization of PB 
samples from BM transplant recipients who had received gender-mismatched grafts 5–
20 months earlier, reported that most circulating CD146+ cells (considered endothelial-
committed cells (A. N. Solovey et al., 2001)) exhibited a recipient genotype. Genotype 
analysis of buffy coat cultures from these subjects revealed an outgrowth of ECs of both 
donor and recipient genotypes. Remarkably, ECs with recipient genotype had expanded 
only 17 ± 9–fold after 27 ± 4 days in culture, whereas cells having transplant donor 
genotype displayed a delayed outgrowth profile but expanded fully 1023 ± 476–fold 
over the same time window. These findings suggest that the majority of circulating 
endothelial committed-cells found in fresh PB were derived from the recipient own 
vessel walls and had limited growth capability (CECs), and the delayed but exuberant 
endothelial outgrowth in culture stemmed from the rarer donor BM-derived circulating 
cells (EPCs).  
 
Other groups have suggested that parenchymatous organs, such as the muscle, adipose, 
dermis, liver, intestine and liver (Aicher et al., 2007), could be alternative EPC source 
contributing to the circulating progenitor cell pool. However, since an insufficient 
phenotyping was carried out at the time and in light of subsequent work, it is likely that 
CD146+CD34-CD133-Syto16+ vascular wall resident ECs could exist in the wall of adult 
blood vessels of those organs (Ergun & Gehling, 2007). 
 
Moreover, reports that myeloid cells can generate endothelial progeny are also a matter 
of debate. CD14+CD34low myeloid cells have been shown to coexpress endothelial 
markers and form tube-like structures ex vivo (Schmeisser et al., 2001). Furthermore, ex 
vivo expansion of purified CD14+ MNCs generated cells with an endothelial phenotype, 
which incorporated in newly formed blood vessels in vivo (Urbich et al., 2003). These 
data would suggest that myeloid cells may transdifferentiate to the endothelial lineage 
cells. Nevertheless, it is possible that these assays might have been contaminated by 
CD45- cells with true endothelial potential.  
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In summary, to date, the in vivo counterpart of the late-outgrowth EPCs is yet to be 
unambiguously demonstrated, due to its rarity in circulation and the lack of a marker 
combination that uniquely identifies these cells. So far, the BM, and possibly the blood 
vessel vascular wall, are considered the most likely repository and processing EPC 
compartments (Simard et al., 2017). Alternatively, there is even the possibility that late-
outgrowth EPCs are culture artefacts resulting from the in vitro selection pressure 
(Timmermans et al., 2009). 
 
EPC homing, engraftment and differentiation 
 
Incorporation of circulating EPCs at the injury site (homing) requires a coordinated 
sequence of multistep adhesive and signalling events including chemoattraction, 
selectin-mediated rolling, integrin-mediated adhesion, diapedesis through the 
endothelial monolayer, invasion in the ECM involving integrin-dependent processes and 
proteases, and finally, differentiation into ECs (Figure 9). 
Once mobilised from the BM, EPCs in circulation respond to gradient signalling in the 
tissues undergoing active remodelling. Some homing chemokines and respective EPC 
receptors upregulated after arterial injury are IL-8 and CXCR2; RANTES/CCL5 and CCR5; 
growth-regulated oncogene-a and CXCR1; and C-C chemokine and chemokine (C–C 
motif) receptors 2 and 5 (Balaji et al., 2013; Hristov & Weber, 2008). Platelet adhesion 
to the injured vascular wall also constitutes a major determinant of re-endothelialisation 
by inducing the release of SDF-1α (also known as CXCL12) (Massberg et al., 2006; Stellos 
& Gawaz, 2007). SDF-1α is a chemoattractant that exerts its role through binding with 
its receptor C-X-C chemokine receptor 4 (CXCR4), expressed on the EPC surface (Walter 
et al., 2005), thus acting as a sensor for circulating EPC cruising through sites of the 
microvasculature wherein an SDF-1α gradient is present. Blocking CXCR4 significantly 
reduces the adhesion of EPCs to mature EC monolayers in vitro (Ceradini et al., 2004) 
and homing of the progenitor cells to the ischemic myocardium (Abbott et al., 2004) or 
after arterial wire injury in vivo (Hristov, Zernecke, Bidzhekov, et al., 2007).  
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Figure 9 | Mechanism of EPC homing, engraftment and differentiation. 
Recruitment and incorporation of late-outgrowth EPCs into injured vessels requires a coordinated 
multistep process including chemoattraction, adhesion, trans-endothelial migration, matrix degradation 
and in situ differentiation. Factors that are proposed to regulate the distinct steps are indicated. Dashed 
green lines correspond to molecular interactivity. The dashed yellow line corresponds to damaged 
endothelium. Adapted from (Urbich & Dimmeler, 2004) and (Caiado & Dias, 2012). BM – bone marrow; 
CD – cluster of differentiation; CXCR2 - C-X-C chemokine receptor type 2; CXCR4 - C-X-C chemokine 
receptor type 4; EC – endothelial cell; ECM – extracellular matrix; EPC – endothelial precursor cell; GF – 
growth factors; IGF – insulin –like growth factor, IL – interleukin; MCP1 - Monocyte Chemoattractant 
Protein-1, MMP - Matrix metalloproteinase, PAC – proangiogenic cell; PDGF – platelet derived growth 




Concordantly, a dysregulation of the SDF-1α/CXCR4 signalling in EPCs from patients with 
stable chronic CAD has been described (Walter et al., 2005). The intrinsic migratory 
capacity of EPCs towards SDF-1α even seems to determine the functional improvement 
of patients receiving stem cell therapy in clinical trials (Britten et al., 2003). The 
upregulation of SDF-1α transcription factor HIF-1α (Schober, Karshovska, Zernecke, & 
Weber, 2006) at injured arteries and in hypoxic tissue promotes the recruitment of 
mobilised EPCs, which characteristically overexpress CXCR4 (Leone et al., 2005), to these 
sites (Ceradini et al., 2004; Karshovska et al., 2007). Therefore, it is not surprising that 
local SDF-1α concentration after AMI is strikingly correlated to the neovascularization 
response (J. Yamaguchi et al., 2003). Interestingly, VEGF-mediated SDF-1α release by 
perivascular myofibroblasts can act as a potent chemoattractant to both EPCs (Kalka, 
Masuda, Takahashi, Gordon, et al., 2000) and PACs (Grunewald et al., 2006), suggesting 
that the same cytokines may cooperate during homing of different BM cell types. 
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Importantly, retention of PACs near damaged vessels enhances chemoattraction of EPCs 
via secretion of more recruiting factors. Moreover, it seems that EPCs and PACs also 
share common adhesion molecules which enable them to adhere to the damaged 
tissues (Z. J. Liu et al., 2010). SDF-1α specifically upregulates the expression of E-selectin, 
an adhesion molecule, on the luminal surface of murine and human mature ECs (Z. J. Liu 
et al., 2010), otherwise minimally expressed constitutively, thus enhancing rolling of 
EPCs and PACs over EC monolayers (Peled et al., 1999; Vajkoczy et al., 2003). 
  
Rolling consists of the brief low-affinity contact of circulating EPCs with the activated EC 
monolayer, platelets and exposed ECM, through a landing mechanism, determining a 
drastic velocity reduction from the hydrodynamic velocity just before their subsequent 
integrin-mediated arrest. Adhesion is initiated by this first tethering event through 
tissue-specific selectins and their carbohydrate ligands. Expression of E-selectin is 
restricted to ECs previously activated by inflammatory cytokines, while  P-selectin can 
be expressed both on ECs and platelets (Chavakis, Urbich, & Dimmeler, 2008). 
Therefore, EPCs, which bear selectins´ ligands P-selectin-glycoprotein ligand-1 (PSGL-1), 
CD162 and CD44 at the surface can roll slowly along the vessel wall (Z. J. Liu et al., 2010; 
Peled et al., 1999; Vajkoczy et al., 2003) before firm adhesion, which is confirmed using 
intravital microscopy (H. Jin et al., 2006). EphB4 mediated EPC activation leads to 
overexpression of PGSL-1 (Zampetaki et al., 2008), which subsequently enhances 
adhesion to P-selectin and E-selectin. Remarkably, E-selectin-deficient mice have an 
impaired homing and recovery after ischemia (Nishiwaki et al., 2007; Oh et al., 2007), 
while HUVECs transfected with E-selectin small interference RNA (siRNA) significantly 
capture fewer EPCs under flow than HUVECs treated with control siRNA (Sharma, 2010), 
further supporting the role of E-selectin for EPC rolling. Additionally, activation of P-
selectin also seems to improve EPC-mediated neovascularization (Foubert et al., 2007). 
On the other hand, the siRNA-mediated inhibition of PSGL-1 impairs the adhesive 
properties of EPCs (Foubert et al., 2007). Still, some studies suggest that the adhesion 
force between EPCs and ECs by PSGL-1/selectins only may not be sufficient unless 
contributions of other bonds are considered (Peled et al., 1999). Concordantly, in 
addition to E-selectin, adhesion molecules such as VCAM-1, ICAM-1 and integrin α4 are 
also upregulated in vascular ECs upon SDF-1α stimulation (Z. J. Liu et al., 2010). 
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The process of rolling is reversible. Many EPCs that roll will not stop, but dissociate from 
the vessel surface and re-enter the bloodstream. Molecular adhesive bonding must form 
rapidly for cells to tether, and the bonding must break rapidly for cells to roll (“docking 
stage”). For the EPC to stop, the low affinity rolling interactions must be replaced by 
high-affinity bonds. Mechanistically, shear flow and rolling triggers specific EPC 
intracellular signalling that induce the upregulation of integrins and their activation into 
high-affinity states for ECM ligands, promoting the subsequent integrin-dependent 
arrest of the activated EPCs at the site of vascular remodelling (“locking stage”) (Green, 
Pearson, Camphausen, Staunton, & Simon, 2004; Urbich & Dimmeler, 2004). Integrins 
are glycosylated heterodimeric proteins which consist of non-covalent linked α- and β-
subunits. Both subunits are considered type I transmembrane proteins, containing large 
extracellular domains and short cytoplasmic domains (Humphries, Byron, & Humphries, 
2006). Mammalian genomes comprise 18 α subunit and 8 β subunit genes, and so far 24 
different αβ combinations have been recognized at the protein level (Humphries et al., 
2006).  Being a transmembrane protein, integrins on the cytoplasmic face of the plasma 
membrane coordinate the assembly of the cell cytoskeleton and signalling complexes 
which may determine cell fate. On the extracellular face, integrins engage both ECM 
macromolecules or counter-receptors on contiguous cell surfaces. A specific integrin can 
bind multiple counter-receptors (Humphries et al., 2006) (Figure 10). Likewise, most 
ECM and cell surface adhesion proteins can bind to different integrin receptors (Plow, 
Haas, Zhang, Loftus, & Smith, 2000). EPCs can express distinct integrin subunits (α1–α6, 
α9, αv, β1–β3, β5, β7) (Balaji et al., 2013).  Integrins families are named after their β 
component, irrespective of their α dimer. Despite their extensive variety, integrin-ligand 
combinations are typically clustered into four main classes, reflecting the structural basis 
of the molecular interaction: RGD- and LDV-binding integrins, or αA-domain-containing 
β1 integrins and non-αA-domain -containing laminin-binding integrins (Humphries et al., 
2006).  
β1-Integrins are recognised as one of the other major integrin families implicated in EPC 
adhesion to activated ECs or directly to the exposed ECM components in denuded 
vessels, namely, VCAM-I and FN (Balaji et al., 2013). In particular, the α5β1 integrin, 
which is highly expressed in EPCs (Balaji et al., 2013), combines with exposed FN to form 
a ligand-receptor complex that not only mediates cell adhesion via focal adhesion 
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complexes formation (Shyy & Chien, 2002) but can also promote cell proliferation, 
survival and even differentiation (Pagan, Khosla, Li, & Sannes, 2002). Other integrins 
such as the α4β1-integrins also play an important part in EPC adhesion to ECM, via 
interaction with vascular cell adhesion molecule I (VCAM-I) (H. Jin et al., 2006). The 
laminin-binding α6β1 integrin also promotes EPC engraftment to the sites of vascular 
repair (Bouvard et al., 2010). β2-Integrins also have an essential role in the retention of 
EPCs by binding to multiple members of the intercellular adhesion molecule family, 
fibrinogen, and polysaccharides (Chavakis et al., 2005). 
 
Figure 10 | Integrin ligands. 
This scheme illustrates the major integrins and their ligands’ molecular interactions. Adapted from 
(Humphries et al., 2006). BSP - bone sialoprotein; Del-1 - developmental endothelial locus-1; EGF - 
epidermal growth factor; ICAM - intercellular cell adhesion molecule; iC3b - inactivated complement 
component C3b; LAP-TGF – latency associated peptide transforming growth factor; MAdCAM-1 - mucosal 
addressin cell adhesion molecule 1; MFG-E8 - milk fat globule EGF factor 8; PECAM-1 - platelet endothelial 
cell adhesion molecule 1 (CD31); PSI - plexin/semaphorin/integrin homology; VCAM-1 - vascular cell 
adhesion molecule 1; vWF - von Willebrand factor. 
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Noticeably, necrotic ECs express high mobility group box 1 (HMGB1) which further 
reinforces the interaction of β1 and β2 integrins with their ligands, enhancing EPC 
adhesion and homing to ischemic areas in vivo (Chavakis et al., 2007). Additionally, 
adhesion of EPCs to denuded vessels and faster reendothelialization of injured carotid 
arteries in vivo can also be mediated by αvβ3- and αvβ5-integrins, which bind to FN and 
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vitronectin (Walter et al., 2002), while inhibition of these integrins with specific cyclic 
RGD peptides impairs this effect. However, is there an integrin participation sequence?  
 
Blocking studies suggest that α5β1 is the primary integrin involved in the initial cell 
arrest (Angelos et al., 2010). α5β1 recognises the RGD sequence (Arg-Gly-Asp-Xaa) 
found in a variety of ECM components, particularly in FN and osteopontin. In fact, this 
interaction can be quite strong, with single molecule studies revealing that α5β1 can 
form catch bonds with FN with a maximum bond lifetime at 40 pN per bond (F. Kong, 
Garcia, Mould, Humphries, & Zhu, 2009). Nevertheless, while high matrix forces are 
primarily supported by clustered α5β1 integrins bond with FN, less stable links to αVβ3 
seem equally important to complement mechanotransduction, resulting in 
reinforcement of integrin-cytoskeleton linkages through talin-dependent bonds (Roca-
Cusachs, Gauthier, Del Rio, & Sheetz, 2009). 
 
Then, once EPCs become adherent at specific homing sites, they need to migrate 
through the endothelial monolayer and invade through the interstitial ECM to arrive at 
tissue repair sites, where they will exert their purpose. The process of trans-endothelial 
migration is partly mediated by β2-integrins, MCP-1, CD99 and VEGF (Balaji et al., 2013; 
Imbert et al., 2006).  Moreover, EPC invasion via proteolytic matrix degradation depends 
on the activity of extracellular proteases, mainly MMP-9 and cathepsin L, and also the 
serine protease urokinase-type plasminogen activator and tissue-type plasminogen 
activator, that break down and remodel the matrix components to allow for EPC 
migration (Basire et al., 2006; Chavakis et al., 2008; Urbich, Heeschen, et al., 2005). In 
particular, the role of cathepsin L, a highly-expressed protease in EPCs, is essential for 
matrix degradation and invasion. Cathepsin L knockout mice exhibited impaired 
recovery after hindlimb ischaemia and cathepsin L knockout EPCs neither homed to sites 
of ischemia nor participated in neovascularization (Urbich, Heeschen, et al., 2005). 
MMP-2 is also intrinsically linked to EPCs’ invasive properties, since EPCs from MMP2-/- 
mice exhibit reduced ECM degradation and as a result, these animals respond poorly to 
hind limb ischaemia because of reduced neoangiogenesis, a phenotype that can be 
rescued upon transplantation of MMP2+/+ wt BM cells (X. W. Cheng et al., 2007). 
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When engrafted at the site of tissue repair, the process of differentiation/maturation 
into EC phenotype and functional integration into vessels comprises VEGF-induced 
differentiation and subsequent proliferation (Caiado, Real, Carvalho, & Dias, 2008; 
Dimmeler et al., 2001). The first step for differentiation depends on integrin-mediated 
adhesion to ECM components (Caiado & Dias, 2012), in particular, it seems triggered by 
the interaction between integrin α5β1 and FN (Balaji et al., 2013; Wijelath et al., 2004). 
Accordingly, the FN-binding integrin subunits αv, α4 and α5 integrins are all expressed 
throughout EPC differentiation, further reinforcing that the interaction of EPCs with FN 
is essential for the differentiation process (Qin et al., 2006). Once activated, the 
maturation and acquisition of an endothelial phenotype is the subsequent step and 
depends mainly on the regulation of the transcription factor HoxA, which is regulated 
by histone deacetylases (Urbich & Dimmeler, 2004). Not surprisingly HoxA9 has been 
linked to the regulation of eNOS, KDR and vascular endothelial cadherin expression 
(Rossig et al., 2005). Moreover, the final step, EPC survival and proliferation, is regulated 
by angiopoietin- tyrosine kinase with immunoglobulin-like, EGF-like domains receptor 
pathways and VEGF (Hildbrand et al., 2004). 
 
VEGF, in particular, has a an essential role in the entire “EPC cycle” (mobilization, 
homing, differentiation and proliferation) enhancing its functional angiogenesis 
phenotype (L. Li et al., 2017) , thus, leading to enhanced vascular repair in vitro and in 
vivo (Aicher, Heeschen, et al., 2003; J. Chen et al., 2016; Hutter et al., 2004), via multiple 
signalling pathways including mitogen-activated protein kinase/extracellular signal-
related kinase (MAPK/ERK)(Kawasaki et al., 2008; J. Xu et al., 2008). EPCs transfected 
with adenovirus encoding for VEGF are more capable of homing to denuded areas and 
differentiating into ECs (Iwaguro et al., 2002). In mammals, the VEGF family consists of 
five members, VEGF-A, VEGF-B, VEGF-C, VEGF-D and placenta growth factor 
(PLGF)(Holmes et al., 2007). The biological importance of VEGF-A is highlighted by the 
fact that VEGF-A−/− mice exhibit severe defects in vascular development and ultimately 
die at E9.5–10.5 (Carmeliet et al., 1996). VEGF-A binds to both VEGFR-1 and VEGFR-2. In 
humans, six VEGF-A splice variants have been detected following alternative splicing of 
a single precursor mRNA(Robinson & Stringer, 2001). VEGF-A165 is the most abundantly 
expressed and biologically active form (Robinson & Stringer, 2001).  
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EPC-mediated endothelial regeneration 
 
Disruption of normal coagulation, fibrinolysis, vascular tone and permeability (Iaconetti 
et al., 2012), are common features related to the removal of the homeostatic regulation 
of the endothelium. Moreover, the depletion of the endothelial source of NO generation 
paves the way for the inducible form of NOS (iNOS), abundantly expressed by infiltrating 
immune cells, to enhance ROS generation, with subsequent activation of oxidant-
sensitive transcriptional pathways that increase VSMC proliferation and migration 
(Cooke, 2003) leading to neointima formation. Re-endothelialisation after vascular 
injury is the compensatory response that counteracts this proliferative cascade. 
Regeneration potential due to the migration and proliferation of the injury adjacent 
mature ECs is now known to be low (Urbich & Dimmeler, 2004). On the contrary, the 
contribution of circulating EPCs to support the re-endothelialisation of injured arteries 
is well established. Besides preventing the contact of VSMC with pro-synthetic 
circulating products, EPCs prevent neointima formation by directly blocking VSMC 
proliferation and migration in a paracrine manner (S. Q. Liu et al., 2011), although many 
of the involved substances are yet to be identified. 
Following acute vascular insults such as angioplastly (Gill et al., 2001) or stenting (Garg 
et al., 2008) a rapid increase in circulating EPCs is observed. Importantly, EPC levels 
remain unchanged in diagnostic angiography alone (Egan et al., 2009; N. L. Mills et al., 
2009), implying that the endothelial injury and ensuing inflammation (Garg et al., 2008) 
characterised by a robust rise in high sensitivity c-reactive protein (hs-CRP) levels, are 
warranted for the mobilisation of EPCs from the BM (Werner et al., 2002). Indeed, an 8-
fold increase in blood G-CSF concentrations, along with milder elevations in SCF, SDF-1α 
and VEGF, have been reported following vascular injury (C. H. Wang et al., 2008). The 
more severe the endothelial injury, the higher the change magnitude of EPCs in 
circulation (M. Gao et al., 2015). Consistently, the therapeutic transplantation of EPCs 
forces an inhibitory feedback reducing hs-CRP, tumor necrosis factor (TNF)-α and SDF-
1α levels early after arterial injury (S. Q. Liu et al., 2011). 
 
EPC recruitment is preceded by a peak 2.6-fold increase in circulating PACs only 6 hours 
post-injury (Bonello, Basire, Sabatier, Paganelli, & Dignat-George, 2006), suggesting an 
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important role for these cells in the immediate response to vascular injury, as opposed 
to the same fold increase in circulating EPCs occurring simply at 24h (Bonello et al., 2006; 
Marboeuf et al., 2008). Interestingly, the magnitude of CD34+CD45+ PACs mobilisation 
independently predicts subsequent in-stent restenosis (Inoue et al., 2007). It is possible 
that an exaggerated response by the hematopoietic precursors (CD45+) over endothelial 
precursors (CD45-) may favour a maladaptive response to vascular injury, therefore 
leading to restenosis.  
 
The proposed timing of events for the EPC-mediated re-endothelialisation is displayed 
in Figure 11 and Figure 12. PACs are mobilised early after vascular injury, and then avidly 
secrete angiogenic factors encouraging resident EC proliferation and migration. Over a 
period of days to months, BM and vessel -derived EPCs home, proliferate and contribute 
to effective reendothelialization and the restoration of vascular homoeostasis.  
 
Figure 11 | Hypothetical role of various cellular players in endothelial denudation injury. 
Following endothelial cell denudation injury, loss, or turnover, EPCs migrate and proliferate to repair the 
middle section of the injured area. There is a minimal adjacent ECs’ regenerative contribution at the ends. 
This follows a series of events where platelets and proangiogenic hematopoietic cells are first drawn to 
the site of injury to facilitate repair by further recruiting EPCs. Adapted from (Richardson & Yoder, 2011). 
CD- cluster differentiation; EC – endothelial cell; EPC – endothelial precursor cell; KDR – kinase domain 
receptor; PAC – proangiogenic cell. 
 
 
Another interesting model used to study neointima formation is vascular allograft 
transplantation. ECs of vascular allografts are damaged at an early stage by the immune-
mediated reaction and regenerated after that. The paradigm that this type of re-
 Introduction - 61 
 
endothelialisation is dependent on the remaining ECs of donor's vessels has been 
challenged by recent findings that establish circulating EPCs as sources of neointimal 
lesions of allografts (Hu, Davison, Zhang, & Xu, 2003). Hu and colleagues, using chimeric 
mice (wild-type/TIE2-LacZ BM and TIE2-LacZ/wild-type BM), provided solid evidence 
that regenerated ECs at arterial allografts originate from β-gal expressing recipient 
circulating EPCs, and not from remaining ECs of donor vessels nor from adjacent 
recipient ECs from carotid arteries where allografts were anastomosed. Another 
pertaining observation from Hu et al. is that circulating EPCs were also involved in 
neovascularization of the neointima, thereby modulating its formation. Usually, 
nourishment of the intima is accomplished by oxygen diffusion from the lumen of the 
vessel, whereas the media and the adventitia are nurtured by vasa vasorum, the 
vasculature microvessels. When vessel wall thickness exceeds the effective diffusion 
distance of oxygen (e.g. ruptured plaque or post-angioplasty neointima), vasa vasorum 
then proliferate in the inner layers of the vessel wall (Fuster, Moreno, Fayad, Corti, & 
Badimon, 2005), where they are usually absent. There is evidence that de novo vasa 
vasorum within allografted vessels are derived from the recipient BM-derived β-gal-
expressing EPCs (Hu et al., 2003). The fact that EPCs may modulate the neointima 
formation is interesting from the therapeutical standpoint, although the purpose of 
angiogenesis in neointimal lesions remains poorly understood. Vasa vasorum coverage 
and neointima growth (Mulligan-Kehoe & Simons, 2014) seem to be associated, possibly 
fuelled by facilitated blood and oxygen delivery and trafficking of resident inflammatory 
cells to the vessel wall, yet, emerging studies provide a different interpretation angle. 
EPC-derived vasa vasorum, rather than being restenosis contributors, may well be a 
biomarker of endogenous vascular repair (Leor & Marber, 2006) and serve as functional 
pathways for reverse lipid transport (Moreno, Sanz, & Fuster, 2009) and as stem cell 
reservoirs (Blum A, 2014), therefore contributing to plaque stabilisation and neointima 
inhibition (Moreno et al., 2009).  
One more possible mechanism by which EPCs can reduce neointima formation is worthy 
of discussion. BM-derived MSCs are also mobilised after vascular injury and participate 
in the remodelling process (C. H. Wang et al., 2008). According to Wang and colleagues, 
on adhesion to the wire injured vessel wall, seeded MSCs proliferate in patches and can 
differentiate into both smooth muscle cell (SMC) and mesoderm-derived ECs. The same 
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study revealed that by co-culturing with late-outgrowth EPCs, helped MSCs differentiate 
towards an EC phenotype, through a paracrine effect. Remarkably, co-transplantation 
of MSCs plus late-outgrowth EPCs in vivo modulated the differentiation of the former 
mostly into an endothelial-like lineage, leading to early re-endothelialisation and 
attenuation of intimal hyperplasia. 
 
Irrespective of the EPC-mediated mechanisms supporting re-endothelialisation, the 
current scientific belief is that the earlier re-endothelialisation is achieved, the less 
neointima will form (Hristov, Zernecke, Liehn, & Weber, 2007; Larsen et al., 2012) 
(Figure 12). On the contrary, an inadequate PAC/EPC ratio after injury may result in 
persistent inflammation and delayed re-endothelialisation, thus potentiating VSMC 
hypertrophy and ECM deposition, leading to restenosis. Concordantly, the numbers of 
CD14+CD45+ cells are higher in patients with subsequent restenosis, which is in line with 
the hypothesis that excessive circulating angiogenic cells contribute to the neointima 
formation (Pelliccia et al., 2010). 
 
Figure 12 | Hypothetical role of circulating EPCs after iatrogenic injury. 
The endothelial monolayer acts as a non-adhesive surface for platelets and leukocytes and regulates 
fibrinolysis and vascular tone. (A) Under resting conditions, circulating concentrations of the 
proangiogenic cells (EC-CFUs) and circulating EPCs are low, particularly in patients with atherosclerotic 
disease. (B) Angioplasty and stent placement causes damage to the endothelium exposing collagen and 
tissue factor, activating platelets and the coagulation cascade, which may result in acute or sub-acute 
thrombosis. In the absence of an intact endothelium, local platelet/platelet and platelet/leukocyte 
complexes form, and intense local inflammatory infiltrate ensues with detectable systemic inflammation. 
A biphasic response to vascular injury caused by percutaneous coronary intervention is hypothesised. (C) 
The early response consists of mobilisation of the precursors of PACs/EC-CFUs involving angiogenic 
monocytes and lymphocytes. PACs home to the site of injury and avidly secrete angiogenic factors, 
encouraging resident endothelial cell proliferation and migration and the mobilisation and homing of 
bone marrow-derived and local EPCs to the site of vascular injury. (D) Over a period of days to months, 
EPCs proliferate, contributing to effective re-endothelialisation and the restoration vascular 
homoeostasis. (E, F) An inadequate PAC/EPC response after percutaneous coronary intervention, due to 
low progenitor engraftment and activity, may lead to delayed re-endothelialisation and persistent 
inflammation, thus potentiating smooth muscle hypertrophy and extracellular matrix deposition, leading 
to restenosis and symptoms of myocardial ischemia. Adapted from (Padfield et al., 2010). CFU - colony-
forming unit; EC – endothelial cell; EPC – endothelial progenitor cell; G-CSF - granulocyte-colony 
stimulating factor; GM-CSF - granulocyte-macrophage- colony stimulating factor; HGF - hepatocyte-like 
growth factor; IL - interleukin; MMP - matrix metalloproteinase; VEGF - vascular endothelial growth factor; 
VEGFR2 - vascular endothelial growth factor receptor-2.  
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The “faster EPC-mediated re-endothelialisation the more suppressed neointima” 
hypothesis has been addressed in several pre-clinical models of arterial injury, 
providing strong supporting evidence (Table 2). 
 
Table 2 | Pre-clinical studies addressing EPC-mediated re-endothelialisation after vascular injury. 
BM – bone marrow; CD – cluster of differentiation; CXCR2 - C-X-C chemokine receptor type 2; CXCR4 - C-
X-C chemokine receptor type 4; eNOS – endothelial nitric oxide synthase; EPC – endothelial precursor cell; 
G-CSF - Granulocyte colony-stimulating factor; GFP - Green fluorescent protein; HO1 - Heme oxygenase 
1; HPB – peripheral blood from healthy volunteers; LDL – low density lipoprotein; KDR – kinase domain 
receptor; MCP1 - Monocyte Chemoattractant Protein-1 ; MNC – mononuclear cell; PB – peripheral blood; 
PPB – peripheral blood from patients;  Sca1 - Stem cells antigen-1; UCB – umbilical cord blood; UEA - Ulex 
Europaeus Agglutinin I; VECAD - vascular endothelial cadherin; vWF - Von Willebrand factor 
Author Year Model Subjects Cell type used Effect 







arterial injury and 
pre-treatment 







EPC mobilisation after 




was accelerated by 
BM-derived cells and 
neointimal hyperplasia 
was reduced 
(Werner et al., 
2002) 
Murine GFP BM 
transfection 
followed by wire 




5 placebo,  
4 rosuvastatin 








was accelerated by 
BM-derived cells and 
neointimal hyperplasia 
was reduced 
(Werner et al., 
2003) 
Intravenous cell 




6 vascular injury Spleen-derived Di-Ac-
LDL-lectin+ 
MNCs with (EPC) or 
without (MNC) a 
period of culture in 
endothelial growth 
medium 




animals and was 
associated 
with a reduction of 
neointima formation, 
but 
MNCs were more 
effective than EPCs 
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Compared with saline 
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CD34+ cells and both 








activation with MCP-1 








grafts in rabbits 




PB Dil-Ac-LDL+ CD34+ 
MNCs differentiated in 
culture 
Transplantation of 
EPCs led to rapid re-
endothelialisation of 
the denuded vessels 
and graft segments, 
resulting in significant 
reduction in neointima 
deposition 
(D. Kong, Melo, 







5 G-CSF,  
5 controls 





derived cells and 
neointimal hyperplasia 
was reduced 
(D. Kong, Melo, 







angioplasty of the 
common carotid 
artery in rabbits 
6 eNOS-EPCs, 
 6 HO1-EPCs, 
6 GFP-EPCs,  
6 saline 
PB Dil-Ac-LDL+ CD34+ 
vWF+eNOS+ VECAD+ 






in denuded carotid 
arteries by promoting 
re-endothelialisation; 
genetic engineering 
further enhanced this 
effect with eNOS 
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22 G-CSF,  
20 controls 
CD34+KDR+ G-CSF reduced 
neointimal hyperplasia 
in 
association with the 
mobilisation of BM-








(Takamiya et al., 
2006) 
1. G-CSF before 
balloon-mediated 







10 G-CSF,  
5 placebo 
CD117+KDR+ 1. G-CSF enhanced 
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(Hristov, Zernecke, 
Bidzhekov, et al., 
2007) 
Wire induced 
arterial injury in 
Apo E-/- athymic 
nude mice 
followed 24h after 




treated with mAbs 
to CXCR2, CXCR4, 
or IgG2a isotype 
control 
 




mAb or isotype 
and injected in 
vivo intracardially 





analysed after 7 
days  






















Blocking CXCR2 in vivo 
and ex vivo inhibited 
the incorporation of 
human EPCs 
expressing CXCR2 at 
sites of arterial injury 
in athymic nude mice 
and reduced re-
endothelialisation 
(X. Zhao, Huang, 




labelled EPCs or 
saline were 
injected through 








MNCs differentiated in 
culture 
Administration of EPCs 
enhanced 
reendothelialization 
and inhibition of 
neointima formation 
at 3 weeks compared 
with that of saline 














MNCs differentiated in 
culture 




to severe stenosis 
in controls; Histology 
revealed significantly 
thinner wall, greater 
internal diameter and 
smaller plaque 
(S. H. Wang et al., 
2009) 
Transplantation 










cells differentiated in 
culture 
EPCs transplantation 




at 4 weeks 
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EPCs participated in 
re-endothelialisation 
directly and reduced 
the increase in intima 
area at days 14 and 28 
 




or GFP infected 
EPCs after carotid 
balloon 









both eNOS-EPCs and 
GFP-EPCs inhibited 
neointimal hyperplasia 
compared with saline 
injection. The 
antiproliferative effect 




(Y. Yin et al., 2015) Balloon 
angioplasty carotid 
artery injury in 




4 UCB-EPCs,  
4 PPB-EPCs,  




MNCs differentiated in 
culture 
2 weeks after 
transplantation, more 
labelled UCB-EPCs and 
HPB-EPCs than PPB-
EPCs were found by 









to the saline control 




injury in rat 
femoral artery 
followed by six 
sequential cell 
injections (1 × 106 
per time at 0, 1, 3, 
5, 7 and 9 days 
after the injury). 
8 sham,  
8 vehicle,  
8 PACs,  
8 EPC,  
8 mature ECs 
BM Di-Ac-LDL+lectin+ 
CD34+CD31+KDR+ 
MNCs differentiated in 
culture 
After 4 weeks, 
transplanted EPCs, but 
not PACs or ECs, 
significantly 
attenuated neointimal 
lesion formation in 
injured arteries 
(N. M. Liu et al., 
2016) 
Intravenous cell 









MNCs differentiated in 
culture 
Infusion of netrin-1 
preconditioned wild 
type EPCs substantially 
attenuated neointimal 
formation 
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PDGFR-β into a 
mouse model of 
carotid 
artery injury after 
splenectomy 
12 pEGFP-N2-
PDGFR- β EPCs, 












Given the observed translational potential of EPCs, therapeutic re-endothelialisation 
strategies to mitigate restenosis after PCI are being pursued in clinical studies. These 
include 1) EPC pharmacological mobilisation, 2) EPC intravenous transplantation and/or 
3) stent-based EPC therapies. 
 
 
EPC pharmacological mobilisation 
 
Statins administred for 4 weeks to CAD patients can increase peripheral EPC numbers 
up to three times (Vasa, Fichtlscherer, Adler, et al., 2001), which occurs in a dose-
dependent manner (Leone et al., 2008), via augmentation of Akt phosphorylation within 
minutes, which yields an increase inmobilization, migration, proliferation, and survival 
of EPCs (Llevadot et al., 2001). In culture, statins induce differentiation of CD34+ cells 
toward ECs (Dimmeler et al., 2001) and enhance their adhesive capacity (Walter et al., 
2002). Together these observations may help to explain the reduced rate of post-PCI 
restenosis in patients treated with statins (Walter et al., 2000), although there are no 
published human statin trials which specifically output EPC-mediated re-
endothelialisation in the context of vascular injury.  Similarly, angiotensin converting 
enzyme inhibitors, like ramipril and enalapril, were shown to increase EPC levels both in 
the experimental model and in patients (C. H. Wang et al., 2006), probably by preventing 
the membrane-bound extracellular CD26/dipeptidylpeptidase from cleaving the EPC 
mobilizer/chemoattractant SDF-1a/ CXCL12. The same effect was reported for valsartan, 
an angiotensin II inhibitor (Bahlmann et al., 2005). The EPC mobilising effect of 
endogenous G-CSF release after AMI is also well established (Leone et al., 2006). 
Unfortunately, despite enhanced endothelialisation, intracoronary G-CSF 
administration in clinical trials has been associated with an increased incidence of in-
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stent restenosis, despite improvement in left ventricular ejection fraction (S. Kang, Yang, 
Li, & Gao, 2008). It is possible that this effect may be mediated by non-specific pro-
inflammatory actions of G-CSF leading to SMC mobilisation from the BM instead 
(Padfield et al., 2010), thus, hampering its translation into clinics. Erythropoietin 
administered following vascular injury, in spite of also enhancing re-endothelialisation 
(possibly through eNOS-dependent mobilisation from BM (Urao et al., 2006)), is 
associated with an increased incidence of neointimal proliferation in animal models, 
again, perhaps because of the non-specific mobilisation of SMC (Reddy, Vasir, Hegde, 
Joshi, & Labhasetwar, 2007). Clinical trials which have considered EPO use in PCI-treated 
AMI patients have confirmed that this strategy is not beneficial for prevention of 
neointimal hyperplasia (Stein et al., 2012; Taniguchi et al., 2010).  
 
EPC intravenous transplantation 
 
According to the results in mouse (Werner et al., 2003) and rabbit (Griese et al., 2003; 
Z. L. Ma et al., 2009) models of endovascular injury, the intraluminal administration of 
EPCs should, theoretically, accelerate vascular healing by quickly populating denuded 
parts of the vessel wall. Nevertheless, data regarding the transfusion of progenitor cells 
into humans are derived from trials using heterogeneous subsets of autologous BM-
derived progenitor populations, and not EPCs differentiated in culture (since the safety 
of phenotypically modified cells in humans is not established yet). BM contains a 
complex assortment of progenitor cells, including HSCs, SP cells, MSCs and 
multipotential adult progenitor cells (MAPCs), a subset of MSCs (Dimmeler, Burchfield, 
& Zeiher, 2008). The potential risk that infusion of BM-derived progenitors may increase 
post-PCI inflammatory signalling and promote differentiation into VSMCs, thus 
aggravating the severity of restenosis, has been raised (Inoue et al., 2007). However, 
only one trial by Bartunek et al. in 2005 reported an increased incidence of restenosis 
after infusion of BM CD133+ progenitor cells (despite improved left ventricular 
performance, increased myocardial perfusion and viability)(Bartunek et al., 2005).   
On the contrary, a meta-analysis of 18 randomised controlled trials on the therapeutic 
effects of adult progenitor cells for acute myocardial infarction (AMI) did not reveal an 
augmented risk for restenosis (M. Jiang et al., 2010). One of the RCTs included was the 
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research by Assmus et al. that refutes an adverse effect of BM-derived progenitor 
therapy on restenosis development in the setting of AMI. If anything, revascularization 
rates were significantly reduced in the BM-derived progenitor group at 2 years’ follow-
up (Assmus et al., 2010). In contrast, a substudy of REPAIR-AMI assessing the effect of 
intracoronary BM-derived MNCs transplantation on coronary flow dynamics by 
intracoronary Doppler flow velocity measurements, indicated a significantly greater 
recovery of coronary blood flow reserve in the MNC-treated arm compared with control 
placebo infusion (Erbs et al., 2007). However, a definitive answer to the question 
whether infusion of BM-derived progenitor cells may alter the process of restenosis 
development (either adversely by incorporation of inflammatory progenitor cells into 
the vascular wall, or beneficially via enhanced re-endothelialisation) is still awaited, 
because the referenced trials used heterogeneous samples of “EPCs” (and none of them 
studied restenosis as a primary endpoint)(Fisher, Zhang, Doree, Mathur, & Martin-
Rendon, 2015). 
 
EPC stent-based therapy  
 
Recently, the concept of in vivo/in situ endothelialisation of stents has been pursued 
with the rationale that accelerated establishment of the endothelial layer covering the 
stent struts would reduce the risk of neointimal hyperplasia and, simultaneously 
thrombosis (which is an adverse effect of drug-eluting stents)(Chong et al., 2016; Simard 
et al., 2017). Capture stents, using a proprietary coating that contains anti-CD34 
antibodies were developed to test this hypothesis. EPCs are proposed to bind to the 
endoluminal face of the bioengineered struts, proliferate and migrate to fill the intra 
strut spaces establishing a confluent, functional monolayer of ECs on the stented arterial 
segment. In HEALING-I, the first human trial using the Genous® stent, CAD patients 
successfully underwent implantation of the capture stent in a single primary target 
lesion in a native coronary artery, which was considered safe and feasible. After 6 
months, coronary angiography and intravascular ultrasound were performed revealing 
negligible late luminal loss and safety (Szmitko et al., 2006). Since then, Genous® stents 
have progressed to phase III clinical trials and have been deployed in over 5,000 patients 
(J. Aoki et al., 2005; Silber et al., 2011). The clinical trials revealed a binary restenosis 
 Introduction - 72 
 
rate for the EPC stent that was 13 percent compared to 26.6 percent for bare metal 
stents at 6 months (Wojakowski et al., 2013). Among the 4,939 patients included in the 
e-HEALING registry, the 12-month cumulative event rate for target lesion 
revascularization was 5.7%, which is similar to that of drug-eluting stents (Lasala et al., 
2008), with minimal incidence of late stent thrombosis (0.2%)(Silber et al., 2011).  
It is important to understand that the long-term results of the capture stents are not yet 
available, and until then, no definitive conclusions about long-term safety or 
effectiveness can be made. A recent study in pigs found that the EPC capture stent 
improved re-endothelialisation at an early stage but ultimately conferred no effect on 
neointimal thickness compared with control stents over long-term observation (van 
Beusekom, Ertas, Sorop, Serruys, & van der Giessen, 2012). On a cautionary note, CD34 
alone is not distinctive of EPCs, and it is shared by several progenitors, including smooth 
muscle progenitor cells (Padfield et al., 2010). Therefore, restenosis with anti-CD34 
coated stents may occur because of the non-specific capture of non-EPC cells, posing 
the theoretical risk of neointima development. This indiscriminate binding effect could 
be particularly striking in individuals susceptible to in-stent restenosis, such as patients 
with CVD RF, where SMP are relatively more abundant in circulation than EPCs (Duckers 
et al., 2007), which could be worsened by low engraftment capability of senescent EPCs.  
 
EPC consumption, senescence and prognosis 
 
Overall regenerative EPC activity has significant prognosis impact and is dependent on 




A competent BM can translate vascular injury into productive EPC recruitment, restoring 
normal endothelial function. However, a high CVD RF profile can perpetuate injury by 
impairing EPC production and mobilisation beyond EPC consumption. The BM then 
becomes incompetent and the repairing EPCs numbers insufficient. Remarkably, the 
HEALING II registry reported that patients with normal CD34+KDR+ EPC titters had lower 
rates of in-stent restenosis than patients with reduced circulating EPCs (Duckers et al., 
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2007). Moreover, circulating EPC numbers remain significantly lower in patients who 
developed restenosis after 6 months (Lei et al., 2007; Wojakowski et al., 2013).  
 
There are several important physiological and pathological stimuli for EPC mobilisation. 
Physical activity and oestrogen levels are included among the physiological factors 
reported to enhance EPC mobilisation from the BM by acting through eNOS-, -MMP9 
(Matrix metalloproteinase-9) and VEGF-mediated mechanisms (Laufs et al., 2004; 
Strehlow et al., 2003). Growth hormone (GH) and insulin growth factor-1 (IGF-1) are 
among hormones that increase NO bioavailability, therefore raising EPC mobilization 
(Thum, Fleissner, et al., 2007). Any reduction in the previous mobilizers could mean 
decreased EPC levels. Else more, ageing has an adverse impact on EPC levels (Scheubel 
et al., 2003) via a reduction in IGF-1 and VEGF circulating levels. Smoking is included 
among the suppressive factors via increased oxidative stress and reduced NO 
bioavailability, resulting in depletion of EPCs for vascular repair in a dose-dependent 
manner (Michaud, Dussault, Haddad, Groleau, & Rivard, 2006) and with a rapid 
amelioration after smoking cessation (Kondo et al., 2004). Diabetes mellitus and 
glycaemia control also negatively influence EPC levels (Fadini et al., 2005). In particular, 
the presence of vascular complications seems strictly correlated with reduced 
peripheral number of EPCs (Fadini et al., 2005), thus suggesting that EPC depletion can 
be involved in its pathogenesis. In fact, in diabetic patients with carotid disease, the 
lowest levels of EPCs are observed in patients with over 70% stenosis (Fadini et al., 
2006). Diabetics with simultaneous CAD show even lower numbers of circulating EPCs 
(Kunz et al., 2006). The abnormality in EPC mobilization in diabetes is presumably due 
to the impairment of eNOS-NO cascade in BM (Z. J. Liu & Velazquez, 2008). Chronic renal 
failure is similarly associated with lower EPC levels, which occurs with reduced 
Erythropoietin production, an established EPC mobilisation trigger in humans 
(Bahlmann et al., 2004). In the setting of severe CAD, higher levels of substances like 
asymmetric dimethylarginine (ADMA), a potent endogenous inhibitor of eNOS, have 
been described and are associated with lower levels of EPCs (Thum et al., 2005). 
Similarly, TNF-α a common CVD inflammation mediator, with its well-known 
myelosuppressive effect, could be responsible for the reduction of EPC-poiesis and 
mobilisation levels observed in the late phases of heart failure (Valgimigli et al., 2004). 
 




In 2015, Ying and colleagues reported that the transplantation of EPCs from UCB and PB 
from CVD patients or healthy volunteers, all increased re-endothelialisation and reduced 
neointima formation in a rat carotid injury model (Y. Yin et al., 2015). However, 
compared with the patient group, more homing EPCs were observed in the 
cryopreserved UCB and PB from healthy controls, and these presented a significantly 
faster re-endothelialisation and reduced neointima. In vitro studies then showed that 
patient-derived PB EPCs displayed decreased migration, proliferation, adhesion, and 
survival activities as compared to PB-EPCs from healthy volunteers and cryopreserved 
UCB-EPCs. The same observations were derived in groups of human patients with in-
stent restenosis, given that their EPCs also exhibit lower migration and proliferation 
capacity in vitro (Lei et al., 2007). 
 
Thus, it seems that impaired quality of EPCs is also intrinsically associated with CVD 
and/or CVD RFs (Chong et al., 2016; Urbich & Dimmeler, 2004; Vasa, Fichtlscherer, 
Aicher, et al., 2001), including diabetes, smoking, hypertension, hyperlipidemia, 
atherosclerosis, smoking, and obesity, which account for the deterioration of 
endothelial regeneration. In the elderly, the migration and proliferation capacity of BM-
EPCs are decreased (Dimmeler & Zeiher, 2004), and flow-mediated brachial artery 
reactivity correlates negatively with this impairment (Heiss et al., 2005). Circulating EPCs 
from healthy smokers also exhibit impaired functional activities (Michaud et al., 2006). 
Enhanced angiotensin II levels present in hypertensive disease induce oxidative stress, 
which in turn accelerates EPC senescence by reducing telomerase activity (Imanishi, 
Moriwaki, Hano, & Nishio, 2005). Hypercholesterolaemia per se determines a reduction 
in EPCs’ migratory, proliferative, adhesive and angiogenesis potential secondary to an 
increase in senescence, as demonstrated after EPC incubation with LDL-oxidized, 
whereas HDL-cholesterol has the opposite effect (J. Z. Chen et al., 2004; X. Wang, Chen, 
Tao, Zhu, & Shang, 2004). Similarly, a severe delay of re-endothelialisation after vascular 
injury is seen in diabetic patients, mostly, due to impaired EPC adhesion, proliferation, 
integrin profile, engraftment and differention (Balaji et al., 2013; Callaghan, Ceradini, & 
Gurtner, 2005). High glucose exposure has been shown to promote EPC senescence and 
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endothelial dysfunction by modifying NO-mediated mechanisms (Y. H. Chen et al., 
2007). Further reinforcing the EPC senescence contribution to delayed re-
endothelialisation, Ii and colleagues injected diabetic and nondiabetic EPCs 
intravenously after arterial injury in diabetic and nondiabetic mice (Ii et al., 2006). 
Notably, diabetic EPCs homing to the denuded vessel were significantly reduced, 
regardless of the diabetic status of the recipient mice. The underlying EPC functional 
diabetic impairment might be due, at least in part, to increased NADPH oxidase-
dependent processes (Sorrentino et al., 2007) and uncoupling of the eNOS (Thum, 
Fraccarollo, et al., 2007), both resulting in excessive superoxide anion formation instead 
of NO, reducing the bioavailability of the latter. CRP, a well-known inflammatory 
mediator present in CVD, has a direct inhibitory effect on EPC activity, influencing 
adhesion through a transcriptional reduction of chemoattractant factors such as 
monocyte chemoattractant protein-1 and -2, macrophage inflammatory protein-1a, 
colony-stimulating factor, and IFN-gamma inducible protein-10 and inducing early EPC 
apoptosis (Fujii, Li, Szmitko, Fedak, & Verma, 2006; Verma et al., 2004). Also, the 
proliferative capacity of EPCs and their ability to support in vitro tube formation were 
reported to be significantly impaired in patients with Cardiac Syndrome X (P. H. Huang 




To date, one's risk for vascular events has focused exclusively on assessing propensity 
for vascular damage, either by evaluating conventional RFs, or more recently by 
evaluating markers of inflammation and other circulating markers related to subclinical 
target organ injury. Nevertheless, vascular health is better represented as a balance 
between ongoing injury and resultant vascular repair. EPC enumeration and functional 
characterization represent the only available assessment of the reparative side of that 
balance. Therefore, the role of EPCs as biomarkers has recently been considered 
(Aragona et al., 2016; Leone et al., 2009). The evidence is there that EPC levels decrease 
in parallel with the presence of RFs. The extent of the EPC pool negatively correlates 
with cumulative indices of cardiovascular event risk, such as the Framingham risk score 
(Fadini, Agostini, Sartore, & Avogaro, 2007; Werner & Nickenig, 2006). The ratio 
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between EPCs and CECs has been proposed as a comprehensive vascular health 
measure, because EPCs inform on the endothelial repair capacity, whereas CECs are 
indicators of ongoing endothelial shedding (Cappellari et al., 2016). At the bedside, EPC 
counts following coronary stenting may potentially serve as a predictor for the risk 
stratification of therapeutic coronary interventions (M. Gao et al., 2015). Mobilization 
of EPCs by acute ischemia was also found to be significantly lower in the patients who 
developed restenosis after 6 months (Wojakowski et al., 2013).  These findings correlate 
nicely with the current view of the EPC pool as an indicator of vascular regenerative 
capacity, based on the observation that serum EPC levels are markedly decreased in 
patients with overt atherosclerotic disease (Aragona et al., 2016; Fadini et al., 2007). 
However, more importantly, EPC may not be simply a marker of vascular fitness. An 
inverse relationship between circulating EPCs and CAD severity, independent of 
traditional RFs, has recently been described (Kunz et al., 2006). For every 10-colony 
forming unit increase in EPCs, the likelihood of multivessel CAD declines by 20% (Kunz 
et al., 2006), revealing a prognostic contribution. To further characterise the 
independent prognostic value of circulating EPCs, Werner and colleagues led the EPCAD 
study. In patients with angiographically documented CAD, the cardiovascular event rate 
at 1 year increased in parallel with the reduction in baseline EPC levels, after adjustment 
for known confounders, such as age, gender, vascular RFs, drug therapy, PCI, etc 
(Werner et al., 2005). Schmidt-Lucke et al. later confirmed that reduced numbers of 
EPCs independently predicted progression of atherosclerotic disease in a mixed 
population of coronary patients and healthy controls (Schmidt-Lucke et al., 2005). These 
data revealed that EPCs are not innocent bystanders but active players in maintaining a 
healthy vascular tree (Leone et al., 2009). In fact, EPC levels are kept in a steady state 
during the inaugural asymptomatic years of CVD RFs (Fadini et al., 2007), suggesting that 
EPCs can efficiently counteract the detrimental effect of RFs on vascular function until 
their pool gets exhausted (Hill et al., 2003), at which point EPC numbers become 
inversely related to the number of CVD RFs present (Vasa, Fichtlscherer, Aicher, et al., 
2001). Following angioplasty, in particular, the individual susceptibility to neointima 
formation could be determined not only by the extent of the endothelial injury, 
exposure to simultaneous RFs but also by the capability to mobilise promptly functional, 
viable EPCs and repair the endothelial damage.  
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1.3 miR-92a inhibitor for EPC priming 
 
EPCs have been used for non-thrombogenic re-endothelialisation of vascular grafts, 
heart valve replacements, and intravascular stent devices (Balaji et al., 2013). A crucial 
aspect concerning EPC therapies is the magnitude of engraftment of transplanted or 
mobilised EPCs into the remodelling vessels as assessed by single-photon emission 
computed tomography, positron emission tomography or magnetic resonance.  
Although studies evaluating the biodistribution of the cells by non-invasive imaging 
cannot give insights into the morphological integration and the cell fate after prolonged 
time (Chavakis et al., 2008), research thus far has documented only limited engraftment 
of EPCs (anywhere between 1 and 50%)(Balaji et al., 2013; Haider et al., 2017). The 
amount of radioactivity detected in the rat ischemic heart was only about 2% after 24 
to 96h following infusion of ex vivo cultured EPCs, indicating that only a minor 
percentage of cells home/are retained at the ischemic site (Aicher, Brenner, et al., 2003). 
Similar results were reported after infusion of uncultured labelled PB MNCs (Hou et al., 
2005) or purified CD34+ cells (Brenner et al., 2004), while most of the radioactivity was 
rather found in the spleen and the liver (Aicher, Heeschen, et al., 2003; Hou et al., 2005). 
The extent of engraftment indicated in clinical trials, in which labelled BM CD34+ or 
CD133+ cells were infused directly into the coronary artery of patients with AMI or 
chronic myocardial infarction, was no different (Caveliers et al., 2007; Goussetis et al., 
2006; Kurpisz et al., 2007). Following infusion, only 2.6 to 11% of the radioactivity was 
sensed in the heart, after that declining to 1 to 7%. Of course, the variation reported so 
far may be due to differences in the target tissues studied, heterogeneity of EPC subsets 
used, genetic differences in the chosen clinical models, and lack of standardised tracking 
techniques (Balaji et al., 2013). However, worryingly there is no question that the 
paucity of EPC levels among PCI patients, combined with the fact that traditional CVD 
RFs impair normal survival, differentiation, proliferation, migration (Fadini et al., 2007) 
and engraftment (Chavakis et al., 2008) of the few EPCs remaining, negatively impacts 
upon PCI outcomes. Paradoxically, it is those patients who undergo vascular 
interventions that have both reduced EPC numbers and function, despite having the 
greatest need for these cells to repair the injured vessels. Thus, the functional 
impairment identified in EPCs from high-risk CVD patients poses itself an additional 
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hurdle for mobilisation strategies or for using autologous cell sources for 
transplantation. At present, there is no pharmacological treatment available to increase 
arterial endothelialisation established as such. Recently, one of the key breakthroughs 
for the study of gene expression regulation has been the discovery of micro ribonucleic 
acids (miRNAs), which may directly regulate 30% (C. Zhang, 2010) to 90% (R. A. Ambros, 
2000) of the genes in a cell. The expression of miRNAs can regulate various aspects of 
stem/progenitor cell functions (Heinrich & Dimmeler, 2012). A priming/regeneration 
therapy utilising miRNAs, designed to increase EPC adhesion, survival and proliferation 
at the site of injury in elderly patients with chronic disease, could considerably facilitate 
vascular repair. 
 
miRNAs as potent transcriptional regulators 
 
microRNAs are a type of regulatory non coding RNAs (ncRNAs) which have been recently 
shown to govern fundamental processes during vascular disease (Iaconetti, Gareri, 
Polimeni, & Indolfi, 2013). Unlike structural ncRNAs, which include ribosomal and 
transfer RNAs, regulatory ncRNAs can further be classified according to their transcript 
size (Iaconetti et al., 2013; X. Liu, Hao, Li, Zhu, & Hu, 2015) (Table 3). 
 
Table 3 | Classification of non-coding regulatory RNAs. 
Noncoding regulatory RNAs Abbreviation Functions 
Small (<50 nucleotide) 
microRNAs 
PIWI-interacting RNA 







DNA methylation, transposon repression 
RNA interference 
Medium (50-200 nucleotide) 
small nucleolar RNAs 
promoter upstream transcripts 






RNA modification, rRNA processing 
Associated with chromatin changes 
Epigenetic regulation 
Long (>200 nucleotide) 
long intergenic ncRNA 
enhancer-like ncRNA 
transcribed ultraconserved regions 
natural antisense transcripts 










Epigenetic regulators of transcription 
Transcriptional gene activation 
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The first miRNA was identified in C. Elegans in 1993 (R. C. Lee, Feinbaum, & Ambros, 
1993). Back then lin-4 was thought to be a worm-specific curiosity, but with the 
subsequent identification of the phylogenetically conserved let-7 (Pasquinelli et al., 
2000), scientists took greater notice and began looking for other similar small non-
coding RNAs. Since then, thousands of miRNAs have been identified, and it is evident 
now that they have a considerable impact on shaping transcriptomes and proteomes of 
eukaryotic organisms (Lim et al., 2005). In fact, miRNA have been shown to control EC 
and VSMC biology and thereby can regulate the progression of vascular diseases, such 
as restenosis (Iaconetti et al., 2013). 
 
 
Biological definition and function of miRNAs 
 
miRNAs are a class of approximately 22-nucleotide long regulatory noncoding RNAs, 
which work at a post-transcriptional level, i.e. between the transcription and the 
translation of a gene at the RNA level. They are now known to be critical regulators of 
signalling pathways in multiple cell types including ECs, EPCs and perivascular cells 
(Garcia de la Torre et al., 2015). miRNAs are assembled into RNA-induced silencing 
complexes (RISC) resulting (mostly) in gene silencing, either by transcript destabilisation, 
translational inhibition, or both (Filipowicz, Bhattacharyya, & Sonenberg, 2008) (Figure 
13). The current notion is that translational inhibition alone seems to be the exception 
rather than the rule, at least for mammalian miRNAs (Siomi & Siomi, 2010). The 
specificity of miRNAs to their target messenger ribonucleic acids (mRNAs) is canonically 
determined by base-pairing of a 6–8-nucleotide seed sequence in the 5′ end of the 
mature miRNA to a perfectly or imperfectly complementary match sequence in the 3′ 
UTR end of the target mRNA (Bartel, 2004; Hausser & Zavolan, 2014). More than 60% of 
human protein-coding genes are predicted to contain miRNA-binding sites within their 
3´UTRs (Friedman, Farh, Burge, & Bartel, 2009). The nature of the miRNA:mRNA 
interaction means that a single miR can target sequentially, on average, hundreds of 
distinct mRNA molecules with related biological functions (Lim et al., 2005; Siomi & 
Siomi, 2010; Urbich, Kuehbacher, & Dimmeler, 2008). Moreover, conversely, individual 
mRNAs can be targeted by multiple miRs which appear to act cooperatively, since 
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mRNAs frequently possess multiple miRNA-binding sites. Hence, it has become evident 
that complementary miRNAs often function by acting in concert, resulting in a highly 
complex miR regulatory potential. Additionally, several miRNAs exhibit tissue-specific 
expression patterning, suggesting a cell type-specific function (W. J. Yang et al., 2005). 
 
 
Biogenesis and maturation of miRNAs 
 
The transcription of miRNAs depends on their localisation within the genome. Primary 
miRNA transcripts (pri-miRNA) are generated individually or in clusters after the 
transcription of specific sequences by RNA polymerase II and III located either in exons 
or introns of coding genes or non-coding genes (Issler & Chen, 2015; Urbich et al., 2008). 
miRNAs that have their promoters are independently expressed, while miRNAs 
organised in clusters share similar transcriptional modulation (Urbich et al., 2008). Pri-
miRNAs form unique secondary hairpin structures (one or more), each composed of a 
stem and a terminal loop (Figure 13). Pri-miRNAs are 5’-capped, spliced, and 
polyadenylated, and they can produce more than one functional miRNA (Siomi & Siomi, 
2010). 
 
The pri-miRNA nuclear processing into stem–loop precursors is mediated by a complex 
containing Drosha and the microprocessor complex subunit DiGeorge syndrome critical 
region 8 (DGCR8). The Microprocessor complex includes several other cofactors such as 
the DEAD-box RNA helicases p68 (DDX5) and p72 (DDX17), as well as heterogeneous 
nuclear ribonucleoproteins (hnRNPs)(Gregory et al., 2004), which may function to 
promote the specificity and activity of Drosha cleavage (Siomi & Siomi, 2010). Following 
cleavage, the RNA molecule is reduced to 70–110 nucleotides in length, and it is referred 
to as precursor miRNA (pre-miRNA). Nuclear processing generates a product with a 2 
nucleotide 30 overhang (Siomi & Siomi, 2010), characteristic of RNase III-mediated 
cleavage. The pre-miRNA is then exported to the cytoplasm through exportin 5 (XPO5) 
which recognises the overhang, in a complex with RAS-related nuclear protein (RAN)–
GTP (Issler & Chen, 2015). 
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Figure 13 | miRNA biogenesis, maturation pathway and mode of action. 
The miRNA biogenesis pathway is a series of biochemical steps that converts the primary miRNA transcript 
(pri-miRNA) to the biologically active, mature miRNA. MiRNAs are transcribed from intergenic or intronic 
genomic sequences as mono- or polycistronic, long, primary precursor transcripts (pri-miRNAs). These are 
cleaved into precursor hairpins (pre-miRNAs) by the nuclear RNase III-like enzyme Drosha. Drosha cleaves 
the 5′ and 3′ arms of the pri-miRNA hairpin, whereas DGCR8 stabilises the complex and determines the 
precise cleavage site. Pre-miRNAs hairpins are then exported to the cytoplasm by Exportin-5 in a Ran-
GTP–dependent manner and are further cleaved by a complex containing the endonuclease Dicer to 
mature miRs of 18 to 25 nucleotide length. Following Dicer-mediated cleavage, Dicer and its interaction-
domain protein TAR RNA binding protein (TRBP) dissociate from the miRNA duplex to form the active 
RNA-induced silencing complex (RISC) that becomes functional upon assembly of one of the two strands. 
The RNA-induced silencing complex directs the miRNA to the target mRNA, which leads either to 
translational repression or degradation of the target mRNA. The re-import of miRNAs into the nucleus or 
its export through exosomes are alternative options. Adapted from (Issler & Chen, 2015), (Kuehbacher, 
Urbich, & Dimmeler, 2008), (Urbich et al., 2008) and (Bauersachs & Thum, 2011). AGO2 – argonaute 2; 
ATP – adenosine triphosphate; DGCR8 -DiGeorge syndrome critical region 8; GTP – guanosine 
triphosphate; mRNA – messenger RNA; miRNA – microRNA; miRISC – miRNA-loaded into RNA-induced 
silencing complex; XPO5 – exportin 5. 
 
 
The pre-miRNA is then cleaved by Dicer to generate a mature ~22-nucleotide miRNA 
duplex. While most miRNAs are produced by this canonical pathway, in certain 
circumstances, splicing can replace Drosha-mediated processing of pri-miRNAs into pre-
miRNAs. The less abundant miRNAs which circumnavigate Drosha processing are called 
mirtrons, and consist of pre-miRNA- like hairpins that are made by splicing and 
debranching of short hairpin introns. If the intron-derived miRNAs resulting from splicing 
from their host transcripts and the debranching lariat enzyme has the appropriate size 
to form a hairpin resembling a pre-miRNA, it then bypasses Drosha cleavage (Winter, 
Jung, Keller, Gregory, & Diederichs, 2009).  
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The double-stranded duplex must be separated into the primary strand (which is 
complementary to the target mRNA) and the passenger strand (which is subsequently 
degraded). Selection of the miRNA strand which will be incorporated into the RISC is 
regulated in a cell type-specific manner, but one important parameter for strand 
selection is the thermodynamic asymmetry of the miRNA duplex (Khvorova, Reynolds, 
& Jayasena, 2003). Typically, the miRNA strand whose 5’ end is less stably base-paired 
will be more frequently sorted as the functional guide (Siomi & Siomi, 2010). 
Nevertheless, recent deep-sequencing studies revealed that pre-miRNAs could be 
bifunctional with individual passenger strands sometimes not being degraded, but 
rather associate with Argonaute2 (AGO2) dependent on specific mismatches (Siomi & 
Siomi, 2010). The strand of the mature miRNA is then loaded into the RISC complex 
together with two major class of proteins (AGO2 and GW182)(Issler & Chen, 2015), 
guiding the complex to target the 3′ untranslated region (3′ UTR) of the mRNAs to 
promote their degradation or simply inhibit their translation. Although the entire 
sequence of miRNA can bind to the target, it is usually nucleotides at position 2-7 that 
compose the seed sequence that determines target specificity (Lai, 2002). Whereas 
mRNA degradation needs a high miRNA-target complementarity, the translational 
repression only requires low miRNA-target complementarity (Lewis, Shih, Jones-
Rhoades, Bartel, & Burge, 2003). The GW182 proteins have been shown to interact with 
the cytoplasmic poly(A)-binding protein (PABP) and together might function as a scaffold 
for the assembly of the multiprotein deadenylation complex that silences miRNA 
targets, including the PAN2-PAN3 and CCR4-NOT (Bauersachs & Thum, 2011). 
Additionally, human AGO2 can endonucleolytically cleave target mRNA (via Rnase H 
recruitment) which is perfectly complementary to the miRNA (Dias & Stein, 2002; D. 
Gibbings & Voinnet, 2010). Of note, miRNAs in the cell are present as miRISC complexes, 
in which both the 5’ and 3’ ends are thought to be bound directly by AGO2, thus being 
protected from instantaneous exonuclease-mediated degradation (Y. Wang, Sheng, 
Juranek, Tuschl, & Patel, 2008). Re-importation of miRNAs into the nucleus is an 
alternative pathway and is especially relevant because there is accumulating evidence 
that miRNAs can regulate gene expression at the transcriptional level (Kim, Saetrom, 
Snove, & Rossi, 2008). 
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Location of the miRNA machinery 
 
There appears to be a link between miRNA -mediated silencing and membrane 
trafficking since formation and turnover of the RISC complex occur at the endosomal 
membrane (Siomi & Siomi, 2009) (Figure 14). Endosome maturation requires gradual 
accumulation of inwardly budding vesicles termed multivesicular bodies (MVB), using 
the Endosomal Sorting Complex Required for Transport (ESCRT). Depleting ESCRT will 
block MVB formation, which results in impaired miRNA silencing (Piper & Katzmann, 
2007). GW182 and AGO2, mutually associated with miRNA gene silencing, are enriched 
in the endosomal MVB fraction in particular foci called GW-bodies (D. J. Gibbings, 
Ciaudo, Erhardt, & Voinnet, 2009), which are GW182-rich and DCP1-poor. In fact,  MVBs 
seem to be the site where miRNA biogenesis and RISC-assembly pathways intersect, 
with continuous removal of GW182 being required for the efficient passage of miRNA 
strand duplex from DICER to AGO2 (Siomi & Siomi, 2009). AGO2 is an essential 
component of the RISC complex that can directly degrade mRNA by slicing (Meister, 
2013). A second AGO2 pool distinct from GW-bodies has been identified. These GW182-
poor cytoplasmic foci are called cytoplasmic processing bodies (P‑bodies). Inside the P-
body, miRNA targets are sequestered from the translational machinery and are 
subjected to mRNA degradation, at least partially, through deadenylation. There, 
enzymes involved in mRNA decapping (DCP1 and DCP2) are usually concentrated and 
promote translational inhibition and mRNA decay (Meister, 2013). RISC complex and 
P‑bodies seem to interact physically (Siomi & Siomi, 2009) with targeted mRNAs being 
pushed away from the translational machinery into the latter. The miRNA-mediated 
silencing occurs by fusion with lysosomes and consequential release of the miR-RISC to 
another repression cycle. Concordantly, blocking the maturation of MVBs into 
lysosomes by the loss of the tethering factor HPS4 enhances miRNA-mediated silencing 
and leads to overaccumulation of GW‑bodies (Y. S. Lee et al., 2009). KRAS-MEK-ERK 
(Extracellular signal–regulated kinase) signalling was shown to occur on late endosomes 
(McKenzie et al., 2016), and in fact,  MEK-ERK signalling downstream of mutant KRAS 
suppresses AGO2 (via phosphorylation) and its association with MVBs, thereby 
inhibiting release of AGO2 and several miRNAs in exosomes, favouring their transfer into 
P-bodies (McKenzie et al., 2016). Alternatively, if AGO2 is not phosphorylated, miRNAs 
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can be packaged inside 50- to 90-nm membrane-derived particles called exosomes, 
which are generated from MVBs and are secreted from the cells after fusion with the 
plasma membrane, into plasma or other cells (Y. S. Lee et al., 2009; Valadi et al., 2007). 
Not to be confused with microvesicles which are directly shed from the cell membrane. 
Of note, there seems to be a protection via association with other molecules (e.g., the 
miRNA– AGO2 complex (Melo et al., 2014)) or modifications of the miRNAs that make 




Figure 14 | miRNA-RISC assembly & turn-over and corresponding cellular compartments 
MVBs are late endosomal compartments, between early endosomes and lysosomes. MVBs can also 
release internal vesicles, called exosomes, into the extracellular space. RISC formation and turnover 
appear to occur in MVBs, specifically at GW bodies. Briefly, PABP binds the CBC, as well as the 3’ polyA-
tail of a 5’ m7G capped mRNA, thereby circularising the mRNA allowing it to be translated by ribosomes. 
Recognition of an mRNA by a miRNA bound to AGO2 which favours the release of CBC from mRNA. Upon 
CBC release, new translation initiation cannot occur, and ribosomes are eventually released from the 
repressed mRNA. Repressed mRNA is no longer circularised by PABP linking the 5’ cap and polyA tail. PABP 
is presumably released at this stage from repressed mRNA since PABP is not enriched in P-bodies. P-bodies 
are enriched in mRNA decapping and deadenylation complexes (DCP1A/DCP2 and CAF1/CCR4-NOT, 
respectively). Cap and polyA tail are removed from repressed mRNA. AGO is released from miRNA and 
repressed mRNA. Then, HSP90 stabilises empty AGO, which is presumably retained on the membrane. 
AGO binds Dicer and acquires the duplex miRNA. On the other hand, phosphorylation of AGO2 specifically 
inhibits AGO2 association with MVBs (reduced slicing activity), diminishes secretion into exosomes, and 
increases association with P-bodies (therefore promoting translational repression). Adapted from (D. 
Gibbings & Voinnet, 2010) and (McKenzie et al., 2016). AGO2 – argonaute 2; CBC - Cap-Binding Complex; 
CAF1 - chromatin assembly factor-1; DCP1 - mRNA-decapping enzyme 1; DCP2- mRNA-decapping enzyme 
2; ESCRT - endosomal sorting complexes required for transport; HPS4 - Hermansky-Pudlak syndrome 4 
protein; HSP90 – heat shock protein 90; MEK – mitogen-activated protein kinase; mRNA – messenger 
RNA; miRNA – microRNA; MVB - multivesicular bodies; PABP - Poly(A)-binding protein; RISC – RNA-
induced silencing complex. 
 




Importantly, most miRNAs exhibit strict developmental stage-specific and tissue-specific 
expression patterns, and moreover, their levels can become altered during disease 
(Siomi & Siomi, 2010). In contrast to the linear miRNA processing pathway that was 
initially thought to be universal for the biogenesis of all mature miRNAs, multiple studies 
led to the understanding that there are several regulatory options to express and 
process individual miRNAs differentially. Many steps can be performed in multiple ways, 
omitted or replaced, and are affected by different mechanisms for individual miRNAs. 
miRNA expression is mainly controlled at the transcriptional level, through feedback 
regulation. For instance, some miRNAs regulate transcription factors that, in turn, 
regulate expression of the miRNA, forming a negative feedback loop (Siomi & Siomi, 
2010). Moreover, host genes harbouring miRNA sequences in their intronic sites impose 
their pattern of expression to the respective miRNAs (Kuchen et al., 2010). Remarkably, 
several miRNAs exhibit a promoter structure similar to that of protein-coding genes (i.e., 
TATA box, initiator elements, frequencies of CpG islands, transcriptions factor bindings 
sites), making them amenable to transcriptional regulation (Figure 15) (Ozsolak et al., 
2008). Particularly, regulatory sequences present in their promoters can lead to tissue 
and development-specific miRNA expression (Obernosterer, Leuschner, Alenius, & 
Martinez, 2006). miRNA editing can be another biogenesis regulation step.  Editing 
corresponds to the post-transcriptional change of RNA sequences by deamination of 
adenosine (A) to inosine (I), altering the base pairing and structural properties of the 
transcript. Editing of miRNA transcripts by ADAR1 and ADAR2 inhibits its cleavage by the 
endonuclease Drosha and leads to the degradation by the ribonuclease Tudor-SN, which 
preferentially cleaves double-stranded RNA containing inosine–uracil pairs (W. Yang et 
al., 2006). Editing can also impact further downstream processing steps such as cleavage 
by Dicer in the cytoplasm (Winter et al., 2009). Additionally, miRNAs’ maturation can be 
suppressed as a consequence of the Drosha or Dicer -processing steps (Obernosterer et 
al., 2006; Thomson et al., 2006).  
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Figure 15 | Transcriptional regulation of miRNAs. 
Most miRNAs are processed by RNA polymerase II from independent genes or introns of protein-coding 
genes. Usually, miRNAs have their promoter region, regulated by numerous transcription factors. In a 
main canonical pathway, primary miRNA precursors (pri-miRNA) are first processed by Drosha and then 
exported to the cytoplasm. Few pre-miRNAs are produced independently (thus bypassing Drosha-
mediated processing) from very short introns of genes (mirtrons) by splicing actions. Drosha associates 
with DGCR8 and many other cofactors to form the Drosha-DGCR8 complex. Many factors associate with 
the Drosha/DGCR8 complex, thereby regulating its stability and activity. The p68 forms heterodimers with 
p72, p53, and Smad factors, whereas further editing of pri-miRNAs occurs by ADARs that affect miRNA 
accumulation and miRNA target specificity. After export to the cytoplasm, pre-miRNAs associate with the 
endonuclease Dicer and several other regulatory proteins, such as TRBP and Argonaute 2. AGO2 and PABP 
can interact with the deadenylases CAF1/CCR4 or with DCP1/2, facilitating mRNA deadenylation and 
uncapping respectively, thus contributing towards mRNA degradation. Additionally, human AGO2 can 
endonucleolytically cleave target mRNA which is perfectly complementary to the miRNA. Adapted from 
(Siomi & Siomi, 2010). ADAR - adenosine deaminases acting on RNA; CAF1 - chromatin assembly factor-1; 
DCP1 - mRNA-decapping enzyme 1; DCP2- mRNA-decapping enzyme 2; hnRNP - heterogeneous nuclear 
ribonucleoprotein; PABP - Poly(A)-binding protein; NF - nuclear factor; KSRP -  KH-type splicing regulatory 
protein; SMAD - mothers against decapentaplegic homolog; SNIP1-   Smad nuclear interacting protein 1; 
TF – transcription factors; TRBP - transactivation-response RNA-binding protein. 
 
 
Other layers of biogenesis modulation have been described such as epigenetic (e.g. 
methylation inactivation) or during export of pre-miRNA from the nucleus to the 
cytoplasm (which may be differentially regulated). Interestingly, many miRNAs are 
encoded in the genome as clusters and are transcribed as polycistronic primary 
transcripts. However, there is evidence that miRNAs located in those clusters can be 
independently regulated (Guil & Caceres, 2007), suggesting that individual miRNAs can 
be regulated post-transcriptionally by factors that confer them specificity. Other post-
transcriptional regulatory mechanisms during miRNA maturation include strand 
selection mechanisms and stabilisation of the transcripts through terminal adenylation 
(Katoh et al., 2009). Also, it seems that miRNA degradation by exonuclease XRN-2 can 
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be blocked by the binding of miRNA-target RNA, suggesting that targets can modulate 
the stability of specific mature miRNAs and help to prevent detrimental overexpression 
of miRNAs when target abundance is low. In summary, it is conceivable that that miRNA 




Several thousands of miRNAs across different species have been identified. Thus, an 
intuitive annotation system had to be adopted (V. Ambros et al., 2003). Newly identified 
miRNA genes are numbered sequentially and prefixed by 'mir' followed by a dash (e.g., 
mir-92). The uncapitalized 'mir' refers to the pre-miRNAs while the capitalised 'miR' 
refers to the mature forms. miRNAs with similar mature sequences are annotated in 
lower case letters to show their similar structure (e.g., miR-92a and miR-92b). Distinct 
precursor sequences that express equal mature sequences are indicated with an 
additional number (e.g., miR-92a-1 and miR-92a-2). Annotation for the species they are 
identified in should come first (e.g., hsa-miR-92a in Homo sapiens). miRNAs originating 
from the 3′ end or 5′ end are denoted with a '-3p' or '-5p' suffix, respectively (e.g., miR-
92a-1-3p and miR-92a-1-5p).  
 
Upregulation of miR-92a following vascular injury 
 
Over the last few years, several miRNAs have been recognised as emerging gene 
regulators in the pathogenesis of vascular remodelling (L. J. Chen, Lim, Yeh, Lien, & Chiu, 
2012). EPCs, ECs, VSMCs and inflammatory cells, all have specific roles in restenosis and 
vascular remodelling after angioplasty and stenting. MiRNAs are ubiquitous and have 
been shown to modulate the stress response of ECs to injury, to drive VSMC phenotype 
switch, and to control macrophage function involved in arterial remodelling (L. J. Chen 
et al., 2012). Evidence of changes in miRNA expression profiles after angioplasty in 
animal models is growing, and a few expression signatures have now been correlated 
with restenosis (Small & Olson, 2011). Compared with uninjured arteries, microarray 
analysis demonstrated that 7 days after balloon angioplasty 113 out of 140 miRNAs were 
differentially expressed: 60 were up-regulated, and 53 were down regulated (Ji et al., 
 Introduction - 88 
 
2007). At 14 days after injury, 63 were upregulated, and 47 were downregulated out of 
140 artery miRNAs, whereas 102 of the 140 artery miRNAs were aberrantly expressed 
(55 overexpressed and 47 downregulated) at 28 days after angioplasty. A large number 
of miRNAs that were found to be upregulated both in VSMCs and in ECs after or during 
vascular injury further highlights their importance in the pathophysiology of arterial 
restenosis after injury (Gareri, De Rosa, & Indolfi, 2016). Using this microarray approach, 
Ji and colleagues noticed that miR-21 was upregulated 5-fold in neointimal lesions, 
which was confirmed by qPCR. This miRNA is particularly interesting because it 
highlights an orchestrated action targeting different molecules in the EPC, EC, VSMC or 
macrophage, leading to various stress-specific responses, but exerting their function in 
a combined mode, across interacting cell types. MiR-21 simultaneously induces EPC 
senescence through High motility group AT-hook 2 (HMGA2) (Zhu et al., 2013), reduces 
EC-mediated angiogenesis and migration by targeting RhoB (Sabatel et al., 2011), 
promotes proliferation and inhibits apoptosis of VSMC via suppression of the 
phosphatase (PTEN) and up-regulation of Bcl-2 (Ji et al., 2007), and enhances VCAM-1– 
and CCL2-dependent monocyte adhesion via suppression of PPAR-gamma (Zhou et al., 
2011).  
 
Given the miR-21 example, the scientific community became convinced that the 
identification of miRNAs that might have specific functions in vascular remodelling by 
advanced high-throughput analyses at the transcriptome levels in injured vessels could 
unveil a new class of potential therapeutic targets for restenosis. Revisiting the 
microarray data, I searched for another miRNA aberrantly expressed after vascular 
injury which could theoretically have a differential effect on ECs and SMCs (Table 4). 
Such miRNA aimed to selectively accelerate the formation of novel endothelium on 
injured segments (and simultaneously inhibit smooth muscle) could putatively be an 
attractive strategy to prevent post-injury restenosis. 
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Table 4 | miRNAs possibly involved in the vascular response to injury. 
(+) or (−), respectively, indicate induction or inhibition of a specific phenotype/biological effect. Adapted 
from (Polimeni, De Rosa, & Indolfi, 2013), (Forte et al., 2014) and (Gareri et al., 2016). BMPR2 - bone 
morphogenetic protein receptor type II; Cdc-42 - cell division control protein 42; EC – endothelial cell; 
FGF1 – fibroblast growth factor 1; FOXO4 - Forkhead box protein O4; HMGA2 - High-mobility group AT-
hook 2; ITGA5 – integrin alpha 5 subunit; KDR – kinase insert domain receptor; KLF-2 - Krüppel-like factor 
2;  KLF-4 - Krüppel-like factor 4; KLF-5 - Krüppel-like factor 5; miR – microRNA; MKK4 - mitogen-activated 
protein kinase kinase 4; PTEN - phosphatase and tensin homolog; RhoB - Ras homolog gene family; 
member B; SDF1 – stromal derived factor 1; SMAD3 - small mother against decapentaplegic; SMC – 
smooth muscle cell; Spred1 - Sprouty-related; EVH1 domain-containing protein 1; STIM - stromal 
interaction molecule; uPA - urokinase-type plasminogen activator - VCAM-1; vascular cell adhesion 
molecule 1; WWP1 - NEDD4-like E3 ubiquitin-protein ligase. 
miRNAs In vitro effect in ECs Modulation 
after injury 
Validated targets 
miR-21 Apoptosis and proliferation (-) ↑ HMGA2, RhoB 
miR-92a 
Angiogenesis, proliferation and 
migration (-) 
↑ ITGA5, KLF-4, MKK4 
miR-126 
Vascular integrity and angiogenesis  
(-) 
↑ Spred-1, VCAM-1, KDR, 
SDF1 
miR221/222 Proliferation and migration (-) ↑ c-kit, eNOS 




Differentiation, migration and 
proliferation (+) 
↑ BMPR2 
miR-21 Apoptosis and proliferation (+) 
↑ PTEN, BMPR2, BCl2, 
WWP1 YOD1, SATB1 
miR-23b 
Differentiation, migration and 
proliferation (-) 
↓ FOXO4, uPA, SMAD3 
miR-31 Pro-synthetic (+) ↑ LATS2 
miR-133a Differentiation and proliferation (-) ↓ Sp-1 
miR-125 




Differentiation, migration and 
proliferation (+) 
↓ KLF-5, KLF-4, 
calmodulin kinase IIδ 
miR-143 Proliferation and migration (-) ↓ KLF-5, Elk-1 
miR-146 Proliferation and migration (+) ↑ KLF-4 
miR-195 Proliferation and migration (-) ↓ Cdc-42, FGF1, Cyclin D1 
miR-221/222 Proliferation and migration (+) ↑ p27, p57 
miR-424 
Differentiation, migration and 
proliferation (+) 
↑ Cyclin D1, STIM, 
Calumenin 
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miR-92a, which was overexpressed at 1.57 in a log2ratio compared to normal arteries 
after 28 days (Ji et al., 2007), seemed to be a match, given that its overexpression results 
in a significant reduction in EC proliferation and migration in vitro, while the same does 
not apply to SMCs when subject to the same treatment (Daniel et al., 2014). These 
findings suggest that the functional impact of miR-92a is predominantly restricted to 
ECs. Vice versa, inhibition of miR-92a produces differential effects on ECs and VSMC, 
reducing proliferation of the latter (Iaconetti et al., 2012). Already during my PhD, miR-
92a was confirmed by qPCR to be significantly up-regulated in ECs adjacent to the 
vascular injury site following wire-induced manipulation of the femoral artery in mice 
(Daniel et al., 2014). This is particularly interesting for EPC priming since there are 
reasons to believe that EPCs, besides sharing some functional features with ECs, also 
have a similar miRNA signature, which includes miR-92a, miR-126, miR-130a and miR-
221/222 (Q. Zhang, Kandic, & Kutryk, 2011).  
 
Circulating miR-92a as biomarker 
 
Interestingly, although miR-92a levels rise locally after vascular injury (Daniel et al., 
2014), circulating miR-92a levels in CAD patients are significantly downregulated 
(Fichtlscherer et al., 2010). The exact mechanisms leading to this reduction remain 
unclear. Possible reasons put forward include exhaustion of miRNAs storage and 
production in vascular cells after bout release and activation of the vasculature, or, 
alternatively, enhanced uptake by blood cells or cells at the atherosclerotic/injury 
lesions. When these patients are treated with statins a trend towards a further reduction 
in the levels of circulating miR-92a is observed (Fichtlscherer et al., 2010; Y. Jiang et al., 
2015), suggesting that low circulatory levels of miR-92a likely represent a global 
compensatory protective mechanism that might be boosted in response to statin 
therapy, while miR-92a overexpression following injury is part of a stress and harmful 
response. This phenomenon reinforces the potential role of circulating miRs as 
biomarkers for diagnosis of CVD. In fact, circulating miR-21, miR-143, miR-145, and miR-
100, which are found to be dysregulated in patients with intra-sent restenosis compared 
to controls, have already been studied as biomarkers for intra-stent restenosis (He et 
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al., 2014), which could easily be exploited to risk stratify patients after PCI non-invasively 
and to assess possible intervention failure (He et al., 2014).  
 
 
The importance of miR-92a in vascular biology 
 
The modulation of vascular-specific processes by some miRNAs which control cell 
growth, migration, apoptosis, capillary tube formation has been extensively studied to 
date (Bonauer, Boon, & Dimmeler, 2010).  In the next section, I focus on the specific role 
of miR-92a in vascular biology. 
 
 
miR-92a-1 is encoded in the mir-17~92 cluster 
 
The polycistronic mir-17~92 cluster maps to human chromosome 13 and encodes 6 
mature miRNAs (miR-17, miR-18a, miR-19a, miR-19b, miR-20a and miR-92a-1) 
transcribed as one common primary transcript (Concepcion, Bonetti, & Ventura, 2012; 
Venturini et al., 2007). The sequence of the mir-17~92 cluster is highly conserved among 
vertebrates, and evolutionary gene duplications followed by subsequent loss of 
individual miRNA components have resulted only in two mammalian paralogs: the miR-
106a~363 cluster and the miR-106b~25 cluster (Figure 16). These are located on 
different chromosomes and contain individual miRNAs that are highly similar to those 
encoded by the mir-17-92 cluster. The miR-106a~363 is located on chromosome X, while 
the miR-106b~25 cluster is located on human chromosome 7.  It is curious to note that 
not only the sequence of each miRNA component is highly conserved across species 
among all 3 paralogs, the entire organisation of these miRNAs within the family also 
exhibits a high level of conservation. Curiously, ablation of miR-106b~25 or miR-
106a~363 causes no obvious phenotype (Ventura et al., 2008). The functional 
significance of this conservation remains still unclear (Olive, Jiang, & He, 2010). Another 
important concept is that of “seed family”. miRNAs with similar seed sequences are 
predicted in silico to target highly overlapping sets of genes and are usually grouped 
functionally in the same “seed family”. 
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Figure 16 | Schematic representation of the gene of miR17~92 cluster and its paralogs. 
miRNAs sharing the same seed sequence are represented by boxes of the same colour. The miRNAs 
encoded by the 3 clusters can be categorized into four separate miRNA families according to their seed 
sequences, including the miR-17 family (miR-17, miR-20a, miR-20b, miR-106a, miR-106b and miR-93), the 
miR-18 family (miR-18a and miR-18b), the miR-19 family (miR-19a, miR-19b-1 and miR-19b-2) and the 
miR-92 family (miR-92a-1, miR-92a-2, miR-363 and miR-25). Black bands represent future mature strand 
regions. Adapted from (Concepcion et al., 2012). chr – chromosome; miR – miRNA. 
 
 
The miR 17~92 polycistron first raised awareness after several studies revealed its 
upregulation in different hematologic (Venturini et al., 2007) and solid (Hayashita et al., 
2005; Volinia et al., 2006) malignancies and that there was an association with cancer-
related angiogenesis (Kuehbacher et al., 2008). Nevertheless, opposing studies showed 
that the DNA region encoding the cluster is deleted in patients with ovarian, breast and 
melanoma cancers (L. Zhang et al., 2006). Moreover, enforced expression of miR-17 in 
breast cancer cell lines reduces the proliferation of the cancer cells, likely via repression 
of AIB1, a transcriptional co-activator of E2F1 and the oestrogen receptors (Hossain, 
Kuo, & Saunders, 2006). Further adding to the complexity of this cluster’s signature, 
there is considerable evidence suggesting that its various members differ in their 
oncogenic potential (Concepcion et al., 2012).  Therefore, one might speculate that the 
mir-17~92 cluster tumorigenicity is context, cell and miR product-dependent, although 
it is also possible that its multiple members can act synergistically, either by converging 
on the same targets or by targeting multiple nodes from a common pathway or 
biological output.  Theoretically, depending on cell type and physiological context, there 
is an enormous plasticity potential for gene regulation here, as different target mRNAs 
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may be repressed by a combination of cluster components. Additional roles for the mir-
17~92 cluster have been identified. These include the regulation of essential immune 
and hematopoietic processes, and of the lung, heart and skeletal development (Bonauer 
& Dimmeler, 2009; Xiao et al., 2008).  In fact, the developmental defects can be severe 
enough to cause death shortly after the birth of mir-17~92 homozygotes null mice, with 
lung hypoplasia and a ventricular septal defect (Ventura et al., 2008). Remarkably, there 
is a lack of an obvious vascular phenotype in mir-17~92–deficient mice, hinting that the 
cluster may not be essential for endothelial differentiation during embryonic 
development (Jevnaker, Khuu, Kjole, Bryne, & Osmundsen, 2011). Although the mir-
17~92 cluster has been associated with fundamental aspects of EC biology, namely, the 
regulation of cell cycle and sprouting angiogenesis, curiously, neither the cluster nor its 
individual members seem to be essential for endothelial differentiation (Treguer, 
Heinrich, Ohtani, Bonauer, & Dimmeler, 2012). Individual and combined inhibition of 
the members of the miR-17–92 cluster during differentiation from ESC or iPS cells did 
not affect the expression of well-established endothelial markers.   
Recently, a hemizygous germline deletion involving the mir-17~92 locus has been 
identified as the genetic determinant of the rare autosomal dominant condition known 
as Feingold syndrome (Marcelis et al., 2008). Patients with this condition present a 
broad range of skeletal defects, including short stature, brachymesophalangy and 
microcephaly. Affected individuals may also present mental retardation and 
gastrointestinal atresia, albeit with lower penetrance (Marcelis et al., 2008).  
 
This syndrome with peculiar phenotype abnormalities highlights the importance of 
miRNA in fine-tuning gene expression in a timely, spatially and coordinated manner. 
Given the functional specificity of different mir-17~92 components, it is evident now 
that the polycistronic cluster is subjected to complex transcriptional regulation. The 
cluster regulation at transcriptional level relies on its promoter (Figure 17). ChIP assay 
has shown the binding of c-Myc, E2F, and cyclin D1 to the upstream promoter region of 
the miR-17–92 cluster (O'Donnell, Wentzel, Zeller, Dang, & Mendell, 2005). Also, an 
STAT3 binding site is present in this promoter (Brock et al., 2009).   
Inhibition of their transcriptional activity or targeting the respective downstream 
signalling pathways have been shown to prevent neointima formation. Venturini and 
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O’Donnell were the first to show that c-Myc stimulated the transcription of the miR-
17~92 cluster in human B-cells and chronic myeloid leukaemia cells (O'Donnell et al., 
2005; Venturini et al., 2007). Remarkably, the cluster can be directly activated by c-Myc 
proto-oncogene alone or in association with RAS (Dews et al., 2006; O'Donnell et al., 
2005). Not surprisingly, the cluster is also documented to be transcriptionally activated 
by c-myc homolog MYCN in neuroblastoma cells (Haug et al., 2011). In fact, the 
observations that either MYCN loss-of-function mutations or miR-17~92 
haploinsufficiency can lead to the very same defective Feingold phenotype are in 
agreement (Marcelis et al., 2008). These findings are consistent with the functions of 
mir-17~92 in promoting proliferation in a diversity of cell types, including cells of 
epithelial, lymphoid and neural origin. An interesting aspect is that, in contrast to the 
expression of the mir17~92 cluster promoter transcription factors, miR-92a alone seems 
to be mainly expressed in ECs (Iaconetti et al., 2012), so that clinical inhibition of miR-
92a might result in higher cell specificity than inhibition of the corresponding 
transcription factors. Further transcriptional activators found to directly bind to the 
promoter of miR-17~92 include E2Fs  (chromatin immunoprecipitation reveals that E2F3 
is the major E2F family member that binds to the promoter region according to 
(Sylvestre et al., 2007)), Smad3 and Cyclin D1, which are regulated by miR-17 and miR-
20a, which in turn can regulate the cluster promoter through a negative feedback loop 
(Bonauer & Dimmeler, 2009; T. Luo, Cui, Bian, & Yu, 2014; Sylvestre et al., 2007; Woods, 
Thomson, & Hammond, 2007; Yu et al., 2008). E2Fs are vital for the progression of the 
cell cycle, as they trigger a large number of S phase genes, including Cyclins E and A, 
thymidine kinase and DNA polymerase. As a consequence, theoretically, cycling cells are 
likely to have elevated mir-17~92 levels due to the periodic surge of E2F activity during 
S phase, while quiescent cells would present reduced cluster levels. This is consistent 
with the high level of mir-17~92 polycistron expression in transformed cell lines, but not 
in the primary cell culture or fully differentiated cell types (Olive et al., 2010). 
Additionally, stimulation of mir-17~92 expression by pro-inflammatory cytokines such 
as IL-6 (Brock et al., 2009) or VEGF (Suarez et al., 2008) may occur, although it was 
recently identified that VEGF-mediated up-regulation of mir-17~92 only elevates the 
expression level of three individual miRNAs of the entire cluster (miR-17, miR-
18 and miR-20) (Suarez et al., 2008) while reducing miR-92a (Iaconetti et al., 2012), to 
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contribute to the control of angiogenic phenotypes.  In summary, there seems to be a 
selective mir-17~92 biogenesis under specific biological contexts. 
 
Figure 17 | Known mechanisms accounting for transcriptional and post-transcriptional regulation of 
the miR-17~92 cluster. 
Adapted from (Bonauer & Dimmeler, 2009). IL-6 – interleukin 6; miR – microRNA; MYCN - N-Myc proto-
oncogene protein; Smad3 - mothers against decapentaplegic homolog 3; STAT3 - signal transducers and 
activators of transcription 3; VEGF – vascular endothelial growth factor. 
 
 
Although initial studies focused only on the transcriptional regulation of mir-17~92, 
more current research has begun to shed light on how members of the cluster are 
individually and uniquely regulated beyond transcription. In fact, the six miRNAs 
encoded by the mir-17~92 cluster are often expressed at different levels, suggesting that 
they are either processed at varying rates or that their stability can be modulated 
(Concepcion et al., 2012). For instance, the RNA-binding protein hnRNPA1 binds to the 
loop structure of miR-18a and facilitate its processing by Drosha,  without affecting the 
processing of the remaining mir-17~92 cluster members (Guil & Caceres, 2007).  
 
Cluster members, if differentially triggered, may be capable of regulating distinct 
pathophysiological components of vascular regeneration, our main focus. The 
redundancy in miRNA function and the occurrence of compensatory mechanisms has 
been emphasised. For instance, overexpressing the entire mir-17~92 cluster in c-Myc-
induced tumours increases angiogenesis (Dews et al., 2006), which is thought to the 
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result of the dominant downregulation of the antiangiogenic molecules 
thrombospondin-1 (TSP-1) and connective tissue growth factor (CTGF) by miR-18 and 
miR-19, respectively (Dews et al., 2006). Similarly, miR-17 has been described to repress 
the anti-angiogenic factor tissue inhibitor of metalloproteinase 1 (TIMP1) (Otsuka et al., 
2008). On the contrary, the overexpression of miR-17 and miR-20a per se blocks 
angiogenic sprouting and migration (via Jak-1 downregulation?)(Doebele et al., 2010; 
Shan et al., 2009), and overexpression of miR-92a interferes with intersegmental vessel 
development in zebrafish (Bonauer et al., 2009). Based on the reported studies it 
appears that the mir-17~92 cluster members may exhibit distinct specific vasculogenic 
effects depending on the cell type, miRNA abundance and context.  Therefore, the effect 
of miRNAs from the cluster differs for ischaemia and tumour-associated angiogenesis, 
which is fundamental if one considers these miRNAs as potential therapeutic targets. 
However, surprisingly, in ECs, the response seems to be highly consistent. All cluster 
members appear to behave as negative angiogenic regulators. Recently Doebele et al. 
revealed that overexpression of the individual members miR-17, miR-18, miR-19a, and 
miR-20a specifically in ECs, reduced angiogenic sprouting in vitro, whereas inhibitors of 
these miRNAs rescued the effect (Doebele et al., 2010). Overexpression of miR-92a in 
HUVECs also suppresses angiogenic sprout formation in vitro, and vice versa, while the 
inhibition of miR-92a in vivo promotes neovascularization and the functional recovery 
after hindlimb ischemia in mice (Bonauer et al., 2009).  
 
 
miR-92a exerts anti-angiogenic actions in ECs 
 
Several members of the miR-17~92 cluster have been shown to control angiogenesis. 
miR-92a too is considered an endogenous repressor of the angiogenic program in ECs 
and a potent regulator of angiogenesis in vivo (Zampetaki & Mayr, 2012). Moreover, 
miR-92a is reported to inhibit EC proliferation, migration, adhesion and vascular 
sprouting in vitro by downregulating the expression of validated target genes, which 
include the class III histone deacetylase sirtuin 1 (SIRT1), integrin subunit α5 (ITGA5) and 
αv (ITGAV), sphingosine-1-phosphate receptor-1 (SIP-1),  Suppressor of cytokine 
signalling 5 (SOCS5)(Loyer et al., 2014), mitogen activated protein kinase kinase-4 (MKK-
4) and the flow-induced atheroprotective transcription Krüppel-like factor 2 and 4 (KLF2 
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and KLF4)(Bonauer et al., 2009; Doebele et al., 2010; Y. Fang & Davies, 2012; Wu et al., 
2011). These genes are all known to contribute to the cell-matrix interaction, cell 
migration, apoptosis and angiogenesis in ECs (Seeger, Zeiher, & Dimmeler, 2013). 
Remarkably, miR-92a is also involved in the modulation of eNOS in ECs (Bonauer et al., 
2009). Namely, its inhibition leads to an increase in NO production, which is paramount 
in fostering endothelial regeneration besides inhibiting VSMCs proliferation, thus 
preventing neointimal hyperplasia (Indolfi et al., 2002). Consistently, the functional 
inhibition of miR-92a enhances EC proliferation and migration (Iaconetti et al., 2012). In 
vivo, miR-92a expression is increased in ischemic tissues within the first days after 
infarction (Bonauer et al., 2009; Hinkel et al., 2013) and the respective antagomir-based 
silencing increases infarct border zone neovascularization and improves heart function 
after AMI (Bonauer et al., 2009). Loyer et al. reported that miR-92a also acts as a 
proinflammatory regulator in ECs by activating inflammatory cytokines, thus promoting 
monocyte adhesion (Loyer et al., 2014). Systemic administration of miR-92a inhibitor 
rescued this effect after AMI and limb ischemia by enhancing blood vessel growth 
(Bonauer et al., 2009). Similarly, systemic administration of miR-92a inhibitor enhanced 
re-endothelialisation and reduced neointima formation after balloon injury (Iaconetti et 
al., 2012).  
 
Besides being involved in neointima formation, miR-92a is also known to promote 
atherosclerosis under disturbed flow (Iaconetti et al., 2012; Loyer et al., 2014), through 
the suppression of KLF2 and its key targets eNOS and thrombomodulin (Cowan et al., 
2010; Salameh, Galvagni, Bardelli, Bussolino, & Oliviero, 2005). The miR-92a induced 
increase in IL-6 and MCP-1 secretion, which are proinflammatory EC cytokines, besides 
promoting monocyte adhesion to ECs via increased ICAM-1 expression are also likely 
contributors (Loyer et al., 2014). Proatherogenic oxidised LDLs strongly activate miR-92a 
expression in ECs in atheroprone areas with low shear stress (oscillatory flow)(Loyer et 
al., 2014). On the contrary, high shear stress (laminar flow) protects ECs cells from miR-
92a induction by oxLDL (Loyer et al., 2014). The in vivo evidence corroborates that miR-
92a is highly expressed in ECs isolated from the atheroprone aortic arch, in contrast to 
non-susceptible regions (Y. Fang & Davies, 2012). Concordantly, a reduction in 
circulating endothelial microparticles (a marker of EC dysfunction)(Rautou et al., 2011) 
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and a reduction of ICAM-1 expression in atherosclerotic lesions is seen following miR-
92a inhibitor treatment in vivo. Also, eNOS expression is restored by miR-92a inhibition 
in vitro (Loyer et al., 2014). Moreover, by specifically blocking miR-92a in 
hypercholesteremic LDLR-/- mice, Loyer et al. managed to reduce endothelial 
inflammation, decrease atherosclerotic plaque burden and promote a more stable 
lesion phenotype (Loyer et al., 2014). 
 
 
miR-92a inhibition for EPC priming 
 
miR-92a seems to be associated with EC senescence. miR-92a expression is upregulated 
in ECs upon aging (X. Lin et al., 2016), which inhibits cell proliferation by targeting SIRT1 
(Iaconetti et al., 2012). Moreover, miR-92a expression is upregulated by ischemia 
(Bonauer et al., 2009; Hinkel et al., 2013) and in ECs and EPCs of CAD patients 
(Fichtlscherer et al., 2010; Q. Zhang et al., 2011). A TNF-α-induced inflammatory 
response also upregulates miR-92a in ECs (Iaconetti et al., 2012). On the other hand, 
miR-92a is decreased during EC differentiation (Kane et al., 2010; Treguer et al., 2012) 
and VEGF stimulation (Iaconetti et al., 2012) (which is needed for differentiation), 
whereas miR-17, miR-18 and miR-19 are upregulated upon induction of differentiation. 
The differential expression pattern is consistent with the observation that after 
induction of hindlimb ischemia only miR-92a from the cluster is significantly upregulated 
(Bonauer et al., 2009). One can, therefore, hypothesise that miR-92a is in a quiescent 
state in active, healthy cells and is only upregulated upon pathophysiological conditions 
(Table 5). 
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Table 5 | miR-92a local expression levels in specific settings. 
(↑) or (↓), respectively, indicate downregulation or upregulation of miR-92a levels. CAD – coronary 
artery disease; EC – endothelial cell; EPC – endothelial precursor cell; miR – microRNA; oxLDL – oxidated 
low density lipoprotein; TNF – tumour necrosis factor; VSMC – vascular smooth muscle cell. 
↓miR-92a (species) Studies 
EC after atorvastatin (human) (Fichtlscherer et al., 2010) 
Laminar blood flow (human) (Wu et al., 2011) 
VEGF stimulation (rat) (Iaconetti et al., 2012) 
↑miR-92a (species) Studies 
EC from CAD patients (human) (Q. Zhang et al., 2011) 
EPCs from CAD patients (human) (Q. Zhang et al., 2011) 
ECs/VSMCs in vascular injury site 
(rat, human) 
(Daniel et al., 2014), (T. Luo et al., 2014) 
 
Ischemic injury (rat, pig, rat) 
 
(Bonauer et al., 2009), (Hinkel et al., 2013), (H. Liu, Li, 
Zhao, & Hu, 2016) 
Inflammation (stimulation with 
TNFα) (rat) 
(Iaconetti et al., 2012) 
 
Oscillatory blood flow (mice) (Loyer et al., 2014) 
Hypercholesterolemia/Atherogenic 
oxLDL (mice) (Loyer et al., 2014) 
 
Up-regulation of anti-angiogenic miR-92a in high CVD risk patients is likely to contribute 
to the dysfunction of their EPCs and reduced regenerative capacity. Everything 
considered, inhibition of miR-92a expression could be exploited to increase endothelial 
regeneration via EPC priming and inhibit neointimal proliferation after vascular injury. 
To inhibit endogenous miRNAs, chemically engineered oligonucleotides assembled as 
single-stranded RNA analogues designed to bind and silence complementary miRNAs 





The use of miRNAs inhibitors offers exceptional advantages over other regulatory 
mechanisms that also control gene expression, such as transcriptional regulators, 
epigenetic modifications or viral vectors. Firstly, miRNAs do not integrate into the 
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genome. Therefore insertional mutagenesis concerns are averted. Secondly, inhibitors, 
by repressing endogenous miRNAs with the ability to concurrently target many mRNAs 
of integrated pathways, result in a more efficient upregulation of combined effectors in 
specific settings. This aspect may also be an advantage, since targeting multiple genes 
simultaneously with a single inhibitor could modulate complex networks such as 
restenosis. In fact, in silico simulations indicate that miRNA -mediated feed-forward 
loops are more effective than transcriptional repressors in buffering gene expression 
under perturbed conditions (Osella, Bosia, Cora, & Caselle, 2011). Given the functional 
network redundancy, miRNAs are known to exert mild effects at baseline but 
pronounced biological functions under stress/pathology (N. Liu & Olson, 2010), which is 
the case in post-angioplasty restenosis. Moreover, by acting post-transcriptionally at the 
cytoplasm level, miRNAs inhibitors can have an immediate effect on protein synthesis, 
thereby achieving greater potency than otherwise possible in a short period. The latter 
seems particularly adequate for a circulating EPC rolling at a denuded vessel. Lastly, 
miRNA inhibition results in a transient expression of the target effectors for a short 
period of days only. miR-92a repression during the first steps of EPC adhesion, migration 
and proliferation is most useful before EPCs already incorporated in the vascular wall 
can return to a wild-type phenotype. This strategy may be of interest to avoid the 
possibility of long-term functional cell modification in vessels, as uncontrolled cell 
proliferation or low differentiation state. 
 
Altogether, these are exciting times for the application of miR-92a inhibitors. However, 
there are certain limitations to therapeutic targeting of miRNAs. This modality carries 
the inherent risk of affecting RNA species other than the intended miRNA target. Hence, 
the specificity of these constructs is among the issues that still need addressing (Thum, 
2012). There are cell type-specific effects, discrepancies between prediction algorithms 
and experimental observations, not to mention differences in targets between humans 
and other species (Anand, 2013). Ideally, inhibitors must be designed to target the seed 
sequence, since targeting other regions of the mature miRNA may have no or limited 
effect on miRNA activity (Stenvang, Petri, Lindow, Obad, & Kauppinen, 2012). 
Interactions are likely to occur through imperfect base pairing, but the recent 
development of chemical modifications have improved the miR antagonism field by 
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reducing mismatch discrimination (Beavers, Nelson, & Duvall, 2015). However, the latter 
have increased complexity versus the simple Watson-Crick base pairing rules making it 
harder to predict interaction sites for fully complementary miRNA inhibitors accurately. 
Another potential miRNA inhibitor -mediated off-target effect is determined by miRISC 
oversaturation (Khan et al., 2009). The exogenous miRNA inhibitor competes for RISCs, 
thereby rendering it unavailable to other endogenous miRNAs (Stenvang et al., 2012). 
The resulting loss of available RISC complexes leads to a global abrogation of 
endogenous miRNA-mediated regulation.  
Another issue still pending is safety. More evidence from large animal studies is 
warranted before therapeutic inhibition of miR-92a can enter human trials for CVD. Even 
though miR-92a has also been implicated in non-cancerous settings, there are reports 
that aberrant expression of miR-92a can be a feature in neoplastic transformation and 
is sometimes associated with enhanced tumour proliferation, survival, invasion and 
metastasis (M. Li et al., 2014). Plasma miR-92a levels have been used to successfully 
distinguish between acute leukaemia or colorectal cancer patients and healthy controls 
(Z. Huang et al., 2010; Tanaka et al., 2009). Remarkably, inhibition of mir-92a in a cell 
line reproducing acute promyelocytic leukaemia prevented cellular proliferation (Sharifi, 
Salehi, Gheisari, & Kazemi, 2013). Hepatocellular carcinoma patients present elevated 
miR-92a levels in the cancerous tissue, albeit they have reduced levels of miRNA in 
plasma compared to healthy donors (Shigoka et al., 2010). The role of miR-92a in breast 
cancer has not been fully clarified. Zhang et al. showed that the miR-17∼92a cluster was 
deleted in 21.9% of analysed breast cancer tissue samples (L. Zhang et al., 2006). More 
recently, Nilsson et al. reported that downregulation of miR-92a in breast cancer cells 
resulted in increased cell migration, possibly through miR-92a affected genes that are 
involved in the regulation of the actin cytoskeleton and Mitogen-activated protein 
kinase (MAPK) signalling pathway. Altogether, evidence indicates that miR-92a 
expression status can differ depending on cancer type and have diverging functional 
implications. It is likely that miR-92a is involved in some cancer hallmarks, tumor-
associated angiogenesis being one. If miR-92a can behave as an oncomir or its 
modulation influence tumour suppressors, then its modulation should be used with 
extreme caution, but this is extensible to every miRNA in study.  
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miRNAs inhibitors can be divided into four type classes: antagomiR oligonucleotides, 
miR sponges (oligos with multiple miR binding sites), miR-masks (oligos with gene 
specific sequences complementary to miR binding sites to act as competitive inhibitors) 
and small-molecule miR inhibitors (molecules that can unspecifically inhibit the miRNA 
pathway). AntagomiRs are the most common class of miRNA inhibitors. They are 
synthetic oligos that bind to and sterically inhibit the binding of the RISC-loaded miRNA 
guide strand to target mRNAs. The first antagomiRs were DNA oligos of complementary 
sequence and equal length to the full target mature miRNAs. Normally, nucleic acids are 
quickly degraded in biological compartments (Thum, 2012). Unmodified DNA oligos 
were very unstable (Hutvagner, Simard, Mello, & Zamore, 2004). Therefore, subsequent 
antagomiR designs have focused on increasing stability and endonuclease resistance, in 
addition to improving binding affinity to miRNA. The earliest modifications included 
methylation of nucleoside ribose 2’ hydroxyl groups (“OMe”), which improved RNA 
binding affinity compared to unmodified sequences, but did little towards increasing 
oligo stability and nuclease resistance (Beavers et al., 2015; Lennox & Behlke, 2011). 
Cholesterol modified antisense oligos were later developed with a 3’ end conjugation to 
cholesterol which imparts nuclease resistance (Krutzfeldt et al., 2007) and improves 
cellular uptake and the biostability (Krutzfeldt et al., 2005). Additionally, the 
hydrophobic cholesterol moiety enables these antagomiRs to better traverse the cell 
membrane and enter cells without the aid of a delivery vector (Krutzfeldt et al., 2005). 
However, clinical translation of this strategy has been limited by the relatively high doses 
to achieve miRNA inhibition (up to 80 mg/kg in a mouse model)(Krutzfeldt et al., 2005), 
and the concerning off-target effects demonstrated in vivo (Krutzfeldt et al., 2005). A 
recently designed, highly efficient, antagomiR by ExiqonTM relies on highly-modified 
locked nucleic acids (LNA). LNAs contain a methylene bridge between the 2’-O and 4’C 
of ribose to “lock” it into an optimal C-3′-endo conformation which results in a 
thermodynamically very strong duplex hybridization with the complementary miRNA 
(Beavers et al., 2015). Consequently, LNA-modified chemistries show higher anti-miRNA 
affinity at lower doses compared with the equivalent antagomiR (Fabani & Gait, 2008). 
LNA nucleotides can be mixed with RNA residues in the oligonucleotide whenever 
desired and hybridize with RNA according to Watson-Crick base-pairing rules. Also, full 
or mixed LNA oligos show a 10-fold increase in serum stability compared with 
 Introduction - 103 
 
unmodified oligonucleotides (Rapozzi, Cogoi, & Xodo, 2006). Recently, very short 8-mer 
fully modified LNA oligomers only directed against the seed region of a miRNA were 
introduced (Obad et al., 2011). This strategy is useful for targeting multiple miRNA from 
seed families, but can also result in significant off-target effects given the small 
oligonucleotide sequence (Thum, 2012). 
 
mirVana® miRNA inhibitor from AmbionTM (used in this study to achieve miR-92a 
repression) are the latest generation of commercially available chemically -modified 
antagomiRs at the time. They are single-stranded oligonucleotides with proprietary 
chemical modifications (3rd generation), that irreversibly bind and inactivate the natural 
miRNAs when transfected into cells, resulting in artificial up-regulation of target mRNA 
translation. According to the manufacturer, these inhibitors have the highest-potency 
inhibition at the lowest miRNA inhibitor concentration in vitro, when compared with 
other two leading competitors (Exiqon or Dharmacon)(Lam, 2012; LifeTecnhologies, 
2012). They are allegedly highly specific, stable and previously validated for in vivo use, 
given their purity and non-toxicity (Lam, 2012). Non-specific off-target effects are 
therefore unlikely. Importantly, the use of miR-92a miRvana mimic and inhibitor has 
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1.4 Aims of this thesis 
 
Restenosis remains a cause of failure in a significant number of coronary interventions, 
requiring innovative solutions. Current strategies to reduce the incidence of restenosis 
are mainly based on suppressing VSMC proliferation (e.g. drug eluting stents) rather 
than increasing endothelial healing. In fact, antiproliferative therapies may even 
interfere with arterial endothelialisation. The contribution of circulating EPCs homing to 
injured vessels is considered essential to selectively promote re-endothelialisation and 
therefore prevent neointima formation (Curcio, Torella, & Indolfi, 2011). However, EPC 
regeneration potential depends greatly on the extent of their engraftment and activity 
at the target site. Often, EPC numbers and function among CVD patients are intrinsically 
impaired leading to low engraftment, which could limit re-endothelialisation. Therefore, 
EPC-priming therapies designed to increase their ability to engraft at the site of vascular 
injury are attractive and have the potential to improve clinical outcomes after PCI. 
miRNAs have emerged as gene network regulators, engaging several distinct mRNAs in 
an orchestrated manner across different interacting cell types. In previous work, miR-
92a was shown in vitro to reduce angiogenesis, proliferation, migration and adhesion to 
ECM in ECs (Bonauer et al., 2009). Since the anti-angiogenic miR-92a was also shown to 
be upregulated in vessels after injury (Ji et al., 2007) and in EPCs from CAD patients (Q. 
Zhang et al., 2011), we hypothesized that miR-92a antagonism in CD34+-derived EPCs 
could result in a more favourable angiogenesis profile in vitro similarly to ECs, with the 
rationale of developing a future functional priming strategy before cell transplantation 
which could lead to increased engrafting/thriving and accelerated re-endothelialisation 
on injured segments, hence, contributing towards post-PCI restenosis prevention.  
 
The specific aims of my research are as follows: 
1. Differentiate and characterise CD34+-derived late-outgrowth EPCs from an enriched 
human source;  
2. Characterise gene expression and demonstrate the functional priming following miR-
92a inhibitor treatment on CD34+-derived late-outgrowth EPCs in vitro, and relate it to 
the target ITGA5 expression  
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• Accustain Solution ADR-1000, NanoEnTek, Pleasanton, USA  
• ABC solution, Vecastain Elite ABC Kit, PK 6100, Vector Laboratories, Peterborough, UK 
• Alexafluor488 AcLDL, L-23380, Biomedical Technologies, Stoughton, USA 
• Anti-biotin microbeads, 130-090-485, Milteny Biotec, Bergisch Gladbach, Germany 
• Antibody one step biotinylation kit, 130-093-385, Milteny Biotec, Bergisch Gladbach, Germany 
• Avidin/Biotin Blocking Kit, SP-2001, Vector Laboratories, Peterborough, UK 
• Bio-Rad Protein Assay Kit, 500-0112, Bio-Rad, Herts, UK 
• Blocker Casein, 37528, ThermoFisher Scientific, Surrey, UK 
• Bovine serum albumin (BSA), 23209, Thermo Fisher Scientific, Surrey, UK 
• Brilliant II SYBR Green qPCR Master Mix, 600828, Agilent, CA, USA 
• Bupivacaine 0.5% with epinephrine 1:200,000, Cook-Waite Marcaine 0.5% with epinephrine, 185-
2557, Carestream dental, Hertfordshire, UK 
• DAB substrate solution, D4168, SigmaFast DAB tablets, Sigma Aldrich, Dorset, UK 
• CD133 Microbead kit, 130-097-049, Milteny Biotec, Bergisch Gladbach, Germany 
• CD34 Microbead Kit, 130-046-702, Milteny Biotec, Bergisch Gladbach, Germany 
• Cell Titer Glo, G7571, Promega, Southampton, UK 
• CellTracker CM-DiI, C7001, Invitrogen, Paisley, UK 
• Collagen type I rat tail, 08-115, Milipore, Temecula, USA 
• Complete Protease Inhibitor Cocktail, 11873580001, Roche, Mannheim, Germany  
• DMEM 10x, 12800-017, Gibco Thermo Fisher Scientific, Surrey, UK 
• DNAse I, 11284932001, Roche Diagnostics, Mannheim, Germany 
• DPX Mountant for histology, slide mounting medium, 06522, Sigma Aldrich, Dorset, UK 
• EDTA (Ethylenediaminetetraacetic acid), 17892, Thermo Scientific, Surrey, UK 
• E-gel precast agarose gel 1.2%, ThermoFisher Scientific, Surrey, UK 
• Endothelial Basal media (EBM), CC-3121, Lonza, Gaithersburg, USA 
• Endothelial Growth Media bullet kit (EGM), CC-3124, Lonza, Gaithersburg, MD, USA 
• Enhanced Chemiluminescence (ECL) Plus Reagent Detection system, PI80196, Thermo Scientific, 
Surrey, UK 
• Ethanol, 20816.298, VWR BDH Prolabo, Leuven, Germany 
• Ethidium bromide, 15585011, Thermo Scientific, Surrey, UK 
• FcR blocking reagent, human, 130-059-901, Miltenyi Biotec, Bergisch Gladbach, Germany 
• Fentanyl/fluanisone (40µg/100g), Hypnorm, Vm21757/4000, Vetapharma, Leeds, UL 
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• Fetal bovine serum (FBS), 10437028, Gibco Thermo Fisher Scientific, Surrey, UK 
• Fibronectin from human plasma, 0,1% solution, F0895, Sigma Aldrich, Dorset, UK 
• Fluoresceinamine, 46930, Sigma Aldrich, Dorset, UK 
• Fms-related tyrosine kinase 3 (Flt3) ligand, 300-19-100, PrepoTech Inc, Rocky Hill, USA 
• Formalin, HT501128-4L, Sigma Aldrich, Dorset, UK 
• Gel, Nu-PAGE Novex 4-12% Bis-Tris gels, NP0321BOX, ThermoFisher Scientific, Surrey, UK 
• Gelatin from porcine, G1890, Sigma Aldrich, Dorset, UK 
• Haematoxylin solution, 51275, Fluka, USA 
• Heparin sodium salt from porcine intestinal mucosa, H3393, Sigma Aldrich, Dorset, UK 
• Histopaque-1077 HybriMax, 10771, Sigma-Aldrich, Dorset, UK 
• Human serum lyophilized albumin (HSA) powder, A9511, Sigma-Aldrich, Dorset, UK 
• Hydrogen peroxide, 216763, Sigma Aldrich, Dorset, UK 
• Hyperfilm, 28-9068-40, GE Healthcare, Buckinghamshire, UK 
• Isoflurane, Isoflo B506, Abbott, MaidenHead Berkshire, UK 
• Krebs solution, K4002, Sigma Aldrich, Dorset, UK 
• LDS Sample Buffer (4x), NuPAGE, NP0007, ThermoFisher Scientific, Surrey, the UK 
• Matrigel Matrix Growth Factor Reduced, 356230, BD Biosciences, Erembodegem, Belgium 
• Midazolam, Versed, Roche, Mannheim, Germany 
• Molecular Weight Marker, Spectra Multicolor Broad range protein ladder, 26634, ThermoFisher 
Scientific, Surrey, UK 
• MOPS SDS Running Buffer (20X), NuPAGE, NP0001, ThermoFisher Scientific, Surrey, UK  
• Opti-MEM and GlutaMAX-I, 51985-026, ThermoFisher Scientific, Surrey, UK 
• Oligofectamine (OF) transfection reagent, 12252-011, ThermoFisher Scientific, Surrey, UK  
• Paraformaldehyde (PFA), P6148, Sigma Aldrich, Munich, Germany 
• Penicillin 100U/ml + Streptomycin 100µg/ml, 15070-063, Life Technologies, Paisley, UK 
• Pentobarbitone sodium 20% (w/v), Pentojet, 05055037400045, Animal Care, York, UK 
• Perfluoro-1,5-crown ether (PFCE), 9312, Fluorochem, Derbyshire, UK 
• Phosphate buffered saline (PBS), 4417, Sigma Aldrich, Dorset, UK 
• Phosphate buffered saline (PBS) with CaCl2 and MgCl2, 14080-048, Gibco ThermoFisher Scientific, 
Surrey, UK  
• Polylactic-co-glycolic acid (PLGA), Resomers 502 H; 50:50 lactic acid: glycolic acid, Boehringer 
Ingelheim, Ingelheim am Rhein, Germany 
• PLGA-PEG Ak12k24 (for the gel), Akina, Inc, IN, USA 
• Pluronic F-127, powder, P2443, Sigma Aldrich, Dorset, UK 
• Polyvinyl alcohol, 363146, Sigma Aldrich, Dorset, UK 
• Prolong Gold anti-fade reagent with DAPI (4',6-diamidino-2-phenylindole); P36931, ThermoFisher 
Scientific, Surrey, UK 
• Pronase, 10165921001, Roche Diagnostics, Mannheim, Germany 
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• Propylene carbonate, 310328, Sigma Aldrich, Dorset, UK 
• Protamine sulphate, P3369, Sigma Aldrich, Dorset, UK 
• QuantiTect Reverse Transcription Kit, +205311, Qiagen, Dusseldorf, Germany 
• Quantum Simply Cellular anti-Mouse IgG Kit, 815A, Bangs Laboratories, Indiana, USA 
• Radio-Immunoprecipitation Assay (RIPA), R0278, Sigma Aldrich, Dorset, UK 
• Reastain Quick Diff Kit, 102164, Gentaur, Kampenhout, Belgium 
• ReBlot Plus Strong antibody stripping solution, 2504, Millipore, CA, USA 
• RPMI 1640 medium, 11875-093, ThermoFisher Scientific, Surrey, UK 
• Sample reducing buffer (10x), NuPAGE, NP009, ThermoFisher Scientific, Surrey, UK 
• Serum donkey, D9663, Sigma Aldrich, Dorset, UK 
• Serum goat, X0907, Dako, Glostrup, Denmark 
• Serum human, AB, 14-490E, Lonza, Gaithersburg, USA 
• Serum porcine, 26250084, Thermo Scientific, Paisley, UK 
• Skin moisturiser, Opsite 66004978, Smith&Nephew, UK 
• Sodium citrate tribasic dehydrate, 54641, Sigma Aldrich, Dorset, UK 
• Stem cell factor (SCF), 300-07-100, PrepoTech Inc, Rocky Hill, USA  
• Transfer buffer (1x), NuPAGE, NP00061, ThermoFisher Scientific, Surrey, UK 
• Trifluoroethanol, T63002, Sigma Aldrich, Dorset, the UK 
• Triton X-100, X100-1L, Sigma Aldrich, Dorset, UK 
• Trypan Blue, 17-942E, Lonza, Gaithersburg, MD, USA 
• Trypsin, 15090-046, Invitrogen, Paisley, UK 
• Tween 20, 23360010, Acros Organics, NJ, USA 
• Vascular endothelial growth factor (VEGF165), 100-20, PrepoTech Inc, Rocky Hill, USA 
• X-VIVO 15, serum free hematopoietic cell medium, 04-744Q, Lonza, Gaithersburg, MD, USA 
• Xylene, 28975.360, VWR BDH Prolabo, Leuven, Germany 
 
  




• Accuchip2x Kit AD2K-200, NanoEnTek, Pleasanton, USA 
• Adam-MC, Cell Counter, NanoEnTek, Pleasanton, USA 
• Angiogenesis 96 Well ibiTreat µ-Plate, 89646, Ibidi, Munich, Germany 
• Axio Observer, Carl Zeiss International, Germany 
• Axiovert A1, fluorescence microscope, Carl Zeiss International, Germany 
• Axiovert 40 C, inverted optical microscope, Carl Zeiss International, Germany 
• BD FACScalibur, Flow cytometer, Becton Dickinson, CA, USA 
• BD FACS Verse, Flow cytometer, Becton Dickinson, CA, USA 
• BD 115 Model, incubator, Binder Gmbh, Tuttlingen, Germany 
• Branson 2510, Ultrasonic Cleaner, Brandson, Danbury, CT, USA 
• Catheter 2Fogarty embolectomy, #120602F, Edwards Lifesciences, Nyon, Switzerland 
• Cell Strainer 100 µm mesh, 352360, Falcon, Corning, Corning, USA) 
• CellTrics 30, separation filters, 04-0042-2316, Sysmex Partec, Görlitz, Germany 
• Ceramic beads pre-filled 0.5 mL tubes, Precellys soft tissue homogenising kits, CK14-KT03961-1-
203.05, Bertin Technologies, France 
• Coverslips, CB00140RA1, 14 mm Menzel-Glaser, Braunschweig, Germany 
• Deskscan, scanner, Hewlett-Packard, London, UK 
• Dialysis membrane (50 kDa), 132 544, Spectrum Labs, Rancho Dominguez, CA, USA 
• Dialysis membrane (12-14 kDa), 132 706, Spectrum Labs, Rancho Dominguez, CA, USA 
• E-Gel® iBase™ Power System, Thermo Scientific, Surrey, UK 
• GENios, Fluorescence, Absorbance and Luminescence Reader, TECAN, Mannendorf, Switzerland 
• Heating mat, 75404, Magnetic heat pad, morphy Richards, the UK 
• ImageLock 96-well Plates, 4379, Essen Bioscience, Herts, UK 
• IncuCyte Cell Migration Kit, 4493, Essen Bioscience, Herts, UK 
• Incucyte Zoom live-cell analysis system, microscope, Essen Bioscience, Herts, UK 
• Jamshidi T-handle, 13 G x 3", TJC3513, Carefusion, Vernon Hils, USA 
• Lab-Tek II, chamber slides, 154534; Nalge Nunc International, IL, USA 
• Leica M80, stereomicroscope, Leica Microsystems, Milton Keynes, United Kingdom 
• Leica Macrofluo, macroscope, Leica Microsystems, Milton Keynes, the UK 
• Minilys, tissue homogenizer, Bertin Technologies, France 
• Mini&MidiMACS, Immunomagnetic sorting system, 130-042-501, Miltenyi Biotec, Bergisch Gladbach, 
Germany 
• Mx3000P qPCR System, Stratagene, CA, USA 
• Nanodrop 3300 spectrophotometer, Thermo Scientific, Surrey, UK 
• NDP Nanozoomer Digital Pathology, Slide scanner microscope, Hamamatsu, Tokyo, Japan 
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• Pap pen for IHC, delimiting pen, S2002, Dako, Glostrup, Denmark 
• PVDF/Filter Paper Sandwich, 0.45 µm pore size, Invitrolon, LC2005, ThermoFisher Scientific, Surrey, 
UK  
• QIAshredder, Tissue and Cell Homogenizer, 79654, Qiagen, Dusseldorf, Germany 
• RNeasy Mini kit, RNA isolation kit, 74104, Qiagen, Dusseldorf, Germany 
• Slide, microscope slide, 6310098, Menzel-Glaser, Braunschweig, Germany 
• Snijders Scientific, Lyophilisator, Tiburg, Holland 
• Surgical micro-clips, S&T B-2 Vascular Clamp, 00398-02, Finescience tools, Heidelberg, Germany 
• Surgical micro-scissors, Vannas Spring Scissors, 15000-00, Finescience tools, Heidelberg, Germany 
• Surgical vessel dilating forceps, S&T D-5a, 00125-11, Finescience tools, Heidelberg, Germany 
• Suture 3-0 mersilk, W587, Johnson & Johnson Intl, St. Stevens-Woluwe, Belgium 
• Suture 3-0 sofsilk, S-304, Covidien Syneture, Dublin, Ireland 
• Suture 4-0 vycril, W9570, Johnson & Johnson Intl, St. Stevens-Woluwe, Belgium 
• Thermo Denley Spiramax 5, roller, ST124080, Thermo Scientific, Paisley, UK 
• Thermomix comfort; Eppendorf mixer, Hamburg, Germany 
• Transwell 8 μm membrane pore size, 353097, Falcon, Becton Dickinson 
• VibraCell, Sonicator, Sonics, CT, USA 
• Zeiss LSM 510 Meta, confocal microscope, Carl Zeiss International, Germany 
• Zeta Pals light scattering analysis, Brookhaven Instruments Corporation, NY, USA  
 




• Axiovision 4.5, Carl Zeiss International, Germany 
• Cell Quest Pro, Becton Dickinson, California, USA 
• FlowJo, Ashland, USA 
• Image J, National Institute of Health, rsb.info.nih.gov/ij 
• Incucyte Zoom software, Essen Bioscience, Herts, UK 
• Simple PCI, HCImage, PA, USA 
• QuickCal, Bangs Laboratories, Indiana, USA 
• Zeta Plus Particle Sizing v. 2.27, Brookhaven Instruments Corporation, NY, USA 
 
  




Animal experiments were conducted by the Animal Care and Ethics Guidelines of UCL, 
Royal Veterinary College, University of London, and the United Kingdom Home Office 
Animals (Scientific Procedures) Act (1986). 
Pigs: Bone marrow (BM) samples were obtained from a total of 35 healthy 2-3-month-
old Yorkshire pigs (25 to 35 kg) immediately after they were euthanised by penetrating 
captive bolt shot to the brainstem. The pigs were being used for a dermal toxicology 
study at the University of Hertfordshire but were not subject to any prior 
treatment/surgery. Pigs were kept at 20º-25ºC all the time with daylight and free access 
to tap water and regular daily food.  
Mice: Mouse aortic rings were obtained from C57BL/6 mice housed at UCL Biological 
Service Unit services, which were culled by schedule 1 procedure.  Mice were kept at 
20ºC to 25ºC all the time with free access to tap water and regular daily food. 
Rats: Male Sprague-Dawley rats (Charles River UK) 350-400g (2-3 months old) were used 
for the carotid artery balloon angioplasty experiments. Specimen retrieval was done 
following perfusion under terminal anaesthesia using pentobarbitone via 
intraperitoneal injection (50 mg/kg), according to the UCL Biological Services Unit 
protocol. Rapid euthanasia was accomplished by exsanguination (liver tear), while 
simultaneously perfusing the arterial tree via an intra-cardiac 200 mL continuous 
injection of 0.9 % saline solution at a physiological pressure. 
 
2.5 Umbilical coord blood collection 
 
Fresh, non-cryopreserved, red blood cell (RBC)-replete umbilical cord blood (UCB) units 
were provided by Anthony Nolan’s Research Institute for Laboratory Research after 
normal delivery from full-term births (≥36 weeks gestational age) using standard 
collection procedures. The collection was approved by the Anthony Nolan Cell Therapy 
Center’s generic research tissue bank ethics approval extendable to external applicants 
for material. Written informed consent from subject mothers was obtained before 
donation. The samples were stored in 100 mL sterile bags containing 35 mL of citrate-
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phosphate-dextrose anticoagulant solution and processed within 24h after collection 
from parturient. All units were transported and stored at room temperature (RT). 
 
2.6 Bone marrow blood collection 
 
Pigs were placed ventrally, and 50 mL of BM were aspirated from the iliac crest using a 
Jamshidi T-handle biopsy needle and syringe (Figure 18), and then transferred to a 50 
mL tube, previously heparinized (final concentration 25 international units/ml) and 
supplemented with 1% (v/v) Penicillin/Streptomycin. The samples were then filtered 
through a Falcon 100 µm cell strainer and kept overnight on a roller at RT for next day 
processing. 
 





2.7 Immunomagnetic sorting of progenitor cells  
 
Enrichment of progenitor cells in suspension is usually performed by fluorescent 
activated (FACS) (Bonner, Hulett, Sweet, & Herzenberg, 1972) or immunomagnetic 
(MACS) (Miltenyi, Muller, Weichel, & Radbruch, 1990) selection systems. Both 
techniques take advantage of the expression of known surface antigens for cellular 
separation, using specific antibody binding. FACS separation depends on the conjugation 
of fluorescent tags to these antibodies, while MACS uses conjugation to 
superparamagnetic iron-dextran containing microbeads. Unlike FACS which requires 
single-cell analysis (excitation above a threshold level signals the corresponding tagged 
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cell to be separated), MACS is more of a bulk method, where unlabelled cells are eluted, 
and labelled cells are retained in the magnetic field, giving the separated populations. 
An obvious consequence is that while FACS can be more accurate (especially if using 
multiple antibodies), it is significantly slower than MACS (Tomlinson, Tomlinson, Yang, 
& Kirkham, 2013), thus negatively impacting on viability (Q. Li et al., 2013). CliniMACS 
(the automated isolation system from the same company) enjoys FDA approval for 
clinical applications and is currently the only Good Manufacturing Practices compliant 
cell separation system available for immunomagnetic separation of progenitor cells 
from blood products (Blake et al., 2012).  
For these reasons, I opted for the MACS system from Miltenyi Biotec to isolate 
progenitor cells from mononuclear cells (MNCs) for its ease of use and reliability 
(Kekarainen, Mannelin, Laine, & Jaatinen, 2006). The mini- and midi-MACS column 
matrix provides a strong magnetic ﬁeld, allowing the positive selection of cells carrying 
speciﬁc antigens on their surface, previously incubated with corresponding 
superparamagnetic microbead-conjugated antibodies. Unlabeled cells pass through the 
column, while the retained labelled cells can then be eluted from the column after 
removal from the magnet. 
 
2.7.1 Isolating human CD34+ or CD133+ cells from UCB 
 
Labelled human CD34 and CD133 progenitor cells were isolated from MNCs using MACS 
immunomagnetic separation system (Mini&MidiMACS) (Figure 19), overall as described 
elsewhere (Jaatinen & Laine, 2007), but with significant optimisation steps introduced 
resulting in higher purity and viability of selected population. Briefly, buffy coats were 
obtained after centrifugation of ~100 mL UCB samples for 45 min at 500g at 20ºC (brake 
0) and diluted 1:3 in RPMI medium.  Buffy coat is the white coloured leukocyte layer that 
resides directly above the RBC/granulocyte layer after crude centrifugation of whole 
blood. MNCs were then obtained after buffy coat density gradient separation using 
Histopaque reagent (40% reagent:60% sample per Falcon). Upon centrifugation, the 
relatively lower density MNCs migrate into a layer that floats on top of the histopaque 
reagent layer, while higher density RBCs contaminants rest below. MNCs were 
resuspended in 300 µl of DNAse (filtered; 1mg/mL in PBS) to prevent unwanted cell 
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clumping (Hering et al., 1989), pooled together and then 10 mL of manufacturer’s 
labelling buffer at 4ºC was added, so that the total yield of MNCs could be estimated 
using a 50-fold dilution in PBS. The sample was then centrifuged for 10 min, 20ºC, 300 
G, accelerator 9/ brake 9 and the cells re-suspended again in 200 µl of DNAse 1mg/mL 
and 1 mL of pre-cooled MACS buffer (BSA 0,5% w/v in PBS with EDTA 2 mM). This was 
followed by a 30-minute incubation at 4ºC of MNCs with paramagnetic microbeads 
conjugated to mouse monoclonal anti-human CD34 or CD133 antibodies (100 µl FcR 
blocking reagent and 100 µl microbeads per 108 cells), in manufacturer’s labelling buffer 
enriched with 20% (v/v) human serum (300 µl per 108 cells). Cells were washed once and 
resuspended in 500 µl DNAse 1mg/mL and MACS buffer (500 µl per 108 cells). After 
application through pre-primed 30µm CellTrics separation filters, labelled cells were 
enriched on a LS column placed in a magnetic field. Eluted cells were labelled a second 
turn with 25 μl FcR blocking reagent plus 25 µl micro beads in 300 µl of MACS buffer for 
15 minutes at 4ºC. After one wash, cells were resuspended in 2 mL of MACS buffer and 
placed in a MS column in the magnetic field for the final elution. After centrifugation at 
1000 rpm for 8 min at RT, cells are then resuspended in the appropriate medium 
according to laboratory assay to be conducted, counted and plated at the desired cell 
density. 
Figure 19 | MACS direct labelling system. 
Column-based separation implies the injection of magnetically labelled cell suspension into a column held 
within a magnet. Cells then flow through the column and those who are labelled will be retained, whereas 
unlabeled cells are washed out. Finally, the column is removed from the magnet stand, and the suspension 
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2.7.2 Isolating porcine CD34+ cells from pig BMB 
 
CD34+ progenitor cells were isolated from pig BM blood MNCs using MACS 
immunomagnetic separation system, overall according to the human UCB isolation 
protocol, but with relevant, original, modifications since no anti-pig CD34 microbeads 
were available. An indirect labelling method was performed instead, where cells were 
labelled with a primary antibody that was biotinylated (Figure 20). In a second step, 
magnetic labelling was carried out by using anti-biotin microbeads. Briefly, following 
buffy coat separation, MNCs were labelled with 50 µl of the biotinylated goat anti-pig 
CD34 antibody (Anti-CD34 Antibody (Extracellular Domain) LS-C35556, LSBio, Seattle, 
USA) for 5 minutes at RT, for a final concentration of 1:20. The anti-porcine antibody 
needed to be biotinylated the day before as per Miltenyi Biotec’s instructions. Cells were 
then washed in 10 mL MACS buffer twice (centrifugation for 10 min, 20º C, 300 g, 
accelerator 9/ brake 9), and re-suspended in 80 µl MACS buffer enriched with 20% (v/v) 
porcine serum per 108 mononuclear cells. The MNC fraction mixture was after that 
incubated with Miltenyi Biotec’s anti-biotin microbeads for 15 minutes at 4ºC, following 
a 20 µl per 107 cells ratio. Again, cells were washed with 10 mL MACS buffer and 
centrifuged for 10 min, 20º C, 300 g, accelerator 9/ brake 9. After pellet resuspension in 
buffer (500 µl per 108 cells), labelled cells were primed with a CellTrics 30 µm meshwork 
and enriched once on a LS column placed in a magnetic field. The sample was eluted 
twice using 5 mL MACS buffer, and, after a final centrifugation at 1000 rpm for 8 min at 
RT, cells were resuspended in medium and plated at the desired cell density.  
 
Figure 20 | MACS indirect labelling schematics. 
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2.8 Automatic cell counting and viability 
determination 
 
Quantification of total cell number and mean cell viability was achieved by using 
Accuchip slides and an Adam-MC haemocytometer-based automated cell counter, 
according to manufacturer’s protocol. Briefly, this technology identifies propidium 
iodide stained cells, by using integrated microfluidic chip technology, LED-based 
fluorescence microscopy and charged coupled device detection. 
 
2.9 Flow cytometry 
 
Flow cytometry captures information about the properties of individual cells, including 
size, intracellular organelle density (forward scatter – side scatter FSC-SSC dot plot) and 
the presence of specific fluorescently labelled antibodies bound to or inside cells. 
Fluorescent activated cell sorting (FACS) can be used to sort cells into populations 
defined by these parameters. A beam of light of a single wavelength generated by a laser 
is directed onto a hydrodynamically focused stream of fluid containing cells conjugated 
with specific fluorophores, allowing the determination of the proportion of cells 
containing that specific antigen, and the degree of expression (intensity).  The antibodies 
used for FACS, and corresponding dilutions, are described in Table 6. The excitation and 
emission maxima of the fluorophores used are given in Table 7. 
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Table 6 | Antibodies used for flow cytometry. 
BMB - bone marrow blood; CD – cluster of differentiation; FITC - Fluorescein isothiocyanate; Ig – 
immunoglobulin; PE – Phycoerythrin; UCB – umbilical cord blood; VEGFR2 – vascular endothelial growth 
factor receptor 2. 
Target antigen Cell type Primary and secondary antibodies 
CD34 human UCB 
progenitor cells and 
human late-
outgrowth EPCs 
1° = mouse monoclonal anti-human CD34-PE 
conjugated (1:11, 130-081-002, Milteny Biotec, 
Bergisch Gladbach, Germany) 
Isotype control = mouse monoclonal IgG2a-PE 
conjugated (1:11, 130-091-835, Miltenyi Biotec, 
Bergisch Gladbach, Germany) 
CD34 pig BMB CD34+ cells 1° = goat anti-pig CD34 (1:11, LS-C35556, LSBio, 
Seattle, USA) 
2° = donkey anti-goat IgG-FITC (1:100, A11055, Life 
technologies, Paisley, UK) 
Isotype control = normal goat IgG (sc-2028, Santa 
Cruz Biotechnology, Heidelberg, Germany) 
 
CD133 human UCB 
progenitor cells and 
human late-
outgrowth EPCs 
1° = mouse monoclonal anti-human 
CD133/1(AC133)-PE (1:11,130-080-801, Milteny 
Biotec,Bergisch Gladbach, Germany) 
Isotype control = mouse monoclonal IgG1-PE (1:11, 
130-098-106, Miltenyi Biotec, Bergisch Gladbach, 
Germany) 
 
VEGFR2/KDR human UCB 
progenitor cells and 
human late-
outgrowth EPCs 
1° = mouse monoclonal anti-human VEGFR2-PE 
conjugated (1:11, 130-093-598, Milteny Biotec, 
Bergisch Gladbach, Germany) 
Isotype control = mouse monoclonal IgG1-PE (1:11, 
130-098-106, Miltenyi Biotec, Bergisch Gladbach, 
Germany) 
 
VEGFR2/KDR pig BMB late-
outgrowth EPCs 
1° = rabbit anti-pig VEGFR2-FITC conjugated (aa8-
290) (1:11, LS-C420389, LSBio, Seattle, USA) 
Isotype control = normal rabbit IgG-FITC conjugated 
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Table 7 | Fluorophores used in flow cytometry 
Approximate fluorescence excitation and emission maxima are indicated (solvent-dependent) from 
corresponding manufacturers’ online resources. FITC - Fluorescein isothiocyanate; miRNA – microRNA; 
NP – nanoparticle; PE – Phycoerythrin. 
Probe Fluorophore Excitation (nm) Emission (nm) 
Conjugated miRNA FITC 494 521 
Conjugated antibody FITC 495 519 
Conjugated NP Fluoresceinamine 495 519 
Conjugated antibody PE 565 573 
 
2.9.1 Determination of the proportion of cells containing a 
specific fluorophore 
 
FACS was used with different cell types and in different experimental settings: 
 
1) To determine the purity of the populations enriched by immunomagnetic sorting for 
CD34 or CD133, cells freshly isolated from blood samples were left to recover 48h in a 
5% carbon dioxide (CO2) incubator at 37ºC (200,000 cells/96 well plate) in 200 uL of X-
VIVO serum-free medium supplemented with Flt3-ligand and SCF at 50 ng/mL, to allow 
the magnetic microbeads used for cell isolation to disintegrate from the cell surface, 
before carrying out the protocol. This was particularly important because the antibodies 
used for flow cytometry were chosen precisely to tag the same epitopes than the 
microbeads antibodies, to increase specificity. 
 
2) To quantify the presence of specific fluorescently-labelled surface antigens, adherent 
cells in culture were harvested by trypsinization (trypsin 0.1% v/v in PBS) and pelleted 
with one centrifugation step, before carrying out the protocol.  
 
3) For confirmation of cellular internalisation of nanoparticles(NP):miRNA complexes 
using FACS analysis, late-outgrowth EPCs were transfected for 4h with 
fluoresceinamine-labelled NPs (500 µg/mL) or NPs conjugated with 5’-fluorescein 
labelled miR-92a (250µg/ml and 100nM respectively). The miRNA used was 5’ 
fluorescein-labelled hsa-miR-92a-1 miRCURY LNA inhibitor, 410456-04, Exiqon, 
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Vedbaek, Denmark. After treatment with particles or complexes, cells were washed 
twice with PBS 1% (w/v) BSA, incubated in a solution of 600 µg/mL Trypan blue for 2 
minutes, at RT, and washed twice with PBS before being trypsinized (trypsin 0.1% v/v in 
PBS) and carrying out the protocol. Trypan blue is used to quench externally attached 
particles/miRNA to differentiate between the signal from membrane-associated 
(external) and internalised fluorochromes (internal)(McNeer et al., 2011). The omission 
of NPs treatment (with or without quenching with trypan blue), and NP-
fluoresceinamine treatment without quenching, were used as controls in the 
confirmation of NP-fluoresceinamine internalisation experiments. Omission of NPs 
treatment (with or without quenching with trypan blue), miRNA- fluorescein labelled 
treatment (with or without quenching with trypan blue), NPs non-fluoresceinamine 
labelled treatment (with or without quenching with trypan blue), and NP:miRNAs- 
fluorescein labelled treatment without quenching, were used as controls in the 
confirmation of NP:miRNAs-fluorescein internalization experiments.  
 
4) For confirmation of cellular internalisation of miRNA using FACS analysis, CD34+-
derived late-outgrowth EPCs were transfected with hsa-miR-92a-1 inhibitor-FITC 
(410456-04, Exiqon, Vedbaek, Denmark) at 30nM for 4h using OF, and cells allowed to 
rest 24h in the transfection mixture supplemented with 10% FBS before carrying out the 
protocol. Treatment with OF only was used as control.  
 
Cells from experimental layouts (1-2) were then transferred into a 1.5 mL Eppendorf 
tube, and centrifuged for 10 minutes at 300g at RT. Cells were then resuspended in 80 
µL of PBS 1% (w/v) BSA with 20 µL of human FcR blocking reagent (or 100 µl PBS/BSA 
1% for non-human samples), after which 10 µL of primary antibody were added, 
according to the manufacturer’s recommendations. In the case of CD34 and CD133, the 
chosen antibodies bound an epitope different from that recognised by the CD34 and 
CD133 monoclonal antibodies used for sorting. The corresponding IgGs were used at the 
same concentration as isotype controls. Samples were kept 10 minutes at 4ºC, before 
adding 1 mL PBS 1% (w/v) BSA and centrifuging for 10 minutes at 300 g. If the primary 
antibody was not conjugated to a fluorophore, then a further incubation step with a 
 Results - 119 
 
fluorescently-labeled secondary antibody was needed, for 10 minutes at RT, covered 
from light before carrying out the protocol. 
Then, cells from experimental layouts (1-4), were washed with PBS 1% (w/v) BSA and 
fixed in PFA 2% (v/v) in PBS for 10 min at RT, again protected from light. The PFA was 
then washed off, and the cells resuspended in 400 µL PBS 1% (w/v) BSA, and the cells 
transferred to FACS tubes before running them on FACS cytometer.  
For time course experiments with a total duration of several days, a small adaptation of 
the protocol was assumed. Cells were harvested at designated time points, fixed with 
PFA 2%, stored in PBS 1% (w/v) BSA at 4ºC and only batch stained on the day of running 
the samples instead.  
A total of 10,000 gated events were recorded per measurement, and each condition was 
measured in duplicate in the corresponding fluorescent channel. Data acquisition and 
analysis were performed using specific software (Cell Quest Pro software for human cells 
or FlowJo for porcine cells).  
 
2.9.2 Antigen surface density quantification 
 
CD34+ progenitor cell and late outgrowth EPC characterization also included 
determining the fluctuation of stem and endothelial lineage surface markers throughout 
the cellular differentiation process. Antigen quantitative analysis was performed as 
described before (Scolnik, Morilla, de Bracco, Catovsky, & Matutes, 2002). Briefly, the 
measurement of CD34, CD133 or KDR antigen surface densities was performed using 
Quantum Simply Cellular anti-Mouse IgG Kit. This kit contains a mixture of four types of 
polystyrene beads coated with anti-mouse IgG, with known antibody binding capacities, 
and one blank population with no specific binding capacity for mouse IgG. The beads 
bind to the fluorochrome-conjugated monoclonal antibodies and act as a set of 
standards to calibrate the fluorescence scale of the flow cytometer.  The beads and the 
human cells were incubated individually with mouse monoclonal anti-human CD34-PE, 
CD133-PE or KDR-PE antibody at the same concentration as experimental conditions, 
according to manufacturer’s protocol. Pig cells were stained with rabbit anti-porcine 
CD34 (FITC conjugated secondary) or KDR-FITC primary antibodies. Cells were then fixed 
with PFA 2% (w/v) in PBS, washed and run in the flow cytometer, using identical intensity 
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parameter settings for the samples and the quantitative beads. For time course 
experiments with a total duration of several days, a small adaptation of the protocol was 
assumed. Cells were harvested at designated time points, fixed with PFA 2% (w/v) in 
PBS, stored in PBS 1% (w/v) BSA at 4ºC and only batch stained on the day of running the 
samples instead. A total of 1,000 or 10,000 gated events were recorded per 
measurement for beads or cells populations, respectively. Host specific isotype 
immunoglobulins conjugated with PE served as negative control, allowing for auto-
fluorescence compensation. The geometric mean fluorescence intensities of the beads 
and cells were entered into the QuickCal software included in the kit, which 
extrapolates, after subtraction of isotype negative control auto-fluorescence, the 
antibody binding capacities of the cells from the standard curve.  If monovalent 
antibody-to-surface receptor binding is presumed, then the antibody binding capacity is 
equal to the number of surface receptors. Each condition was measured in duplicate in 
the corresponding fluorescent channel. 
 
2.10 Differentiation of CD34+ cells into late-
outgrowth EPCs 
 
Freshly isolated CD34+ cells were differentiated into EPCs using a published in-house 
protocol (Pedroso et al., 2011). Briefly, cells were plated onto 1% (w/v) gelatin coated 
24-well plates (2x105 cells/well). Gelatin was prepared at the desired concentration in 
milQ and allowed full dissolution at autoclaving temperature for at least 1 hour. Then 
cells were incubated in Endothelial Growth medium (EGM) with 20% (v/v) FBS and 50 
ng/mL VEGF, at 5% CO2, 37ºC. After 5 days and then every other day, half of the volume 
of the medium was replaced with fresh one, until the 3rd passage of a nascent adherent 
cell population was reached, at which point, EGM 10% (v/v) FBS medium was used for 
nurturing instead. Bright-field images during differentiation were captured using an 
inverted Axiovert 40 C optical microscope. 
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2.11 EPC culture 
 
Human late-outgrowth EPCs were cultured in the same fashion than HUVECs usually are, 
i.e., they needed to be seeded in 1% (w/v) gelatin coated vessels and incubated in EGM 
10% (v/v) FBS medium at 37ºC and 5% CO2 (see gelatin preparation method in section 
2.10). Expanding EPCs were split into new vessels by trypsinization (trypsin 0.1% v/v in 
PBS) when 80% confluency was reached, until passage 6, at which time they were 
discarded. Unless stated otherwise, experiments were performed on cells at 
approximately 80% confluency. 
 
2.12 Matrigel angiogenesis assay 
 
A tube formation assay using Matrigel is well established to demonstrate the angiogenic 
activity of vascular endothelial cells in vitro (Shao et al., 2004). This is a short-term 
culture assay in a gelatinous protein mixture obtained from Engelbreth-Holm-Swarm 
mouse sarcoma, which stimulates vascular phenotype cells to form capillary-like 
hexagonal structures within just a few hours (Figure 21). The assay was performed using 
matrigel overall according to manufacturer’s instructions, on 96 µ-Plates specifically 
designed for the angiogenesis assay. The latter uses the validated “well-in-a-well” 
feature to avoid meniscus formation in individual wells and allowing more efficient 
imaging as all cells are in one focal plane while requiring 90 % less Matrigel than 
compared to standard 96-well plate. 
 
Figure 21 | Matrigel angiogenesis assay performed in the µ-slide plate.  
Adapted from IBIDI online resources. 
 




Briefly, the growth factor reduced Matrigel solution was thawed at 4ºC overnight and 
10 μL dispensed into each well of a pre-cooled 96 µ-Plate Angiogenesis well plate. The 
plate was then placed in humidified chamber at 37°C for 1 h to allow for jellification. 
Cells were dissociated with 0.1% (v/v) trypsin solution, re-suspended at 1x105 cells/mL 
in serum-free medium EBM, and 50 μL dispensed on top of the matrigel and left 
undisturbed in the incubator. For the purpose of EPC characterization, samples were left 
for 6 hours in an Incucyte Zoom incubator microscope, that allows time-lapse live cell 
and tubule-like formation imaging always at the same gridlock position. Five replicates 
were used for each experimental condition.  
 
2.13 VEGF activation of p-ERK and p-Akt signalling 
 
Pig CD34+-derived EPCs (~80% confluency) from day 21 of differentiation were starved 
in SFM for 2 hours at 37ºC, before being challenged for 10 mins with either 25 ng/mL 
VEGF, PDGF or SFM. The reactions were terminated by adding 2 ml of ice-cold PBS. 
 
2.14 miRNA and siRNA transfection 
 
miRNAs and siRNAs can silence gene expression via interaction with RISC complex. 
miRNAs are short, noncoding RNAs, that are assembled into miRNA-induced silencing 
complexes that localise to miRNA seed sites (usually in the 3’- untranslated region) of 
specific mRNAs with perfect and imperfect strand complementarity, resulting (mostly) 
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in post-translational cleavage or repression (Filipowicz et al., 2008). siRNA-induced 
silencing of gene expression after complementary mRNA base pairing is a result of the 
action of the RNaseH enzyme argonaute /slicer, which initiates nucleolytic degradation 
of the target cellular mRNA (Hammond, 2005). miRNAs and siRNAs are negatively 
charged and are, thus, not readily taken up by most cells. Liposome-like reagents such 
as Oligofectamine (OF) or cationic NPs can be used to introduce miRNAs/siRNAs into the 
cell, given their solubility in the cell membrane. Table 8 lists the used oligonucleotides 
in the transfections. 
 
Table 8 | miRNAs and siRNAs used. 
EPC – endothelial precursor cell; hsa – homo sapiens; miR- microRNA; si – siRNA. 
Oligonucleotide Specificities Concentrati
on 
hsa-miR-92a-1-5p mirVana mimic, MC12696, 4464066 Thermofisher Scientific, 
Paisley, UK 
EPCs (30 nM), 
Arteries (1 
µM) 
hsa-miR-92a-1-3p mirVana mimic, MC10916, 4464066 Thermofisher Scientific, 
Paisley, UK 
EPCs (30 nM) 
hsa-miR-92a-1-5p mirVana inhibitor, MC12696, 4464084, Thermofisher 
Scientific, Paisley, UK 
EPCs (30 nM), 
Arteries (1 
µM) 
hsa-miR-92a-1-3p mirVana inhibitor, MC109166, 4464084, Thermofisher 
Scientific, Paisley, UK 
EPCs (30 nM) 
miR scrambled mirVana inhibitor, negative control 1, 4464076, 
Thermofisher Scientific, Paisley, UK 
EPCs (30 nM), 
Arteries (1 
µM) 
si ITGA5 ON-TARGET Plus human ITGA5 SMARTpool, 3678, 
Dharmacon, UK 
EPCs (30 nM) 
si scrambled ON-TARGET Plus non-targeting siRNA #1, D-001810-01-05, 
Dharmacon, UK 
EPCs (30 nM) 
 
2.14.1 Oligofectamine EPC transfection 
 
OF reagent is a proprietary formulation for transfecting oligonucleotides into eukaryotic 
cells, used in this case for EPC and HUVECs transfection. For each transfection sample (1 
well of a 6-well plate with 80% confluent adherent cells), complexes were prepared as 
follows. First, a dilution of oligonucleotide in warm basal media Opti-MEM I was 
prepared by mixing 1,5 µL oligonucleotide (20 µM stock) with 176 µl of basal media and 
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allowed to rest for 10 minutes at RT. Simultaneously, a second dilution of transfection 
reagent in basal media was set by mixing 10 µL OF with 10 µl of Opti-MEM I and 
incubated for 10 minutes at RT. The diluted oligonucleotide with the diluted OF was 
combined for a total volume of 200 µL and incubated for 25 minutes at RT with 
occasional mixing. While the complexes were forming, cells were washed once and then 
800 µL of Opti-MEM I per well were added. The complexed oligonucleotides solution 
(200 µL) was gently added to the cells (for a total volume of 1 mL and 30nM 
oligonucleotide transfection concentration), and incubated for 4h at 37ºC. After this 
period, 500 µL of Opti-MEM I 30% (v/v) FBS were added to the well (for a final 
concentration of 10% serum), and cells allowed to rest overnight with transfection 
mixture for 24h at 37ºC. The following day, cells were washed once with EBM before 
2mL of complete medium EGM 10% (v/v) FBS were added. Cells were incubated for a 
further 24h if doing a 48h knockdown. For 96 well plate format, the transfection was 
scaled down proportionally, assuming 100 µL transfection volume per well. 
 
2.14.2 Nanoparticle-mediated EPC transfection 
 
For cell culture transfection, a total of 2×105 adherent human late-outgrowth EPCs 
plated in gelatin 1% pre-coated wells (see gelatin preparation method in section 2.10) 
were washed twice with PBS to remove any excess FBS which might adsorb and 
sequester NPs and miRNAs. Cells were incubated for 4h(Duinhouwer et al., 2015) at 
37ºC with serum free EBM containing NPs or NP:miRNA complexes at a final NP and 
miRNA concentration of 125 µg/mL and 200 nM, respectively. Different well sizes and 
cell densities were used according to prospective assay, always keeping the same NP 
mass (:miRNA molecules):cell number ratio (Table 9). Following the incubation, cells 
were gently washed 2 times with serum-free medium and left in EGM 10% (v/v) FBS 
overnight before conducting any assay. miR knockdown occurred during the assay itself. 
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Table 9 | EPC transfection protocol using nanoparticles. 
Transfection numbers used to keep same NP(:miRNA):cells ratio, irrespective of the assay; Final NP and 
miRNA (when applicable) concentration of 125 µg/mL and 200nM, respectively. IF – immunofluorescence; 
rt-PCR – real-time polymerase chain reaction. 








1 mL rt-PCR 
4 wells (24 well plate) 50.000 cells 250 µL Confocal microscopy, IF, 
wound healing 
10 wells (96 well 
plate) 
20.000 cells 100 µL Survival 
 
2.14.3 Nanoparticle-mediated arterial wall transfection 
 
In the in vivo setting, an intravascular delivery of the NPs or NP:miRNAs was carried out 
by exposing the external carotid artery (ECA) and performing the arteriotomy, before 
infusing intra-luminally 200 µl of a 5mg/mL NP-fluoresceinamine or 5mg/mL:1µM 
NP:miR-92a inhibitor-FITC solution in Opti-MEM I at an infusion rate of 10 µL/min. After 
a total of 20 min of occlusion time the artery was finally flushed with PBS, before 
excluding the ECA proximally and resuming blood flow. 
 
Rat carotid ring segments were used for ex vivo transfection with NPs or NP:miRNAs. 
Each ring was incubated with 200 µl of NP- fluoresceinamine (5 mg/mL) or NP:miR-92a 
inhibitor-FITC solution (5 mg/mL; 1 µM respectively) in Opti-MEM I in 96 well plates for 
4 h, at 37ºC.  
 
2.14.4 Pluronic mediated arterial wall transfection 
 
In the in vivo setting, a 30% (w/v) Pluronic F-127 solution was prepared the day before 
surgery by dissolving the powder in cold double-distilled deionized water and allw. The 
solution was placed on a windmill rotating platform overnight at 4°C to ensure the 
polymer was homogenously mixed. The common carotid artery (CCA) was separated 
from the surrounding tissue using blunt tissue scissors, and a total volume of 300 µL ice 
cold pluronic solution containing NP (5 mg/mL), NP:miRNAs (5 mg/mL:1 µM) or 1 µM 
miRNA was applied externally to the adventitial surface of the exposed carotid artery 
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with a 100 µL micropipette, overall as described elsewhere (Kee et al., 2011). The 
solution jellified as soon as it came in contact with the rat tissue. Depending on the 
experimental layout, the administration was done on uninjured arteries or immediately 
after balloon angioplasty. 
For ex vivo assays, NP-fluoresceinamine (5 mg/mL) or NP:miR-92a inhibitor-FITC solution 
(5 mg/mL; 1 µM respectively) was resuspended in Pluronic or Poly(lactic-co-glycolic acid) 
(PLGA) gel, before being applied to the rings for 24h. 
 
2.15 Mouse aortic ring angiogenesis 
 
The mouse aortic ring assay to study angiogenesis was generally performed as described 
previously (Baker et al., 2012). C57BL/6 mice were culled by schedule 1 procedure, after 
which the aortas were harvested and transferred into Opti-MEM I supplemented with 
Penicillin 100 U/mL + Streptomycin 100 µg/mL. Under a Leica M80 dissection 
microscope, fat tissue and branching vessels were removed using forceps and 
microdissection scissors. The vessel was cut into 0.5 mm thick rings with a scalpel, with 
6-12 rings being placed per well in a 24 well plate. Rings were then transfected overnight 
using OF with the miRNA of interest (at a final concentration of 30 nM and a total volume 
of 1 mL/well), at 37 ºC and 5% CO2 in Opti-MEM I supplemented with Penicillin 100 U/mL 
+ Streptomycin 100 µg/mL. On the following day, rings were transferred into a 96 well 
plate (1 ring/well) to be embedded in 50µl of a collagen matrix, obtained by adding on 
ice 0.5 mL 10X DMEM, 3.13 mL dH2O, 1.37ml collagen type I (rat tail) and 10 µL 5 N NaOH 
(measures needed per 96 well plate). After 1-hour incubation at 37 ºC, the embedded 
rings were fed with 150 µl Opti-MEM I supplemented with 2.5% (v/v) FBS, 30 ng/mL 
VEGF and Penicillin 100 U/ml + Streptomycin 100 µg/ml, again to be placed in the 
incubator (Figure 22). In each experimental condition, a non-VEGF supplemented well 
was tested as a negative control. Rings were fed on day 5 by removing 130 µL and adding 
150 µL of fresh medium, and the protocol was stopped on day 7. At this point, bright 
field pictures were captured using an Axiovert 40 C inverted optical microscope before 
culture media was removed and rings washed with PBS with CaCl2 and MgCl2. Rings were 
then processed for IF (as described in Section 2.18.3) and the concentric peripheral 
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angiogenesis network coverage area estimated (in triplicates in the red channel), using 
Image J imaging software (after digital subtraction of the ring area itself). 
 
Figure 22 | Aortic ring setup. 
 
 
2.16 Time-lapse microscopy 
 
The Incucyte Zoom (Essen Biosciences) comprises a microscope inside a tissue culture 
incubator, capable of recording live cell imaging experiments over several days while 
providing consistent standard tissue culture conditions for the growing cells (37°C, 95% 
air, 5% CO2). Bright field and fluorescent images and videos of cells were captured and 
analysed using the proprietary software.  
 
2.17 Long-term fluorescence cell labelling 
 
For certain assays, EPCs were stained using CellTracker CM-DiI lipophilic, photostable 
fluorescence compound (excitation 553 nm, emission 570 nm), according to the 
manufacturer’s protocol. Briefly, the probe was resuspended in PBS to 2 μM and 
incubated with pre-washed adherent cells in culture for 5 minutes or less at 37°C, and 
then for an additional 15 minutes at 4°C. Incubation at this lower temperature appears 
to allow the dye to label the plasma membrane but slows down endocytosis, thus 
reducing dye localisation into cytoplasmic vesicles. 
 
2.18 Fluorescence microscopy 
 
Fluorescence is a type of luminescence. When molecules with luminescent properties 
absorb light, they emit light of a different wavelength. With fluorescence, the emission 
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of light occurs extremely rapidly after the absorption of excitation light. Fluorescent 
materials give off light because of their atomic structure. Electrons are arranged in 
discrete energy levels surrounding the atom’s nucleus with each level having a 
predetermined amount of energy. When an electron absorbs the energy from a photon 
of light, it becomes “excited” and jumps to a higher, less stable energy level. The half-
life of the excited state is generally less than 10 seconds. The electron loses a small 
amount of energy as heat, and the remainder of the extra energy is given off in the form 
of a photon. The emitted fluorescence has a lower energy than the absorbed light, so 
the wavelength of the emitted light is longer than that of the excitation light. A range of 
wavelengths of light can excite the electrons of a fluorochrome. Table 10 lists the 
fluorochromes used and corresponding excitation/emission spectra. 
 
 
Table 10 | Fluorochromes used in fluorescence microscopy. 
Approximate fluorescence excitation and emission maxima are indicated (solvent-dependent) from 
corresponding manufacturers’ online resources. DAPI - 4',6-diamidino-2-phenylindole; FITC - fluorescein 
isothiocyanate; LDL – low density lipoprotein; miRNA – microRNA; NP – nanoparticle. 
Probe Fluorochrome Excitation (nm) Emission (nm) 
Prolong Gold anti-fade 
reagent 
DAPI 350 461 
Conjugated Acetylated LDL Alexafluor-488 495 519 
Conjugated miRNA FITC 494 521 
Conjugated antibody FITC 495 519 
Conjugated NP Fluoresceinamine 495 519 
Conjugated antibody Alexafluor-488 519 495 
Lipophilic carbocyanine CM-DiI 553 570 
Conjugated antibody Alexafluor-555 555 568 
Conjugated miRNA DyLight 547 557 570 
Conjugated antibody PE 565 573 
Conjugated isolectin B4 DyLight 594 592 617 
Conjugated antibody Alexafluor-594 617 590 
Conjugated antibody DyLight 649 652 647 
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2.18.1 Acetylated LDL internalisation  
 
The endothelial commitment of EPCs was evaluated by incubating cells with acLDL 
conjugated to Alexafluor-488 and determining its uptake by fluorescent microscopy, a 
feature typical of ECs and microglial cells in primary cell culture (Sunada, Masuda, & 
Fujiwara, 1993). If the lysine residues of LDL’s apoprotein have been acetylated, the LDL 
complex no longer binds to the LDL receptor, but rather is taken up by macrophage and 
endothelial cells that possess “scavenger” receptors specific for the modified LDL (Voyta, 
Via, Butterfield, & Zetter, 1984). Once the acetylated LDL complexes accumulate within 
these cells, they assume an appearance similar to that of foam cells found in 
atherosclerotic plaques. Briefly, AlexaFluor488 conjugated Ac-LDL was added directly to 
cells growing in culture in 1 mL serum-free media EBM to yield a final concentration of 
10 μg/ml and left to incubate for 4 h at 37ºC. The medium was then aspirated, and the 
cells washed twice with PBS, before analysis. Imaging was captured using Axio Vert A1 
fluorescence (human EPCs) or Incucyte Zoom microscopes (pig EPCs) in the bright-field 
and green channels, before being processed in Simple PCI or Incucyte Zoom softwares, 
respectively. 
 
2.18.2 Fluoresceinamine internalisation 
 
Rat carotid artery rings were incubated at 37ºC with either NPs-fluoresceinamine 
labelled or NPs conjugated with hsa-miR-92a-1-fluorescein labelled (410456-04 Exiqon, 
Vedbaek, Denmark) at increasing concentrations of NPs (0-5mg/mL) and miRNAs (0-
1µM) in Opti-MEM I medium (for 4h) or gel (for 24h). Treatment with non-labelled NPs 
and omission of any treatment were used as negative controls. The samples were 




IF is the visualisation of antigens in cells/tissues specifically using antibodies as 
fluorescent probes. In IF techniques, antibodies are chemically conjugated to 
fluorescent dyes, which bind (directly or indirectly) to the antigen of interest allowing 
 Results - 130 
 
for antigen detection through fluorescence or confocal microscopy. The specific 
antibodies used for these assays are listed in Table 11. Advantages of direct IF include 
shorter sample staining times and simpler dual and triple labelling procedures. 
Disadvantages of direct IF include lower signal, higher cost, less flexibility and difficulties 
with the labelling procedure when commercially labelled direct conjugates are 
unavailable. Advantages of indirect IF include greater sensitivity than direct IF. There is 
an amplification of the signal in indirect IF because more than one secondary antibody 
can attach to each primary. Commercially produced secondary antibodies are available 
in an array of colours. Disadvantages of indirect IF include the potential for cross-
reactivity and the need to find primary antibodies that are not raised in the same species 
or of different isotypes when performing multiple labelling experiments. 
  
Table 11 | Antibodies used for immunofluorescent staining. 
CD – cluster of differentiation; EPCs – endothelial precursor cells; FITC - Fluorescein isothiocyanate; Ig – 
immunoglobulin; PE – Phycoerythrin; VEGFR2 – vascular endothelial growth factor receptor 2; vWF – von 
Willebrand factor. 
Target antigen Cell type Primary and secondary antibodies 
CD31 human 
EPCs 
1° = mouse monoclonal anti-human CD31 (JC70A) (1:20, M0823, Dako, 
Glostrup, Germany) 
2° = Dylight 649 donkey anti-mouse IgG (1:400, AP192SD, Milipore, 
Temecula, USA) 




1° = mouse monoclonal anti-human CD34-PE (1:11, 130-081-002, Milteny 
Biotec) 
2° = Alexafluor-594 goat anti-mouse IgG (1:500, A11005, ThermoFisher 
Scientific, Paisley,UK) 
Isotype control = mouse monoclonal IgG2a-PE (130-091-835, Miltenyi 





1° = polyclonal rabbit anti-FITC (1:50, 71-1900, Invitrogen ThermoFisher 
Scientific, Paisley,UK) 
2° = Alexafluor-555 donkey anti-rabbit IgG (1:500, A31572, ThermoFisher 
Scientific, Paisley,UK) 
2° = Alexafluor-488 donkey anti-rabbit IgG (1:500, A21206, ThermoFisher 
Scientific, Paisley,UK) 






1° = polyclonal rabbit anti-FITC (1:50, 71-1900, ThermoFisher Scientific, 
Paisley,UK) 
2º = Alexafluor-555 donkey anti-rabbit IgG (1:500, A31572, ThermoFisher 
Scientific, Paisley,UK) 
Isotype control = normal rabbit IgG (sc2027, Santa Cruz Biotechnology, 
Heidelberg, Germany) 
 




1° = rabbit polyclonal anti-human SMA (1:100, ab5694, Abcam, Cambridge, 
UK) 
2° = Alexafluor-488 donkey anti-rabbit IgG (1:500, A21206, ThermoFisher 
Scientific, Paisley,UK) 






1° conjugated = mouse monoclonal Anti-Actin, α-Smooth Muscle – FITC, 
clone 1A4 (1:100, F3777, Sigma-Aldrich, Dorset, UK) 
Isotype control = mouse monoclonal IgG2a-PE (130-091-835, Miltenyi 





1° = mouse monoclonal anti-human/pig VE-cadherin (1:50, sc9989, Santa 
Cruz Biotechnology, Heidelberg, Germany) 
2° = Alexafluor-488 goat anti-mouse IgG (1:500, A11001, ThermoFisher 
Scientific, Paisley, UK) 
Isotype control = mouse monoclonal IgG1 (NCG01, Abcam, Cambridge, UK) 
 
VEGFR2/ KDR human 
EPCs 
1° = mouse monoclonal anti-human VEGFR2-PE (1:50,130-093-598, Milteny 
Biotec, Bergisch Gladbach, Germany) 
2° = Alexafluor-594 goat anti-mouse IgG (1:500, A11005, ThermoFisher 
Scientific, Paisley, UK) 
Isotype control = mouse monoclonal IgG1-PE (130-093-188, Miltenyi Biotec, 
Bergisch Gladbach, Germany) 
vWF human 
EPCs 
1° = polyclonal rabbit anti-human vWF (1:100, A0082, Dako, 
Glostrup,Germany) 
2° = Alexafluor-488 donkey anti-rabbit IgG (1:500, A21206, ThermoFisher 
Scientific, Paisley, UK) 
2º = Alexafluor-488 goat anti-rabbit IgG (1:2000, A11034, ThermoFisher 
Scientific, Paisley, UK) 
Isotype control = normal rabbit IgG (sc2027, Santa Cruz Biotechnology, 
Heidelberg, Germany) 
 
IF for EPC surface epitope characterization 
 
At the end of the differentiation, expression of EC markers was evaluated by IF staining. 
Briefly, 6x104 EPCs (from human or pig origin) were plated in 1% gelatin coated Lab-Tek 
II chamber slides and left to rest overnight in 500 µl EGM 20% (v/v) FBS (see gelatin 
preparation method in section 2.10). The cells were fixed with PFA 4% (w/v) in PBS for 
15 min at RT and washed twice with PBS 1% (w/v) BSA.  Then, PBS/0.1% (v/v) Triton X-
100 was added to each chamber well to permeabilize the cell membrane. The solution 
was aspirated after 10 minutes at RT, and the cells were washed twice with PBS. CD34, 
KDR, vWF, VE-cadherin and SMA primary antibodies were prepared in PBS/0.1% (v/v) 
Tween-20/ 1% (w/v) BSA. After the addition of the primary antibody, the chamber slide 
was left overnight at 4°C on a shaking platform. Negative controls were obtained by 
using isotype-matched IgG control. Next morning, cells were washed 3 times with PBS. 
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The appropriate secondary antibodies were prepared in the same solution as before and 
added to the cells for 1 h at RT, protected from light. The wells were again washed 3 
times with PBS. The nuclei of the cells were counter-stained with 4',6-diamidino-2-
phenylindole (DAPI) for 5 minutes at RT, protected from light, which also functioned as 
a mounting reagent (DAPI propriatery concentration). The cells were examined and 
photographed under a Carl Zeiss Axio Vert.A1 fluorescence microscope. 
 
IF for confirmation of cellular internalisation of miRNA 
 
After miR transfection using OF or NPs, confirmation of internalisation was done by IF 
staining. Briefly, 4x105 human EPCs were seeded in coverslips pre-coated with 1% gelatin 
(see gelatin preparation method in section 2.10) inserted in 6 well plates and incubated 
overnight in EGM 30% (v/v) FBS. The following day cells were transfected with 30nM 
hsa-miR-92a-1 inhibitor-FITC (410456-04, Exiqon, Vedbaek, Denmark) using OF protocol. 
The omission of OF or incubation with the miR only were the negative controls. 
Alternatively, for NP assays, NPs-fluoresceinamine labelled (250 µg/ml) or NPs 
conjugated with miRNA-fluorescein labelled (250 µg/ml and 100nM) were the 
transfection vectors. Treatment with non-labelled NPs, treatment only with labelled NPs 
and omission of treatment were used as negative controls for NP transfections. After 
24h, cells were fixed in PFA 2% (w/v) in PBS for 15 min at RT and washed twice with PBS 
2% (w/v) BSA. Then, PBS/0.1% (v/v) Triton X-100 was added to the well to permeabilize 
the cell membrane. The solution was aspirated after 10 minutes at RT, and the cells were 
washed twice with PBS 2% (w/v) BSA. Primary anti-FITC antibody was prepared in 
PBS/0.1% (v/v) Tween-20/ 1% (w/v) BSA. After the addition of the primary antibody at 
1:50, the 6 well plate was left overnight at 4°C on a shaking platform. Negative controls 
were obtained by omission of primary antibody. Next morning, cells were washed 3 
times with PBS 0.1% (v/v) BSA. The appropriate secondary antibodies were prepared in 
the same solution as before and added to the cells for 1 h at RT, protected from light. 
The wells were again washed 3 times with PBS 0.1% (v/v) BSA. The nuclei of the cells 
were counter-stained with DAPI (proprietary concentration) for 5 minutes at RT, 
protected from light, which also functioned as a mounting reagent. The cells were 
photographed under a Carl Zeiss Axio Vert.A1 fluorescence microscope. 
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IF for confirmation of arterial wall internalisation of NP and miRNAs 
 
Carotid arteries once harvested and cleaned from the exceeding surrounding connective 
tissue were left to fix overnight in 4% PFA (w/v) in PBS at 4°C. They were then transferred 
to 70% ethanol until they were embedded in paraffin and cut perpendicularly to their 
longitudinal axis at Barts Cancer Institute pathology services, London, UK. 7µm cuts were 
performed along the arteries at 6 different levels (approximately every 1.5 mm along 
the average 1-1.2 cm total length of the artery). For rat carotid rings one cross-section 
per sample was performed at the midpoint level. Retrieved 5 µm-thick paraffin cross-
sections were dewaxed and hydrated, by sequentially passing the slides through the 
following steps: Xylene 5 min, Xylene 5 min, Xylene 5 min, absolute ethanol 5 min, 
absolute ethanol 5 min, 95% ethanol 3 min, 80% ethanol 2 min, distilled water 5 min. 
Antigen retrieval was performed by boiling in Citrate buffer pH 6.0 for 10 minutes. 
Citrate buffer was prepared by dissolving 2.94g of Trisodium citrate in 5.4 mL 1M HCl, 
topped up to 1L of milQ water. The sections were washed 3 times with PBS-Tween 20 
(PBS-T). PBS-T was prepared by dissolving 4 tablets of PBD in 2 mL of Tween 20 and 2 
mL of milQ water. A boundary was made around the tissue section using a DAKO pen. 
Non-specific antibody binding to proteins in tissue preparations was prevented by 
applying 5% donkey serum/0.5%Triton X100/PBS-T to each slide for 30 minutes at RT, 
the serum being from the species which provided the second layer antibody. The 
primary antibody rabbit anti-FITC was diluted in the same solution at 1:50 and pipetted 
on the tissue sections within the boundary (~100 µl). The slides were then placed at 4ºC 
overnight in a humidified chamber. Negative controls were obtained by omitting the 
incubation with primary antibody. Next morning, the slides were washed 3 times with 
PBS-T and the Alexafluor-555 donkey anti-rabbit IgG secondary antibody diluted 1:500 
in the same buffer was applied for 1h30m at RT, protected from light in a humidified 
chamber. Following 3 more PBS-T washes the tissue sections were counterstained and 
mounted with DAPI reagent (proprietary concentration) for 5 minutes at RT, protected 




 Results - 134 
 
IF for quantification of mouse aortic ring angiogenesis 
 
After a 4% formalin fixation step for 30 minutes at RT, rings were permeabilized with 
PBS with CaCl2 and MgCl2 and 0.25% Triton X-100 for 15 minutes at RT twice and then 
blocked using 1 drop of 2x casein buffer per well for 30 minutes at RT. Overnight 
incubation at 4ºC with DyLight 594 Labelled GSL I - isolectin B4 (1:100 dilution in PBLEC; 
DL-1207, Vector Labs, Burlingame, USA) and monoclonal anti-actin alpha-Smooth 
Muscle-FITC (1:100 dilution in PBLEC) then followed. PBLEC was constituted by diluting 
10X PBS with CaCl2 and MgCl2 in dH2O and add 0.1ml of 1M MnCl2 and 1% Tween 20. 
Next day, each well was washed three times in PBS and 0.1% Triton X-100 for 15 minutes 
and then wash once more with distilled water. The gel was detached from the walls of 
the well using curved thin forceps before being carefully transferred to a slide (6 
embedded rings per slide). Fluorescence mounting medium with DAPI (proprietary 
concentration) was added, before placing a coverslip over (avoiding air bubble 
formation). The slides were examined and photographed under a Carl Zeiss AxioVert A1 
fluorescence microscope.  
 
IF for quantification of co-culture angiogenesis 
 
Co-culture samples were fixed in ethanol 100% for 2 hours at RT. After one PBS-T wash, 
cells were blocked in dry milk 5% (w/v) in PBS-T for 1h at RT on an orbital shaker. Then, 
the coculture was incubated overnight at 4ºC on an orbital shaker with 200 µl of primary 
vWF antibody (1:1000) in 5% (w/v) dry milk in PBS-T. The next day, cells were washed 
twice with PBS-T, before secondary goat anti-rabbit Alexafluor 488 conjugated antibody 
diluted in PBS-T (1:2000) was added for 60 minutes at RT, on the shaker and protected 
from light. After 2 more washes with PBS-T, samples were stored in MilQ water and 
images of the wells captured on demand using Incucyte Zoom fluorescent microscope 








The joint application of immunofluorescent staining with confocal microscopy allows the 
visualisation of protein localisation within the cell in a single plane. For confirmation of 
cellular internalisation of miRNA, 50 000 human late-outgrowth EPCs were plated in 
gelatin 1% pre-coated coverslips (see gelatin preparation method in section 2.10) placed 
in a 24 well plate, and incubated overnight with EGM/20% (v/v) FBS at 37ºC. In the 
following day, after 2 washes with PBS, cells were transfected with dual labelled NPs-
fluoresceinamine conjugated with sham miRNA-Dy547 (CP-004500-01-05, miRIDIAN 
microRNA Mimic Transfection Control Dy547, Thermo Scientific, Surrey, UK) at 125 
µg/mL and 100 nM respectively. Exclusive NP, miRNA or no treatment were used as used 
as control conditions. Following the 4 h of treatment, cells were washed twice with PBS 
1% (w/v) BSA for 2 mins, before fixation in situ with PFA 4% (w/v) in PBS for 15 min at 
RT. Cells were gently washed twice with the coverslip inverted on top of a PBS drop, 
followed by anti-CD31 incubation for 2 h at RT and protected from light. The antibody 
predominantly displays staining of the cell membrane, with weaker cytoplasmic 
staining, according to the manufacturer. Cells were gently washed twice with the 
coverslip inverted on top of a PBS drop, before staining with the secondary antibody for 
1h at RT, protected from light. Again, cells were washed twice on a PBS drop, before 
counterstaining with DAPI mounting media (proprietary concentration) for 5 min at RT 
in the same fashion, and then placed on a microscope slide. Digital micrographs and z-
stack videos were taken on a Zeiss LSM 510 Meta confocal laser microscope using an oil 




Carotid arteries and rings were processed as in page 130 until the antigen retrieval step. 
Then, antigen retrieval was performed by treating the tissue sections with Pronase for 
15 minutes at RT. After 3 washes in PBS-T and 1 wash with distilled water, the sections 
were then treated with 3% (v/v) Hydrogen peroxide in milQ water for 15 minutes to 
block endogenous peroxidases. The sections were washed once with distilled water and 
twice with PBS-T before a boundary was made around the tissue section using a 
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hydrophobic PAP pen. The Avidin/Biotin Blocking Kit was used, according to 
manufacturer’s instruction, to block all endogenous biotin, biotin receptors, and avidin 
binding sites present in tissues. The slides were washed 3 times with PBS-T and blocked 
in 5% goat serum/0.5%Triton X100/PBS for 30 minutes at RT. The primary rabbit anti-
FITC antibody (71-1900, ThermoFisher Scientific, Paisley, UK) was applied at 1:50 
dilution and samples left overnight in a humidified chamber at 4ºC. Negative controls 
were obtained by omitting the incubation with primary antibody. Next morning, the 
slides were washed 3 times with PBS-T before adding secondary goat anti-rabbit 
biotinylated IgG (E0432, Dako, Glostrup, Denmark), at 1:100 in 5% goat 
serum/0.5%Triton X100/PBS. The slides were kept at RT for one hour. During the last 
half hour of incubation, the ABC solution was prepared as per manufacturer’s protocol 
and allowed to stand at RT for at least 30 minutes. The slides were then washed with 
PBS-T (1 wash). The ABC solution was added to the tissue sections after gently drying off 
the excess buffer. The slides were further incubated at RT for 30 min. Towards the end 
of incubation, the 3-3’diaminobenzidine (DAB) substrate solution was prepared. Briefly, 
1 golden and 1 silver tablets were dissolved in 1 ml of PBS (vortex). The slides were 
washed with PBS-T, before adding the DAB solution dropwise. The slides were allowed 
to stain for about 15 minutes under the microscope before the reaction was stopped by 
transferring the slides to PBS-T. The stained sections were counterstained for 10 seconds 
with Mayer’s haematoxylin solution (solution previously filtered) and differentiated in 
tap water. The slides were then washed one final time in PBS-T and dehydrated by 
passing through an ascending alcohol gradient, followed by 2 changes in xylene. They 
were finally mounted in DPX -  a mixture of distyrene + plasticiser (tricresyl phosphate) 
+xylene -, and covered with a slip. The slides were examined under an inverted optical 
microscope, and the appropriate primary antibody concentration was determined, after 
which all remaining slides were stained using this concentration. The slides were 




The gene expression profile of specific targets of hsa-mir-92a-1-5p mirvana mimic and 
hsa-mir-92a-1-5p mirvana inhibitor were evaluated in EPCs transfected with NPs 
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complexed with miRNA at 250 µg/mL and 200 nM respectively in 6 well plates. EPCs 
transfected with NP:Dy547 (CP-004500-01-05, miRIDIAN microRNA Mimic Transfection 
Control Dy547, Thermo Scientific, Surrey, UK) served as negative transfection controls. 
Cell lysates were homogenised with QIAshredder, and total RNA was extracted with 
RNeasy Mini kit, according to the instructions of the manufacturer. Total RNA was 
quantified using Nanodrop 3300 spectrophotometer, and cDNA was prepared from 1 µg 
total RNA using QuantiTect Reverse Transcription Kit. Real-time PCR was carried out 
with the Brilliant II SYBR Green QPCR Master Mix on a Mx3000P qPCR System, following 
the manufacturer’s instructions. Each cDNA was analysed with the target gene and 
housekeeping gene primer sets that approached 100% amplification efficiency, allowing 
direct comparison of threshold cycle (Ct) values to determine relative gene expression. 
The target gene signal was first normalised to b-actin and then expressed relative to the 
value obtained with control EPCs by using the formula 2-Δ Δ Ct, as described elsewhere (X. 
Yang et al., 2005). The mean minimal Ct were calculated from triplicate reactions. Primer 
sequences, reaction conditions, and optimal cycle numbers are outlined in Table 12. 
Quality control checking included melting curve analysis after amplification of original 
template (95°C, 1min; melt ramp 30 sec from 65ºC to 95° rising by 1°C per step; 95°C, 
30 sec), and running a 1.2% pre-cast agarose gel electrophoresis of PCR products stained 
with 0.01% Ethidium bromide in E-gel iBase powersystem (Thermofisher Scientific). 
 
Table 12 | Primers for rt-PCR 
rt-PCR conditions: Initial denaturation step at 95ºC, 3min; 40 cycles of denaturation at 95ºC for 5 sec, 
primer annealing/elongation at 60ºC for 20 sec. ACTB – β actin; ITGA5 – integrin α5 subunit; rt-PCR – real-
time polymerase chain reaction. 
Target gene Sense primer sequence 
(5’->3’) 
Anti-sense primer sequence 
(5’->3’) 
Concentration (nM) 
ACTB TGTCCCCCAACTTGAGATGT TGTGCACTTTTATTCAACTGGTC 500 
ITGA5 TCTTCCCCGCCATGTTCAACCC AAGGTTGATGCAGGCCACAGGG 500 
 
2.21 Western blotting 
 
Cell lysate samples are prepared with a denaturing buffer, containing an anionic 
surfactant such as sodium dodecyl sulphate (SDS) or lithium dodecyl sulphate (LDS), and 
a reducing agent such as beta-mercaptoethanol, dithiothreitol (DTT) or Tris(2-
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carboxyethyl)phosphine (TCEP). This denaturing buffer causes the loss of native protein 
conformation by disrupting non-covalent intra- and inter-molecular protein bonds. 
Denatured cell lysate samples are run by electrophoresis through a polyacrylamide gel. 
Proteins are separated by size, as larger proteins migrate more slowly through the pores 
of the gel than smaller proteins. Proteins separated on the gel are then transferred via 
electrophoretic blotting to a protein-binding polyvinylidene fluoride (PVDF) membrane. 
After electrophoretic transfer, the membrane can be cut into strips based on the known 
molecular weight of the proteins of interest. Membranes are initially incubated in a 
protein solution such as BSA or milk to block non-specific binding sites. The specific 
protein of interest is detected by incubation with an antibody to that protein. This 
antibody is then visualised via incubation with a secondary antibody conjugated to an 
enzyme such as Horse-radish peroxidase (HRP). Upon addition of a substrate solution, 
the conjugated antibody catalyses a reaction to produce a tightly localised 
chemiluminescent product, which is then detected using a photographic film. 
Western blotting can be considered a semi-quantitative technique, as the amount of 
protein present in the cell lysate, is proportionally represented by the amount of bound 
antibody on the membrane. This, in turn, is represented by the amount of light produced 
by the chemiluminescent reaction which is detected by the photographic film. The 
intensity of the band produced is the representation of the level of the specific protein 
in the sample and can be quantified by densitometry after scanning, using software such 
as ImageJ. 
 
2.21.1 Protein extraction from EPC cultures 
 
Cells cultured in 6 well plates were washed twice with cold PBS on ice and lysed in RIPA 
buffer (50 μl per well) including complete protease inhibitor cocktail (working 
concentration 1x). The cells were scraped off the plate and the lysates transferred to 1.5 
mL tubes. The samples were centrifuged for 15 minutes at 13 000 x g at 4 °C to pellet 
the insoluble material. The supernatant containing the protein lysate was removed and 
kept on ice, or at -20 °C for longer-term storage. 
 
 Results - 139 
 
2.21.2 Protein extraction from rat arteries  
 
Rat carotid arteries were harvested, incubated in Krebs solution (10x solution 
reconstituted in milQ water), cleared out of extraneous tissues under a 
stereomicroscope and snap frozen in liquid nitrogen. Protein extraction involved the 
sample lysis, bead-beating homogenization and retrieval of the protein lysate. Briefly, a 
solution of RIPA buffer containing Complete Protease Inhibitor Cocktail was prepared at 
4° C as per manufacturers’ recommended dosages, and 100 µl dispensed into Precellys 
ceramic beads pre-filled 0.5 mL tubes. The frozen artery was inserted into the tube, and 
the samples homogenised for 3 x 60 seconds at full speed in a Minilys tissue 
homogenizer. The tubes were kept at 4 °C for 60 seconds in between the homogenizer 
runs. The uniform sample was transferred to a 1.5 mL Eppendorf and centrifuged at 13 
000 rpm for 15 minutes at 4 °C. The supernatant was then transferred to a clean tube 
and stored at -20 °C. 
 
2.21.3 Determination of protein concentration and normalisation 
 
The Bradford protein assay allows the determination of protein concentration in tissue 
and cell lysate samples as essentially described elsewhere (Ramagli, 1999). There are 
commercially available kits for this assay. Therefore the Bio-Rad Protein Assay Kit was 
used. It is a colorimetric test based on the absorbance shift of the dye Coomassie Brilliant 
Blue G-250 under acid conditions when a redder form of the dye is converted into a 
bluer form on binding to the protein. The characteristic blue colour produced by the 
reaction has a maximum absorbance at 750 nm and the minimum absorbance at 405 
nm due to the amino acids tyrosine and tryptophan and to a lesser extent cysteine and 
histidine (from the Bio-Rad instruction manual). The amount of the blue-coloured 
complex in solution is a measure of protein concentration and can be quantified using 
absorbance reading to determine the protein concentration.  
Protein standards were prepared using BSA diluted in the same buffer in which protein 
extraction had been performed. The following dilutions of BSA were prepared – 2.0, 1.5, 
1.0, 0.5, 0.25, 0.125, 0.0625, 0.03125 and 0 mg/mL protein. Protein concentration was 
measured by taking 5 µL of cell lysate sample or standard and adding to 25 µl of the Bio-
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Rad A’ solution (alkaline copper tartrate solution) and mixing in a 96-well plate with 
200ul of the B solution (a dilute Folin reagent). The mixture was incubated at RT for 15 
minutes, shaking, protected from light. The absorbance of each well was measured at 
595 nm using a Tecan Genios plate reader. Every serial dilution or tissue sample was 
tested on two wells and the final result taken as the average. The absorbance values for 
the calibration dilutions were plotted against the standard concentrations of BSA to 
produce a linear calibration curve (Figure 23), and the protein concentration of the 
tissue samples was determined against it. Tissue samples that gave a higher absorbance 
reading than that of the highest standard (2.0 mg/mL) were re-diluted so that their 
absorbance fell within the linear range of the assay. 
 
Figure 23 | Bradford assay standard curve. 
A representative standard curve generated with BSA used to determine the concentration of protein 
extracts from EPCs and rat carotid arteries. 























3.21.4 SDS-PAGE and immunoblotting 
 
Different volumes of protein samples normalised to the same lowest concentration, 
were added to 4x loading buffer and 10x reducing buffer and topped up with RIPA+PIC 
buffer to make up 25 µl final volume, which was then reduced by boiling at 80 °C for 4 
minutes and vortexed for 2 seconds prior to loading. The reduced samples were 
separated using SDS-polyacrylamide gel electrophoresis (SDS-PAGE), by running them 
on a 4-12% Bis-Tris Gel in 5% MOPS-SDS Running buffer alongside a molecular weight 
marker. The protein was then transferred to a 0.45-μm pore size protein-binding 
polyvinylidene fluoride (PVDF) membrane using a wet transfer apparatus in 1x NuPAGE 
transfer buffer containing 20% methanol. The transfer was carried out at 35V for 90 
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minutes. Membranes were blocked in 5% (w/v) non-fat milk made up in PBS + 0.1% (v/v) 
Tween20 (PBS-T) for an hour at RT. Membranes were incubated with appropriate 
primary antibody diluted in the 5% milk-PBST solution overnight on a rocker at 4°C. A 
list of used antibodies and corresponding titrations can be seen in Table 13. Next 
morning, membranes were given three rounds of 5-minute washes with PBST (on a 
rocker), prior to addition of the HRP conjugated secondary antibody of the appropriate 
species, in 5% milk-PBST solution. This was incubated for 1 hour with rocking at RT and 
was then subjected to three 5 minute rounds of washing in PBST (with rocking). Protein 
bands were visualised using ECL-plus western blotting detection system on Hyperfilm 
ECL. The hyper film was scanned using the HP Deskscan system. β-actin (ACTB) was 
usually probed for as a loading control in Western blotting. As this is considered a house-
keeping gene, its level can be used to determine the relative amounts of protein loaded 
in each well. Accordingly, protein expression results were then quantified by scanning 
densitometry using Image J software. 
 
Table 13 | Antibodies used for western blotting. 
ACTB – β actin; Akt – protein kinase B; CD – cluster of differentiation; eNOS – endothelial nitric oxide 
synthase; EPCs – endothelial precursor cell; ERK1/2 - Extracellular signal–regulated kinase 1/2; FITC - 
Fluorescein isothiocyanate; GAPDH - Glyceraldehyde 3-phosphate dehydrogenase; HRP – horse-radish 
peroxidase; Ig – immunoglobulin; ITGA5 – integrin α5 subunit; ITGAV – integrin αv subunit; kDa – 
kilodaltons; MKK4 - Mitogen-activated protein kinase kinase 4; PE – Phycoerythrin; SIRT1 – sirtuin 1; 
VECAD – vascular endothelial cadherin; VEGFR2 – vascular endothelial growth factor receptor 2; vWF – 
von Willebrand factor. 
Target 
antigen 






1° = monoclonal mouse anti-rat ACTB, Clone AC-15 (1:20,000, A5441, Sigma 
Aldrich, Dorset, UK) 








1° = monoclonal mouse anti-human/pig, Clone AC-15 (1:106, A5441, Sigma 
Aldrich, Dorset, UK) 





pig EPCs 1° = rabbit anti-pig (Ser 473) (1:1000, 9271, Cell signalling, Massachusetts, 
USA) 
2° = goat anti-rabbit IgG-HRP (1:10000, SC2030, Santa Cruz Biotechnology, 
Heidelberg, Germany) 
 




pig EPCs 1° = rabbit anti-pig (C73H10) (1:1000, 2938, Cell signalling, Massachusetts, 
USA) 







1° = rabbit anti-human/rat (Ser 1177) (C9C3) (1:000, 9570, Cell signalling, 
Massachusetts, USA) 










1° = mouse anti-human/pig (1:3000, 610296, BD Biosciences, USA) 





pig EPCs 1° = rabbit anti-pig (Thr202/Tyr204) (D13.14.4E) (1:000, 4370, Cell signalling, 
Massachusetts, USA) 





pig EPCs 1° = rabbit anti-pig (1:1000, 9102, Cell signalling, Massachusetts, USA) 







1° = polyclonal goat anti-human/rat/mouse, V-18, HRP conjugate (1:2000, 









1° = mouse monoclonal anti-human ITGA5, Clone IgG2A (2ug/mL, MAB18642, 
R&D systems, MN, USA) 








1° = rabbit anti-human ITGA5, c-terminus, intracelular (1:1000, AB1928, 
Milipore, Temecula, USA) 








1° = rabbit anti-human (1:000, 4711, Cell signalling, Massachusetts, USA) 






1° = rabbit anti-human (1:000, 9152, Cell signalling, Massachusetts, USA) 







1° = rabbit anti-human (1:1000, C14H4 Cell signalling, Massachusetts, USA) 





pig EPCs 1° = mouse monoclonal anti-human/pig VE-cadherin (1:50, sc9989, Santa 
Cruz Biotechnology, Heidelberg, Germany) 
2° = goat anti-mouse IgG-HRP (1:10000, SC2005, Santa Cruz Biotechnology, 
Heidelberg, Germany) 
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2.21.5 Stripping and reprobing western blot membranes  
 
Membranes were occasionally stripped of the bound antibodies following the 
development of the western blot. Reblot Plus Strong stripping solution was used 
according to the manufacturer’s instructions to remove bound antibodies. Briefly after 
2 washes with PBS-T, the membrane was incubated with the stripping solution for 15 
minutes at room temperature in the roller (1mL of 10x Milipore solution + 9 mL of 
molecular biology grade water). Then, the membrane was washed in running milQ water 
for 1 minute. The stripped membranes were then blocked in 5% milk (w/v)-PBS-T 
solution and incubated with the relevant primary and then secondary antibodies, and 
Western blots were then developed as previously described. 
 
2.22 EPC functional assays 
 
2.22.1 Luminescence-based survival 
 
Following the miRNA transfection procedure with OF in two white-walled multiwell 96 
well plates (30,000 cells/well), human EPCs were incubated for 48 h in EGM 10% (v/v) 
FBS to allow miRNA knockdown. Survival in serum-free medium after 6h was assessed 
using a Luminescent cell viability Adenosine triphosphate (ATP)-based assay (Cell Titer 
Glo), following the manufacturer's instructions. This assay is a homogeneous method of 
determining the number of viable cells in culture based on quantitation of the ATP 
present, an indicator of metabolically active cells. The assay system utilises the 
properties of a thermostable luciferase to enable reaction conditions that generate a 
stable luminescent signal while simultaneously inhibiting endogenous enzymes released 
during cell lysis (e.g., ATPases). The ATP-based detection of cells has been shown to be 
more sensitive than other methods (Maehara, Anai, Tamada, & Sugimachi, 1987; Petty, 
Sutherland, Hunter, & Cree, 1995) and has already been used to assess endothelial cell 
viability (Logie et al., 2010).  
Briefly, one of the 96 well plates was used for the baseline reading. Cells were washed 
once, before equilibrating in 50 µl in EBM for 15 mins at 37°C, following the 
manufacturer's instructions. Then an equal volume of Cell Titer Glo reagent was added 
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per well and the plate inserted on an orbital shaker (to induce cell lysis) for 2 mins at RT. 
The mixture was allowed to rest for 15 minutes, covered with a lid in the dark, before 
being read in a Genios Tecan luminometer (firefly luciferase peak emission 560 nm). 
Replicates of 6 were used for each experimental condition. The medium without cells 
was used as a blank control and deducted from the values in experimental wells. As for 
the second well plate, cells were washed once and incubated in EBM serum free medium 
for 6h, before executing the luminescence assay. 
If NPs were used as the transfection vector in 96 well plates (20,000 cells/well), then 
EPCs would be incubated in EBM under normal FiO2 (21%) and the assay conducted 
using Cell Titer Glo, as described previously but using a 48h endpoint instead. The 
medium without cells was used as a blank control and deducted from the values in 
experimental wells, and treatment with only NPs was used as an internal control when 
evaluating NP:miRNA effect. Replicates of 5 were used for each experimental condition. 
An interference assay demonstrating that NPs do not block the luciferase reporter was 
conducted with the following experimental conditions: NP 125 µg/mL + ATP 50 µM in 
PBS; ATP 50 µM in PBS as a positive control and only medium as a negative control 
(Figure 24). 
 
Figure 24 | Nanoparticles were incubated with ATP revealing no luciferase reporter interference. 
 
 
2.22.2 Co-culture angiogenesis 
 
Late outgrowth EPCs were transfected using OF in 6 well plates for 4 hours with miRNA 










NP 125 µg/mL +
ATP 50 µM
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20,000 transfected EPCs in 100 µl of EGM 5% (v/v) (i.e. 2x105 cells/mL) were added to 
confluent fibroblast monolayers already in 400 µl of the same medium. The fibroblasts 
had been previously seeded in 24 well plates 3 days before at a density of 1x105 cells/mL 
and allowed to expand on DMEM 10% (v/v) FBS. Next day, medium was replaced to EGM 
1% (v/v) FBS + VEGF 25 ng/mL, and co-cultures grown for 96h. Replacement of medium 
occurred at 48h. The omission of VEGF treatment was the negative control condition. At 
the end of the assay, brightfield pictures of the coculture taken with Incucyte Zoom 
microscope, while the effects of angiogenic stimuli were assessed by IF (as described in 
section 2.18.3). Images of the wells were captured on demand using Incucyte Zoom 
fluorescent microscope. All experimental conditions were measured in triplicate. 
Angiogenesis network length, area and number of branch points based on fluorescence 
signal were automatically calculated using proprietary Incucyte Zoom software 
algorithm (Figure 25). 
 
Figure 25 | Co-culture angiogenesis network analysis algorithm run by Incucyte Zoom software. 
wWF – von Willebrand factor 
 
 
2.22.3 Luminescence-based proliferation 
 
The proliferation assay consisted in a luminescent method using Cell Titer Glo reagent 
to determine the number of viable cells in culture based on quantitation of the ATP 
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using OF in two white opaque 96 well plates, EPCs (30 000 cells/well) were incubated 
overnight in Opti-MEM I 30% (v/v) FBS, before starting the proliferation assay itself. The 
next day, one of the 96 well plates was used for the baseline reading. Following the 
manufacturer's instructions, cells were washed once, before equilibrating in 50 µl in 
EBM for 15 mins at 37ºC. Then 50 µl of Cell Glo Titer reagent was added per well (1:1 
ratio) and the plate inserted on an orbital shaker (to induce cell lysis) for 2 mins at RT. 
The mixture was allowed to rest for 15 minutes, covered with a lid in the dark, before 
being read in a Genios Tecan luminometer (firefly luciferase peak emission 560 nm). 
Replicates of 4 were used for each experimental condition. The medium without cells 
was used as a blank control and deducted from the values in experimental wells. As for 
the second well plate, cells were washed once and incubated in EGM 10% plus or minus 
VEGF 25 ng/mL for 48 h, i.e. during oligonucleotide knockdown, before executing the 
luminescence assay. 
 
2.22.4 Cell-matrix adhesion 
 
Cell population adhesion studies, as opposed to single cell studies, involve the analysis 
of attachment events for a group of cells. In a wash assay as the one used, cells are 
cultured in static 96 multiwell plates for the cell attachment events, followed by cell 
washing, providing basic quantitative adhesion data by determining the fraction of cells 
which remains attached. Briefly, the day before running the assay, black walled 96 well 
plates were coated overnight at 4°C with 1 μg/mL FN (7 replicates per condition) or 3% 
(w/v) BSA to control for unspecific binding (3 replicates per condition). The coating was 
then blocked for one hour at RT with 3% (w/v) BSA. 72h after vital fluorescence labelling 
with CellTracker CM-DiI and 48h after oligonucleotide transfection in 6 well plates, EPCs 
were detached with trypsin (trypsin 0.1% v/v in PBS), resuspended in EBM with 0.05% 
HSA, and immediately seeded at 10 000 cells/100 μL/coated well. Cells not stained with 
DIi served as internal controls. Cells at baseline were captured using Incucyte Zoom at 
10x magnification, focused to the centre of the well, benefiting from gridlocked 
immunofluorescent imaging. After 20 mins at 37°C, nonadherent cells were washed 
away with warm EBM, and adherent cells were then photographed already in EGM 10% 
(v/v) FBS at the same gridlocked focus point. Baseline and final red object count were 
quantified using Incucyte zoom software (Figure 26), and data are expressed as mean 
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adhesion on FN minus mean unspecific adhesion on HSA.  The excitation and emission 
maxima of the fluorophore used are given in Table 10. 
Figure 26 | Incucyte red object count algorithm. 
 
 
2.22.5 Wound healing migration 
 
This method is based on the observation that, upon creation of a new artificial gap, so-
called ‘‘scratch’’, on a confluent cell monolayer, the cells on the edge of the newly 
created gap will move toward the opening to close the ‘‘scratch’’ until new cell–cell 
contacts are established again. Compared to other methods, the in vitro scratch assay is 
particularly suitable for studies on the effects of cell-matrix and cell-cell interactions on 
cell migration (Liang, Park, & Guan, 2007). EPCs grew to an 80% confluent monolayer in 
gelatin 1% coated ImageLock 96-well plates (see gelatin preparation method in section 
2.10) were transfected with 30 nM miRNA using OF (as described in section 2.14.1). After 
48h knockdown in EGM 10% (v/v) FBS cells were washed once with PBS and subject to 
2h incubation in serum-free medium (EBM). Then, an identical wound was made in the 
monolayer of each well using IncuCyte woundmaker. After washing once with warm 
PBS, the medium was replaced with EBM 0.5% (v/v) FBS (200 µL/well) ± VEGF at 25 
ng/mL. Cells were placed in Incucyte Zoom incubator time-lapse microscope, and images 
were captured every 2h at the desired magnification for a total duration of 48h. Each 
experimental condition was repeated in 6 replicates. The rate of wound closure was 
calculated using the Incucyte Zoom software and expressed as relative wound density. 
Figure 27 represents brightfield images of assay baseline and endpoint and 
corresponding masks automatically defined and used by Incucyte Zoom software to 
calculate the rate of wound closure. 
 
  
Red channel (Dii+ cells) Incucyte algorithm mask Merge (red channel + mask + phase) 
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Figure 27 | Scratch assay Incucyte algorithm. 
 
 
For EPCs that were transfected with NP:mir-92a inhibitor in 24 well plates, a manually 
performed scratch was performed as reported elsewhere (Liang et al., 2007). The day 
following transfection, the cell monolayer was scraped in a straight line to create a 
‘‘scratch’’ with a P200 pipet tip. The debris were removed by aspirating the medium. 
The remaining cells were washed with EBM and incubated without serum and VEGF over 
48 hours, under normal FiO2 (21%) content. Cells were photographed at 5x using an Axio 
Observer inverted optical microscope and the denuded area (µm2) at the end of the 
follow-up period was quantified with Axiovision 4.5 digital image analysis software. 










Incucyte software mask Brightfield 
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2.22.6 Chemotaxis migration 
 
A transwell assay was used to assess cellular migration through a porous membrane 
towards the chemoattractant in the lower chamber as described before (Pellet-Many et 
al., 2011; Sadahira, Ruan, Hakomori, & Igarashi, 1992). The principle of the transwell 
assay was initially developed for the study of leukocyte chemotaxis by S.V. Boyden in 
1962 and is thus also known as the modified Boyden chamber assay. Briefly, 48h prior 
to the migration assay, EPCs were transfected with different miRNAs at 30nM using OF 
in a 6 well plate. Transwell inserts with 8 μm membrane pore size were coated with FN 
2.5 µg/mL at RT for 1h, before being inserted into 24-well plate with 700 μl EBM ± 50 
ng/mL VEGF in the lower chamber (Figure 28). Cell suspensions in serum-free medium 
were then added to the upper chamber (at a density of 5x105 cells/well in 500 μl) and 
incubated at 37ºC for 5 h. Each treatment was performed in duplicate. Unmigrated cells 
were removed by scraping the upper side of the membrane with a cotton bud, and the 
migrated cells were fixed, stained with the Reastain Quick Diff and mounted onto glass 
slides. The inserts were seen and photographed under a Leica Macrofluo macroscope 
(×8 magnification). A total number of nuclei of migrated cells per insert were counted 
digitally using Image J imaging software. No VEGF was used as internal migration 
negative control, 10% FBS as positive internal control, and miRNA scrambled was used 
as transfection control.  
Figure 28 | Chemotaxis migration assay setup. 
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2.23 Rat Carotid Artery Balloon Angioplasty 
 
Male Sprague-Dawley rats (Charles River, UK)  350-400g (2-3 months) were used for the 
arterial injury, following the surgical recommendations described elsewhere (Tulis, 
2007). Male rats were preferred due to the potential impact of hormone levels on 
various cellular functions that have been identified in females (Tulis, 2007). It was 
important to use fully grown animals as vessel calibre will directly impact the severity of 
the injury from use of a standard-sized (2 French) inflated balloon catheter. Briefly, 
animals were induced by anesthesia using a combination of intraperitoneal midazolam 
(625 µg/100g animal weight) and intramuscular Fentanyl/fluanisone (40 µg/100g animal 
weight) and supported by Isoflurane 0.5-2% at 2 L/min O2 flow, following the UCL 
Cruciform Biological service unit (BSU) protocol. Other pre-operative procedures 
included placement of the animal in heating, clipping of the neck hair, topical 
disinfection of the surgical field with an antiseptic solution followed by 70% alcohol, and 
the subcutaneous + topical administration of 1:10 Bupivacaine 0.5% with epinephrine 
1:200 000 at the site of the incision. The local anaesthetic lasts up to 6 hours, has 
prolonged soft-tissue pain control for up to 7 hours, decreases the incidence of muscular 
spasm of the carotid vasculature, and offers a moderate degree of vasodilation to 
simplify insertion of the catheter through the arteriotomy incision. Following a midline 
neck skin incision, the left CCA was exposed at the bifurcation to the ECA and internal 
carotid artery (ICA) via blunt tissue dissection and the use of 3-0 mersilk sutures to 
retract the subcutaneous tissue (Figure 29). The superior thyroid artery, the first branch 
of the ECA, was identified and ligated to ensure a bloodless operating field. The ECA was 
permanently ligated cranially. Surgical micro-clips were placed on the ICA and proximal 
CCA for temporary exclusion of the ECA, followed by a transverse arteriotomy in the ECA 
3mm distally from the bifurcation produced with micro-scissors. A 2F Fogarty 
embolectomy catheter was inserted via the arteriotomy with the aid of vessel dilating, 
and the catheter advanced proximally into the CCA down to just above the aortic arch. 
The catheter was then inflated using 100 µL of air and then rotated while retracting. This 
manoeuvre was repeated three times ensuring complete endothelial denudation and 
exposure of the subendothelial ECM consisting of the internal elastic lamina. The length 
of the injured segment was similarly defined proximally by the carotid bifurcation and 
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distally by the edge of the omohyoid muscle. The balloon was removed from the vessel, 
and a proximal 3-0 sofsilk suture placed previously was tied to ligate the arteriotomy 
hole. The clips at the CCA and ICA were released, and the blood flow was restored. The 
subcutaneous tissue and skin were closed with continuous 4-0 vycril.  The mean total 
duration of the surgery was 30 minutes.  Post-operative procedures leading to swift 
animal recovery included top up of local anaesthesia/analgesia, the application of a 
topical antiseptic, spraying of the wound with skin moisturiser and the administration 
of supplemental fluids.  
 
Figure 29 | Rat carotid balloon angioplasty model. 
CCA – common carotid artery; ECA – external carotid artery; ICA – internal carotid artery. 
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2.24 Intravascular transplantation of EPCs 
 
In order to study the engraftment capacity of transfected EPCs at the angioplasty site, 
human late-outgrowth EPCs were previously labelled with CellTracker CM-DiI lipophilic, 
photostable fluorescence compound. The day after labelling, EPCs were transfected in 
6 well plates with the selected miRNAs using OF. After 48h of knockdown and 
immediately before rat carotid artery injury, 5x105 cells were resuspended in 300 µL of 
EBM in 1.5 mL Eppendorf. After retraction of the balloon catheter, a 26G needle catheter 
was inserted into the site of the arteriotomy. The cell suspension was gently infused into 
the clamped carotid artery over a total 10 min occlusion period. A PBS flush through the 
needle was then performed before ligating the artery. Rats were sacrificed 24h post-
transplantation of DIi-labelled EPCs, perfused with PBS and their carotid arteries 
harvested and incubated in Krebs solution. In order to quantify the number of EPC 
transplanted at the injury site, arteries were then opened longitudinally and examined 
“en face” on a fluorescent Leica macroscope (red channel), following anatomical 
references (S1- distal CCA, S2 – middle CCA, S3 – proximal CCA as displayed in Figure 30. 
Engrafted cellular area was quantified using freehand selection tool in Image J. 
 
Figure 30 | Carotid artery normal anatomy.  
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2.25 Harvesting of the arteries for post-mortem 
analysis  
 
Following left carotid artery exposure using forceps and small scissors, the distal end of 
the CCA at the bifurcation suture was cut, gently lifted, and the entire length of the 
artery separated from extraneous tissues in a caudal direction to the aorta. Extraneous 
tissues still attached to the vessel were gently clean, and the lumen was freed of blood 
clots, if any, gently flushing the lumen with Krebs. The suture knot allowed to maintain 
proper orientation of the vessel. The sample was placed in 1:10 Krebs Solution for 
protein, fluorescence and histomorphometric assays. Alternatively, for ex vivo 
transfection assays, the samples were placed in Opti-MEM I medium supplemented with 
Penicillin 100 U/ml + Streptomycin 100 µg/ml, before being sliced into smaller 2-5 mm 
thick rings under a Leica M80 stereomicroscope. The uninjured right carotid arteries 
were also excised as controls. 
 
2.26 Histomorphometric analysis to quantify 
intima/media ratio 
 
Four serial cross-sections (5 µm thick) of hsa-mir-92a (5p) inhibitor transfected arteries 
(using pluronic gel), were sectioned at equally spaced intervals, and stained with 
hematoxylin and eosin at Barts Cancer Institute pathology services, to quantify the 
intima/media ratios 7 days after injury. Arteries transfected with scrambled miRNA were 
used as controls. The analysis was done at UCL by examining 4 cross-sectional 
photomicrographs (NDP Nanozoomer Digital Pathology) of each carotid artery segment 
in Image J software to obtain the mean relative areas of the intimal and medial layers 
and their respective ratios. Briefly, the medial area was calculated by subtracting the 
area defined by the internal elastic lamina (IEL) from the area defined by the external 
elastic lamina (EEL), and the intimal area was determined by subtracting the lumen area 
from the area defined by the IEL. Finally, the intima to media area ratio (I/M) of each 
section was calculated. The average I/M of the six sections was used as the I/M of this 
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animal. All measurements were performed twice by the same observer, who was 
blinded to the treatment applied to the carotid artery. 
 
2.27 Double emulsion-solvent evaporation synthesis 
of NPs  
 
PLGA NPs can be synthesized using different techniques, which yield different size and 
structural characteristics accordingly. Emulsion–solvent evaporation is a common 
synthesis method, and two types of this technique can be used depending on the 
hydrophilicity of the drug to be encapsulated: the single and double emulsion. The 
emulsion is defined as the mixture of two or more entirely or partially immiscible liquids 
obtained in the presence or absence of a surface active agent. In the single emulsion–
solvent evaporation strategy, both drug (hydrophobic) and polymer are first dissolved 
in a water immiscible organic solvent, to form a single-phase oil solution. A suitable 
solvent should be able to dissolve the polymer, be poorly soluble in the continuous 
phase, and exhibit high volatility and low toxicity.  Then, the organic oil phase is 
emulsified in water containing an appropriate emulsifier (O/W emulsion). This 
surfactant should promote a considerable reduction of the interfacial free energy, thus, 
avoiding the coalescence and agglomeration of drops, leading to a stabilised emulsion. 
If the molecule to encapsulate is hydrophilic (such as Perfluoro-1,5-crown ether - PFCE), 
it is necessary to prepare two emulsions instead. The drug is first dissolved in an aqueous 
phase (Trifluoroethanol - TFE), then added to the oil phase (water-on-oil emulsion). Then 
sonication allows breaking up the primary droplets of dispersed oil into nanosized 
droplets before the solution is again added to an aqueous solution (water-oil-water 
emulsion). The subsequent removal of the organic solvent transforms droplets of 
dispersed phase into solid particles. An extra dialysis step allows selecting NPs according 
to size. If needed certain electrostatic linkers can be added to the surface of the NP to 
modify its surface charge.  
 
  




Briefly, our NPs were prepared by dissolving 100 mg PLGA in a 5 mL solution of propylene 
carbonate (water immiscible organic solvent). Where required, PLGA was covalently 
conjugated to fluoresceinamine according to a protocol reported elsewhere(Horisawa 
et al., 2002). The PLGA solution was mixed with 100 mg PFCE dissolved in 1 mL TFE 
(aqueous solvent). This solution was then added dropwise to 10 mL of an organic 
stabiliser Polyvinyl alcohol solution (PVA) 1% (w/v) in milQ water, sonicated for 90 
seconds (50% amplitude, 0% pulse), diluted 1:6 in milQ water, and stirred for 3h at RT. 
The NPs were then transferred to a dialysis membrane and dialysed (Molecular weight 
cut off or MWCO of 50 kDa) against distilled water consecutively for 2 days. Then, NPs 
were coated with protamine sulphate by means of a 15-minute incubation with a 1 
mg/mL (in PBS) at a 1:1 concentration ratio under agitation, at RT. After the incubation 
period, the NPs were dialysed (MWCO of 12-14 kDa) against distilled water for 2 days, 
freeze-dried and lyophilized (Figure 31). 
 
Figure 31 | Synthesis of PLGA NP containing a fluorine compound. 
O – oil: PC – polycarbonate; PFCE - perfluoro-1,5-crown ether; PLGA - poly(lactic-co-glycolic acid); PS – 
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2.28 Complexation of miRNAs with NPs 
 
The complexation of miRNA to the NP surface was achieved by modifying the surface 
chemistry of the NP since the NP are overall negatively charged.  Thus, NPs were coated 
with protamine sulphate (PS), a polycationic peptide that makes the overall charge of 
the particle positive (Figure 32), permitting miRNA electrostatic adsorption and also 




Briefly, for cell transfection, NPs were weighed, sterilised under ultraviolet light for 30 
min and resuspended in EBM serum-free medium to a final concentration of 500 µg/mL. 
The suspension of NPs was vortexed and dispersed by ultrasound twice for 10 seconds. 
MicroRNAs were added at 400 nM and allowed to complex electrostatically with the NPs 
for 1 hour at 37ºC, with intermittent agitation. The resulting complexes were diluted 1:4 
in the same medium. For tissue transfection, complexation was accomplished the same 
way in Opti-MEM I (ex vivo applications) or in PBS (in vivo applications) at 30 mg/mL, 
and miRNAs added at 6 µM. The resulting complexes were further diluted 1:6 in Opti-
mem for ex vivo applications, and in either PBS or a thermoreversible gel for in vivo 
applications. 
 
Figure 32 | Adsorbing miRNA to the surface of PFCE encapsulating NPs is possible using a cationic 
peptide linker. 
Overall NP charge in brackets. miR – microRNA; PFCE - perfluoro-1,5-crown ether; PLGA - poly(lactic-co-
glycolic acid); PS – protamine sulphate. 
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2.29 NP characterization by dynamic light scattering 
 
Dynamic light scattering (DLS) is a well-established method to determine the size of NP 
in solution and Polydispersity index (PdI), an indicative of the heterogeneity of NPs sizes 
in a suspension. PdI is obtained from the photon correlation spectroscopic analysis. It is 
a dimensionless number extrapolated from the autocorrelation function. A PdI of <0.1 
is expected for a near-monodisperse sample (Nobbmann et al., 2007). In the presence 
of aggregates the equipment analyses them as a large size single particle, resulting in 
higher PdI results. Additionally, DLS also allows the determination of the surface charge 
density by zeta potential. When a particle is immersed in a fluid, a range of processes 
causes the interface to become electrically charged. Some of the most commonly found 
charging mechanisms include adsorption of charged surfactants to the particle, loss of 
ions from the solid crystal lattice and ionisation of surface groups. These processes lead 
to the production of a surface charge density. The charge cannot be measured directly, 
but only via the electrical field it creates around the NP. Thus, the surface charge is 
usually characterised in terms of a voltage at the particle surface, the surface potential, 
rather than a charge density. The zeta potential occurs at a distance from the surface, 
and this will be different to the surface potential. In the simplest approximation, the 
potential decays exponentially with distance from the surface of the particle. The rate 
of decay is dependent on the electrolyte content of the fluid. 
 
Estimation of NP diameter 
 
NP size was determined by Zeta Pals light scattering analysis using Zeta Plus Particle 
Sizing Software, as described previously (Maia et al., 2011). Briefly, NPs or NP:miR 
complexes were resuspended at 125 µg/mL in 1 mM KCl pH 5.5 solution and then 
dispersed by Branson 2510 ultrasound and vortexed twice for 30 s each time. All size 
measurements were performed at 90° angle after an equilibration time of 5 min at 25°C, 
and all data was recorded following individual run times of 60 seconds (3 runs per 
measurement).   
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Estimation of NP charge 
 
The zeta-potential of NPs was determined using a Zeta PALS Zeta Potential Analyser 
software. All data were recorded with at least five runs with a relative residual value of 
0.03 (a measure of data fit quality).  
 
2.30 Statistical analysis  
 
All the experiments were performed independently at least 3 times, i.e. the definitive 
quantitative results were obtained from at least 3 different biological samples. Each 
sample generated an averaged result ± standard error of deviation following the reading 
of experimental replicates (the exact number of replicates per protocol are indicated in 
the corresponding figure legend). All data are presented as mean ± standard error of 
mean (SEM).  
Normality was checked using Shapiro-wilk test or assumed when the n number was 
insufficient to test. Multiple group comparisons (for more than two groups) on normally 
distributed data were done by 1-way (1 independent variable) or 2-way ANOVA (>1 
independent variable), using the Bonferroni's test (post-hoc) for multiple comparisons 
to locate statistical differences between conditions. Within subject or repetead 
measures analysis used when appropriate. For only two groups, these were compared 
by two-tailed student´s t-test (paired when necessary). P≤0.05 was considered 
statistically significant. The specifics of each statistical analysis performed are indicated 
in the appropriate figure legend, with the adjusted p values. Data statistical analysis was 






 Results - 159 
 
Results 
Chapter 3: Establishment of a 
primary cell culture of CD34+ -
derived late-outgrowth EPCs 
 
 
Aims: This chapter describes the results of a stepwise process to establish a human primary 
CD34+-derived endothelial precursor cells (EPC) culture in which I could study the in vitro effects 




• Isolation of CD34+ progenitor cells from human umbilical cord blood (UCB) 
• Differention in culture of the former into vascular progeny (late-outgrowth EPCs) 
• Characterization of the resulting EPCs both phenotypically and functionally to ascertain 
about the simultaneous presence of stem features and endothelial commitment.  
 
 
What is new: Optimization of a CD34+ MACS enrichment method; an original indirect labelling 
enrichment method for pig BM CD34+ progenitor cells (appendix I).  
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3.1 Enrichment of CD34+ and CD133+ cells from 
human UCB 
 
As discussed in the Introduction, CD34+ (and arguably CD133+) populations are likely 
enriched in cells with endothelial progenitor capacity. On average, using MACS 
microbeads system after technical optimization, I was successful in isolating 1.05 ± 0.12 
x106 cells from each UCB  unit sorted for CD34 (Table 14). Recovered cells were present 
at a frequency of 0.38 ± 0.07 % of total mononuclear cells (MNCs), and their mean 
viability, as determined by an automated cell counter, was 78.33 % ± 1.03. As for CD133+ 
selection, an average of 5.10 ± 1.10 x105 cells were recovered from each unit, 
corresponding to 0.16 % ± 0.02 from the total MNC fraction. Cell viability after the 
selection was maintained at a mean 76.66 % ± 5.48. 
 
Table 14 | Quantification of CD34+ and CD133+ cells obtained from human UCB. 
CD34+ and CD133+ cells were isolated from human UCB MNCs using MACS immunomagnetic separation 
system and then counted following staining with propidium iodide. Data from 9 independent (CD34+) and 
3 independent (CD133+) isolations is presented as mean values ± SEM. CD – cluster of differentiation; MNC 
– mononuclear cell; SEM - standard error of the mean; UCB – umbilical cord blood 
Enriched 
population 
MNCs (x108) Recovered cells 
(x105) 
Recovered cells (% 
of MNCs) 
Viability of 
recovered cells (% 
total cells) 
UCB CD34+ cells 3.31 ± 0.4 1.05 ± 0.12 0.38 ± 0.07 78.33 ± 1.03 
UCB CD133+ cells 3.43 ± 1.13 0.51 ± 0.11 0.16 ± 0.02 76.66 ± 5.48 
 
 
Viable and functionally active CD34+ and CD133+ cells can be used in various 
downstream applications, such as flow cytometry and cell culture, but highly pure cell 
fractions are required. After using the optimised immunomagnetic sorting protocol with 
two successive column separations, the retrieved CD34+ and CD133+ labelled cell 
populations revealed a high degree of purity (99.53 % ± 0.14 and 98.27 % ± 0.21, 
respectively) as determined by FACS using antibodies for the same epitope (Figure 33). 
When sampling flow through cells, I specifically focused on the gate region R3, 
containing cells with low granularity which included MNCs as well as progenitor cells, 
and examined the expression of CD34 and CD133. The R1 gate (used for enriched cells) 
was similar to R3 for homogeneity of results. 
 
 Results - 161 
 
Figure 33 | CD34+ and CD133+ cell fractions isolated from human UCB were highly pure. 
To determine the purity of the populations enriched for CD34+ or CD133+ by immunomagnetic sorting, 
cells were stained with anti-CD34 or anti-CD133 antibody conjugated with PE, before being processed by 
flow cytometry. Mouse immunoglobulins of the relevant IgG subclass conjugated with PE served as 
negative controls. (A) Representative FSC-SSC dot plots (R1=R3 gate) and histograms are presented. (B) 
Enriched cells exceeding a threshold fluorescence defined by the IgG control were considered positive for 
the corresponding CD and quantified. Results are presented in a tabular format as mean antigen positive 
cells percentage ± SEM from 3 independent experiments (each condition measured in duplicate). CD – 
cluster of differentiation; FSC – forward scatter; IgG – Immunoglobulin; PE – phycoerythrin; SEM - 




 Results - 162 
 
B 
Enriched population Antigen Positive cells (%) 
UCB CD34+ cells CD34 99.53 ± 0.14 
UCB CD133+ cells CD133 98.27 ± 0.21 
 
FACS analysis revealed that most cells enriched for CD34+ (86.62 % ± 2.03) also co-
expressed CD133 (Table 15). Remarkably, nearly all CD133+ cells were positive for 
surface CD34 (98.28 % ± 0.15).  
 
Table 15 | Most human UCB cells enriched for CD34+ also co-expressed CD133 and vice-versa. 
To quantify the specific CD133 and CD34 antigen in the populations enriched for CD34+ or CD133+ cells by 
immunomagnetic sorting, respectively, cells were stained with anti-CD34 or anti-CD133 antibody 
conjugated with PE, before being processed by flow cytometry. Mouse immunoglobulins of the relevant 
IgG subclass conjugated with PE served as negative controls. Enriched cells exceeding a threshold 
fluorescence defined by the IgG control were considered positive for the corresponding CD and 
quantified. Results are presented in a tabular format as mean antigen positive cells percentage ± SEM 
from 3 independent experiments (each condition measured in duplicate). CD – cluster of differentiation; 
PE – phycoerythrin; SEM - standard error of the mean; UCB – umbilical cord blood. 
Enriched population Antigen Positive cells (%) 
UCB CD34+ cells CD133 86.62 ± 2.03 
UCB CD133+ cells CD34 98.28 ± 0.15 
 
To further characterise the levels of expression of cell surface CD34 and CD133 on 
enriched populations, I used flow cytometry and commercially available microbeads 
with known antibody binding capacity (Figure 34). Assuming monovalent antibody-
receptor binding, I was able to estimate the cell surface receptor density using an 
antibody binding capacity standard curve derived from microbeads fluorescence 
analysis. The isolated CD34+ population expressed over 200,000 CD34 receptors per cell 
and only a residual density of CD133 surface molecules. On the other hand, CD133 
enriched population exhibited a higher density of CD34 membrane receptors (> 
300,000/cell). 
 
Figure 34 | Antigen surface density quantification in CD34+ and CD133+ cells isolated from human UCB. 
CD34 and CD133 antigen surface density quantification were performed in human UCB CD34+ and CD133+ 
cells by flow cytometry using Quantum Simply Cellular Kit. (A) A representative beads FSC-SSC dot plot 
and a fluorescence histogram of the distinct beads population with increasing avidity towards anti-CD34-
PE is presented. The beads fluorescence intensities were entered in QuickCal software, which 
extrapolated the CD34 antibody binding capacity standard curve. (B) A representative FSC-SSC dot plot, 
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plus CD34-PE and CD133-PE histograms of CD34+ cells are presented. (C) Box plot exhibiting the 
quantification of CD34, CD133 surface antigen density in CD34+ and CD133+ cells (mean values ± SEM, 
n=3, samples run in duplicate). CD – cluster of differentiation; FSC – forward scatter; MESF/ABC - 
Molecules of Equivalent Soluble Fluorochrome/Antibody binding capacity; SEM – standard error mean; 
SSC – side scatter; PE – phycoerythrin. 
 




There is substantial evidence that progenitors expressing CD34 or CD133 include a 
population of proangiogenic cells (PACs) with a specific role in regenerative angiogenesis 
(Fadini et al., 2008). Since these cells can be harvested from a donor and transplanted 
within a few hours with minimal tissue culture-associated risks (infection, mutations), 
which contributes towards their clinical applicability, it would have been interesting to 
test these cells for miR-92a inhibitor modulation. Nevertheless, using them would pose 
significant technical problems, as their isolation is time-consuming and expensive. Blood 
donations would be needed daily. Moreover, absolute cell numbers isolated from each 
sample are heterogeneous from donor to donor and usually low (Janic et al., 2010), thus, 
it would be challenging to meet the count requirements per experimental setup. 
Moreover, MNCs have a very scarce cytoplasm, making them less ameneable to 
transfection, even with electroporation, which may result in varying efficiencies, with 
several cell lines and primary cells showing poor transfection rates and cell death (H. Yin 
et al., 2014). Adittionaly, PACs should be used with caution because of their monocytic 
nature and possible role in enhancing tissue inflammation (Medina et al., 2010), which 
could exacerbate a pre-existing pathology such as diabetic vasculopathy (Awad, Jiao, 
Ma, Dunnwald, & Schatteman, 2005). Moreover, CD34 and/or CD133 positivity is not a 
synonym of PACs. The CD34 marker can also be present in mesenchymal stem cells 
(MSCs) and other nonhematopoietic cell types including muscle satellite cells, epithelial 
progenitors, corneal keratinocytes, interstitial cells, and vascular endothelial 
progenitors (Sidney et al., 2014). In the blood, CD133 is a marker of both immature 
haematopoietic and progenitor cells (A. H. Yin et al., 1997). In other words, studying miR-
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92a inhibitor biological effects in this miscellaneous population of circulating cells would 
possibly not be very informative.  
 
Remarkably, among CD34+ progenitor cells a small minority are known to have true 
endothelial differentiation potential (Medina et al., 2010) and display postnatal 
vasculogenic activity (Yoder et al., 2007), unlike primary PACs promoting angiogenesis 
via paracrine effects. Therefore, as an alternative to using monocyte-committed PACs 
(“early EPCs”), having optimized the protocol for isolation of highly pure fractions of 
CD34+ cells from human UCB, I attempted to demonstrate that these progenitor cells 
comprehend/can be differentiated into functional late-outgrowth EPCs by culture assay. 
The rationale was that EPCs are equally fundamental (compared to PACs) in the re-
endothelialisation process, but at a later stage (Fadini et al., 2008). The ability to amplify 
EPCs by in vitro expansion, while preserving their angiogenic potential, was considered 
the single most important technical advantage of using the late-outgrowth progenitors 
instead.  Other advantages included higher transfectability and more robustness under 
tissue culture conditions compared to “early EPCs”, and a predictable EC-like phenotype 
which could be evaluated by well-established functional assays (Medina et al., 2017; 
Timmermans et al., 2007).  
 
 
3.2 Differentiation of late-outgrowth human EPCs 
from CD34+ cells 
 
Culturing UCB CD34+ cells, using a protocol established during my collaboration with 
Biocant Institute in Portugal during my first PhD year, reproducibly generated CD34+-
derived late-outgrowth EPCs. Initially, freshly purified CD34+ cells were small and round. 
After 2-6 days of tissue culture, non-adherent cells started clumping in the middle of the 
well, while showing a more elongated morphology with some spindle-shaped extensions 
(Figure 35, A), which correspond to PACs/“early EPCs”. By day 14, the cells in suspension 
were more elongated (Figure 35, B) and Endothelial cell – colony forming units (EC-CFUs) 
could be seen (Figure 35, C). CFU is defined as a cell mass composed of a central cord of 
round cells that sits on top of elongated spindle–shaped cells sprouting at the periphery 
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of the colony. These cellular clusters were first described by Asahara (Asahara et al., 
1997). Over time the clusters disappeared, revealing beneath a uniform adherent cell 
population that displayed features characteristic of more mature endothelial cells (ECs) 
(Figure 35, B). Namely, these possessed large nuclei that were deeply indented one or 
several-fold. Typically, after 14–20 days of culture, these adherent CD34+-derived EPCs 
had formed a confluent monolayer with cobblestone appearance (Figure 35, C) and 
could be expanded by tissue culture. 
 
 
Figure 35 | Late-outgrowth EPCs were successfully differentiated from human UCB CD34+ cells. 
UCB human CD34+ cells were differentiated into late-outgrowth EPCs. Bright-field images during 
differentiation were captured. (A) CD34+ cells 2-4 days after isolation tend to accumulate in the centre of 
the culture well as seen at 20x; (B) At 14-16 days post-isolation, some of the differentiating cells assume 
a cobblestone-like morphology (see arrowed, 20x). (C) Occasionally, colony forming units from which 
elongated spindle-like cells radiate in all directions were also observed at 5x. (D) After 20 days of culture, 
internalisation of Ac-LDL was confirmed by IF at 20x. (E-I) After 20 days of culture, the presence of 
endothelial lineage markers was evaluated by IF. CD34+-derived EPCs stained positive for (E) vWF (40x), 
(F) VE-cadherin (60x) and (G) KDR (60x), and negative for (H) SMA (20x). (I) Negative controls were 
obtained by using isotype-matched IgGs (20x). CD – cluster of differentiation; DAPI - 4',6-diamidino-2-
phenylindole; EPC – endothelial precursor cell; IF – immunofluorescence; IgG – immunoglobulin; KDR – 
kinase insert domain receptor; LDL - low-density lipoprotein; SMA – smooth muscle α- actin; VE – vascular 
endothelial; vWF – von Willebrand factor. 
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After having established EPC differentiation, I attempted different adaptations to the 
protocol to have a better understanding and to narrow down the source of the late-
outgrowth CD34+-derived EPCs. Starting from the observation that within 24 hours in 
culture a limited number of CD34+ cells had promptly attached to the gelatin-coated 
flasks, I transferred non-adherent CD34+ cells to fresh gelatin-coated flasks at first 
medium change. These cells did not become adherent and eventually died. It was also 
noteworthy that in the absence of the non-adherent cells, and despite the continuation 
of VEGF supplementation, the sparsely attached cells that were left in original flask also 
ultimately died. Culturing freshly isolated CD34+ cells in uncoated flasks also prevented 
cell attachment and successful differentiation. Likewise, in the absence of VEGF, all 
CD34+ cells failed to attach or proliferate and at that point died, indicating their 
dependence on exogenous vascular growth factors.  
 
The next step was to confirm the endothelial commitment of the CD34+-derived EPCs 
with IF, flow cytometry and functional assays, as other have done previously following 
their differentiation protocols (Melero-Martin et al., 2007). To do so, I initially 
performed IF analysis using a selected set of endothelial specific markers (Medina et al., 
2017; Nguyen et al., 2009). The late-outgrowth EPCs stained positively for vascular 
endothelial cadherin (VE-cad), von Willebrand factor (vWF) and kinase insert domain 
receptor (KDR) and did not stain for Smooth muscle cell (SMC)-specific α-actin, the 
negative control, as expected (Figure 35, E, F and G). Furthermore, EPCs efficiently 
incorporated Alexafluor488-conjugated ac-LDL (Figure 35, D), which is another 
important function of mature ECs (Nguyen et al., 2009), and previously described for 
BM-derived EPCs (Rafii et al., 1994). Most interestingly, CD34+-derived EPCs continued 
exhibiting the immature marker CD34 (Figure 36), suggesting a likely maintenance of 
specific progenitor cell activity, despite the acquisition of many features from terminally 
differentiated ECs during differentiation. 
 
 
Figure 36 | Late-outgrowth human EPCs maintained CD34 expression. 
After 20 days of culture, the presence of stem markers was evaluated by IF at 40x magnification. Negative 
controls were obtained by using isotype-matched IgGs (20x). The arrows represent human CD34+-derived 
EPCs which were still positive for CD34. They revealed an elongated morphology with extending filopodia. 
CD – cluster of differentiation; DAPI - 4',6-diamidino-2-phenylindole; EPC – endothelial precursor cell. IF 
– immunofluorescence; IgG – immunoglobulin. 





The observation that cultured cells preserved progenitor features, was further 
investigated by quantifying the changes in stem-like and endothelial lineage surface 
markers throughout the cellular differentiation process, using flow cytometry. Freshly 
isolated CD34+ primary cells expressed approximately 10-fold more surface CD34 
molecules than CD133 and expressed virtually no KDR at the surface, an EC lineage 
commitment marker (Eichmann et al., 1997) (Figure 37). During the differentiation 
process CD34 antigen density decreased significantly but never ceased to be expressed 
at the surface, unlike CD133, another progenitor immaturity marker, which was absent 
by day 40 in culture. On the contrary, there was a KDR upregulation trend observed in 
CD34+-derived EPCs.  
 
Figure 37 | Late-outgrowth human EPCs maintain stemness marker CD34 while acquiring vascular 
marker KDR. 
Quantification of CD34, CD133 and KDR surface antigen density was performed in primary human UCB 
CD34+ cells and corresponding derived late-outgrowth EPCs (3rd passage) by flow cytometry, using 
Quantum Simply Cellular kit. (A) Representative FSC-SSC dot plots of cells are displayed, as well as the 
corresponding CD34, CD133 and KDR conjugated PE intensities’ histograms. (B) Box plot displaying 
quantification of surface antigen density for CD34+ primary cells vs. CD34+-derived late-outgrowth EPCs 
(mean values ± SEM; all conditions were measured in duplicate; results in this graphic are representative 
of 1-3 experiments cells, depending on cell type and markers used, and therefore preliminary except for 
CD34 surface characterization). (C) Bright-field images of CD34+ cells (top) and CD34+-derived EPCs 
(bottom) were captured at 20x. CD – cluster of differentiation; EPC – endothelial precursor cell; FSC – 
forward scatter; KDR – kinase insert domain receptor; SEM – standard error mean; SSC – side scatter; PE 
– phycoerythrin; UCB – umbilical cord blood. 




KDR upregulation in CD34+-derived EPCs was further characterised by time course 
analysis (Figure 38). Interestingly, KDR levels rose progressively to become higher than 
mature HUVECs by the end of differentiation, a finding also reported by others (Lavergne 
et al., 2011). The increase in KDR expression was sustained despite termination of FBS 
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and VEGF supplementation by day 25, according to the protocol, suggesting definitive 
commitment.  
 
Figure 38 | CD34+-derived late-outgrowth EPCs acquire KDR expression during their differentiation. 
Quantification of KDR density was performed in human UCB CD34+ cells (non-adherent), CD34+-derived 
late-outgrowth EPCs (adherent) and mature endothelial cells (HUVECs) by flow cytometry, using Quantum 
Simply Cellular. (A) Representative FSC-SSC dot plots of cell subtypes are presented, as well as 
corresponding KDR conjugated PE intensity histograms. (B) The graphic presents the mean KDR density 
per cell for CD34+ cells versus CD34+-derived EPCs. The dashed line represents the mean surface KDR 
density expressed in HUVECs. Results in this graphic are representative of 1 (CD34+ cells and HUVECs) to 
3 (late-outgrowth EPCs) experiments (mean values ± SEM; all conditions were measured in duplicate). CD 
– cluster of differentiation; EPC – endothelial precursor cell; FSC – forward scatter; HUVEC - Human 
Umbilical Vein Endothelial Cell; KDR – kinase insert domain receptor; PBS - phosphate-buffered saline; 
SEM – standard error mean; SSC – side scatter; PE – phycoerythrin. 
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Finally, the generated CD34+-derived EPCs were able to form tube networks on Matrigel 
(Figure 39), a typical feature of endothelial commitment (Nguyen et al., 2009). Within 
just 6 hours of incubation, EPCs assembled into a capillary-like network on a Matrigel-
coated surface, indistinguishable from those formed by HUVEC under the same 
conditions. 
 
Figure 39 | UCB CD34+-derived late-outgrowth EPCs exhibit angiogenic potential. 
The angiogenesis assay was performed using a Matrigel matrix with reduced growth factor content. A set 
of representative brightfield images (10x magnification) taken at 15 min, 2h and 6h post incubation is 
presented for EPCs, revealing tubule-like formation ability. HUVECs were used as positive controls and rat 
colonic SMC as negative controls. CD – cluster of differentiation; EPC – endothelial precursor cell; HUVEC 
- Human Umbilical Vein Endothelial Cell; SMC – smooth muscle cell; UCB – umbilical cord blood. 
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Later, I replicated the strategy with a porcine BM source generating CD34+derived late-
outgrowth pig EPCs, to pave the way for future autologous transplantation pre-clinical 
experiments with miR-92a inhibitor transfected EPCs (Appendix I). 
 
 
3.3 Differentiation of late-outgrowth human EPCs 
from CD133+ cells was unsuccessful  
 
Peichev and colleagues postulated that a small subset of CD34+ cells from UCB, G-CSF–
mobilized peripheral blood (PB) and human fetal liver, co-expressing CD133 and KDR 
had EPC -potential (Peichev et al., 2000). But, in fact, triple positive CD34+CD133+KDR+ 
cells despite being proangiongenic, have an haematopoietic origin (CD45+) and do not 
represent true EPCs (Case et al., 2007) since they do not possess the postnatal 
vasculogenic profile that was originally proposed for a cell with endothelial progenitor 
properties (Estes et al., 2010). Nevertheless, some groups still reported that CD133+ cells 
can differentiate into endothelial progeny (Friedrich, Walenta, Scharlau, Nickenig, & 
Werner, 2006; Gehling et al., 2000; Nguyen et al., 2009). With the hypothesis that 
another subset of CD133+ cells could comprehend a possible EPC source, I applied the 
same culture differentiation protocol used for CD34+ cells in UCB CD133+ cells. However, 
I was unable to generate cells with endothelial phenotype, i.e. cells did not adhere and 
form cobblestone shaped cell clusters, despite VEGF supplementation and 3 weeks in 
culture (Appendix II). Hence, I studied the effects of miR-92a inhibitor in CD34+-derived 








Human UCB were the preferred EPC source 
 
CD34+ progenitor cells are present in different blood sources. Their collection is possible 
from mobilised PB, bone marrow blood (BMB) and UCB. The latter has been emerging 
as a valuable source (Kekarainen et al., 2006), due to some unique advantages compared 
to the counterparts. Cord blood stem cells are immunologically naïve (Slovinska et al., 
2011), present enhanced human leukocyte antigen (HLA) mismatch tolerance (Riordan, 
Chan, Marleau, & Ichim, 2007), and thus contribute to a reduced risk of graft-versus-
host disease compared to transplantation from other sources (Grewal, Barker, Davies, 
& Wagner, 2003). UCB is readily available from public/private tissue banks, which are on 
the increase, and can safely be cryopreserved without loss of cell viability (Liao, Geyer, 
Yang, & Cairo, 2011; R. Z. Lin, Dreyzin, Aamodt, Dudley, & Melero-Martin, 2011). 
Reassuringly, outgrowth EPCs obtained from culturing UCB cryopreserved MNCs are 
described to be phenotypically and functionally indistinguishable from those arising 
from freshly isolated MNCs like the ones used in this study (R. Z. Lin et al., 2011), 
including their ability to generate blood capillaries in vivo. UCB donation is painless in 
contrast to that of BM or PB. Moreover, there is a lesser risk of transmitting viral 
infections or somatic mutations compared with using adult tissues (Roura, Pujal, Galvez-
Monton, & Bayes-Genis, 2015). Strikingly, the acquisition of phenotypic and functional 
characteristics of the endothelial lineage has also already been reported for progenitor 
cells isolated from UCB (Janic et al., 2010; Pedroso et al., 2011). Compared to PB or BM, 
UCB-isolated CD34+ cells’ enhanced engraftment potential (Vormoor et al., 1994) allied 
with a faster proliferation rate in response to cytokine stimulation (Hao, Shah, 
Thiemann, Smogorzewska, & Crooks, 1995), and the generation of sevenfold more 
progeny under culture conditions (Hao et al., 1995), make the use of this progenitor 
source very promising for vascular therapy (Janic & Arbab, 2012). UCB-derived late EPCs 
are at a higher frequency (Yoder et al., 2007), display greater telomerase activity (Ingram 
et al., 2004) and are more efficient in actively forming vascular structures within 
ischaemic tissues than those derived from adult PB (Ingram et al., 2004). In fact, a longer 
stability of the vascular networks formed in vivo was described (Au et al., 2008). EPC 
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colonies from CB-MNCs emerge 5-7days earlier, were 3-fold higher in number, and 
consistently larger in size than in PB-MNCs(X. Gao, Yourick, & Sprando, 2017). Colonies 
originated from UCB progenitors can give rise to secondary and tertiary colonies, a 
property not shared by PB progenitors (Ingram et al., 2004), suggesting that these cells 
despite having undergone some degree of differentiation maintain more immature 
features, which may confer upon them greater tissue repair capacity. Indeed, the 
transcriptomic analysis shows that expression levels of progenitor markers CD34 are 
higher in UCB-derived late-outgrowth EPCs than their PB counterparts, confirming the 
apparent cell immaturity which would be consistent with their more primitive 
developmental stage (van Beem et al., 2009).  
This might explain the fact that iPSC colonies generated from CB-EPCs are 2.5-fold higher 
in number than from PB-EPCs, indicating CB-EPCs have a higher reprogramming 
efficiency than PB-EPCs (X. Gao et al., 2017). The differences in the gene expression 
pattern between CB-EPCs and PB-EPCs as revealed by the transcriptomic study by Gao 
et al. using microarrays, especially those involved in the human embryonic stemcell 
pluripotency pathway, may result in increased endogenous expression in CB-EPCs of 
someof the key transcription factors such as SOX2 and OCT4, thus promote the 
reprogramming process and ultimately lead to an increased reprograming efficiency in 
these cells compared to PB-EPCs(X. Gao et al., 2017). 
 
Consistingly, generation of EPC colonies from PB sometimes cannot be obtained from 
all donors, especially in relation to age and the presence of CVD (Meneveau et al., 2011). 
Even though the use of PB from CVD subjects would better portray EPC clonogenic and 
biological activity in patients with real restenosis risk, given the invasive nature of its 
collection, reduced circulating progenitor numbers and heterogeneous success of 
differentiation from patient to patient, I chose to pursue the isolation of CD34+ 
progenitors from UCB instead for in vitro miR-92a inhibitor proof-of-principle studies. 
Indeed, the use of cryopreserved CB products for autologous use in the presence of 
adulthood CVD might be a promising strategy for cellular angiogenic therapies in the 
future.  
 
 Results - 175 
 
The advantage of using a mixed methodology for isolation of 
CD34+-derived EPCs 
 
If the identification of putative EPCs has been most controversial (Hristov et al., 2003; 
Medina et al., 2017), their isolation has not been any less challenging. Generally 
speaking, two primary isolation methods from MNCs are used (Fadini et al., 2012): 
(1) Cell sorting according to surface phenotype, i.e. enriching a progeny population 
(Casamassimi et al., 2007; Ott et al., 2005) 
(2) Colony assays, i.e., selecting EPCs by their ability to form endothelial-cell like 
clusters in culture, in the presence of specific differentiation growth factors 
(Fadini et al., 2012; Hill et al., 2003) 
 
The direct isolation of cell populations using surface antigen markers has the advantage 
to specifically select defined enriched populations of cells without the need for ex vivo 
manipulation, which may induce cellular senescence and impair their regenerative 
function. However, a low isolation yield and the fact that it can take some time to reach 
a minimum cell number suitable for clinic applications are possible limitations of this 
technique.  Moreover, given the absence of a unique cell signature that exclusively 
defines EPCs, a sorted population at an early state of differentiation may not reflect the 
putative EPCs (R. Z. Lin et al., 2011) exclusively. Indeed, comparing six flow cytometric 
methodologies for EPC identification using anti-CD34 and KDR markers revealed only 
poor to a reasonable agreement among strategies (Van Craenenbroeck et al., 2008). On 
the other hand, MNC culture assays have the advantage that they generate and expand 
late-outgrowth EPCs depending on protocol used (Fadini et al., 2012). However, it 
remains unclear when starting with a preparation of total unselected MNCs, how the 
interaction/plasticity of the different cells present in varying percentages 
(hematopoietic stem cells, mesenchymal stem cells, side population cells) may influence 
EPC phenotype (Rehman et al., 2003). Unselected MNCs can be stimulated by a variety 
of host growth factors that promote expression of numerous proteins, and such may 
lead to differential pathways of alternative macrophage activation. Thus, use of culture 
methods for putative EPC isolation from MNCs is fraught with complexities in identifying 
which cell may be playing a functional role. Additionally, most culture protocols used so 
far differ regarding the culture time, the type of substrate, and the positive or negative 
 Results - 176 
 
selection of cellular subtypes during the assay. Particularly, to what extent the use of 
different growth factors/substrates/conditions and how the in vitro environment can 
reprogram the cells and generate an artificial phenotype, is still debatable (Muscari et 
al., 2010; Simard et al., 2017; Timmermans et al., 2009).   
In summary, both surface phenotype sorting and MNC adherent culture methods have 
considerable limitations. In fact, we should keep in mind that flow cytometrically 
isolated EPCs probably have little in common with EPCs derived from cultured MNCs. 
Two profoundly different techniques may yield profoundly different biological 
information. Exactly to circumvent these shortcomings, I used a more reliable strategy, 
combining cell sorting technology with subsequent differential attachment. By first 
enriching a primary cell population of CD34+ cells before culturing them (instead of using 
MNCs as the starting material), I reduced the complexity of cell composition and 
narrowed down possible sources for EPC generation via differential attachment, 





The CD34+ cells recovery yields obtained using MACS system are in concordance with 
the literature, with progenitor recovery from human UCB for CD34 usually ranging from 
0.1 to 0.5% of total MNCs (Chaisiripoomkere et al., 1999; D'Arena et al., 1996; 
Kekarainen et al., 2006). The CD133+ cells recovery numbers are lower than the 0.5 to 1 
% published retrieval rates using MACS system, which follow single tagging/two-step 
enrichment and single tagging/single column enrichment (Pelagiadis, Relakis, Kalmanti, 
& Dimitriou, 2012; Slovinska et al., 2011). Instead, my methodology included an extra 
labelling step with CD133 microbeads before the second column enrichment, which 
could account for the reduced recovery. Also, a wide donor heterogeneity of progenitor 
numbers could be suspected, as other groups also reported the different percentage of 
CD133+ cells, often beyond the accepted range, resulting from each isolation procedure 
(Pelagiadis et al., 2012).  
 
  




In an attempt to optimise cell viability 20% AB human supplemented MACS buffer was 
used during the prolonged incubation with microbeads at 4ºC instead of plain buffer. 
The mean viability of recovered human CD34+ progenitors (78.33 % ± 1.03) from UCB is 
in keeping with published post-selection results obtained by others (74 % ± 4.1)(Blake 
et al., 2012). The mean human UCB CD133 progenitor viability was maintained at 76.66% 
± 5.48 after selection, which is similar to what is found in the literature (70-
80%)(Slovinska et al., 2011). The assessment of cell viability at the end of the isolation is 
essential since the downstream applications required live cells. However, the fact that 
cells are alive may not necessarily mean they will exhibit differentiation capacity. Live 
cell assays, like the propidium iodide method used, miss out on cells that are pre-
apoptotic or senescent due to the harsh separation. The colony forming assay is 
reportedly the best one to give a more relevant assessment of the ability of the 
progenitor cells to be used in downstream applications, taking into consideration 
additional factors other than whether the cells are merely alive (Tomlinson et al., 2013). 
Apparently, given the results of CD34+ cells differentiation, one would assume cell were 




Purity is linked with the enrichment of cells of interest from a heterogeneous population 
based on defined features known to be present, such as surface markers. In the 
separated fraction, the percentage of target cells compared to isolated non-target cells 
can be calculated. According to the literature, producing highly pure progenitor fractions 
from UCB with good recovery has revealed to be a challenging task so far. Wynter and 
colleagues tested the purity after enrichment of CD34+ cells from different blood 
sources using MACS and described outputs of 73.8% from UCB (de Wynter et al., 1995). 
Other groups described even lower average purities around 60% (Melnik et al., 2001). 
Belvedere and colleagues tested a two-step enrichment, and they reported mean CD34+ 
cell purities of 41% and 85% after first and second passage through the MACS columns, 
respectively (Belvedere et al., 1999). Lately, optimised protocols have been published 
where purities after CD34+ enrichment achieved have been boosted considerably. 
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Nguyen and Kekarainen groups reported > 90% purity (Kekarainen et al., 2006; Nguyen 
et al., 2009), while Pelagiadis et al. obtained 93% (Pelagiadis et al., 2012). Regarding 
CD133 enrichment, Ma et al. also used two cell separation cycles with Mini-MACS 
columns for CD133 selection, and they reported average purity of 91% of the CD133-
enriched UCB cell products (N. Ma et al., 2006), results which are consentaneous with 
mine (98%). Other groups acknowledged wider variation in their purity results following 
their protocol, which ranged from 10% to 85% (median 60%)(Pelagiadis et al., 2012).  
To my knowledge, the purity reported in this chapter is the highest (98-99%) ever 
reported for both progenitor types.  This may be attributed to specific modifications (to 
the manufacturer protocol) introduced to increase the output target cell purity. The 
handling of UCB can be challenging due to the relatively high content of nucleated 
erythroid precursors and granulocytes, which may have a similar density to MNCs, thus 
negatively influencing their isolation (Kekarainen et al., 2006). Separation of MNCs, the 
initial step of progenitor isolation, was performed from diluted buffy coats using a 
histopaque density centrifugation method. However, there are even problems with 
specificity at this stage, as the differing densities of MNCs and granulocytes are, in some 
instances, not large enough to be separated by the histopaque. Therefore, to prevent 
unwanted cell clumping (Hering et al., 1989) and maximise single cell labelling I 
incubated the cell solution with DNAse after each following centrifugation. Plus, 30 µm 
pre-separation filters were used before injecting the cell solution into the magnetic 
column with the objective of promoting individual cell retention. Additionally, to 
increase the purity of the isolated human progenitor cells, the eluted fraction was 
labelled and enriched once more over a second magnetic column, to take further 
advantage of the antibody–antigen specificity, a methodology also applied by others 
(Kekarainen et al., 2006). Single column separation of CD34+ cells may result in low 
purity (typically <50%), yet a relatively large number of cells can be obtained. Two 
successive column separations with the additional labelling step increased the purity to 
>90%, without significantly lowering the yield recovery. It is worth mentioning that the 
choice to use QBEnd10 microbead-conjugated antibodies for human CD34 isolation was 
deemed appropriate according to literary evidence. There are over 30 monoclonal 
antibodies against CD34 selecting for different epitopes which may be sensitive to 
cleavage with neuraminidases (sialidase) and glycoproteases (Lanza, Healy, & 
 Results - 179 
 
Sutherland, 2001). Their binding is dependent on sialic acid residues remaining on the 
antigen. QBEnd10 is one of the most frequently used antibodies since it has been shown 
to detect both sialylated and desialylated CD34 successfully and as the epitope is at the 
N-terminus, it is ideally suited to selection protocols such as MACS (Sidney et al., 2014). 
Also of particular note, cells were left to recover 48h in serum free medium 
supplemented with Flt3 ligand and SCF before flow cytometry phenotyping. This 
technicality was particularly important because the antibodies used for flow cytometry 
were chosen precisely to tag the same epitopes than the microbeads antibodies, to 
increase analysis specificity. The selected period was sufficient to allow the magnetic 
microbeads used for cell isolation to disintegrate from the cell surface, according to 
Miltenyi Biotec reply to my questions.  
Even after all the pursued modifications, in the end, there will always be a residual pool 
of contaminating granulocytes, but the evidence is that they do not adhere to culture 
dishes during the differentiation of EPCs in culture (M. Aoki, Yasutake, & Murohara, 
2004), and thus are easily removed for the first replacement of culture medium.  
 
The origin of CD34+-derived late-outgrowth EPCs 
 
The baseline levels of the immature marker CD133 expression (86.62 % ± 2.03) observed 
in freshly isolated UCB CD34+ cells are in keeping with the literature, as some groups 
have also highlighted that most CD34+ cells (anywhere over 80%) also expressed CD133 
(Nguyen et al., 2009; C. Zhang et al., 2014). Baseline flow cytometry also revealed that 
nearly all retrieved UCB CD133+ cells (98.28 % ± 0.15) co-expressed CD34 surface 
marker, a result also witnessed by others (Gehling et al., 2000; Herrmann et al., 2014). 
In fact, in the hematopoietic system, CD133 expression seems to be narrowed to a 
subset of CD34bright progenitor cells in human fetal liver, BM, UCB and PB (Buhring et al., 
1999; A. H. Yin et al., 1997), and the double positive cells should not be regarded as EPCs 
because they lack endothelial markers and mostly represent HPCs which are also CD45-
positive (Case et al., 2007; Gehling et al., 2000; Medina et al., 2017; Timmermans et al., 
2007).  
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I believe that the relatively small number of putative EPCs that became adherent in 
culture were not simultaneously CD34+ and CD133+ (Figure 40). According to the flow 
cytometry results, CD34+CD133+ cells were confined to the cellular suspension which 
was discarded after the first medium change. Transfering those non-adherent CD34+ 
cells to gelatin-coated flasks cells did not generate adherent EPCs, therefore possibly 
narrowing the EPC source to the originally attached CD34+ cells within the first hours in 
culture. I envision that these adherent cells were CD34+CD45-KDR+, as suggested by 
others (Timmermans et al., 2009). By attaching to the matrix within 24 hours in culture, 
the KDR+ (VEGF receptor) cells were then able to complete their differentiation driven 
by VEGF, while further benefiting from the paracrine provision of PACs in suspension. In 
fact, the supporting role of PACs cells in suspension was highlighted by the fact that their 
removal early in the differentiation protocol (despite VEGF supplementation), 
conditioned the sparsely attached cells to senesce and die. If not for the supporting role 
of PACs in the differentiation, I believe that adding CD45 (negative selection) or KDR 
(positive selection) MACS step to CD34+ enriched cells would contribute to narrow down 
even further the EPC source to CD34+KDR+ precursors.  
 
Alternatively, the possibility that late EPCs originate from a rare population of cells 
within the PACs must be acknowledged. The environment may influence the cultured 
cells’ fate and function. It is possible that a particular subset of CD34+(CD45+CD133+/-?) 
PACs might have lost CD45 positivity and gained KDR expression in culture, allowing 
them to become VEGF-responsive (Figure 40). KDR positivity then would grant the 
progenitor cells the ability to respond to the external VEGF stimuli driving further 
maturation and expansion. Remarkably, regardless of the true EPC origin, in the absence 
of VEGF, all CD34+ cells failed to attach or proliferate and at that point died, indicating 
their dependence on exogenous vascular growth factors. 
 
Figure 40 | Hypothetical origin of CD34+-derived late-outgrowth EPCs. 
KDR positivity grants the progenitor cells the ability to respond to the external VEGF stimuli driving 
differentiation and expansion. Therefore, CD34+-derived EPCs might have originated from a minuscule 
and outnumbered subset of CD34+ cells (likely CD45-KDR+) which adhere to the gelatin coating within the 
first days. Alternatively, a particular subset of CD34+CD45+ PACs might have lost CD45 positivity and gained 
KDR expression in culture, allowing them to respond to VEGF.  In both pathways, adherent CD34+ cells 
were supported paracrinally by the PACs in suspension, allowing for the acquisition of terminally mature 
EC markers and expansion of the former.  CD – cluster of differentiation; KDR – kinase insert domain 
receptor; PAC – proangiogenic cells; VEGF – vascular endothelial growth factor. 




This theory is plausible also when interpreting the unsuccessful differentiation of 
CD133+ cells into EPCs. To understand this result, we need to go back to Timmermans’s 
experiments (Timmermans et al., 2007). He did not detect CD133 expression in 
CD34+CD45-KDR+ cells (best late-outgrowth EPC candidate to date), seconding Delorme’s 
findings (Delorme et al., 2005). He then examined whether highly purified CD133+ cells 
were able to generate cells with endothelial phenotype, but he failed to show 
endothelial commitment. Unlike CD34+ enriched cells, no CD45- cells could be 
demonstrated in the MACS-purified CD133+ population given that all CD133+ cells were 
limited to CD45+ cells (i.e PACs). Contrastingly, Gehling and Quirici reported having 
generated EPCs from CD133+ cells (Gehling et al., 2000; Quirici et al., 2001). The 
contradictory results from Gehling and Quirici may be because progenitor populations 
used in these studies were selected by highly variable protocols yielding suboptimal 
enrichment purities: 72% (range 62%-98%) and 90% ± 5, respectively. It is possible that 
contaminating CD34+CD133-KDR+ cells within the heterogeneous CD133+ enriched 
fraction might have originated the derived late-outgrowth EPCs. Alternatively, since the 
cells generated were not extensively phenotyped (using morphology, proliferative 
capacity, surface markers FACS, in vitro functionality tests), they might not be late-
outgrowth EPCs, but rather CD45+ PACs, just like the ones generated by others from 
CD34+CD45+ cells (Timmermans et al., 2007), CD14+ monocytes (Yoon et al., 2005), CD34- 
cells (Harraz, Jiao, Hanlon, Hartley, & Schatteman, 2001) and total CD45+ cells 
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(Timmermans et al., 2007). In summary, the use of higher cell purities, such as described 
in this chapter, appears to mitigate against effects of population heterogeneity and 
points to the true EPC source being a very small subset of CD34+CD45-KDR+ cells. 
However, to validate the EPC differentiation capacity of a candidate CD34+ progenitor 
cell, a single cell type study would offer the most rigorous approach. However, several 
biological and technical obstacles need to be overcome in performing such a clonal 
assay. For instance, an isolated single cell population may behave differently in the 
absence of other cells, as revealed when non-adherent cells were removed from the 
culture. Hence, culturing a single cell may not be an appropriate EPC culture assay, but 
may require the presence of supporting cells with a different phenotype or function.  
 
The phenotype of CD34+-derived late-outgrowth EPCs 
 
The culture of UCB and BM CD34+ cells yielded two cell types, as previously described 
for whole MNC assays (Fadini et al., 2012). Initially, non-adherent spindle-shaped PACs 
developed after 4–7 days in culture (Figure 35). At a later stage in culture (14-16 days 
post-isolation), CD34+-derived late-outgrowth cells appeared, fully matching the 
described EPC-defining criteria, based on morphology (monolayer with cobblestone 
pattern as seen in Figure 35) and the presence of surface markers detected by IF and 
FACS. EPCs are characterised by including hematopoietic stemness and endothelial 
commitment markers in combination (Medina et al., 2017). Hence, the expression of the 
stemness marker, CD34, was followed during the culture protocol. Research indicates a 
correlation between CD34 expression and cell plasticity, with the loss of CD34 suggestive 
of lineage commitment (J. H. Jang et al., 2007; Sidney et al., 2014). Accordingly, CD34 
antigen density was highest on early progenitors and gradually reduced as the cells 
attached and matured, but it was still detectable at the end of differentiation in contrast 
to most cultured ECs (Siemerink et al., 2012). This was demonstrated in the CD34+-
derived late-outgrowth EPCs both by IF and flow cytometry. Remarkably, most ECs are 
also negative for CD34 in vivo, particularly in larger veins and arteries (Fina et al., 1990). 
However, there is a subset of adult ECs that do express CD34, and these are more 
prevalent in smaller blood vessels (Siemerink et al., 2012). These specialised vessel 
CD34+-ECs seem to be quiescent (Siemerink et al., 2012) and when activated become 
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involved in migration and adhesion at the tip of vascular sprouts (Fina et al., 1990). They 
are more elongated, lack tight junctions, and extend filopodia (Siemerink et al., 2012), 
in contrast to the typical cobblestone ECs. The sialomucin CD34 is largely expressed on 
the filopodia at the luminal membrane of these tip cells, and evidence underlines the 
critical role of CD34 in sites of active angiogenesis (Schlingemann et al., 1990). CD34 is 
proposed to act as an anti-adhesive molecule during lumen formation in developing 
blood vessels, by maintaining or promoting the separation between contralateral apical 
endothelial cell surfaces in a luminal tube, while allowing the migration of tip cells and 
the movement and probing of their filopodia through the tissue matrix (Nielsen & 
McNagny, 2009). According to my CD34 IF images, some of the CD34+-derived late-
outgrowth EPCs seem remarkably similar to these tip cells. Thus, it is fair to assume that 
after differentiation we might end up with a mixed population of CD34bright EPCs which 
are more associated with migration/adhesion, and CD34dim to neg EPCs with more of a 
proliferative phenotype. The corresponding flow cytometry histogram in Figure 37 
seems to confirm exactly the existence of that mixed CD34 population corresponding to 
two distinct spikes. Importantly, and in agreement with others (Medina et al., 2017), the 
EPCs did not express the leukocyte markers CD133 as shown by flow cytometry (Figure 
37). Unlike cells in suspension identified as CD34+CD133+, adherent cells did not exhibit 
surface CD133.  Either all CD133+ cells were confined to cells in suspension 
corresponding to PACs (a possibility already addressed) or differentiating adherent 
CD34+ cells abolished the expression of CD133 on their surface, a phenomenon similarly 
seen in the maturation of CD133+ HSCs (Miraglia et al., 1997; Quirici et al., 2001; A. H. 
Yin et al., 1997). Regarding commitment markers, KDR is known to be involved in the 
early stages of vasculogenesis (T. P. Yamaguchi, Dumont, Conlon, Breitman, & Rossant, 
1993). The expression of cell surface KDR is inducible by VEGF (Tang et al., 2008) and 
considered to be mostly EC-specific (J. H. Jang et al., 2007). I have noted that as soon as 
the CD34+-derived EPC colonies were formed (day 14), the cells started showing (as 
expected) a progressive upregulation of KDR, which persisted beyond the withdrawal of 
VEGF supplementation, demonstrating definitive EC-commitment. Remarkably, 
CD34+derived-EPCs positively incorporated ac-LDL. Contrary to traditional belief the 
ability to uptake ac-LDL is not unique to committed ECs. Recently, it was demonstrated 
that monocytes and macrophage could also take up ac-LDL and bind lectin (Ouchi et al., 
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2001). That is one of the reasons why a combined characterization of the putative EPCs 
was sought using additional IF to identify lineage commitment markers and functional 
assays. The continuous culturing revealed de novo expression of mature EC markers. 
CD34+-derived EPCs stained positive for vWF, VE-cadherin and was negative for SMA, a 
typical EC-expression profile also obtained with other EPC differentiation attempts 
(Fujiyama et al., 2003; J. H. Jang et al., 2007). Confirmation of endothelial phenotype 
came from directly testing for endothelial angiogenesis capacity in a Matrigel assay, 
which was positive. Although Matrigel has been shown to direct ECs along the 
differentiation pathway, there is some debate as to whether tubules generated on 
Matrigel represent functional capillaries, as the presence of lumen has been shown by 
some groups using electron and light microscopy (Connolly, Simpson, Hewlett, & Hall, 
2002) and disputed by others who could not detect a lumen(Bikfalvi, Cramer, Tenza, & 
Tobelem, 1991). Moreover, it should also be noted that some non-EC types including 
primary human fibroblasts, glioblastoma cells and human prostate carcinoma cell line 
have been shown to also form ‘tubules’ on Matrigel (Donovan, Brown, Bishop, & Lewis, 
2001), thus, the results should be interpreted with caution. An alternative assay to test 
angiogenesis capacity is the organotypic co-culture model in which fibroblasts are co-
cultured with ECs, which I have used to test the functionality of miR-92a inhibitor in EPCs 
in the next chapter. The fibroblast secretes matrix components that act as a scaffold and 
enables the EC to form sprouting tubules that contain lumen, which more closely 
resemble the capillary bed in vivo (Donovan et al., 2001). However, as this assay is time-
consuming (it lasts up to 12–14 days), the results measure proliferation as well as 
differentiation.  
 
One might speculate that the mere occurrence of outgrowth is insufficient evidence to 
confirm the presence of EPCs. To make things more complicated, CECs also proliferate 
in culture (A. Solovey et al., 1997) and are CD34+KDR+ like EPCs (Cappellari et al., 2016). 
However, unlike late EPCs (Y. Lin et al., 2000), CECs (or other ECs for that matter)  bear 
low proliferative potential in culture (Blann et al., 2005) (as evidenced by the routine 
use of vessel segments as sources for endothelial culture in vitro which stop proliferating 
after a few passages). Despite EPC robustness and endurance to oxidative stress (Rossig, 
Urbich, & Dimmeler, 2004), I did not use CD34+-derived late-outgrowth EPCs for 
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experiments beyond their 6th passage in culture. At that point, EPC senescence in culture 
and transition from endothelial to other lineage cells have (rarely) been described 
(Ikutomi et al., 2015). Ikutomi and colleagues reported that older EPCs presented de 
novo staining with a fibroblast marker vimentin and CD90 compared to younger EPCs, 
which likely supports my observation that the cultivated EPCs did progressively lose their 
proangiogenic potential over time.  
 
In summary the generated CD34+-derived EPCs ticked all the the minimum requirements 
for the definition by Medina et al. of an endothelial cell forming colony (ECFC): 
unequivocal endothelial cell phenotype (depicted as positive for CD31, VE-Cadherin, von 
Willebrand factor, and VEGFR2), significant proliferative potential, and possess vascular 
network forming potential in vitro and in vivo (Medina et al., 2017), the latter condition 
not tested for time restraints. 
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Chapter 4: Post-transcriptional 
modulation of miR-92a inhibitor on 
CD34+-derived late-outgrowth EPCs 
 
 
Aims: This chapter describes the optimisation of a priming strategy capable of enhancing the 




• Transfection of human CD34+-derived late-outgrowth endothelial precursor cells’ (EPCs) 
transfection with miR-92a inhibitor using oligofectamine (OF) 
• Testing treatment with both miR-92a inhibitor strands, its optimal concentration and 
treatment duration for maximal target protein upregulation. 
• Demonstration of the post-transcriptional modulation of miR-92a inhibitor on its target 
proteins, namely Integrin alpha 5 subunit (ITGA5), and the subsequent in vitro and ex 
vivo functional repercussions on EPCs.  
• Clarification of the mechanistic pathways by which miR-92a inhibition exerts its 
functions in EPCs by co-transfection studies with si-ITGA5 
 
 
What is new: Demonstration of pro-angiogenic,-migratory,-proliferative, and -adhesive effects 
of miR-92a inhibitor treatment on CD34+-derived EPCs, which are partially abrogated by ITGA5 
knockdown (adhesion). 
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4.1 miR-92a inhibitor is efficiently internalised by 
EPCs using oligofectamine 
 
 
Bonauer et al. used Lipofectamine RNAiMAX (Invitrogen) to transfect miR-92a mimic 
and inhibitor into Human Umbilical Vein Endothelial Cell (HUVECs) (Bonauer et al., 
2009), whereas Iaconetti et al. utilised siPORT NeoFX Transfection Agent (Ambion) in rat 
aortic ECs (Iaconetti et al., 2012). Moreover, the mirVana™ miRNA manufacturer has 
validated Lipofectamine® RNAiMAX for transfection of its mimics and inhibitors in cell-
based systems. Therefore, I have attempted to use both transfection reagents in CD34+-
derived EPCs to facilitate miR-92a (mimic and inhibitor) internalisation, but with no 
success (Appendix III).  
 
 
Successful transfection of miR-92a and its inhibitor into CD34+-derived EPCs at 30 nM 
was only accomplished using OF (Figure 41), a liposomal reagent previously used to 
transfect oligonucleotides into HUVECs, bovine and human aortic endothelial cells (ECs) 
(Chamorro-Jorganes et al., 2011).  The IF staining demonstrated that internalisation of 
miR-92a inhibitor only occurred when using the liposomal transfection reagent since 
miRNAs are negatively charged particles unable to transmigrate across the cellular layer 
by themselves. 
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Figure 41 | miR-92a is internalised by CD34+-derived EPCs using oligofectamine 
After OF transfection, confirmation of FITC conjugated miR-92a internalisation was evaluated by IF 
staining at 20x. AB – antibody; DAPI - 4',6-diamidino-2-phenylindole; FITC - Fluorescein isothiocyanate; 
miR – microRNA; OF – oligofectamine; PFA – paraformaldehyde. 
 
 
The efficiency of cellular transfection using OF was 93.7 % as assessed by flow 
cytometry, i.e. almost every cell internalised the miRNA of interest using the proposed 
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Figure 42 | Internalisation of miR-92a inhibitor by CD34+-derived EPCs using oligofectamine is highly 
efficient. 
The OF transfection of human CD34+-derived late-outgrowth EPCs with miR-92a inhibitor was confirmed 
by flow cytometry.  Cells treated only with OF were used as negative transfection controls. Preliminary 
results are plotted as mean values ± SD after 1 independent experiment. FITC - Fluorescein isothiocyanate; 
miR– microRNA; SD – standard deviation. 
 
 
Mature miRNAs after exerting their biological post-transcriptional repression activity are 
degraded (Y. Lee et al., 2003). However, because there are a plethora of post-
transcriptional regulatory options to process individual miRNAs differentially, little is 
known about the half-life of individual miRNAs in specific cell types (Winter et al., 2009). 
Bonauer et al. in a seminal work published in Science demonstrated the endogenous 
expression of miR-92a in HUVECs (Bonauer et al., 2009). In their studies where 
supplemental miR-92a and its inhibitor were transfected into HUVECs to control 
angiogenesis, they opted for a 48h post-transfection duration in most in vitro functional 
experiments (Bonauer et al., 2009). Given the phenotypic similarities between ECs and 
CD34+-derived EPCs, I assumed endogenous miR-92a presence in the latter and pursued 
the ideal post-transfection period to allow for maximal target protein modulation before 
miRNA decay and normalisation of target protein levels. Therefore, I tested 24h, 48h 
and 72h with the rationale that CD34+-derived EPCs’ RNA-induced silencing comples 
(RISC) machinery should be similar to that of HUVECs. Since ITGA5 is a validated miR-
92a target protein (Abdellatif, 2012; Bonauer et al., 2009), I determined the post-
transfection change in endogenous ITGA5 expression. According to the results obtained, 
48h was considered the optimal duration for miR-92a knockdown in CD34+-derived 
EPCs, since there was no further reduction in ITGA5 protein levels past that time point 
(Figure 43). Regarding miR-92a inhibitor modulation, the maximum target protein levels 
were also obtained after 48h of processing, although in the optimisation experiment 
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overexpression was not attained. Verification of the degree of miR-92a overexpression 
and inhibition by quantitative reverse transcription–polymerase chain reaction would 
have added valuable information to the time course. In this particular experiment, one 
can hypothesise that cells could have had low baseline levels of the anti-angiogenic miR-
92a. Hence transfection with the antisense miRNA would not capture many endogenous 
sense strands and impact significantly at the protein level. Nevertheless, because of 
miRNA biogenesis and maturation complexity, the cellular concentration of mature 
miRNAs does not always reflect transcriptional changes (Kuchen et al., 2010). One single 
miRNA molecule can reversibly hybridise with several mRNA molecules before being 
degraded. Therefore, target protein levels should be regarded as the gold standard 
endpoint for biological efficacy of miRNA transfection, which is the method I used.  
 
Figure 43 |48h miR-92a (inhibitor) processing duration seems to generate the maximal target protein 
modulation in human CD34+-derived EPCs. 
Cells were transfected with either 30nM control scrambled miRNA, miR-92a-5p or miR-92a-5p inhibitor 
using oligofectamine. (A) Following a time course incubation, the cells were lysed and its proteins were 
separated by SDS-PAGE and immunoblotted with the antibodies indicated. (B) Levels of ITGA5, a direct 
miR-92a target protein, were quantified by scanning densitometry and expressed as relative units 
compared to ACTB. Results in this figure are preliminary and reflective of one experiment. ACTB - β-actin; 
ITGA5 – Integrin α5 subunit; miR – microRNA; RU – relative units. 




Then, the working concentration of miR-92a mimic and inhibitor was selected based on 
dose-response experiments (Figure 44). Of note, all experimental control samples were 
treated with an equal concentration of a non-targeting control mimic sequence to adjust 
for non-sequence-specific effects in miRNA experiments. Our results suggested that 30 
nM was the optimal concentration for miR-92a knockdown in human late-outgrowth 
EPCs, since there was no added reduction in ITGA5 protein levels at higher 
concentrations which may result in more detrimental side effects. Also, miR-92a 
inhibitor processing seemed to yield maximum target protein levels at 30 nM. 
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Figure 44 | CD34+-derived EPC transfection using oligofectamine seems equally effective at 30 nM or 
200 nM concentration of miR-92a (inhibitor). 
Cells were transfected in 6 well plates with 30nM or 200nM control scrambled miRNA, miR-92a-5p or miR-
92a-5p inhibitor using oligofectamine. (A) Following 48h knockdown in complete medium cells were lysed, 
proteins were separated by SDS-PAGE, and immunoblotted with the antibodies indicated. (B) Levels of 
ITGA5, a direct miR-92a target protein, were quantified by scanning densitometry and expressed as 
relative units compared to ACTB. Results in this figure are preliminary and reflective of one experiment.  




4.2 miR-92a inhibitor downregulates angiogenesis-
related target proteins in EPCs 
 
In the stem-loop structure of the precursor miRNA, the 5p strand is present in the 
forward (5'-> 3') position, and the 3p strand (which will be almost complementary to the 
5p strand) is located in the reverse position. Following cleavage of the stem-loop by 
Dicer, two mature strands are produced. The resulting 5p and 3p miRNA molecules are 
biologically different in terms of stability and functionality, and in general, only the more 
stable strand will be incorporated into the RISC, and guide the complex to target the 3′ 
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untranslated region (3′ UTR) of the imperfectly paired mRNAs to inhibit their translation 
or promote their degradation. The less stable partner arm, the *-strand (star or 
passenger strand), accumulates in lower levels and is presumed to be mostly degraded. 
However, in some cases, both mature strands can be functional. Therefore, to 
determine which one was the primary and minor miR-92a strands in CD34+-derived 
EPCs, I tested both synthetic miRs and its inhibitors at 30 nM and allowed 48h 
processing. The 5p mature form of mir-92a and its corresponding inhibitor had a more 
potent effect than the 3p strand in CD34+-derived EPCs according to the change in 
selected target proteins´ levels (Figure 45). The latter included Mitogen-activated 
protein kinase kinase 4 (MKK4), sirtuin1 (SIRT1), ITGA5, integrin alpha v subunit (ITGAV), 
all previously used as mir-92a targets by others (Bonauer et al., 2009). EPC transfection 
with miR-92a-1 (5p) significantly reduced ITGA5, ITAGV and total endothelial nitric oxid 
synthase (T-eNOS) protein expression, whereas its (5p) inhibitor significantly enhanced 
ITGA5 and T-eNOS levels, comparing both treatments to miR scrambled. 
 
Figure 45 | miR-92a (5p) and its inhibitor produce more potent protein levels reduction and rescue in 
CD34+-derived EPCs than the (3p) forms. 
Cells were transfected with either 30nM control scrambled miRNA, miR-92a-1 or miR-92a-1 inhibitor using 
oligofectamine. Both 3p or -5p strands of miR-92a and its inhibitor were tested. (A) Following 48h 
incubation in complete medium, cells were lysed, proteins were separated by SDS-PAGE, and 
immunoblotted with the antibodies indicated. (B-E) MKK4, SIRT1, ITGAV, ITGA5 (direct miR-92a targets) 
and T-eNOS (indirect target) protein levels were quantified by scanning densitometry and expressed as 
relative units compared to housekeeping protein ACTB or GAPDH. Combined results after up to 8 
independent experiments are plotted as means, with errors bars representing ± SEM. *P<0.05, **P<0.01, 
and ***P<0.001 compared with miR scrambled transfected EPCs (1-way ANOVA, Bonferroni´s test for 
multiple comparisons).  EPC – endothelial precursor cell; ITGA5 – Integrin α5 subunit; ITGAV - Integrin αv 
subunit; miR – microRNA; MKK4 - Mitogen-activated protein kinase kinase 4; RU – relative units; SEM – 
standard error of mean; T-eNOS – Total endothelial nitric oxide synthase. 





Transfection with 3p strands did not produce a statistically significant change from miR-
scrambled treated cells, except for reduced ITGA5 levels with miR-92a-1 (3p) treatment. 
On the other hand, EPC transfection with miR-92a-1 (5p) significantly reduced ITGA5 and 
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ITAGV (direct miR-92a targets) protein expression, whereas its (5p) inhibitor significantly 
enhanced ITGA5 levels, compared to miR scrambled treatment. 
MKK4 and SIRT1 both predicted targets in miRbase were not specifically affected by 
treatment with miR-92a (or its inhibitor) in CD34+-derived EPCs. Curiously, despite miR-
92a downregulating ITGAV, its overexpression was not apparent following miR-92a 
inhibitor treatment. It was interesting as well to note a statistically significant miR-92a-
dependent regulation of T-eNOS when CD34+-derived EPCs were treated with the 
primary strand (5p), although eNOS was not present in miRBase as a predicted miR-92a 
candidate target. Mechanistically, ITGA5 is a crucial regulator of EC functions and vessel 
growth by mediating cell-matrix interactions, cell migration and anti-apoptotic signalling 
(Francis et al., 2002; Urbich et al., 2002; N. Yang et al., 2011). On the other hand, NO is 
equally important for EC and vessel homeostasis since it controls re-endothelialisation, 
neovascularization and vascular tone (B. Cui et al., 2011; Murohara et al., 1998; Palmer, 
Ferrige, & Moncada, 1987; Y. Zhao, Vanhoutte, & Leung, 2015). Given the essential 
functions of both these targets in ECs, we next sought the functional relevance of miR-
92a (5p) inhibitor treatment in CD34+-derived EPCs. 
 
4.3 miR-92a inhibitor -treated EPCs exhibits 
enhanced angiogenesis, migration, proliferation and 
adhesion  
 
To demonstrate the pro-angiogenic activity of miR-92a (5p) inhibitor, CD34+-derived 
EPCs were seeded with fibroblasts in a coculture system grown for 96 hours (Figure 46).  
miR-92a inhibitor exerted a statistically significant proangiogenic effect in EPCs. Cell 
treatment with miR-92a inhibitor significantly increased vascular network length (133 % 
± 3.62 vs. 100%, p < 0.05, % of controls), area (126.5 % ± 3.28 vs. 100%, p < 0.05, % of 
controls) and number of branch points (164.5 % ± 0.12 vs. 100%, p < 0.05, % of controls) 
compared to miR scrambled, whereas miR-92a seemed to have the opposite effect 
regarding the absolute reduction of network length compared to miR scrambled. 
 
Figure 46 | miR-92a (5p) inhibitor is proangiogenic in CD34+-derived EPCs. 
Suspensions of EPCs previously transfected with 30nM miR scrambled, miR-92a (5p) and miR-92a (5p) 
inhibitor using oligofectamine, were added to the fibroblast monolayer, so that an EPC-fibroblast co-
culture assay (96h) could be pursued in the presence or absence VEGF, before cells were fixed and stained 
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for vWF using a secondary antibody conjugated to Alexafluor-488. (A) Representative brightfield picture 
of the coculture taken at 4x magnification. (B) Representative network sprouting fluorescent images 
captured at the end of the assay at 10x magnification (C-E). Angiogenesis network length, area and 
number of branch points based on fluorescence signal are represented. All experimental conditions were 
measured in triplicate. Results after 2 independent experiments are plotted as means, with errors bars 
representing ± SEM. ***P<0.001 compared with Null VEGF-treated condition (1-way ANOVA, Bonferroni’s 
test for multiple comparisons); ^P<0.05, ^^P<0.01 compared with miR scrambled treated with VEGF (1-
way ANOVA, Bonferroni’s test for multiple comparisons). EPC – endothelial precursor cell; FBS – fetal 
bovine serum; miR – microRNA; SEM – standard error of mean; VEGF – vascular endothelial growth factor; 
vWF – von Willebrand factor. 
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The scratch assay was used to assess the effects of miR-92a inhibitor delivery on EPC 
wound closure migration (Figure 47). EPCs treated with miR-92a inhibitor managed to 
narrow the wound gap area significantly more than controls by 48 hours under VEGF 
deprivation (58.48 % ± 3.41 vs. 45.22 % ± 6.04, p<0.05, % of baseline wound area), an 
effect size which was attenuated upon VEGF co-stimulation (63.94 % ± 4.09 vs. 59.56 % 
± 5.86, p>0.05, % of baseline wound area). In contrast, miR-92a significantly delayed 
wound closure at 48h compared with miR scrambled either in the presence (47.65 % ± 
6.52 vs. 59.56 % ± 5.86, p<0.001, % of baseline wound area) or absence (35.12 % ± 6.31 
vs. 45.22 % ± 6.04, p<0.05, % of baseline wound area) of VEGF supplementation.  
 
Figure 47 | miR-92a (5p) inhibitor significantly enhances wound closure migration in CD34+-derived 
EPCs in the absence of VEGF. 
Cells were transfected with either 30 nM miR scrambled (black line), miR-92a (5p) (red line) or miR-92a 
(5p) inhibitor (green line) using oligofectamine. After a 48h knockdown, wound closure migration in EBM 
0.5% FBS was assessed in the presence or absence of 25 ng/mL VEGF by live-cell Imaging. Images were 
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captured at 10x every 2h for a total duration of 48h. (A) Representative brightfield images of wound 
closure over time in the presence of 25 ng/mL VEGF by EPCs transfected with either miR scrambled, miR-
92a or miR-92a inhibitor. (B) Relative wound closure quantification results after 9 independent 
experiments (each condition was repeated in 6 replicates) are plotted as means, with errors bars 
representing ± SEM. *P<0.05 compared with miR scrambled/no VEGF supplementation; ^^^P<0.001 
compared with miR scrambled/VEGF supplementation (2-way ANOVA, Bonferroni’s test to compare 
multiple means by row). EPC- endothelial precursor cell; FBS – fetal bovine serum; miR – microRNA; SEM 
– standard error of mean; VEGF – vascular endothelial growth factor. 
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EPC homing and engraftment into an active site of injury is essential for a prompt re-
endothelialisation and is mechanistically associated with cytokines/growth factor 
signalling. Thus, the effect of miR-92a inhibitor treatment on EPC migration towards 
VEGF was studied using an in vitro transwell assay (Figure 48). The results showed that 
EPCs transfected with miR-92a inhibitor revealed a significantly enhanced migration 
towards VEGF stimuli compared to miR scrambled-treated controls (63.67 ± 14.72 vs. 
5.67 ± 5.67, p<0.001, migrated cells after 5h/well). 
 
Figure 48 | Inhibition of mir-92a enhances VEGF-induced chemotaxis migration of CD34+-derived EPCs. 
Cells were transfected with either 30 nM miR scrambled (transfection control), miR-92a (5p), miR-92a (5p) 
inhibitor using oligofectamine. After 48h cells were transferred to transwell inserts and chemotaxis 
migration was determined as the number of migrated cells after 5h in response to 50 ng/mL VEGF or no 
treatment (internal negative control). Treatment with 10% FBS was tested as a positive internal control. 
(A) Representative images of transwell inserts are shown for each treatment, and illustrative stained cells 
are arrowed for each condition (8x magnification). (B) Quantification of migration is presented as mean ± 
SEM from 3 independent experiments, and each treatment was performed in duplicates. **P<0.001 
compared with miR scrambled; ^^^P<0.001 compared with no VEGF (1-way ANOVA, Bonferroni’s test for 
multiple comparisons). EPC- endothelial precursor cell; FBS – fetal bovine serum; miR – microRNA; SEM – 
standard error of mean; VEGF – vascular endothelial growth factor. 




The effect of miR-92a inhibitor on EPC proliferation was determined by an ATP-based 
luminescence assay (Figure 49). The follow-up at 48h post miRNA treatment indicated 
that miR-92a inhibitor modestly enhanced VEGF-induced proliferation (168.07 ± 23.61 
vs. 162.12 ± 22.84, p<0.01, % change from baseline after 48h), while miR-92a had the 
opposite effect regardless of VEGF supplementation status (without VEGF: 137 ± 11.66 
vs. 151.10 ± 19.96, p<0.05; with VEGF: 157.87 ± 22.84 vs. 162.12 ± 22.84, p<0.05, % 
change from baseline after 48h). 
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Figure 49 | miR-92a (5p) inhibitor enhances VEGF-induced proliferation of CD34+-derived EPCs. 
Cells treated with 30nM miR scrambled, miR-92a (5p) or miR-92a (5p) inhibitor were incubated with an 
ATP quantifying luciferase reporter at baseline. For the time course, cells in a second well plate were 
incubated in enriched medium for 48h before performing the luminescence assay. Results in (A-B) are 
plotted as means, with errors bars representing ± SEM after 4 independent experiments (4 replicates for 
each experimental condition). *P<0.05, ***P<0.001 compared with baseline condition; &P<0.05 
compared with miR scrambled processed for 48h with no VEGF; #P<0.05, ##P<0.01 compared with miR 
scrambled processed for 48h with VEGF (1-way ANOVA, Bonferroni’s test for multiple comparisons). ATP 
- adenosine triphosphate; EGM – endothelial growth medium; EPC – endothelial precursor cells; FBS - 
fetal bovine serum; miR- microRNA; RLU – relative light units; SEM – standard error mean; VEGF – vascular 
endothelial growth factor. 
 
One of the most important properties of EPCs contributing to re-endothelialisation is 
their ability to adhere to ECM at denuded vascular sites.  I used an in vitro static culture 
assay to determine whether mir-92a inhibitor treatment could enhance EPC adherence 
to FN (a ligand for ITGA5), through upregulation of ITGA5 receptors (Figure 50). The 
results revealed that, indeed, miR-92a inhibitor significantly enhanced EPC adhesion to 
FN after 20 minutes compared to miR scrambled control (23.57 % ± 6.43 vs. 14.46 % ± 
5.22, p<0.05, specific adhesion to FN, % from baseline). This equated to 87% more cells 
adhering to the matrix within the designated period than the sham-treated EPCs. 
Conversely, an EPC reduced adhesion following miR-92a treatment trend was observed 
(7.47 % ± 3.71 vs. 14.46 % ± 5.22, p>0.05, specific adhesion to FN, % from baseline).  
 
Figure 50 | mir-92a (5p) inhibitor enhances adhesion of CD34+-derived EPCs to fibronectin. 
FN specific adhesion capacity was determined in fluorescently -labelled cells previously transfected with 
30nM miR scrambled, miR-92a (5p) or miR-92a (5p) inhibitor using oligofectamine. (A) Representative 
images of labelled EPCs transfected with indicated miRNAs captured at baseline and after one wash 20 
minutes past at 10x. (B) Representation of labelled and unlabeled EPCs, the latter used as an internal 
assay control, seeded on FN. (C) Baseline and final red object count were quantified, and data are 
expressed as mean adhesion on FN (7 replicates per experiment) minus mean unspecific adhesion on HSA 
(3 replicates per experiment). Results are representative of a total of 4 independent experiments and are 
plotted as means, with errors bars representing ± SEM. *P<0.05 compared with miR scrambled (1-way 
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ANOVA, Bonferroni’s test for multiple comparisons).  EPC – endothelial precursor cell; EBM – endothelial 
basal medium; EGM – endothelial growth medium; FBS – fetal bovine serum; FN – fibronectin; HSA – 
human serum albumin; miR – microRNA; SEM – standard error mean. 
 





4.4 miR-92a inhibitor does not change survival of 
EPCs under starvation 
 
 
To investigate the effects of miR-92a inhibitor on the viability of CD34+-derived EPC 
subject to a starvation period (to recapitulate the oxidative stress they might experience 
on injury sites), cells were transfected with miR-92a, mir-92a inhibitor or miR scrambled 
for two days, and then starved for 6 hours. No significant relative survival benefit was 




Figure 51 | miR-92a (5p) inhibitor does not significantly enhance CD34+-derived EPC survival in serum-
free medium. 
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Survival of cells treated with the 30nM miR scrambled, miR-92a (5p), miR-92a (5p) inhibitor in serum-
deprived medium after 6h was assessed using a Luminescent cell viability ATP-based assay. Survival from 
baseline results are representative of a total of 6 independent experiments and are plotted as means, 
with errors bars representing ± SEM. Replicates of 6 were used for each experimental condition. Results 
in (A-B) are representative of a total of 6 independent experiments and are plotted as means, with errors 
bars representing ± SEM. ***P<0.0001 compared with baseline condition (1-way ANOVA, Bonferroni’s 
test for multiple comparisons). ATP - Adenosine triphosphate; miR- microRNA; RLU – relative light units; 
SEM – standard error mean. 
 
 




To test if the observed effects of mir-92a inhibitor on EPCs could influence their 
engraftment capacity in vivo, I used a rat carotid artery balloon injury model, which 
typically causes the removal of the endothelium. To follow up transplanted human EPCs 
at the injury site for a short-term period, cells were labelled with a lipophilic, 
photostable fluorescence compound. After the injury, a needle catheter was inserted 
into the arteriotomy, and a suspension of fluorescently labelled EPCs was gently infused 
into the clamped carotid artery over a 10-minute occlusion period. The potential for mir-
92a inhibitor to enhance circulating EPCs’ engraftment potential, as initially 
hypothesised, was then investigated in vivo (Figure 52). Following balloon-induced 
injury, cell engraftment to the denuded intima was evident, as revealed by en face 
fluorescence microscopy, apparently with no discernible complications suggesting host 
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versus graft rejection by 24h. No intraluminal thrombosis was reported, and the animals’ 
behaviour appeared normal after transplantation. 
 
Figure 52 | miR-92a (5p) inhibitor seems to enhance CD34+-derived EPC engraftment after 
intravascular transplantation. 
To study the engraftment capacity of transfected human EPCs at a vascular injury site, cells were 
previously labelled with a vital dye. Cells treated with 30 nM miR scrambled, miR-92a (5p) or miR-92a (5p) 
inhibitor were transplanted intra-luminally in the rat carotid artery immediately after angioplasty. (A) 
Representative fluorescent macroscopy images of the rat carotid arteries taken 24h following angioplasty 
at different topographic levels at 3.2x in the red channel. These were opened longitudinally and mounted 
en face, revealing engrafted cells stained with the red cell DIi tracker dye. (B) The agglomerate of 
engrafted miR-92a inhibitor-transfected EPCs seen at higher magnification (8x). (C) Preliminary results 
following quantification of EPC engraftment area per artery after 2 individual experiments (6 rats). EPC – 
endothelial precursor cell; CCA – common carotid artery; miR – microRNA. 
 




Although the difference between conditions did not reach statistical significance, a trend 
was noticed in this pilot study. miR-92a inhibitor treated EPCs were observed in higher 
numbers in the luminal arterial face. miR-92a, on the other hand, seemed to cause 
decreased EPC engraftment, though the difference was not statistically significant.  
 
4.5 ITGA5 knockdown abrogates miR-92a inhibitor 
adhesion effect in EPCs  
 
 
To determine whether the overexpression of ITGA5 (direct miR-92a target) contributed 
to the enhanced proliferation, adhesion to FN and migration exhibited by human CD34+-
derived EPCs after miR-92a inhibitor treatment, ITGA5 expression was repressed by co-
transfecting cells with the targeted siRNA.  Confirmation of successful knockdown by si-
ITGA5 was verified by western blot 48h after treatment (Figure 53). 
 
 
Figure 53 | si-ITGA5 cancelled miR-92a (5p) inhibitor-mediated ITGA5 and T-eNOS overexpression in 
CD34+-derived EPCs. 
Cells treated with either miR-scrambled, miR-92a (5p), mir-92a (5p) inhibitor, siTGA5, mir-92a (5p) + si-
ITGA5 or miR-92a (5p) inhibitor + si-ITGA5 (all at 30 nM) were lysed, proteins separated by SDS-PAGE and 
immunoblotted with the indicated antibodies. (A) Representative western blot, with (B) ITGA5, (C) T-eNOS 
and (D) SIRT1 protein expression quantified by scanning densitometry. Protein of interest levels was 
normalised to levels of the housekeeping gene ACTB. Combined results from 6 independent experiments 
are plotted as means, with errors bars representing ± SEM. *P<0.05, **P<0.01 and ***P<0.001 compared 
with miR scrambled (1-way ANOVA, Bonferroni’s test for multiple comparisons). EPC – endothelial 
precursor cell; miR – microRNA; Si – small interfering; RU – relative units; SEM – standard error of mean. 




Co-transfection experiments revealed that ITGA5 overexpression as result of miR-92a 
inhibitor treatment (129.80 % ± 7.91 vs. 100%, ITGA5/ACTB RU, % vs control) was 
abrogated by si-ITGA5 (38.55 % ± 17.44 vs. 100%, ITGA5/ACTB RU, % vs control). 
Moreover, T-eNOS overexpression following miR-92a inhibitor treatment (140.04 % ± 
11.80 vs. 100%, T-eNOS /ACTB RU, % vs control) was also lost when EPCs were co-
transfected with si-ITGA5 (94.75 % ± 8.04 vs. 100%, T-eNOS /ACTB RU, % vs control). 
Contrastingly, SIRT1 levels remained unchanged in all experimental settings. 
 
Then, to determine the contribution of ITGA5 overexpression to the previously 
described enhanced adhesive profile of miR-92a inhibitor-treated EPCs, a new cell-
matrix assay was performed where I knocked down ITGA5 using the specific siRNA 
(Figure 54).  
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After co-transfecting cells with both miR-92a inhibitor and si-ITGA5, there was a 
significant decrease in adhesion when compared to cells treated with mir-92a inhibitor 
(41.98 % ± 1.93 vs. 49.61 % ± 0.76, p<0.001, specific adhesion to FN, % from baseline) 
and also when compared with control EPCs treated with miR scrambled + si scrambled 
(41.98 % ± 1.93 vs. 46.31 % ± 0.87, p<0.05, specific adhesion to FN, % from baseline). 
Remarkably, EPCs treated with both miR-92a inhibitor + si-ITGA5 adhered in higher 
numbers than cells treated with si-ITGA5 (41.98 % ± 1.93 vs. 35.52 % ± 1.50, p<0.05, 
specific adhesion to FN, % from baseline), revealing a still likely higher ITGA5 relative 
expression caused by miR-92a inhibitor, or that there are other players besides ITGA5 
involved in EPC adhesion which is also upregulated by miR-92a inhibitor.  
Oddly, when adding si-scrambled to miR-92a inhibitor, I failed to reproduce the 
statistically significant enhancement of adhesion caused by miR-92a inhibitor seen 
before, a topic which will be discussed later. 
Figure 54 | si-ITGA5 abrogated the miR-92a (5p) inhibitor adhesion effect in CD34+-derived EPCs. 
FN specific adhesion capacity was determined in fluorescently -labelled cells previously treated with with 
a combination of 30nM miR scrambled, miR-92a (5p) inhibitor, si-scrambled and si-ITGA5, as indicated. 
Baseline and final red object count were quantified, and data are expressed as mean adhesion on FN (7 
replicates per experiment) minus mean unspecific adhesion on BSA (3 replicates per experiment). The 
adhesion results are representative of a total of 3 independent experiments and are plotted as means, 
with errors bars representing ± SEM. *P<0.05 and **P<0.001 compared with miR scrambled + si-
scrambled; ^P<0.05 and ^^P<0.01 compared with miR-92a inhibitor + si-scrambled; #P<0.05 compared 
with miR scrambled + si-ITGA5 (1-way ANOVA, Bonferroni’s test for multiple comparisons). BSA – bovine 
serum albumin; EPC – endothelial precursor cell; FN – fibronectin; ITGA5- integrin alpha 5 subunit; miR – 
microRNA; si – small interfering; SEM – standard error mean. 
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Because we had also witnessed an enhanced EPC proliferation (under VEGF stimulus) 
resulting from miR-92a inhibitor treatment, and since integrin outside-in signalling has 
been linked to cell proliferation (Shen, Delaney, & Du, 2012), ITGA5 was downregulated 
with siRNA in miR-92a inhibitor -treated EPCs and tested as an additional experimental 
condition in a new proliferation assay (Figure 55). Remarkably, the knockdown of ITGA5 
with the siRNA did not influence EPC cumulative proliferation after 48 hours, either in 
the absence or presence of VEGF, suggesting the implication of alternative miR-92a 
targets to explain the previously described effects. Oddly enough, when adding si-
scrambled to miR-92a inhibitor, I failed to reproduce the miR-92a inhibitor 
enhancement of proliferation with VEGF seen before, a topic which will be discussed 
later. 
Figure 55 | si-ITGA5 had no effect on the proliferation of CD34+-derived EPCs. 
Cells treated with a combination of 30nM miR scrambled, miR-92a (5p) inhibitor, si-scrambled and si 
ITGA5, as indicated, were incubated with an ATP quantifying luciferase reporter at baseline. For the time 
course, cells in a second well plate were incubated in enriched medium plus or minus VEGF 25 ng/mL for 
48h before performing the luminescence assay. The results are representative of a total of 4 independent 
experiments (each condition run in replicates of 4) and are plotted as means, with errors bars representing 
± SEM. ***P<0.001 compared with baseline condition; ^^P<0.01 and ^P<0.05 compared with the VEGF-
negative condition at 48h (1-way ANOVA, Bonferroni’s test for multiple comparisons). Adenosine 
triphosphate; EPC – endothelial precursor cells; miR- microRNA;  SEM – standard error mean; VEGF – 
vascular endothelial growth factor. 
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Integrins are mechanistically involved in cell migration(Bokel & Brown, 2002). Therefore, 
one would expect to see at least a reduction of miR-92a inhibitor-induced enhancement 
on wound healing migration by si-ITGA5 co-transfection into EPCs. To test the 
hypothesis that miR-92a target protein ITGA5 is involved in the enhanced EPC wound 
healing regeneration seen after miR-92a inhibitor treatment, I performed a new scratch 
assay (Figure 56). The data exhibited represents a single experiment, thus the results 
are still preliminary, but it seemed to point towards a reduction of EPC wound closure 
migration in the conditions where si-ITGA5 was applied. When adding si-scrambled to 
miR-92a inhibitor, I failed to reproduce the miR-92a inhibitor enhancement of wound 
closure migration, hinting at a possible si-scrambled off-target effect to be discussed 
later. 
Figure 56 | si-ITGA5 could abrogate the miR-92a (5p) inhibitor effect on CD34+-derived EPC migration. 
Cells were treated with either si scramble + miR scrambled (black line), si scramble + miR-92a (5p) inhibitor 
(green line), si-ITGA5 + miR-92a (5p) inhibitor (red dashed line) and si-ITGA5 + miR scrambled (red line). 
All oligonucleotides were transfected at 30 nM concentration. After a 48h knockdown, wound closure 
migration in EBM 0.5% FBS was assessed in the presence or absence of 25 ng/mL VEGF by live-cell Imaging. 
Images were captured every 2h for a total duration of 48h. The line graphic represents the effect of 
siITGA5 on EPC migration. Each condition counted 6 replicates and data exhibited represents one single 
experiment, therefore the results are still preliminary. EPCs – endothelial precursor cell; FBS–fetal bovine 
serum; ITGA5–integrin alpha 5; Si–small interference; miR–microRNA; VEGF–vascular endothelial growth 
factor. 
 




Inhibition of miR-92a for EPC priming: what grounds? 
 
Developing a miRNA priming strategy for EPCs was based on the premise that aberrantly 
expressed miR-92a contributes towards a dysfunctional EPC phenotype (Q. Zhang et al., 
2011), and that antagonising it could provide gain-of-function therapeutic benefit.  Using 
antisense sequences which sequester the mature miRNA in competition with cellular 
target mRNAs, would lead to the functional inhibition of the endogenous miRNA and 
derepression of the direct targets.  
 
The choice of miR-92a-1 inhibitor 
miRNAs with similar seed sequences are predicted in silico to target highly overlapping 
sets of genes and are usually grouped functionally in the same “seed family”. Together 
the group of highly conserved miRNAs miR-92a-1, miR-92a-2, miR 363, miR25 and miR-
92b (which is generated independently from chromossome1) constitute the miR-92 
seed family (Table 16).  
Table 16 | Sequence of the miR-92 seed family. 
The mature miRNA sequences of the miRNAs belonging to the miR-92 seed family are displayed in the 
table. The predicted seed sequence is shown in bold for both miR strands. Adapted from (Concepcion et 
al., 2012). Chr – chromosome; miR – miRNA 
3p strand miRNA Annotation Location 
UAUUGCACUUGUCCCGGCCUGU  hsa-miR-92a-1-3p  Chr. 13 
UAUUGCACUUGUCCCGGCCUGU  hsa-miR-92a-2-3p  Chr. X 
AAUUGCACGGUAUCCAUCUGUA  hsa-miR-363-3p  Chr. X 
CAUUGCACUUGUCUCGGUCUGA  hsa-miR-25-3p Chr. 7 
UAUUGCACUCGUCCCGGCCUCC hsa-miR-92b-3p  Chr. 1 
5p strand miRNA Annotation Location 
AGGUUGGGAUCGGUUGCAAUGCU  hsa-miR-92a-1-5p  Chr. 13 
GGGUGGGGAUUUGUUGCAUUAC  hsa-miR-92a-2-5p  Chr. X 
CGGGUGGAUCACGAUGCAAUUU hsa-miR-363-5p  Chr. X 
AGGCGGAGACUUGGGCAAUUG  hsa-miR-25-5p  Chr. 7 
AGGGACGGGACGCGGUGCAGUG hsa-miR-92b-5p  Chr. 1 
 Results - 214 
 
 
I have opted to study the modulation of miR-92a-1 on EPCs (and not any other paralogs), 
since most of the literature published on the effects of miR-92 on angiogenesis, in 
particular in ECs (Bonauer et al., 2009), comes from studying the mir-17~92 cluster 
(Bonauer & Dimmeler, 2009; Concepcion et al., 2012). Despite the possibility that miR-
92a-1 inhibition can also repress other seed family paralogs being more than theoretical 
(Hinkel et al. used LNA-92a inhibitor and showed miR-25 repression in pig arteries(Hinkel 
et al., 2013)), I did not test for paralog targeting by qPCR. I have assumed high oligo 
specificity as described by the manufacturer, an assumption also made by Bonauer 
(Bonauer et al., 2009), Iaconetti (Iaconetti et al., 2012) and Daniel (Daniel et al., 2014) 
groups’ when inhibiting miR-92a in ECs and VSMCs in their critical research. Then, after 
testing the potency of both 5p and 3p strands of the mimic and inhibitor of miR-92a-1 
regarding target gene expression, I have opted to pursue the functional assays using 
solely the miR-92a-1 5p strand, which was considered the primary strand, i.e. most 
efficient and consistent in CD34+-derived EPCs.  
 
 
Suitability of oligofectamine for internalisation of miR-92a 
inhibitor 
 
AntagomiR-based therapies must overcome commonly described obstacles to nucleic 
acid delivery, including cell membrane impermeability, trafficking to the desired 
intracellular compartment (cytoplasm), recognition by the innate immune system, and 
nuclease-based degradation reducing the half-life (Sakurai, Kawabata, Sakurai, 
Nakagawa, & Mizuguchi, 2008). Efficient delivery of miRNAs mimics into cells can bypass 
the endogenous miRNA biogenesis pathway and alter miRNA abundance instantly, 
whereas inhibitors can repress the endogenous species. A variety of agents has been 
tested for non-viral miRNA transient transfection. Examples include nanoparticles (NP), 
amphiphilic polymer micelles, cell penetrating peptides and liposomes. The latter, also 
known as lipofection, is a widely used technique to transfect nucleic acids material into 
a cell using liposomes, which are vesicles that can easily merge with the cell membrane 
since they are both made of a phospholipid bilayer (Felgner et al., 1987). Lipofection 
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uses a positively charged (cationic) lipid to form an aggregate with the negatively 
charged (anionic) miRNA. Lipofection needs no specialised equipment (like 
electroporation), and it is widely available since several companies have developed 
commercial kits, with suitable experimental reproducibility. Such lipofection commercial 
kits have been previously validated for miR-92a transfection into ECs. Bonauer et al. 
used Lipofectamine RNAiMAX (Invitrogen) to transfect miR-92a mimic and inhibitor into 
HUVECs (Bonauer et al., 2009), whereas Iaconetti et al. utilised siPORT NeoFX 
Transfection Agent (Ambion) in rat aortic ECs (Iaconetti et al., 2012). Therefore, I have 
attempted to use both transfection reagents in CD34+-derived EPCs to facilitate miR-92a 
(mimic and inhibitor) internalisation, but with no success. Regarding the transfection 
results in CD34+-derived EPCs, one can argue that cells were either resistant to some of 
the miRNA cationic lipid transfection reagents previously validated for ECs due to cell 
type-specific membrane structural or endocytosis-related differences, or, alternatively, 
if the miR-92a (mimic or inhibitor) was indeed internalized, then the miRNA was not able 
to be incorporated in the RISC machinery (compartmentalization issue? liposome 
sequestration?). 
OF was one of the first lipid formulations to be examined for the in vitro delivery of 
siRNA. Since our group had significant experience in using it for siRNA transfection into 
ECs, and given that OF was previously shown to also be effective for miRNA transfection 
into ECs (Ye & Steinle, 2015), I attempted to use this methodology for the transfection 
of miR-92a (mimic and inhibitor) into CD34+-derived EPCs. The commercially available 
cationic lipid OF is a proprietary formulation able to transfer RNA interference 
oligonucleotides into eukaryotic cells. The transfection complex is thought to enter the 
cell through endocytosis, defined as the process where a localised region of the cellular 
membrane uptakes the complex by forming a membrane bound/intracellular vesicle. 
Since the RISC machinery is also located in the endosomal compartment, exogenous 
miRNA can be almost immediately processed. The transfection method is simple to 
perform and ensures consistently reproducible results. Despite some cationic lipid 
formulations eliciting inadvertent gene expression (Omidi et al., 2003), OF is reported to 
have minimal cytotoxicity in EC cells. According to the IF and FACS results, OF was shown 
to be highly efficient in miR-92a inhibitor transfection into EPCs. 
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Assessment of miR-92a inhibition 
 
Several methods can assess the effect of miRNA inhibition by antagomiR 
oligonucleotides. Approaches that directly measure changes in miRNA levels following 
antagomiR -mediated inhibition by hybridization techniques (such as qPCR or small RNA 
Northern blotting) present some limitations and should be analysed with caution due to 
possible assay interference. Firstly, the antagomiR chemistry may dictate the fate of the 
targeted miRNA. Chemically modified oligonucleotides like LNAs sequester the targeted 
miRNA in a heteroduplex (meaning that sometimes they can still be detected in 
hybridization studies), whereas lower affinity modified oligonucleotides, such as 2’-OMe 
and cholesterol-conjugated 2’-OMe antagomiRs, promote miRNA degradation 
(Stenvang et al., 2012). Secondly, the presence of excess miRNA inhibitor in the RNA 
sample may interfere with the detection step of the assay, for example, primer 
annealing or extension in miRNA-specific real-time qPCR (Stenvang et al., 2012). The 
observed readout in some settings may, thus, constitute underestimated reductions in 
the concentration of the miRNA of interest due to assay interference by the miRNA 
inhibitor. Therefore, assays that measure a functional readout of miRNA inhibition by 
antagomiRs should be preferred (Stenvang et al., 2012). These include the assessment 
of the de-repression of direct targets by real-time qPCR or Western blot analysis. In most 
cases, there is a striking correlation between mRNA and protein levels following miRNA 
disturbance (Baek et al., 2008). However, since miRNA-mediated mRNA repression 
involves both mRNA degradation and translational repression, the cellular 
concentration of target mRNAs following antagomiR treatment may not always reflect 
their true “availability to be translated”. Translationally -repressed mRNAs captured by 
miRISCs can contribute to the overestimation of target mRNAs. Hence, assessing target 
de-repression at the protein level by Western blotting seemed more in line with true 
effector concentration, which was the methodology used in this study. 
 
After having optimised the transfection conditions of EPCs in what concerns miRNA 
working concentration and processing duration, I sought proof of miR-92a inhibition at 
the protein level. According to the obtained results, inhibition of miR-92a-1-5p by the 
corresponding mirVana inhibitor led to significant upregulation of ITGA5 and T-eNOS 
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protein levels in EPCs (direct and indirect miR-92a targets, respectively) compared to the 
transfection control. Bonauer et al. in their seminal paper on miR-92a inhibition impact 
on EC biology described the same results (Bonauer et al., 2009) but using qPCR.  
Likewise, Ohyagi-Hara et al. demonstrated that miR-92a inhibitor upregulated ITGA5 
mRNA levels in non-EC cells (Ohyagi-Hara et al., 2013). More recently, Iaconetti et al. 
also confirmed the T-eNOS upregulation at the protein level in ECs following miR-92a 
inhibitor treatment (Iaconetti et al., 2012). Sadly, ITGA5 levels were not assessed by 
them. This group also described that protein expression of MKK4 (another validated 
miR-92a direct target) was up-regulated in ECs following miR-92a inhibitor treatment, a 
result we failed to see in EPCs. Of note, to the best of our knowledge, our study was the 
first to report MKK4 expression in late-outgrowth EPCs. The discrepancy regarding MKK4 
results in ECs and EPCs might be due to cell type specific variations, or as a consequence 
of the different protocoled miR inhibitor and transfection reagents used. However, one 
also needs to be aware that the degree of miRNA target de-repression can often be 
modest, with some proteomic studies reporting average changes limited to less than 
two-fold (Baek et al., 2008). In some cases, the upregulation of specific target protein 
may not be apparent or significant (like MKK4 in EPCs), and still, a cellular phenotypical 
change occur (like the gain-of-function reported in our work). This phenomenon is likely 
explained by the combined interplay between targets de-repressed.  
 
On the other hand, treatment with miR-92a-1 (5p) mimic was pursued throughout the 
thesis as a negative treatment control. Currently in microRNA research, both the 
microRNA precursor and mimic (the mature form) are commercially available. 
Theoretically, utilising the miRNA mimic should lead to clearer results, as the effects of 
the minor strand miRNA are avoided. Hence, I have chosen to use the mirVana™ mimic 
for validation of target gene repression following transfection with OF in CD34+-derived 
EPCs. The mimic is a double-stranded oligonucleotide (with two nucleotide overhangs) 
that reproduces the endogenous microRNA. These molecules do not have any loops or 
additional bases, but some proprietary chemical modifications are often operated, such 
as nucleotide changes in the passenger strands, to improve mimic stability, to facilitate 
guide miRNA loading to RISC, and to selectively exclude the passenger strand (H. Y. Jin 
et al., 2015). The observed downregulation of targets ITGA5 and T-eNOS (which have 
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been previously described as direct and indirect miR-92a target genes) obtained in 
CD34+-derived EPCs following miR-92a transfection had been previously observed by 
others in ECs, both at mRNA (Bonauer et al., 2009; Daniel et al., 2014; Iaconetti et al., 
2012) and protein level (Bonauer et al., 2009). However, while we have reported 
downregulation of ITGAV at the protein level in EPCs, the reduction of this integrin at 
mRNA level in ECs did not reach statistical significance (Bonauer et al., 2009). In contrast, 
MKK4 (Bonauer et al., 2009; Iaconetti et al., 2012) and SIRT1 (Daniel et al., 2014) mRNAs 
were significantly downregulated after miR-92a treatment in ECs, a finding that I could 
not reproduce at the protein level in EPCs. Altogether, the individual target regulation 
discrepancies pointed in our work may be cell type specific, or, simply result from the 
different synthetic miR-92a oligonucleotides and transfection reagents used by the 
various groups. However, in the overview, it appears that the miR-92a target signature 
is quite similar in both CD34+-derived late-outgrowth EPCs and mature ECs, with ITGA5 
targeting now being established as common ground for the first time, according to our 
literature review. 
 
The functional outcome of miR-92a inhibition in CD34+-derived 
EPCs 
 
Validation of exogenous miR-92a inhibitor activity in CD34+-derived EPCs at the protein 
level was considered essential before I could test the hypothesised functional outcomes 




The inhibition of miR-92a in EPCs lead to a significant pro-angiogenesis effect in vitro as 
reported by the co-culture with fibroblasts. A similar result was obtained by other 
groups after treating ECs with miR-92a inhibitor in a Matrigel model in vitro (Bonauer et 
al., 2009; Doebele et al., 2010; L. Zhang, Zhou, Qin, Weintraub, & Tang, 2014). On the 
other hand, I have observed a non-significant reduction in the angiogenic potential of 
EPCs following miR-92a treatment, which is in agreement with the results by Bonauer et 
al. also using a Matrigel assay in vitro (Bonauer et al., 2009). 




Using an automated scratch wound assay, we have noticed that miR-92a inhibitor 
treatment lead to enhanced wound closure migration in CD34+-derived EPCs (only 
statistically significant when compared to transfection control in the absence of VEGF 
stimulus). Previously, Iaconetti et al. had also reported that functional inhibition of miR-
92a on rat aortic ECs significantly enhanced wound healing migration in a 36h assay 
(Iaconetti et al., 2012). The wound healing test is well suited for the investigation of cell-
cell interactions on cell migration. However, one must recognise that the mechanics of 
cell movement are difficult to interpret. Cell population assays do not consider single 
cell locomotion or distinguish between the roles played by cell migration and cell 
growth. Often, experimental conditions will impact on both proliferative and motile 
activity. Therefore, a transwell cell culture experiment might be more informative for 
cell migration, since cells must first digest the artificial ECM before their migration, 
similarly to the in vivo context. In the modified Boyden chamber assay, CD34+-derived 
EPCs treated with miR-92a inhibitor showed significantly enhanced VEGF-induced 
chemotaxis migration ability compared to controls.  
 
On the other hand, we witnessed a reduction in EPC migration capacity after miR-92a 
treatment, albeit not reaching statistical significance. Bonauer et al. reported similar 
results, with the migration of ECs being non-significantly reduced by pre-mir92a 
treatment (Bonauer et al., 2009). Daniel et al. had also tested miR-92a treated ECs in a 
modified Boyden chamber assay and detected impaired migration compared to controls 
(Daniel et al., 2014). The results from head-to-head comparison do not necessarily 
correlate with the cells’ ability to traverse the matrix in response to a chemoattractant. 
Protocol differences, such as cell density and the size of the filter pores, could have 




By using an ATP quantifying luciferase reporter assay, it was possible to document that 
miR-92a inhibitor enhanced VEGF-induced EPC proliferation at 48h. Iaconetti et al. also 
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reported a similar significant increase in VEGF-induced EC proliferation after functional 
inhibition of miR-92a, according to a BrdU assay (Iaconetti et al., 2012). Following a 
different strategy, Liu et al. also verified increased relative proliferation under basal 
conditions (by MTT assay) of ECs infected with recombinant miR-92a inhibitor lentivirus 
(H. Liu et al., 2016). 
 
On the other hand, we have shown that miR-92a significantly reduced EPC proliferation, 
either in the presence or absence of VEGF. As expected, upregulation of miR-92a 
reduced the mitogenic effect of VEGF stimulation compared to transfection control. Our 
observation reproduced what was previously described by Iaconetti et al. for ECs 





The critical initial event for re-endothelialisation, regarding late outgrowth progenitor 
contribution, would be the attachment of the circulating EPCs to the denuded arterial 
wall. It is hypothesised that the engraftment and differentiation of EPCs depend largely 
on their adhesion to ECM components, such as FN, and the resultant signalling cascade 
that occurs on cell binding. Hence, modulating EPC adhesion activity with miR-92a 
inhibitor, which upregulates ITGA5, was a key consideration of ours. To accomplish this, 
passive in vitro EPC adhesion to FN, under static conditions, was tested. FN had been 
previously validated for EPC cultures, in fact, with superior adhesion compared to ECs 
(Vartanian et al., 2009). In this type of assay, the initial adhesive interaction between 
the cells and the substrate are said to be driven by specific integrins-ECM ligand bonding 
pairs (Hong, Ergezen, Lec, & Barbee, 2006). In the next hours, subsequent receptor-
ligand bonds will form and quickly enhance in number, forming focal adhesions with 
increased tensile strength and flattening the cell (Khalili & Ahmad, 2015). Cells then start 
spreading beyond the projected area to reach their maximum area through expansion 
and adhesion strength will then become fully stable (Khalili & Ahmad, 2015). According 
to our results, miR-92a inhibitor significantly enhanced EPC adhesion to the FN matrix 
(a ligand for ITGA5). The expression of ITGA5 had been demonstrated by us and others 
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(Chavakis et al., 2005), and concordantly, ITGA5-KO ECs have shown reduced adhesion 
to FN, which can be rescued by ectopic (over)expression of ITGA5 (van der Flier et al., 
2010). Given that a short termination period for the assay was used (20 mins), it is fair 
to assume that the relatively increased adhesion was related to miR-92a inhibitor -
mediated ITGA5 upregulation. In fact, the involvement of integrin 𝛼5𝛽1 in late-
outgrowth EPCs’ interaction with ECM is in agreement with other published works 
(Angelos et al., 2010; Brown, Wallace, Angelos, & Truskey, 2009) with the cell contact 
area growing during the first 20 minutes of attachment (Brown et al., 2009).  
To our knowledge increased EPC adhesion following ITGA5 overexpression induced by 
miR-92a inhibitor has never been attempted neither in ECs nor EPCs, but our results are 
in agreement (by contrast) with the observation by Bonauer and colleagues, that 
exogenous miR-92a transfection impairs EC adhesion to FN (Bonauer et al., 2009). 
Ohyagi-Hara et al. reported to the same observation but in cancer cells, with 
transfection of precursor miR-92a reducing ITGA5 expression and inhibiting cancer cell 




In theory, cells that successfully adhere to the ECM will have a higher chance of survival 
by avoiding anoikis, which can be defined as apoptosis caused by lack of adhesion to 
ECM. This enhanced adhesion capacity may play a major role in cell survival, particularly 
in the restenosis environment. However, our results failed to demonstrate a significant 
increase in CD34+-derived EPC survival after miR-92a inhibitor treatment in serum-free 
medium. This result contrasts with the observation by Liu et al. in ECs, where miR-92a 
inhibitor significantly reduced the apoptosis rate compared with control groups (H. Liu 
et al., 2016). Using siRNA against KLF2 or KLF4 (miR-92a direct targets), they were able 
to antagonise the miR-92a inhibitor effect on the rate of EC apoptosis, directly involving 
this pathway in EC survival. Contrastingly, Ohyashiki et al. demonstrated that anti-miR-
92a treatment increased apoptosis in human myeloid and lymphoid cells (Ohyashiki et 
al., 2010). More recently, a study in human glioma cells described an increased cell 
apoptosis outcome after antisense inhibition of miR-92a, via targeting the Bim gene (Niu 
et al., 2012). These findings suggest a differential role for miR-92a inhibitor in regulating 
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viability of EPCs, ECs and malignant cells, possibly through different target genes 
according to cell and context specificities. 
 
When we treated CD34+-derived EPCs with miR-92a, again no significant change in 
survival was seen when comparing with controls. Similarly, Bonauer and colleagues 
could not find any significant change in EC viability after miR-92a overexpression 
(Bonauer et al., 2009). Daniel and colleagues also reported no effect of pre-miR-92a 
treatment on EC apoptosis (Daniel et al., 2014). Contrastingly, there is a study by Zhang 
et al. reporting that miR-92a overexpression enhanced EC viability (under oxidative 
stress), through the release of Akt signalling, suggesting a vasculoprotective effect that 
is likely mediated through a PTEN-dependent mechanism (L. Zhang, M. Zhou, Y. Wang, 
et al., 2014). These findings suggest a differential role for miR-92a in regulating viability 
of ECs, possibly through different target genes according to context specificities, which 
still warrants further investigation. 
 
miR-92a targets which could contribute to the functional results 
 
The studies on miRNA function have been limited by several obstacles. Given the 
ubiquitous nature of miRNAs it is hard to predict all their targets accurately, but with 
the recent development of new computational algorithms, this task has become 
facilitated (John et al., 2004; Lewis et al., 2003). Molecules with distinct functions like 
ITGA5 and ITAGV (cell-matrix interaction)(Bonauer et al., 2009), SIRT1 (histone 
deacetylase)(O'Donnell et al., 2005), MKK4 (mitogen kinase)(L. Zhang, M. Zhou, Y. Wang, 
et al., 2014) and KLF2/KFL4 (flow-induced transcription factors)(Y. Fang & Davies, 2012; 
H. Liu et al., 2016; Wu et al., 2011) are some of the predicted miR-92a targets that have 
since been validated. Curiously, all of them render an embryonic lethal phenotype if 
knocked down, suggesting they have significant activities in the organism (H. L. Cheng 
et al., 2003; D. Yang et al., 1997; J. T. Yang, Rayburn, & Hynes, 1993), only to be fine 
tuned by miR-92a. 
 
We found that miR-92a inhibition enhanced VEGF-A -induced CD34+-derived EPC 
proliferation, a result previously described in ECs and thought to be at least in part 
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caused by the phosphorylating activation of mitogenic ERK and JNK signalling (Iaconetti 
et al., 2012), a pre-requisite for EC proliferation (Salameh et al., 2005). Since miR-92a 
controls MKK4 levels in ECs and JNK has been shown to be phosphorylated by MKK4 (Y. 
Fleming et al., 2000), it has been hypothesised that miR-92a inhibitor stimulates JNK 
activation through de-repressing MKK4 (Iaconetti et al., 2012). Indeed, Liu and 
colleagues also found that treatment with miR-92a inhibitor significantly upregulated 
relative EC proliferation compared to controls, an effect which could be antagonised by 
siRNA KLF2 and KLF4 (H. Liu et al., 2016), suggesting an important role of these 
transcription factors in EC proliferation. Unfortunately, we could only observe an 
enhanced MKK4 expression trend with miR-92a inhibitor treatment, suggesting that 
other pathways might be involved in enhanced proliferation. Indeed, Cui and colleagues 
described and alternative pathway that can be accountable for enhanced proliferation 
in EPCs (B. Cui et al., 2011). They have shown that in vitro gene transfer of eNOS 
improved the proliferation of EPCs. Similarly, in our study we observed a miR-92a 
inhibitor indirectly induced eNOS expression, which could, eventually, explain the 
proliferation results. 
 
Besides the pro-proliferative contribution, inhibition of miR-92a might, in theory, 
accelerate EPC-mediated re-endothelialisation (and hence attenuate experimental 
restenosis) at the injury site through additional mechanisms. SIRT1, which promotes EC 
angiogenesis, and ITGA5, which enables EC migration and angiogenesis (Potente, 
Gerhardt, & Carmeliet, 2011), are among the validated targets of miR-92a (Bonauer et 
al., 2009). Daniel and colleagues reported that both targets were strongly increased in 
arterial ECs in miR-92a inhibitor -systemically treated mice two weeks after wire-
induced injury (Daniel et al., 2014), hinting that therapeutic inhibition of miR-92a 
stimulates re-endothelialisation, at least in part, by de-repressing the two proangiogenic 
factors.  
SIRT1 per se has been shown to have an inhibitory effect on neointima formation (L. Li 
et al., 2011). SIRT1 deacetylation of FOXO1 inhibits its antiangiogenic activity in human 
vascular ECs (Potente et al., 2007) while targeting eNOS for deacetylation leads to NO 
production and corresponding enhanced endothelial-dependent vasodilation 
(Mattagajasingh et al., 2007), survival, migration and neovascularization (Aicher, 
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Heeschen, et al., 2003). Overexpression of SIRT1 prevents hydrogen peroxide-induced 
endothelial senescence suggesting that SIRT1 might prevent stress-induced endothelial 
dysfunction. In EPCs the expression and activity of SIRT1 also correlate inversely with 
senescence (Lemarie et al., 2011). However, in CD34+-derived late -outgrowth EPCs we 
were unable to demonstrate a statistically significant upregulation of SIRT1 following 
miR-92a inhibitor treatment compared to control transfection, making this contribution 
less likely to justify the observed EPC functional enhancement. 
 
The ECM is a non-cellular component that not only provides a physical scaffold for cells, 
but also triggers essential biomechanical cues that contribute towards determining EPC 
differentiation, proliferation, survival, polarity and migration (Caiado & Dias, 2012).  In 
particular, the EPC transmembrane integrin α5β1 combines with FN to form a ligand-
receptor complex that does not only mediate cell adhesion but can also promote cell 
proliferation, survival and even differentiation (Pagan et al., 2002). In 2009, Bonauer and 
colleagues demonstrated that ITGA5 (one of the subunits of α5β1) is a direct target of 
miR-92a in ECs (Bonauer et al., 2009). Ohyagi-Hara et al. came to the same conclusion 
but in cancer cells (Ohyagi-Hara et al., 2013). In our work, we have shown ITGA5 to be 
upregulated in CD34+-derived EPCs following miR-92a antagonism. Therefore, given its 
interaction with ECM components, ITGA5 is considered a necessary prerequisite for 
vascular regeneration following injury (Koyama & Reidy, 1998; Stenzel et al., 2011) since 
it facilitates the adhesion, proliferation, and migration of ECs (thus, possibly EPCs as 
well) in the process of re-endothelialisation (Daniel et al., 2014). Moreover, vascular ECs 
rely heavily on their interactions with the ECM and their neighbouring cells to avoid cell 
death. In fact, various integrins, including 𝛼5𝛽1 or 𝛼V𝛽3 have been shown to prevent 
apoptosis of ECs (Scatena et al., 1998; Z. Zhang, Vuori, Reed, & Ruoslahti, 1995), an effect 
that we were unable to see in CD34+-derived EPCs using an indirect metabolic 
luminescence assay. 
Besides 𝛼5𝛽1, the interaction of late-outgrowth EPCs with FN is also strongly dependent 
on integrins 𝛼V𝛽1, 𝛼V𝛽3 and 𝛼V𝛽5 (Kokubo, Uchida, & Choi, 2007; J. Zhao, Mitrofan, 
Appleby, Morrell, & Lever, 2016). Since we failed to see any upregulation of ITGAV in 
miR-92a inhibitor treated cells (although miR-92a successfully downregulated it), ITGAV 
contribution to enhanced EPC adhesion in our study is less likely in comparison to ITGA5 
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(which was successfully upregulated following miR-92a inhibitor treatment), although 
others have reported that direct inhibition of 𝛼V𝛽3- and 𝛼V𝛽5-integrins blocks EPC-
mediated re-endothelialisation of denuded arteries (Kokubo et al., 2007). 
 
miR-92a has also been found to target KLF2 and KLF4 (Y. Fang & Davies, 2012) (genes 
that were not unfortunately included in my WB experiments). These transcription 
factors typically exert an anti-inflammatory and atheroprotective effect in ECs after 
injury (Y. Fang & Davies, 2012), which can modulate proliferation and survival. This is 
done possibly through enhanced NO production (Boon & Horrevoets, 2009; Y. Fang & 
Davies, 2012; Hamik et al., 2007; Iaconetti et al., 2012; Parmar et al., 2006). In fact, 
although eNOS is not a direct target of miR-92a, a direct correlation to ITGA5 (Bonauer 
et al., 2009), KLF2 (Boon et al., 2011) or KLF4 (Hamik et al., 2007) expression levels has 
been shown in previous studies. Also, SIRT1 was also shown to deacetylate and thereby 
activate eNOS (Ota et al., 2007). This off-target phospho-eNOS increased expression has 
been described previously for ECs as a consequence of miR-92a inhibition (Iaconetti et 
al., 2012). Therefore, the indirect upregulation of eNOS (which we have also observed 
in our study) may represent an additional effect which could contribute to the EPC-
mediated enhanced re-endothelialisation following the knock-down of miR-92.  
 
 
Integrin α5 has a pivotal role in miR-92a inhibitor EPC priming 
 
In vessels, adhesion of EPCs to injury sites are thought to involve both cell-cell and cell-
ECM interactions. However, Zhao and colleagues demonstrated that under flow 
conditions in vitro late -outgrowth EPCs interact little with confluent ECs, but readily 
adhere to and spread where there are discontinuities in the EC monolayer, namely at 
gaps in the intercellular junctions between ECs (J. Zhao et al., 2016). Similarly, vascular 
damage in vivo is characterised by loss of endothelial integrity. Where the EC monolayer 
is disrupted, the basement membrane and its matrix components (including FN) are 
exposed to blood flow (Timpl, 1996). FN is an important regulator of various cellular 
processes including survival, differentiation, growth and migration (Hynes, 2002). FN is 
actively deposited in the ECM mainly by ECs and can be found circulating freely in the 
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plasma as well (Kaiser, Friedrich, Chavakis, Bohm, & Friedrich, 2012). FN is abundant at 
the site of vascular injury, a feature that might be expected to facilitate EPC 
incorporation (Bauters et al., 1995).  The interaction between late-outgrowth EPCs with 
FN has been previously validated (Angelos et al., 2010; Kaiser et al., 2012) and the 
generated adhesion strength estimated as very strong (J. Zhao et al., 2016). In fact, late-
outgrowth EPCs are much more adhesive to FN than to collagen IV, collagen I, and 
laminin under flow conditions (J. Zhao et al., 2016). This interaction with FN is strongly 
dependent on integrins 𝛼5𝛽1 (Angelos et al., 2010; Brown et al., 2009; Kaiser et al., 
2012; J. Zhao et al., 2016). α5β1 binds to the Arg-Gly-Asp (RGD) tri-peptide motif in FN 
(van der Flier et al., 2010), and it is composed of α5 (ITGA5/CD49e) subunit, which 
undergoes post-translational cleavage in the extracellular domain to yield disulfide-
linked light and heavy chains, that join with β1 (ITGB1/CD29) to form a FN receptor. Not 
coincidently, late-outgrowth EPCs express abundant numbers of the integrin monomers 
𝛼5, 𝛼v, 𝛽1, and 𝛽3 (Chavakis et al., 2005; J. Zhao, Bolton, Randle, Bradley, & Lever, 2014), 
which are exactly the components of the major FN ligands 𝛼5𝛽1, 𝛼V𝛽1 and 𝛼V𝛽3 
(Johansson, Svineng, Wennerberg, Armulik, & Lohikangas, 1997), densely present at the 
EPC surface (J. Zhao et al., 2014).  Concordantly, Zhao et al. tested blocking antibodies 
against integrins 𝛼5𝛽1, 𝛼v𝛽1 and 𝛼v𝛽3 and showed a significant decrease in EPC 
adhesion to FN (J. Zhao et al., 2016),  suggesting that the interaction between EPCs and 
ECM is largely mediated by these 3 integrins heterodimers. Promisingly, by using miR-
92a inhibitor in CD34+-derived EPCs we were exactly able to de-repress both ITGA5 and 
ITGAV monomers simultaneously, hence contributing to increased EPC adhesion to FN. 
Angelos and colleagues took a closer look at integrin-mediated EPC adhesion and 
concluded that, in fact, α5β1 seems to be the primary integrin responsible for initial cell 
capture to FN (Angelos et al., 2010). Their setup included adhesion experiments to FN 
under static and dynamic conditions where monoclonal antibodies against 
both α5β1 and αVβ3 were used. The adhesion of EPCs was significantly reduced relative 
to both static and flow controls when α5β1 integrins were blocked, which did not 
happen with cells blocked with anti-αVβ3. Hence, one may assume that the initial arrest 
of EPCs to FN is directly dependent on α5β1 and not αVβ3 integrin. Moreover, they 
estimated the number of α5β1 integrin receptors on the cell surface by flow cytometry 
to be 3 times higher than αVβ3’s. Thus, the greater role of α5β1 in adhesion may, 
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partially reflect their increased density per EPC. EPC adhesion to FN via α5β1 integrin 
was further characterized using a parallel plate flow chamber (Angelos et al., 2010). FN 
supported cell arrest and limited EPC rolling, by making multiple small attachments 
via α5β1 integrin. The integrin contact area was less than the area of the cell membrane 
within 50 nm of separation from the surface. Once attached (maximum adhesion seen 
at 1.0 dyn/cm2), EPCs adhered firmly with little subsequent detachment, even when 
exposed to 20 dyn/cm2 shear stress. Further dissecting the individual effect of α5-
blockade on EPCs compared to β1-blockade, Kaiser et al. found that α5 contribution to 
EPC adhesion is markedly more pronounced (Kaiser et al., 2012). 
 
Walter and colleagues described enhanced adhesiveness of cultured human EPCs 
following statin treatment, an effect that was associated with the drug-induced 
upregulation of ITGA5 (among other integrin monomers)(Walter et al., 2002). In vivo, 
statins have been shown to accelerate reendothelialization in balloon-injured carotid 
arteries via enhanced BM-derived EPC engraftment. Tying everything up, Walter then 
showed that this effect could be abrogated by administration of RGD peptides (Walter 
et al., 2002), which specifically block integrin receptors (including ITGA5) on EPCs (J. M. 
Muller, Chilian, & Davis, 1997). 
 
Besides anchoring cells to ECM, integrins α5β1 are known to participate in cell-surface 
mediated bidirectional signalling (Figure 57). 
 
Figure 57 | Integrin conformation-function relationships. 
Representation of the conformational changes that are associated with integrin α5β1 signalling. Inside-
out signaling is mediated by 1) an inactive conformation where the integrin adopts a bent conformation 
in which the α- and β-subunits are closely associated; 2) a primed conformation arising from intracellular 
signaling which culminates in the binding of talin to the β-subunit tail, causing relaxation of the leg 
restraints, allowing some further unbending. The latter primes the ligand-binding pocket to achieve a 
high-affinity conformation that is ready to accept FN; 3) an active extended conformation able to bind 
theFN, representing the end-point of inside-out signalling. Outside-in signalling is initiated after binding 
of talin and FN. As the cytoskeleton matures, tension is generated on integrin α5β1 across the cell 
membrane. The force applied to the integrin headpiece triggers further distancing of the heterodimer 
units, strengthening receptor-ligand binding and allowing the formation of stable focal adhesions and the 
initiation of intracellular signaling cascades which end in gene expression modulation, the end-point of 
outside-in signalling. Adapted from (Askari, Buckley, Mould, & Humphries, 2009) and (Ramjaun & 
Hodivala-Dilke, 2009). Akt - Protein Kinase B; ERK - extracellular signal-regulated kinase; FAK – focal 
adhesion kinase; FN – fibronectin; NFkB - factor nuclear kappa B; PI3K - Phosphoinositide 3-kinase; Rac1 - 
Ras-related C3 botulinum toxin substrate 1; Src - Proto-oncogene tyrosine-protein kinase. 
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Integrins can shift between high- and low-affinity conformations for ligand binding. In 
an inactivated state, the α5- and a β1- chain are connected at the cytosolic end, while 
the extracellular heads are found in a bent-down position (Askari et al., 2009). α5β1 
integrins can be activated from the cytosolic end by attachment of talin to the β1 chain. 
Upon talin activation the two subunits move apart, and their heads at the extracellular 
end assume an upright posture. Inside-out signalling allows for the interaction of α5β1 
integrins with immobilised ligands, such as FN. Upon binding, the Rho GTPase family 
(including Rho, Rac, and Cdc42) is activated which will control stress fibre formation and 
the assembly of focal adhesions, involved in cell spreading and migration (Hall, 1998). 
Several integrins then cluster at these focal adhesion complexes, which are capable of 
transmitting adhesive and traction forces to the cytoplasmic actin filaments. This way, 
clustered integrins can convert mechanical information, such as adhesion strength and 
shear stress, via specific adapter proteins, into chemical signals inducing multiple 
cellular functions, also known as outside-in signalling. Briefly, ligand binding activates 
focal adhesion kinase (FAK) through direct interaction at the cytoplasmic tail of the β1-
integrin subunit (Schaller, Otey, Hildebrand, & Parsons, 1995). FAK plays an essential 
role in several activation pathways downstream of integrins, regulating both signalling 
cascades and cytoskeleton changes. The signalling molecules initiate transcription of 
multiple genes that promote cell survival, proliferation and another key phenomenon. 
One of the targets of FAK is the protein kinase Src, which phosphorylates several other 
downstream proteins and additional sites on FAK (Ramjaun & Hodivala-Dilke, 2009). 
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Importantly, integrin-mediated pro-angiogenic Src activity has been observed in 
ECs(Zaric & Ruegg, 2005). Also, Src also plays a role in linking ECM adhesion with 
intercellular adhesion, which is achieved by regulating VE-cadherin activity and other 
components of the adherens junction (J. Wang & Milner, 2006). Another important 
target of FAK is PI3K (Sudhakar et al., 2003). In ECs, adhesion-induced PI3K activity 
signals via the Akt-mTOR-4E-BP1 pathway, leading to EC survival and proliferation 
(Sudhakar et al., 2003). Concordantly, Zhang et al. observed that inhibition of Akt 
phosphorylation by Ly294002 abrogated most of the protective effects of anti-miR-92a 
on EC-mediated angiogenesis in the setting of oxidative stress (L. Zhang, M. Zhou, G. 
Qin, et al., 2014). FOXO1, another downstream effector of the PI3K-Akt signalling axis, 
has also been implicated in angiogenesis (Ramjaun & Hodivala-Dilke, 2009). FAK can also 
bind p130Cas and PLC-ϒ following integrin activation (X. Zhang et al., 1999), both 
proteins involved in cell adhesion signalling pathways important in EC migration 
(Nagashima et al., 2002). α5β1 also plays a key role during the vascular remodelling and 
maturation of newly established vascular structures, since shear-stress has been 
reported to stimulate ITGA5 in ECs (Ramjaun & Hodivala-Dilke, 2009), which in turn,  
induces PI3K activity leading to the activation of a PLC-ϒ-PKC cascade (Sasamoto et al., 
2005). Activation of the well-characterized angiogenesis ERK signalling cascade 
following integrin activation has also been described in ECs (Short, Talbott, & Juliano, 
1998). Integrin ligation to FN induces the sequential activation of Raf, MEK and ERK 
(Sudhakar et al., 2003), regulating EC survival, migration and proliferation (Ramjaun & 
Hodivala-Dilke, 2009), although direct integrin activation of ERK has also been proposed 
(Roberts, Woods, Shaw, & Norman, 2003).  Another established signalling pathway 
employed by integrins in ECs involves the activation of the NF-kB pathway (S. Klein et 
al., 2002). Integrin-mediated NF-kB signalling triggers the expression of a specific set of 
genes (S. Klein et al., 2002), conferring protection from apoptosis to ECs (Reidy, 
Zihlmann, Hubbell, & Hall, 2006). Among them is the prostaglandin synthesis enzyme, 
cyclooxygenease-2 (COX-2), which is involved in the induction of VEGF and FGF-2 growth 
factors, which in turn can stimulate angiogenesis (Boosani et al., 2007). 
Altogether, it is easy to understand why ITGA5, the α subunit of α5β1 integrins, has been 
shown to mediate a variety of biological phenomena including mesoderm induction, 
vascular development, and neural crest development (van der Flier et al., 2010; J. T. 
 Results - 230 
 
Yang et al., 1993). Concordantly, ITAG5-null mice die early in gestation (E10.5) partly as 
a result of various vascular defects (Goh, Yang, & Hynes, 1997; J. T. Yang et al., 1993). 
Similarly, FN-null mice also die at embryonic day (E) 9.5 exhibiting severe defects in 
vascular development (Francis et al., 2002). An endothelial-specific ITGA5 conditional 
knockout mouse (ITGA5-floxed mouse line and ablated ITGA5 in ECs using Tie2-driven 
expression of Cre recombinase) was specifically created to study the role of ITGA5 in 
vascular biology (van der Flier et al., 2010). Surprisingly, the ITGA5 conditional knockout 
mice were viable and lacked any immediately obvious phenotype. Characterization of 
ITGA5 knockout ECs suggested compensation by ITGAV by redistributing to focal 
adhesions, suggesting a functional overlap of these two integrins. 
 
In summary, α5β1 is involved in several essential EC functions, such as survival, 
migration, proliferation and vascular remodelling (Ramjaun & Hodivala-Dilke, 2009). It 
is likely that the same pathways are triggered upon α5β1 integrin activation in CD34+-
derived late-outgrowth EPCs treated with miR-92a inhibitor, which overexpress ITGA5. 
Since α5β1 is the primary integrin involved in the initial cell arrest (Angelos et al., 2010) 
and its subunit ITGA5 is a direct target of miR-92a (Bonauer et al., 2009), we investigated 
whether miR-92a inhibitor functional  effects on EPCs were abrogated by the knockdown 
of ITGA5. By using a siRNA interference strategy directed against ITGA5 we were able to 
successfully repress ITGA5 protein levels in miR-92a inhibitor -treated CD34+-derived 
EPCs, without interfering significantly in other target proteins, like SIRT1. This strategy 
allowed us to individualize the contribution of ITGA5 for the EPC functional effects 
following miR-92a inhibitor treatment. 
Previously, ITGA5-KO ECs have shown reduced adhesion to FN, which can be rescued by 
ectopic (over)expression of ITGA5 (van der Flier et al., 2010). In concordance, we have 
shown that miR-92a inhibitor treatment augments EPC adhesion to FN. After co-
transfecting cells with both miR-92a inhibitor and si-ITGA5, the enhanced EPC adhesion 
was abrogated when compared to cells treated with mir-92a inhibitor alone. This results 
suggests that the enhanced EPC adhesion following miR-92a inhibitor priming seems to 
be mediated by the downstream target ITGA5, in a significant proportion. 
Migration involves a coordinated sequence of adhesion and release of molecules on the 
cell surface as the cell moves along a chemotactic gradient. In this complex process, 
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ITGA5 is a critical effector. In EPCs, migration is markedly reduced when ITGA5 is blocked 
(Kaiser et al., 2012). Although the scratch assay results following EPC si-ITGA5 
knockdown are only preliminary, they could point towards a reduction of EPC wound 
closure migration following si-ITGA5 + miR-92a inhibitor co-transfection compared with 
the condition of single miR-92a inhibitor treatment. 
Remarkably, si-ITGA5 treatment had no effect on the proliferation rate of miR-92a 
inhibitor treated EPCs when compared to EPCs -treated with miR-92a inhibitor alone. 
This result suggests that ITGA5 may not be the most relevant miR-92a target when it 
comes to explaining the seen miR-92a inhibitor -enhanced EPC proliferation. 
In all si-ITGA5 functional assays, it appears that the scrambled siRNA could have had 
some potential off-target effect (such as hybridizing with miR-92a inhibitor and reducing 
its bioavailability). That is a possibility since we were unable to reproduce the increased 
EPC adhesion/migration/proliferation effect following miR-92a inhibitor treatment 
when compared to transfection control treatment (the option for si-scrambled + miR 
scrambled was made in the functional assays, whereas for gene expression miR 
scrambled was used alone). To overcome this issue, a simultaneous ITGA5 western blot 
should have been performed for each assay to quantify ITGA5 abundance in all 
conditions. EPC ITGA5 levels in si-scrambled+miR-scrambled condition should differ 
from si-scrambled+miR-92a inhibitor condition. 
A word of caution concerning ITGA5 overexpression. ITGA5 activation in some settings 
may have a negative impact. Sun et al., recently, described that atheroprone flow 
induces ITGA5 translocation into lipid rafts in ECs and hence activation to cause 
activation of NLRP3 inflammasome resulting in endothelial dysfunction in vitro and in 
vivo (X. Sun et al., 2016). Lipid rafts are plasma membrane microdomains which are 
enriched in sphingolipids, cholesterol, and a variety of signaling messengers, and that 
interact F-actin-based cytoskeleton. Knockdown of ITGA5 seems to have ameliorated EC 
dysfunction in partially ligated carotid arteries of LDLR−/− mice. Furthermore, functional 
inhibition of ITGA5 in mice improved EC function in the atheroprone area. These findings 
have revealed a mechanism by which atheroprone flow causes endothelial dysfunction 
via ITGA5 activation, possibly jeopardizing our strategy of ITGA5 overexpression in 
CD34+-derived EPCs for restenosis prevention. But if miR-92a inhibitor is to exert its 
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function only transiently following EPC transfection, long enough simply to allow for 
enhanced engraftment ability, then the dysfunction phenotype might not be apparent. 
 
 
The link between integrin α5 and nitric oxide in EPC priming 
 
Human eNOS is an enzyme that is constitutively expressed mainly in ECs,  which 
catalyses L-arginine oxidation to generate L-citrulline and NO (I. Fleming & Busse, 2003). 
NO is a potent vasodilator with a short half-life that contributes to vessel homoeostasis 
and remodelling by inducing VSMC relaxation, platelet aggregation, and leukocyte 
adhesion to ECs (Dimmeler et al., 1999; Rudic et al., 1998; Zhou, Chen, Fan, Jiang, & 
Wan, 2014). Moreover, NO production is paramount in fostering endothelial integrity 
and regeneration (Gareri et al., 2016), as well as regulating progenitor cell function 
(Chavakis et al., 2008). In fact, eNOS overexpression is known to enhance the 
vasculoprotective effect of EPCs (D. Kong, Melo, Mangi, et al., 2004), suggesting that our 
hypothesis to use a combinatorial approach with EPCs for transfer of increased NO levels 
may be an effective strategy to enhance endothelium regeneration in damaged vessels. 
This might be particularly relevant in CVD states, which are associated with reduced 
levels of NO bioavailability (Gallagher et al., 2007). The basal release of NO is reduced 
during ageing or the presence of simultaneous CVD RFs, as the activity of eNOS is 
suppressed in senescent ECs (Gerhard, Roddy, Creager, & Creager, 1996). As EC and EPC 
dysfunction cause further NO insufficiency (Ignarro, Napoli, & Loscalzo, 2002), a 
negative feedback loop is installed perpetuating vascular damage following injury 
(Evora, Baldo, Celotto, & Capellini, 2009; Ignarro et al., 2002). Moreover, impaired eNOS 
function is thought to be, in part, responsible for impaired mobilisation of EPCs from the 
BM (Padfield et al., 2010) which further contributes to the delayed vascular healing. BM 
cells treated with an eNOS transcriptional enhancer exhibit enhanced migratory and 
neovascularization capacity, when administered in a model of hind-limb ischemia, 
improved neovascularization (Thum, Fraccarollo, et al., 2007). Furthermore, this 
beneficial effect can be reversed by the use of eNOS inhibitors, strongly implicating NO 
in the process of vascular repair (Thum, Fraccarollo, et al., 2007). The reduced NO 
bioavailability can be counteracted by statins, oestrogen and EPO, all of which enhance 
eNOS expression, reduce senescence in ECs (Hayashi et al., 2006; Vasa, Breitschopf, 
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Zeiher, & Dimmeler, 2000), and are known to promote reendothelialization following 
vascular injury (Iwakura et al., 2003; Landmesser et al., 2004; Urao et al., 2006).  
 
To date, there is no convincing evidence of direct regulation of eNOS by miRNAs also 
contributing to the remodelling process. However, recently, miR-92a has been shown to 
be involved in the modulation eNOS expression and activity in ECs, by repressing it 
(Bonauer et al., 2009; Daniel et al., 2014). Conversely, miR-92a inhibitor increases NO 
bioavailability in ECs (Gareri et al., 2016; Iaconetti et al., 2012; Wu et al., 2011).  
Therefore, it seems consensual that eNOS may also play a role in EPC-mediated 
endothelium regeneration following miR-92a antagonism. The inexistence of miR-92a 
binding sites in the 3’ untranslated region of eNOS’ gene suggests that a mechanism 
other than the direct targeting of miR-92a is involved (Wu et al., 2011). In fact, miR-92a 
(indirectly) -induced eNOS downregulation has been shown to be mediated by ITGA5 
(Bonauer et al., 2009), KLF2 (Boon et al., 2011) and KFL4 (Hamik et al., 2007) in previous 
research. Furthermore, SIRT1 directly deacetylates and thereby activates eNOS and 
leads to more NO production (Ota et al., 2010; Rudic et al., 1998). All of these are miR-
92a direct targets.  
 
Because of the fundamental role of ITGA5 in EPC physiology we sought to understand 
the link between ITGA5 and eNOS in specific. As it seems, activation of eNOS can also be 
accomplished in a Ca2+-independent manner, via PI3K/Akt -dependent phosphorylation 
(at serine 1177), which has a clear beneficial role in the number and function of EPCs (B. 
Cui et al., 2011; Dimmeler et al., 1999). Akt levels are reduced in senescent ECs, causing 
reduced eNOS phosphorylation by Akt. Therefore, as the activity of eNOS is suppressed 
in senescent ECs (Gerhard et al., 1996), the basal release of NO is reduced during ageing 
and the presence of further CVD risk factors. Importantly, Akt -mediated activation of 
the eNOS in ECs depends on the integrin pathway (Dimmeler, Assmus, Hermann, 
Haendeler, & Zeiher, 1998; Dimmeler et al., 1999). Consistent with this finding, shear 
stress–induced vessel relaxation is antagonised by RGD peptides, which block α5β1 
integrins (J. M. Muller et al., 1997). Therefore, a miR-92a antagonising strategy aiming 
to enhance ITGA5 expression could presumably enhance NO bioavailability in EPCs. 
Indeed, in ECs, ITGA5 was found to interact with integrin- linked kinase (ILK) at the focal 
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adhesion which activates protein kinase B/Akt and triggers eNOS activation (Dimmeler 
et al., 1998; Goligorsky, Li, Brodsky, & Chen, 2002). As NO is necessary for vascular 
remodelling, an Akt-mediated increase in eNOS activity might represent a major 
determinant of vessel regeneration via EPCs. This EPC-derived NO production has been 
shown to exert antioxidant action and prevent further endothelial injury (L. Gao et al., 
2014). Therefore, miR-92a inhibition might promote EPC function also by improving 
eNOS activation and NO production. 
 
The indirect upregulation of eNOS seen after priming CD34+-derived late-outgrowth 
EPCs with miR-92a inhibitor, possibly, accounts for some of the reported functional 
effects. EPC proliferation in vitro has previously been shown to be enhanced by eNOS 
gene transfer (B. Cui et al., 2011). Moreover, the activation of eNOS by Akt might explain 
the relevant Akt pro-proliferative effects (Dimmeler, Haendeler, Nehls, & Zeiher, 1997). 
Akt also seems to play a positive role in VEGF-induced EC migration (Dimmeler, 
Dernbach, & Zeiher, 2000). Concordantly, eNOS is required for the basal and -VEGF-
induced migration of EPCs in vitro (Sasaki et al., 2006). In contrast, the reported 
enhanced EPC adhesion following miR-92a inhibitor treatment does not seem to be 
linked to indirectly augmented eNOS expression/activation, since adhesion experiments 
using NO donators by Kaiser et al. found no impact on adhesion of ECs (Kaiser et al., 




In an attempt to test the main thesis theory that miR-92a inhibitor would be a suitable 
priming strategy to enhance CD34+-derived late-outgrowth engraftment in injured 
vessels, I resourced to a rat carotid balloon angioplasty model for proof-of-principle. 
 
It would have been possible to use autologous CD34+-derived EPCs from rat BM (instead 
of human EPCs), and, thus, avoid allo-immunogenicity associated with human EPC 
transplantation (N. Yang et al., 2011). According to Yang and colleagues, cultured MNCs 
from rat BM can be differentiated into early EPC-like cells in FBS, VEGF and FGF-
supplemented M199 medium, or late EPC-like cells in EGM-2MV medium. Nevertheless, 
I have opted not to use this strategy, though, for several reasons. First, it meant 
 Results - 235 
 
sacrificing many animals to harvest their bones. Given that only a few µL of BMB are 
retrieved from each bone, several samples would have to be pooled together to have 
enough volume to perform a MNC isolation by gradient density. Secondly, EPCs 
separated from MNCs exclusively by adherent culture comprise many subpopulations, 
therefore obtaining a uniform cell population that expressed CD34 homogeneously by 
MACS would be further challenging in these conditions. Thus, for the EPC 
transplantation experiments in rats, I proceeded with the well-characterized human 
CD34+-derived late -outgrowth EPCs that I had generated from UCB, a blood source said 
to have less HLA immunogenicity (Riordan et al., 2007), and because the engraftment 
output was to be read in 24h from surgery. Moreover, most reports have found little 
evidence of fusion between EPCs and cells of other lineages (Koyanagi, Brandes, 
Haendeler, Zeiher, & Dimmeler, 2005). As an example, the proportion of ECs displaying 
evidence of human–mouse cell fusion is reported to be less than 3% in previous 
mismatch transplantation studies (S. Lee & Yoon, 2013). In fact, most recent studies 
have suggested that although fusion and transdifferentiation of EPCs are possible, such 
phenomenon is not at all prevalent (S. Lee & Yoon, 2013). 
 
Also on the technical side, EPCs were often administered systemically in early 
investigations. However, more recently, experiments have tended to employ cell 
transplantation instead (i.e. injection directly into the injured artery), to overcome the 
low retention rates seen when systemically administering cells (S. Lee & Yoon, 2013). 
Hence, my choice for temporarily isolating the target arterial segment with combined 
techniques to clamp the proximal end and to ligate the distal artery against inserted 
balloon catheter before deploying the cells. Our results indicate that the transplantation 
technique appeared efficacious as proven by the fact that the DIi-labeled EPCs could be 
successfully deposited in the injured artery and seen by fluorescent microscopy 24h 
after cell administration. 
 
Although the transplantation results are only preliminary since statistical significance 
could not be reached due to limited PhD time to perform more n numbers, in the present 
experiment, the engraftment of locally delivered miR-92a inhibitor -treated EPCs 
appeared promisingly greater compared to controls. Given the previous in vitro 
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demonstration of the role of upregulated ITGA5 (following miR-92a inhibitor treatment) 
in EPC-FN adhesion assay, we are lead to believe that the in vivo trend follows the same 
integrin-ECM bonding principles. 
 
However, due to EPC scarcity in the circulation (or lack of identification parameters), 
there is a requirement for ex vivo expansion and miR-92a inhibitor treatment before 
primed CD34+-derived late-outgrowth cells could provide a useful cell therapy in vivo.  
Thus, following the indication that miR-92a inhibitor might enhance EPC adhesion to 
injured arteries, I conducted a series of preliminary experiments (Appendix IV) which 
sought to describe the initial steps towards establishing a target tissue pre-activation 
strategy by transfecting miR-92a inhibitor into injured arteries. This could maximise 
endogenous EPC capture via ITGA5 upregulation, contributing to the prevention of post-
angioplasty restenosis, instead of having to transplant pre-activated ex vivo -expanded 
EPCs. With target tissue modulation secured, I envisioned a NP-based strategy that could 




 Discussion - 237 
 
Discussion 




New signalling molecules and cell types controlling the progress of restenosis are 
continuously being discovered. In particular, microRNAs and vascular progenitor cells 
have recently been shown to play a vital role in this pathophysiological process. In fact, 
the contribution of circulating EPCs homing to injured vessels is considered essential to 
promote re-endothelialisation and prevent neointima formation following PCI (Curcio et 
al., 2011). Moreover, it is possible that vascular wall EPCs may also contribute (Psaltis & 
Simari, 2015). However, EPC numbers and function among CVD patients are often 
intrinsically impaired leading to low engraftment rates at the target site, which could 
limit re-endothelialisation (Templin, Luscher, & Landmesser, 2011). Therefore, priming 
therapies designed to increase the ability of EPCs to engraft at the site of vascular injury 
are attractive and have the potential to improve the post-PCI clinical outcomes, similarly 
to the angiogenesis outcomes seen with primed EPCs (Table 17). 
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Table 17 | Priming strategies to enhance EPCs function. 
Adapted from (Haider et al., 2017). AAV: Adeno-associated virus; ECM: Extracellular matrix; EPC: 
Endothelial progenitor cell; HUVEC: Human umbilical vein endothelial cell; I/M: Intramyocardial; LAD: Left 
anterior descending; MI: Myocardial infarction; SDF-1: Stromal cell-derived factor-1α 

























Decreased cardiomyocyte apoptosis 
with increased retention of genetically 
modified cells, increased capillary and 
arteriolar density and incorporation of 
the delivered cells into the blood 
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increased cardiomyocyte proliferation, 
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peri-infarct region and improved 









Growth factor (SDF-1 
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Enhanced VEGF expression in the 
border zone; enhanced blood vessel 
density, improved microvascular 
perfusion, attenuated remodeling, 
reduced scar formation and preserved 
cardiac function 
 
Priming EPCs may improve their survival, proliferation, mobilization, paracrine behavior 
and differentiation for enhanced repair and angiogenic potential. Various priming 
strategies have been reported and include, genetic modification, pretreatment with 
recombinant growth factor proteins, treatment with established pharmacological 
agents (Haider et al., 2017). Several vascular miRNAs have been identified in restenosis 
pathophysiology, therefore its therapeutic modulation seems feasible (Table 18). 
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Table 18 | Summary of recently identified miRNAs involved in (re)stenosis progression in animal 
models of disease and tested as targets in pre-clinical therapeutic strategies. 
Adapted from (Forte et al., 2014). LRRFIP1 - leucine-rich repeat (in Flightless 1)-interacting protein-1; 
MKK4 - MAPK kinase 4; Myl9 - myosin, light chain 9; ND - not determined. 















Vessel transfection with 
antisense miR-146a 
oligonucleotides in 
pluronic gel (S. G. Sun et al., 
2011) 
miR-133 
Carotid artery balloon 
injury in Wistar rats 
↓ (early phase 
after injury); 




Vessel transfection with 
miR-expressing 




Carotid artery balloon 
injury in rat 
↑ 
Cyclin D1 and 
calumenin 
Vessel transfection with 
miRNA-expressing 
adenovirus (Merlet et al., 
2013) 
miR-663 
Carotid artery ligation 
injury in C57BL/6N 
mice 
↓ JunB and Myl9 
Vessel transfection with 
miR-expressing 
adenovirus (P. Li et al., 2013) 
miR-132 
Carotid artery 
catheter injury in 
Sprague–Dawley rats 
↓ (early phase 
after injury) 




gel-mediated delivery of 
miR-132 mimic (Choe et al., 
2013) 
miR-195 
Carotid artery balloon 




Vessel transfection with 
miR-expressing 




Carotid artery balloon 




Vessel transfection with 
antisense 
oligonucleotides in 
pluronic gel (X. Liu, Cheng, 
Yang, Xu, & Zhang, 2012) 
miR-92a 
Carotid artery balloon 
injury 
in the rat; stent 
deployment 
in rat carotid artery 
↑ KLF4, MKK4 
Systemic infusion by tail 
vein of antagomiR-92a 
at 0, 1 and 2 days after 
injury (Iaconetti et al., 2012) 
 
miR-92a is linked to anti-angiogenic effects, via ITGA5 downregulation (Bonauer et al., 
2009). α5β1 is involved in several essential EC functions, such as survival, migration, 
proliferation and vascular remodelling (Ramjaun & Hodivala-Dilke, 2009). It is likely that 
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the same pathways are triggered upon α5β1 integrin activation in CD34+-derived late-
outgrowth EPCs treated with miR-92a inhibitor, which overexpress ITGA5.  Given that 
α5β1 is the primary integrin involved in the initial EPC arrest (Angelos et al., 2010), and 
miR-92a levels are usually high in EPCs from CAD patients (Q. Zhang et al., 2011), we 
thought that inhibiting miR-92a in EPCs would facilitate engraftment at the injured 
arterial segments by increasing its ITGA5-mediated adhesiveness to FN. EPC grafting 
would theoretically accelerate re-endothelialisation by paracrine and structural 
contribution, hence, reducing neointima formation (Walter et al., 2002).  
 
Therefore, the overarching aim of this thesis was to characterise the effect of miR-92a 
inhibition in CD34+-derived late-outgrowth EPCs, which had never been reported to the 
best of our knowledge. 
To accomplish the objectives of this research, the following milestones were reached: 
1. Differentiation and characterization of CD34+-derived late-outgrowth EPCs 
from human and porcine sources;  
2. Characterization of gene expression and demonstration of the functional 
priming following miR-92a inhibitor treatment on CD34+-derived late-
outgrowth EPCs in vitro and in vivo, correlating it to the target ITGA5 
expression; 
 
Soon after in vitro proof of concept of the EPC increased adhesiveness to FN and 
subsequent enhanced thriving following miR-92a inhibition, we tested the 
transplantation of primed human EPCs into a rat carotid injured artery for a short 
duration trial. The preliminary results evidenced a possible increase in engraftment 
capacity of the injected EPCs. Meanwhile, Iaconetti’s group, and then Daniel’s, 
attempted a systemic delivery of an inhibitor to attenuate miR-92a activity in the injured 
arteries and were the first to confirm that miR-92a inhibitor stimulated re-
endothelialisation and decreased SMC hyperplasia, at least in part, through direct pro-
proliferative effects on ECs (Daniel et al., 2014; Iaconetti et al., 2012).  
 
Thus, it seems that the in vitro results from this thesis are clinically translatable and add 
important evidence to the expanding research field of therapeutic modulation of miR-
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92a activity to rescue the damaged endothelium after coronary interventions via an 
unexplored player - EPCs.  The possible role of miR-92a inhibition in post-injury 
restenosis prevention, taking into account the overall effect in (5.1) engrafting 
circulating EPCs and (5.2) other interacting partners is discussed next. 
 
5.1 The role of miR-92a inhibitor in EPC-mediated 




EPC mobilisation and homing to the vascular injury site is a multi-step process involving 
detachment from the BM niches, entry into circulation, rolling along vessel endothelium, 
adhesion to denuded ECM and transmigration where they participate in re-
endothelialisation (B. Cui et al., 2011; Werner et al., 2003; X. Zhao et al., 2007). However, 
a critical limitation for the therapeutic application of EPCs is their low number in the 
circulation, which is even lower in patients with CVD RFs (Fadini et al., 2006; Padfield et 
al., 2010; Vasa, Fichtlscherer, Aicher, et al., 2001). Moreover, EPCs isolated from patients 
with diabetes or hypertension exhibit a reduced activity in promoting re-
endothelialisation of denuded arteries when transplanted into nude mice (Giannotti et 
al., 2010; Landmesser et al., 2004; Sorrentino et al., 2007), highlighting a significant 
limitation of current cell therapies in these patients. The functional deficits that cause 
these reduced in vivo activities are likely associated with diminished NO availability and 
an accelerated senescence (Giannotti et al., 2010; Sorrentino et al., 2007). 
Consequently, the impaired functionality of BM-derived EPCs in specific assays, such as 
migration or colony formation capacity in vitro, has been linked with disappointing 
outcomes in cell therapy trials (Assmus et al., 2007). Remarkably, one of the major 
challenges for the therapeutic application of EPCs has been the poor engraftment and 
cell survival rates. Numerous factors contribute to the meagre cell retention, which 
include exposure of the cells to inflammation, relative hypoxia, nutrient deprivation, and 
mechanical washout of cells from the coronary vasculature (B. Cui et al., 2011). Overall, 
most cells enter apoptosis within the first few days after interacting with the injury 
site.  Therefore, an EPC priming and stabilisation strategy likely to promote longer cell 
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retention and engraftment can potentially be accomplished by manipulation of the 
integrin presentation on EPCs. Since FN, an ECM protein that may influence cellular 
migration and differentiation, accumulates rapidly at the site of balloon injury, an 
overexpression of integrins is expected to facilitate EPC incorporation (Bauters et al., 
1995). EPCs’ integrin expression profile has been previously described and includes the 
following subunits: α1, α2, α3, α4, α5, α6, α9, αv, β1, β2, β3, β5 αnd β7 (Caiado & Dias, 
2012). They have been implicated in EPC mobilisation, homing, transendothelial 
migration, invasion, and differentiation (Caiado & Dias, 2012). Integrin α5β1 is the 
primary integrin involved in the initial cell arrest (Angelos et al., 2010) and its subunit 
ITGA5 is a direct target of miR-92a (Bonauer et al., 2009). In fact, α5β1 is involved in 
several other essential EC functions, such as survival, migration, proliferation and 
vascular remodelling (Ramjaun & Hodivala-Dilke, 2009). In EPCs, we were able to 
demonstrate pro-angiogenic,-migratory,-proliferative, and -adhesive effects of miR-92a 
inhibitor treatment on CD34+-derived EPCs, which were partially abrogated by ITGA5 
knockdown. Given that ECs and EPCs share similar processing machinery, it is likely that 
our reported functional effects following miR-92a inhibitor treatment in EPCs (and 
subsequent ITGA5 upregulation) were at least partially explained by the triggering of 
same EC pathways upon α5β1 integrin activation.  
Briefly, ligand binding activates FAK through direct interaction at the cytoplasmic tail of 
the β1-integrin subunit (Schaller et al., 1995), which activates several downstream 
pathways downstream which are implicated in survival, proliferation and cytoskeleton 
changes. In fact, ITGA5 seems to even be involved in EPC differentiation to EC through 
FN-integrin α5β1 interaction (Caiado & Dias, 2012; Wijelath et al., 2004). The formation 
of VEGF/FN complexes via direct interactions with FN heparin-II domain leads firstly to 
the physical interaction between VEGFR-2 and integrin α5β1 (Caiado & Dias, 2012) and 
consequently to the activation of downstream pathways that may potentiate EPC 
endothelial differentiation. Moreover, in ECs, ITGA5 was found to interact with integrin- 
linked kinase (ILK) at the focal adhesion which activates protein kinase B/Akt and triggers 
eNOS activation (Dimmeler et al., 1998; Goligorsky et al., 2002). Ultimately, miR-92a 
inhibitor increases protein levels of serum response factor (SRF), a downstream 
mediator of VEGF signalling through the MEK–ERK pathway in ECs (Iaconetti et al., 
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2012), which is a requirement for VEGF-induced in vitro angiogenesis and endothelial 
cells migration, proliferation, actin cytoskeleton rearrangements (Iaconetti et al., 2012) 
 
Besides ITGA5 main role in EPC function which was our main focus of interest, several 
other vasculoprotective genes can be repressed by miR-92a in ECs (and in EPCs we 
extrapolate) and could potentially explain the observed results (Figure 58). 
 
Figure 58 | miR-92a target genes in EPCs implicated in the post-injury restenosis response. 
Inhibition of restenosis by miR-92a antagonism involves the de-repression of the pro-angiogenic and anti-
inflammatory factors SIRT1, ITGA5 and KLF2/4 in both EPCs and ECs which promotes their proliferation, 
migration and differentiation. Akt - Protein kinase B ; EC – endothelial cell; EPC – endothelial precursor 
cell; eNOS – endothelial nitric oxide synthase; ERK 1/2 - Extracellular signal–regulated kinase; ILK - 
Integrin-linked kinase; ITGA5 – integrin α5; ITGAV – integrin αv; JAK/STAT –Janus Kinase/Signal Transducer 
and Activator of Transcription; KLF2/4 - Krüppel-like factor 2/4; miR – microRNA; MKK4 - MAPK kinase 4; 
nF-kB – factor nuclear kappa B; (p) – phospho; SIRT1 – sirtuin 1; SOCS5 - Suppressor Of Cytokine Signaling 
5; SRF – stromal release factor; VSMC – vascular smooth muscle cell. 
 
 
SIRT1, which prevents eNOS acetylation and inactivation (O'Donnell et al., 2005), is one 
such example.  Overexpression of SIRT1 has been shown to reduce atherosclerotic lesion 
formation and to protect against neointima formation following vascular injury in mice 
(L. Li et al., 2011; C. Zhang, 2008). SIRT1 is part of the family of sirtuins (SIRT1 to 7), a 
highly conserved protein family of histone deacetylases (HDACS) that promote longevity 
and exert protective effects against age-related diseases such as cancer, CVDs and 
diabetes, through the modulation of epigenetic information by direct deacetylation of 
specific histone acetylation marks (D'Onofrio et al., 2015). Sirtuins play an essential role 
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in regulating cellular differentiation and senescence in response to nutrient availability 
(Potente et al., 2007). Among all sirtuins, SIRT1 is the most critical modulator of the 
vascular function.  At vascular level, SIRT1 is the only family member shown to regulate 
vasodilation uniquely and the regenerative functions of ECs, EPCs and SMCs through the 
modulation of eNOS, forkhead box O1 (FOXO1), p53, and angiotensin II type 1 receptor 
(AT1R)(D'Onofrio et al., 2015). Overexpression of FoxO1 inhibits EC migration and tube 
formation and represses eNOS expression (Potente et al., 2005). SIRT1 deacetylation of 
FOXO1 inhibits its antiangiogenic activity in human vascular ECs (Potente et al., 2007), 
while targeting eNOS for deacetylation leads to NO production and corresponding 
enhanced endothelial-dependent vasodilation(Mattagajasingh et al., 2007), survival, 
migration and neovascularization (Aicher, Heeschen, et al., 2003). Therefore, it comes 
as no surprise that blocking the function of SIRT1 abolishes endothelial EC sprout 
formation and migration in vitro (Yuan et al., 2014). In vivo, disruption of SIRT1 gene 
expression in zebrafish and mice also results in dysregulated vascular growth. Numerous 
studies describe the protective role of SIRT1 in endothelial senescence, and conversely, 
SIRT1 levels progressively decline during the development of endothelial senescence 
(D'Onofrio et al., 2015). SIRT1 inhibits senescence by the deacetylation of FoxO proteins, 
which are meant to upregulate antioxidant and cytoprotective enzymes, such as 
catalase and MnSOD (Yamakuchi, 2012). Pharmacological or siRNA inhibition of SIRT1 
induces premature senescence in ECs (Ota et al., 2007). Conversely, overexpression of 
SIRT1 prevents hydrogen peroxide-induced endothelial senescence suggesting that 
SIRT1 might prevent stress-induced endothelial dysfunction, a transversal component in 
several CVDs (Ota et al., 2007). In EPCs the expression and activity of SIRT1 also correlate 
inversely with senescence (Lemarie et al., 2011). Particularly, exposure to high glucose 
has been shown to reduce SIRT1 expression levels in EPCs, consequently blocking 
deacetylation of FOXO1 by SIRT1 and reducing eNOS phosphorylation levels(Balestrieri 
et al., 2008). Consistent with these findings, levels of SIRT1 protein were found to be 
decreased in EPC from individuals with diabetes and, especially, in patients with poor 
glycemic control (Balestrieri et al., 2013). In vitro and ex vivo studies revealed reduced 
EPC activity in the presence of hyperglycaemia which is associated with lower SIRT1 
protein levels (Balestrieri et al., 2013). In fact, EPC number, differentiation ability and 
SIRT1 protein levels can be enhanced in patients with ST-elevation myocardial infarction 
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undergoing PCI provided there is an intensive peri-procedural glycaemic control 
(Marfella et al., 2013). Based on these considerations, it is predictable that 
overexpression of SIRT1 (for instance via miR-92a inhibition) would not only beneficially 
affect established RFs, but would also prevent endothelial dysfunction. Because SIRT1 
targets several proteins in distinct pathways for deacetylation, overexpression of SIRT1 
could alter the biological activity of entire signalling networks and thereby enhance EPC-
mediated regeneration of injured vessels.  
 
ITGAV is also an in silico predicted target of miR-92a (Bonauer et al., 2009). Integrins 
𝛼V𝛽3- and 𝛼V𝛽5 also play a role in EPC engraftment to sites of vascular repair. 𝛼V 
integrins are known to bind different ligands, including vitronectin, FN, osteopontin, 
fibrinogen and vWF, by binding the RGD motif (Hynes, 2002). Remarkably, EPC adhesion 
seems to also be mediated by 𝛼V𝛽3- and 𝛼V𝛽5-integrins, since their inhibition with 
cyclic RGD peptides blocks EPC-mediated re-endothelialisation of denuded arteries 
(Kokubo et al., 2007).  
 
miR-92a also suppresses KLF2 and KLF4 expression by binding to their 3’ UTR (H. Liu et 
al., 2016). Endothelial flow-induced transcription factors KLF4 and KLF2 confer a vascular 
anti-oxidant, vasodilatory and antithrombotic phenotype, being implicated in protection 
against atherogenesis (Neth, Nazari-Jahantigh, Schober, & Weber, 2013). Shear stress 
with a laminar flow upregulates KLFs in ECs (Nayak, Lin, & Jain, 2011) which in turn 
modulates the expression of over 70% of the genes that are responsive to shear 
stress(Fledderus et al., 2008). In swine aortic arch endothelium, a site of 
atherosusceptibility, both KLFs are expressed at low levels relative to protected thoracic 
aorta (Y. Fang & Davies, 2012). Overexpression of KLF4 in ECs activates expression of 
anti-inflammatory eNOS and antithrombotic thrombomodulin (Hamik et al., 2007), 
while KLF2 induces eNOS expression (Boon & Horrevoets, 2009; Parmar et al., 2006). 
Additionally, endothelial expression of KLF2 reduces cocultured SMC migration capacity 
via paracrine modulation (Mack et al., 2009). Fang and colleagues demonstrated that 
the upregulation of miR-92a expression is inversely correlated with KLF2 and KLF4 
expression in atherosusceptible endothelium (Y. Fang & Davies, 2012), and then 
functionally validated two evolutionarily conserved miR-92a sites in KLF4 3'UTR and 1 
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site in KLF2 3'UTR. Atherodisruptive flow patterns are thought to increase the level of 
miR-92a, which in turn decreases KFLs. Overexpression of miR-92a inhibited the 
expression of eNOS and administration of miR-92a into mice decreased the arterial 
expression of KLF2 and eNOS (Wu et al., 2011). Concordantly, mouse carotid arteries 
receiving pre-miR-92a exhibited impaired vasodilatory response to flow (Wu et al., 
2011). Knockdown of miR-92a by using an antagomir partially suppressed TNF-induced 
endothelial proinflammatory marker expression (monocyte chemotactic protein 1, 
vascular cell adhesion molecule-1, E-selectin) and upregulated eNOS through KLF4 and 
KLF2, therefore inhibiting TNF-induced leukocyte adhesion to ECs in vitro. Altogether the 
reported studies seem to suggest that miR-92a regulates KLF4 and KLF2 expression in 
arterial endothelium and contributes to phenotype heterogeneity associated with 
regional atherosusceptibility and protection in vivo. Moreover, in addition to the 
regulation of NO and its consequent vasodilation, the mechanism involving miR-92a 
targeting KLF2 may also regulate other KLF2-regulated genes such as vWF, FLK1, and Tie-
2, which are essential for EC vascular functions (Wu et al., 2011). Moreover, KLF2 and 
KLF4 can also enhance eNOS activity, which inhibits VSMC proliferation through 
enhanced NO production (Boon & Horrevoets, 2009; Y. Fang & Davies, 2012; Hamik et 
al., 2007; Iaconetti et al., 2012; Parmar et al., 2006). In summary, several of the miR-92a 
direct targets like ITGA5 (Bonauer et al., 2009), SIRT1 (Ota et al., 2010; Rudic et al., 1998), 
KLF2 (Boon et al., 2011) and KFL4 (Hamik et al., 2007), seem to seem to downregulate 
eNOS. miR-92a inhibition also results in a reduction of activated NFκB through increased 
KLF4 expression, which probably accounts for the anti- inflammatory phenotype 
observed after miR-92a blockade (Loyer et al., 2014). These studies provide insight into 
proatherogenic functions of miR-92a under disturbed flow through suppression of 
KLF2/KLF4 and its key targets eNOS and thrombomodulin. 
 
SOCS5 expression is upregulated in the aortic arch and descending aorta of 
normocholesterolemic mice but markedly decreased in the aortic arch of 
hypercholesterolemic mice, where expression of miR-92a is reported to be highest 
(Loyer et al., 2014). SOCS5, whose expression is induced by shear stress and which 
confers anti-inflammatory properties to ECs via activation of JAK-STAT pathway (Zhuang 
et al., 2012), was recently been validated as a miR-92a target (Loyer et al., 2014). 
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Inhibition of SOCS5 by siRNA was shown to increase IL-6 and monocyte chemoattractant 
protein-1 (MCP1) release without disturbing KLF2, KLF4, and eNOS levels, suggesting 
that SOCS5 directly protects against endothelial activation and overall post-injury 
inflammation (Loyer et al., 2014). 
 
 
5.2 The role of miR-92a inhibitor in EPC-mediated 
regeneration of injured arteries: Indirect effects in 
EPC interacting players 
 
In addition to their role as a structural tissue component, EPCs express many factors that 
contribute to tissue regeneration, including the eNOS and proangiogenic or anti-
apoptotic GFs, including VEGF, hepatocyte growth factor (HGF), insulin-like growth 
factor 1 (IGF-1)(Urbich, Aicher, et al., 2005). GF release stimulates the recruitment of 
new EPCs to the injured and influences the proliferation, migration and survival of both 
EPCs and pre-existing mature ECs. ECs exposed to the increased NO produced by the 
EPCs activated by miR-92a inhibitor enhance the coverage of the injured area, while the 
rate of vascular VSMC proliferation and the level of platelet adhesion are significantly 
reduced. Thus, EPCs contribute to a surface that more closely mirrors a normal vascular 
endothelial phenotype via the interaction with different cellular players. In fact, EPCs, 
ECs and the supporting ECM exist in a state of “dynamic reciprocity” to serve and 
regulate each other. ECM not only provides a substrate for cell attachment and 
spreading, contact guidance for cell migration, and a scaffold for building tissues but also 
serves as a reservoir for growth factors (Davis & Senger, 2005). Zhao and colleagues 
found that FN provided superior adhesion for late -outgrowth EPCs compared to mature 
ECs, and Vartanian et al. revealed that EPCs deposited collagen IV, FN, and laminin to a 
greater extent than ECs (Vartanian et al., 2009). Therefore, primed late -outgrowth EPCs 
could amplify these benefits and enhance endogenous repair.  Moreover, the exocytosis 
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Figure 59 | miR-92a target genes in VSMCs and PACs implicated in the post-injury restenosis response. 
Inhibition of restenosis by miR-92a antagonism results from the de-repression of the pro-apoptotic/pro-
inflammatory MKK4 and anti-proliferative BMPR2 in VSMCs, and of the anti-inflammatory SOCS5 in PACs. 
BMPR2 - Bone morphogenetic protein receptor type II; EC – endothelial cell; EPC – endothelial precursor 
cell; ITGA5 – integrin α5; JNK – c-Jun N-terminal kinases; miR – microRNA; MKK4 - MAPK kinase 4;(p) – 
phospho; SOCS5 - Suppressor of Cytokine Signaling 5; VSMC – vascular smooth muscle cell. 
 
 
VSMC miR-92a expression is lower in comparison with ECs (Iaconetti et al., 2012), but it 
still plays an essential role in modulating restenosis since it exerts pro-proliferative and 
anti-apoptotic actions in VSMCs (L. Zhang, M. Zhou, Y. Wang, et al., 2014). miR-92a 
expression in VSMC is known to be low in the basal (quiescent) state, but its post-injury 
overexpression is protective against apoptosis induced by H2O2-mediated oxidative 
stress in VSMCs. This is explained mechanistically, since miR-92a targets MKK4 and JNK1, 
reducing their protein level. This reduction leads to attenuation of both p54 and p46 JNK 
activation and a significant decrease in the level of phospho-c-Jun implicated in cellular 
apoptosis. Moreover, JNK can also initiate TNF-α and ischemia-induced apoptosis by 
promoting Smac/Diablo release (Nijboer et al., 2010). JNK activation is also known to 
phosphorylate Bcl2 protein and hence antagonise its anti-apoptotic activity 
(Dhanasekaran & Reddy, 2008). In contrast, overexpression of MKK4 abrogated the 
antiapoptotic effects of miR-92a in VSMC under oxidative stress. In summary, MKK4 and 
JNK1 are down-regulated by miR-92a thus inhibiting VSMC apoptosis induced by 
oxidative stress. It is noteworthy that all members from the mir-17~92 cluster are 
upregulated in restenotic carotid arteries (miR-92a included) and all target (miR-18 
being the only exception) the bone morphogenetic protein receptor type II (BMPR2) 
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inhibiting the proliferation of VSMCs (T. Luo et al., 2014). It was Luo and colleagues who 
first uncovered the crosstalk between the two critical TGF-β superfamily signalling 
pathways, TGF-β1/Smad3 and BMP/BMPR2, through miR-92a. Smad3 is one of core 
transcription factors of the profibrotic cytokine TGF-β, which enhances neointimal 
formation by stimulating ECM synthesis and accumulation (FN mostly)(Ryer et al., 2006; 
Tsai et al., 2009). Simultaneously, upregulation of Smad3 can activate the transcription 
of miR-17~92 cluster by binding to its promoter region. Then, miR-17~92 family 
members, namely miR-92a, down-regulate BMPR2, an inhibitor of VSMC proliferation, 
to further promote VSMC proliferation and neointimal formation in the carotid artery 
restenosis. These observations are in agreement with Smad3 and miR-92a being 
upregulated in carotid restenosis, while BMPR2 is reduced, compared with control 
normal arteries. 
 
In inflammatory cells, the effect of miR-92a antagonism is still largely unknown. It 
appears that in macrophages miR-92a expression is blocked upon by TLR activation. The 
result is the reduction in the release of pro-inflammatory IL-6 and TNF-α, via the 
targeting of the proinflammatory MKK4. On the contrary, macrophages transfected with 
miR-92a inhibitor have been shown to produce higher concentrations of IL-6 and TNF-α 
upon LPS presentation. Moreover, in contrast to EPCs which have the expression of α5 
and β1 upregulated during differentiation and α4 markedly decreased, MNCs have a 
higher proportion of surface α4 integrin but still present α5β1 (Kaiser et al., 2012). 
Therefore, localised miR-92a antagonism via an epigenetic stent can theoretically create 
a relative increase in their adhesive profile, further promoting an inflammatory cascade 
in situ. In summary, the effect of the delivery of miR-92a on peri-injury inflammatory 








The present study had some limitations that warrant discussion. The potential clinical 
translation of miR-92a inhibitor for EPC-mediated re-endothelialisation in the context of 
post-PCI injury would preferably warrant the use of EPCs from CVD patients in the pre-
clinical studies. The present research used EPCs obtained from umbilical cord blood 
(UCB) and thus may not fully represent the impaired EPC of elderly patients with 
cardiovascular disease. Nevertheless, given the fact that UCB is more widely accessible 
and possesses a bigger pool of C34+ cells when compared to peripheral blood, this 
strategy has often been used in many cell therapy studies reviewed elsewhere (Chong 
et al., 2016).  
 
Clonally expanded CD34+-derived EPCs were used for the in vitro validation of miR-92a 
inhibitor impact in cellular function. However, a major caveat to clinical translation is 
that it is not known whether cultured cells exist in circulation in vivo as such or whether 
they mainly represent an artificial phenotype generated by tissue culture conditions 
(Fadini et al., 2012). One may wonder if progenitor CD34+ cells might only give rise to 
putative EPCs depending on an exact combination of growth factors to which the cells 
have been exposed in vitro. Future efforts should be focused on the development of a 
straightforward standard protocol and source to specifically define and validate EPCs so 
that investigators can have a benchmark for comparison (Medina et al., 2017). And if it 
is an artificial phenotype is it safe to use in man or have the cells been subject to 
mutational and epigenetic modifications? Although using MNC culture-derived EPCs in 
pre-clinical models seem to be safe for the animals, particularly, for EPC-mediated 
endothelial regeneration, there are still concerns that need to be addressed before 
human therapeutic application of CD34+-derived EPCs.  
 
Another limitation of our study was the use of human EPCs delivered into rat carotid 
artery, which prevented us from conducting long-term engraftment studies due to 
rejection implications. Others have used this strategy for similar short-term (24h) 
studies, and it to be safe and effective (Kyrtatos et al., 2009).  
 
 Discussion - 251 
 
Together the group of highly conserved miRNAs miR-92a-1, miR-92a-2, miR 363, miR25 
and miR-92b constitute the miR-92 seed family and share the same seed sequence used 
to design anti-miR oligonucleotides. Therefore, the used anti-miR-92a oligonucleotides 
may potentially have cross-targeted several other mature miRNAs. Based on the above, 
potential co-targeting of distinct miRNA species from the miR-92a seed family should 
have formally excluded in this study. 
 
CD34+- derived EPCs were generated and expanded in gelatin 1%, as others have also 
done (Pedroso et al., 2011). While the majority of EPC functional assays were conducted 
on gelatin (co-culture angiogenesis, proliferation, survival and wound healing assays), 
some of the EPC functional assays were performed on Fibronectin instead (cell-matrix 
adhesion and chemotaxis migration assays), since I wanted to scrutinize the upregulated 
ITGA5-FN interaction, specifically. I was unable to apply the same methodology to every 
functional assay due to pricing issues (Fibronectin ~630.00€ for 5mg vs Collagen powder 
~41.25€ for 100g, both from SIGMA). I opted for collagen whenever a higher area of 
plasticware had to be coated. This constitutes a limitation for the generalization of my 
results, since the interaction of integrin alpha 5 subunit is expected to be different with 
the different ECMs. 
Siavashi and colleagues scrutinized the possible role of three different natural 
extracellular substrates, including collagen, gelatin, and fibronectin, on multiple 
parameters of EPCs such as cell morphology, phenotype, clonogenic, and vasculogenic 
properties (Siavashi, Nassiri, Rahbarghazi, Vafaei, & Sariri, 2016). EPCs from GFP-positive 
mice were pre-expanded on each of these ECM substrates and then systemically 
transplanted into sub-lethally irradiated mice to analyse the potency of these cells for 
marrow reconstitution. Their results revealed considerable promise for fibronectin (FN) 
for EPC expansion, with maintenance of stemness characteristics, whereas gelatin and 
collagen matrices directed the cells toward a mature endothelial phenotype. Indeed, 
late EPCs pre-expanded on collagen and gelatin exhibited superior tube formation 
properties than EPCs pre-expanded on FN. Overall, the low angiogenic activity of the 
cells expanded on the FN substrate, particularly in the early stage, could be related to 
stable blockage of terminal differentiation of EPCs by FN. In support of this statement, 
we found the lowest number of CD31+ mature cells on the FN matrix compared with 
 Discussion - 252 
 
other matrices indicating little cell differentiation on FN. Transplantation of EPCs pre-
expanded on FN resulted in widespread distribution and appropriate engraftment to 
various tissues with habitation in close association with the microvasculature. In 
addition, FN pre-expanded cells were gradually enriched in the bone marrow after 
transplantation, resulting in marrow repopulation and hematologic recovery, leading to 
improved survival of recipient mice whereas gelatin- and collagen-expanded cells failed 
to reconstitute the bone marrow. 
It is conceivable that if EPCs in different ECM substrates exhibit different proliferation 
and differentiation potential leading to different reconstitution potency after in vivo 
transplantation, then EPC functional assays can be also modulated by the supporting 
matrix. Indeed, integrin–ECM interactions, namely, via β5-integrins, can mediate EPC 
paracrine factor production (Balaji et al., 2013). EPCs plated on different matrices 
express different cytokines levels, such as SDF-1, VEGF, monocyte chemotactic protein 
1 (MCP-1), insulin-like growth factor 1, platelet-derived growth factor and macrophage 
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5.4 Future work 
 
 
Low engraftment rates of EPCs may limit vascular regeneration (Chavakis et al., 2008; 
Haider et al., 2017). To increase the engraftment of cells to the target tissue either the 
cells could be pre-treated (e.g. modified by overexpression of genes or by incubation 
with small molecules) or the target tissue could be pre-activated (e.g. induction of 
cytokines, small molecules and miRNAs). 
 
Having validated some interesting features of miR-92a inhibition in vitro in EPCs that 
could potentially translate into improved engraftment of these cells in the carotid injury 
model, we are left with some challenges for the next level - in vivo. AntagomiR delivery 
to EPCs prior to their transplantation may be quite challenging due to the need to 
harvest them and all protocols using short-term culture will, by their very nature, not 
yield sufficient numbers of EPCs for systemic therapy in the human. To treat a patient of 
80 kg with a high dose cell strategy as described in some animal studies (1 x 107 
cells/25g) would require 32 x 109 cells (adjusted to body weight)(Templin et al., 2011), 
which exceeds the number of cells used in original clinical trials by a factor of ~3000 
(Assmus et al., 2002). Therefore, progenitor cells would need to be to be expanded in 
vitro before reinjection, however, long-term culture may induce cellular senescence and 
introduce deviations in the phenotype of the EPC detrimental to their therapeutic 
efficacy. Moreover, the ideal strategy would not be to increase endogenous mobilisation 
nor provide increase BM-derived EPCs during transplantation, since that could hasten 
inflammation post-PCI or fasten the differentiation into SMC-like cells. Therefore, I 
envision the focus on EPC -mediated re-endothelialisation shifting to strategies aimed 
at maximising the recruitment and adherence of endogenous circulating EPCs to the 
sites of endothelial damage. Bearing all advantages and disadvantages in mind, I think 
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Table 19 | Overview of the potential advantages and disadvantages of putative EPC-based strategies 
for therapeutic re-endothelialisation and restenosis prevention. 
Adapted from (Williams & Silva, 2015). 
Strategy Advantages Disadvantages 
Systemic infusion 
of primed EPCs 
Simple preparation of cells in solution 
Ease of administration 
Lengthy ex vivo expansion 
Large number of cells required 
Poor survival of administered 
cells 
Low engraftment efficiency 






Simple preparation of cells in solution 
Locally delivered near site of injury 
Fewer cells required than that for systemic 
infusion 
Long ex vivo expansion of cells 
Poor survival of administered 
cells 
Low engraftment efficiency 




EPCs and priming 
factors 
Targeted local delivery 
Enhanced survival of cells due to dual 
delivery with small molecules 
Greater engraftment efficiency 
Fewer cells required than that for first two 
methods 
Enhanced engraftment efficiency 
Enhanced outward migration and function 
of transplanted cells 
Long ex vivo expansion of cells 
Complex preparation of cells 
within biomaterial system 
Possible immune response to 
chosen biomaterial 
Deployment of 
priming factors in 
target tissue 
 
In situ regeneration 
No ex vivo manipulation of cells 
Enhanced function of endogenous cells 
Enhanced regenerative potential by 
recruitment of endogenous EPCs 
Approach limited by capability 
and functional response 
of endogenous cells 
 
I have developed several efforts in building that strategy (Appendix IV). Future work will 
include the completion of the comparison of the Pluronic peri-adventitial delivery of 
miR-92a inhibitor to promote re-endothelialisation (as detected by vWF or eNOS IHC 
analysis and Evans blue staining) and prevent restenosis post-injury with the systemic 
administration previously validated for these purposes (Daniel et al., 2014; Iaconetti et 
al., 2012). Furthermore, to confirm the relevance of in situ miR-92a inhibitor -mediated 
ITGA5 upregulation in increasing the capture and thriving of circulating endogenous 
EPCs, I envisioned a BM transplantation models in nude rats. Briefly, lethally irradiated 
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nude rats would receive BM cells from transgenic Tie2/lacZ rats, which constitutively 
expressed β-galactosidase encoded by lacZ under the transcriptional regulation of an 
endothelium-specific promoter, Tie 2. Carotid arteries would be denuded 4 weeks after 
BM transplantation with the balloon angioplasty technique and the miR-92a inhibitor 
applied peri-adventitially using the pluronic gel. The same strategy would be used in 
miR-scrambled and miR-92a treated rats. X-gal staining would be performed on whole-
mounted vessels to visualise and quantify BM– derived Tie2/lacZ-positive endothelial 
lineage cells per square millimetre of surface area. The stent coating with NP:miR-92a 
inhibitor would have to be developed and validated within a stent in a flow chamber 
with circulating porcine EPCs (engraftment validation through electronic microscopy) 
before advancing into the pig carotid injury model. Finally, before clinical application of 
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Appendix I – EPC differentiation from 




Pig vascular biology appears to be relatively similar to that of humans (Zaragoza et al., 
2011). For that reason, pigs are considered a more predictive model for CVDs and 
stenting outcomes than other animal models (Tsang et al., 2016). Several studies have 
been published about biodevices in pigs, including stents, artificial prostheses, grafts, 
shunts and ventricular assist devices.  Additionally, the autologous transplantation of 
EPCs per se for the treatment of ischemic diseases (Dimmeler et al., 2008; Fadini, 
Agostini, & Avogaro, 2010; Lipinski et al., 2007) and restenosis prevention (Werner et 
al., 2003) is also an active area of translational research. However, as the pigs are usually 
immunocompetent (except for specific athymic models), human progenitor cells cannot 
be infused in these animals. Hence techniques for autologous EPC purification and 
expansion are warranted for this animal model. To date, pig cell therapy studies have 
relied on the infusion of pools of unselected MNCs or ex vivo expanded late-outgrowth 
EPCs derived from unselected MNCs (Chade et al., 2009; Doyle et al., 2008; Dubois et 
al., 2010; Tianhang et al., 2013), i.e. from heterogeneous starting populations. The use 
of phenotypically uncharacterized subsets of PACs derived from tissue culture is 
undesirable and is probably due to the fact that there are no commercially available 
magnetic sorting systems incorporating antibodies against porcine CD34. In fact, very 
few of the latter exist, and no human anti-CD34 antibody with known porcine cross-
reactivity has been published to date, which complicated the implementation of an 
effective enrichment strategy. I described an original method, using indirect labelling, 
capable of enriching a primary CD34+ population from pig BMB, and further 
differentiated them into pig CD34+-derived EPCs. This strategy will enable future 
autologous transplantation experiments with miR-92a inhibitor transfected EPCs, and 
also allow the in vitro validation of the possible benefits of deploying a miR-92a inhibitor 
coated stent capable of locally transfecting engrafted EPCs. On a larger scale this 
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enrichment methodology might lead the way for a new generation of porcine 
autologous EPC transplantation trials (using primary or expanded CD34+-derived EPCs). 
 
There is only one other study, to my knowledge, reporting the isolation of these 
progenitors from pig BM (Layton et al., 2007). Layton et al. incubated cells with (mouse) 
anti-porcine CD34 antibodies which were then cross-linked to (goat) anti-mouse IgG 
microbeads, whereas, my strategy involved the incubation of cells with a (goat) anti-
porcine CD34 biotinylated antibody instead, which was then made to bind with anti-
biotin microbeads. Considering the success in isolating BM-derived CD34+ cells, I 
consider BM to be an efficient and accessible source of CD34+ progenitor cells for 
autologous use/differentiation in the pig. 
 
 
Enrichment of CD34+ cells from porcine BM blood 
 
Since in vivo vascular restenosis studies are long (days to weeks), human EPCs cannot be 
used in pigs due to immunocompatibility issues. Fortunately, the pig is large enough to 
allow sufficient BM cells to be harvested from its iliac crest for autologous 
transplantation without having to be sacrificed (unlike collection of BM blood from 
smaller species which must be pooled from several animal femurs). So, to test the 
transplantation of autologous miR-92a inhibitor-treated CD34+-derived EPCs and 
determine the possible benefits of deploying a miR-92a inhibitor coated stent in pigs, I 
had to adapt techniques concerning CD34+ purification and EPC differentiation to this 
animal model. The results of a failed isolation attempt using MACS immunomagnetic 
separation system with the proprietary anti-human CD34 antibody microbeads working 
previously for human UCB are represented in (Figure I.1). There was no specific 
enrichment of porcine CD34+ cells. Alternatively, it is possible that there was no specific 
labelling of porcine CD34 receptor with mouse anti-human CD34-PE conjugated 
antibody. Either way, I was unable to identify CD34+ cells derived from pig BM using the 
MACS direct labelling system. 
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Figure I.1 | Inability to identify CD34+ cells from pig BM blood using MACS direct magnetic cell labelling. 
An attempt to isolate CD34+ cells from pig BM blood using MACS Immunomagnetic separation system and 
the proprietary mouse anti-human CD34 antibody microbeads was made, followed by flow cytometry 
analysis. For each set of samples, the fluorescent intensity of the isotype control was compared with the 
fluorescent intensity of the test sample and the corresponding histograms are presented. The results 
presented were obtained after one single experiment, with each condition measured in duplicate. BM – 





I next attempted an indirect labelling method to enrich the primary CD34+ population 
from pig BM blood (Table I.1). By using an anti-porcine biotinylated CD34 antibody and 
matching anti-biotin microbeads instead, I was able to successfully separate 8.945 ± 1.06 
x106 CD34+ cells from each pig BM unit following the previously used two-step 
immunomagnetic enrichment method. Cell viability after sequentially passing through 
the LS + MS column averaged at 87.5 % ± 2.5. By using one enrichment step only (a single 
microbead incubation period and a single transfer through a LS column) I was able to 
optimize cell viability (97% ± 1.5) with matching yield (9.2±2.42x106 CD34+cells/BM unit). 
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Table I.1 | Quantification of CD34+ cells isolated from pig BM blood using MACS indirect magnetic cell 
labelling. CD34+ cells were isolated from 50 mL of pig BM blood using MACS Immunomagnetic separation 
system with specific modifications. For optimization purposes both single and double enrichment 
strategies were essayed. The total number and viability of freshly isolated CD34+ cells were measured 
using an automatic cell counter. Data from 2 independent (double enrichment) and 3 independent (single) 
isolations is presented as mean values ± SEM. BM – bone marrow; CD – cluster of differentiation; MNC – 
mononuclear cell; SEM - standard error of the mean.  
 




CD34 (% of MNCs) 
Viability of CD34+ 
recovered cells (% 
total cells) 
Two-step sorting 13.6 ± 0.9 8.945 ± 1.06 0.65 ± 0.03 87.5 ± 2.5 
Single-step sorting 3.87 ± 1.04 9.2 ± 2.42 2.55 ± 0.49 97 ± 1.5 
 
 
As for the recovery of CD34+ cells from pig BMB, the described 2.55 % ± 0.49 (from total 
MNCs) is slightly lower that the only previously published 4% incidence for this animal 
(Layton et al., 2007). One might speculate that Layton et al. by using 1-week-old 
Landrace cross pigs (as opposed to the 3-month Yorkshire pigs that were employed in 
this study) might be more enriched in progenitor cells.  
 
Pig CD34+ cells recovered from BMB following single-step enrichment were 97 ± % 1.5 
viable, revealing that the reduction of the protocol was the correct option also regarding 
cell viability (double labelling generated 87.5 % ± 2.5 viable cells only). Layton et al. did 
not publish the viability of pig BM CD34+ cells retrieved by single-step enrichment with 
IgG Mouse microbeads for comparison (Layton et al., 2007). 
 
The retrieved CD34+ fraction from pig BM blood exhibited similar purity (by flow 
cytometry) following either enrichment methods (Figure I.2). The single step labelling 
strategy yielded a highly pure fraction (92.72 % ± 1.17), as did the alternative double 
labelling (90 % ± 2.05). 
 
Figure I.2 | CD34+ cell fractions isolated from pig BM blood using MACS indirect magnetic cell labelling 
are highly pure. To determine the purity of the populations enriched for CD34 by immunomagnetic 
sorting, flow cytometry was used. (A) Representative FSC-SSC dot plots of pig BM CD34+ cells and CD34- 
flow through are presented. For each set of samples, the fluorescent intensity of the isotype control was 
compared with the fluorescent intensity of the test sample and the corresponding histograms are 
presented. (B) Cells exceeding the threshold fluorescence defined by the IgG Control were quantified and 
considered positive for CD34. Results are presented in tabular format as mean antigen positive cells 
percentage ± SEM, after three independent experiments (single enrichment) and two independent 
experiments (two-step enrichment). Each condition was measured in duplicate. BM – bone marrow; BSA 
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– bovine serum albumin; CD – cluster of differentiation; FSC – forward scatter; Flt3 - Fms-like tyrosine 
kinase 3; HSC – hematopoietic stem cell; PBS - phosphate-buffered saline; SCF – stem cell factor; SEM - 
standard error of the mean; SSC – side scatter.  
 
B 
Isolation method Antigen Positive cells (%) 
Two-step enrichment CD34 90 ± 2.05 
Single-step enrichment CD34 92.72 ± 1.17 
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Differentiation of late-outgrowth porcine EPCs from 
CD34+ cells 
 
I subjected the freshly isolated pig BM CD34+ cells to the differentiation protocol 
previously established for human samples, enabling the appearance of late-outgrowth 
EPCs in culture (Figure I.3). By day 20 of the differentiation protocol, CD34+ cells had 
assumed a cobblestone-like morphology and became adherent to the gelatin substrate. 
The phenotype was further characterized by ac-LDL internalization capacity and vascular 




Figure I.3| Late outgrowth EPCs were successfully differentiated from pig BM blood CD34+ cells. 
CD34+ cells from pig BM blood were differentiated into late outgrowth. (A) The bright-field image on the 
left captures freshly isolated pig BM CD34+ cells (20x). By differentiation day 7 some CD34+ cells become 
adherent and assumed a cobblestone like morphology (see arrowed), as captured in the middle image 
(20x) and in the blow out (40x). After 11 days of differentiation most of the cells at the periphery were 
adherent, as seen in the right picture (20x). (B) After 20 days of cells in culture, internalization of Ac-LDL 
conjugated to Alexafluor-488 was demonstrated at 20x magnification. HUVECs were used as positive 
controls. (C) Further confirmation of endothelial like phenotype after 20 days of cells in culture was 
evident from the VECAD western blot results. (D) After 20 days of culture, the presence of VECAD 
endothelial specific marker was evaluated in pig CD34+-derived EPCs by If at 60x. ac-LDL – acetylated low-
density lipoprotein; CD – cluster of differentiation; DAPI - 4',6-diamidino-2-phenylindole; EPC – 
endothelial precursor cell; PAECs – pig aortic endothelial cells; VECAD – vascular endothelial cadherin. 
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To further illustrate endothelial commitment, I performed a Matrigel based-
angiogenesis functional assay, which revealed that pig CD34+-derived EPCs also had the 
ability to form tubule-like structures (Figure I.4). 
 
Figure I.4| Pig late outgrowth CD34+-derived EPCs showed angiogenic potential. 
The assay was performed using a Matrigel matrix with reduced growth factor content. A set of 
representative brightfield images (10x magnification) taken at 6h post incubation in a time-lapse imaging 
incubator is presented for EPCs, revealing tubule-like formation ability. HUVECs were used as positive 
controls and colonic SMC as negative controls. CD – cluster of differentiation; EPC – endothelial precursor 




The presence of KDR (a receptor for VEGF) in preliminary flow cytometry studies, further 
highlighted the endothelial commitment by a significant proportion of the CD34+-
derived EPCs (Figure I.5).  
 
Figure I.5 | KDR is present in pig BM CD34+-derived EPCs after their differentiation. 
The presence of KDR antigen on the surface of pig BM late-outgrowth EPCs was sought by flow cytometry. 
(A) Representative FSC-SSC dot plots of EPCs at different time points are presented, as well as 
corresponding KDR conjugated FITC intensity histograms. (B) The graphic presents the percentage of KDR 
positive cells in the adherent fraction at the different time points in culture. (C) Graphical representation 
of fluorescence geometric mean difference to control, a surrogate of antigen mean surface density. All 
results are representative of 1 experiment and are therefore preliminary; all conditions were measured 
in duplicate. BM – bone marrow; EPC – endothelial precursor cell; FITC - Fluorescein isothiocyanate; FSC 
– forward scatter; IgG – Immunoglobulin; KDR – kinase insert domain receptor; SSC – side scatter. 







VEGF-A, the main KDR ligand, is a well described EC-specific mitogen/chemoattractant 
associated with vascular repair (Ferrara, 2001; Holmes et al., 2007), whereas PDGF-BB 
is a major growth factor released from stimulated platelets which stimulates the 
proliferation, migration and survival of VMSCs at the sites of vascular insults.  
Both serine/threonine kinase Akt and ERK1/2 are downstream kinases which get 
activated by phosphorylation upon VEGF (Fujio & Walsh, 1999) and PDGF-BB (Razmara, 
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Heldin, & Lennartsson, 2013) stimulation of their receptors. ERK 1/2 and Akt are of 
particular relevance because of their strong association with the regulation of 
mitogenesis and activation of eNOS (Gifford et al., 2004).  
ECs are rich in KDR VEGF receptor (Waltenberger, Mayr, Pentz, & Hombach, 1996). 
However, they are believed to lack PDGF receptors (usually present on fibroblasts and 
SMCs) and to be unresponsive to PDGF (Beitz, Kim, Calabresi, & Frackelton, 1991).  
So, to test the activation profile of the pig BM CD34+-derived EPCs, I challenged them 
with VEGF and PDGF (Figure I.6). Reassuringly, the EPCs exhibited Akt and ERK 
phosphorylation upon VEG stimulation, but produced no response to PDGF, which is an 
expected feature of endothelial phenotypes (KDR+PDGFR- cells). Both Akt and ERK 1/2 
are highly expressed in HUVECs (Gifford et al., 2004).  
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Figure I.6 | Pig BM CD34+-derived EPCs exhibited phosphorylation of Akt and ERK1/2 upon VEGF 
stimulation. 
Cells were challenged for 10 mins with either 25 ng/mL VEGF, PDGF or SFM before its proteins were 
separated by SDS-PAGE, and immunoblotted with the antibodies indicated. (A) The single western blot is 
shown. (B) Akt and ERK1/2 phosphorylation were quantified by scanning densitometry. Phosphoprotein 
levels were normalised to levels of the corresponding total protein and presented in relative units. Results 
in this figure are derived from 1 single experiment, and therefore preliminary. PDGF – platelet derived 
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Appendix II – Unsucessful EPC 
differentiation from human umbilical 
cord blood CD133+ cells 
 
 
Figure II.1 |Late-outgrowth EPCs could not be successfully differentiated from human UCB CD133+ cells. 
UCB human CD133+ cells could not be differentiated into late-outgrowth EPCs Bright-field images during 
differentiation were captured at 10x. The image represents CD133+ cells still in suspension 3 weeks after 
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Appendix III – Failed CD34+-derived 
late outgrowth EPC transfection 
attempts 
 
Figure III.1 | CD34+-derived EPC transfection of miR-92a (inhibitor) using SIPORT NeoFX was 
unsuccessful. Human late-outgrowth EPCs (~80% confluency) were transfected in 6 well plates with 80 
nM control scrambled miRNA, miR-92a-1-5p or miR-92a-1-5p inhibitor (-FITC) using SiPORT NeoFx, 
according to manufacturer’s instructions. Following 72h knockdown in complete medium cells were lysed, 
proteins were separated by SDS-PAGE, and immunoblotted with the antibodies indicated. Results in this 
figure are preliminary and reflective of one experiment.  SIPORT NeoFX was not suitable for miRNA 
transfection into CD34+-derived EPCs, since no discernible change in ITGA5 levels compared to control 
miR scrambled transfection were seen. ACTB - β-actin; ITGA5 – Integrin α5 subunit; miR – microRNA. 
 
Figure III.2 | CD34+-derived EPC transfection of miR-92a (inhibitor) using Lipofectamine RNAimax was 
unsuccessful. Human late-outgrowth EPCs (~80% confluency) were transfected in 6 well plates with 200 
nM control scrambled miRNA, miR-92a-1-5p or miR-92a-1-5p inhibitor (-FITC) using Lipofectamine 
RNAimax, according to manufacturer’s instructions. Following 72h knockdown in complete medium cells 
were lysed, proteins were separated by SDS-PAGE, and immunoblotted with the antibodies indicated. 
Results in this figure are preliminary and reflective of one experiment.  Lipofectamine RNAimax was not 
suitable for miRNA transfection into CD34+-derived EPCs, since no discernible change in ITGA5 levels 
compared to control miR scrambled transfection were seen. ACTB - β-actin; ITGA5 – Integrin α5 subunit; 
miR – microRNA. 
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Appendix IV: The effect of miR-92a 
inhibitor localised treatment on 
arteries and development of an 
nanoparticle-based delivery for EPC 
capture 
 
Following the indication that miR-92a inhibitor might enhance EPC adhesion to injured 
arteries, this appendix chapter seeks to describe my initial steps towards establishing a 
target tissue pre-activation strategy by transfecting miR-92a inhibitor into injured 
arteries, since that harvesting of EPCs and their in vitro expansion before reinjection is 
labour intensive. Besides, tissue culture conditions could alter the phenotype of these 
cells. This could maximise endogenous EPC capture and thrive, contributing to the 
prevention of post-angioplasty restenosis, instead of having to transplant pre-activated 
ex vivo -expanded EPCs. Therefore, I developed an in vivo method for localized 
transfection of miR-92a inhibitor into the arteries using a thermo-reversible gel. Then, I 
sought the functional outcome of miR-92a antagonism in the injured arteries. miR-92a 
inhibitor presence became evident across all layers of the vascular wall 24h after 
deployment of the pluronic gel, and a reduced neointima formation trend was witnessed 
just 7 days after compared to scrambled control. Unfortunately, there was not enough 
time in the PhD to validate statistically the reduction in neointima formation, nor to 
document the enhancement in re-endothelialisation on account of increased EPC 
engraftment. After the neointima reduction proof-of-principle pilot experiments using 
the gel delivered peri-adventitially, we envisioned an NP-based strategy that could be 
used to transfect miR-92a inhibitor into arteries intraluminally via a stent. The intention 
was to incorporate a coating composed of miR-92a inhibitor complexed to 
biodegradable NPs into a future stent capable of a controlled miRNA release, thus 
priming the captured EPCs (Figure IV.1). The NP -based delivery method could allow for 
a timed release of the miR-92a inhibitor, in a first instance enhancing EPC engraftment 
via ITGA5 upregulation once the rolling cells on the luminal surface were locally 
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transfected, and in a second stage enhancing re-endothelialisation and reducing 
neointima by increasing NO production. 
Figure IV.1 | Scheme of an epigenetic stent eluting NP:miR-92a inhibitor complexes. 
The diagram represents a hypothetical stent scaffold able to elute miR-92a inhibitor. This could be an 
efficient approach to enhance the endothelial regeneration through the promotion of the homing, 
survival and re-endothelialisation activity of captured EPCs (and neighbour niche), via the placement of a 
therapeutic biodegradable stent coated with miR-92a inhibitor complexed to biodegradable poly(lactic-
co-glycolic acid) nanoparticles. miR – microRNA; NP – nanoparticles.  
 
In tissue culture, miR-92a inhibitor was successfully transfected into EPCs when 
conjugated with the NPs, and as soon as the miRNA is released from the electrostatic 
bonds with the NP surface at the endosome, it seems to become available to be 
processed by the miRNA machinery only to produce (at least) pro-survival and pro-
migratory effects. In vivo, NP:miR-92a were seen across the entire vascular wall 
following intraluminal (and peri-adventitial) arterial transfection, with preliminary 
results revealing a likely upregulation of miR-92a target molecules. Although the 
reduction in neointima formation in injured arteries following miR-92a inhibitor 
treatment administered systemically has been previously established (Daniel et al., 
2014), it is the first time that peri-adventitial miR-92a inhibitor delivery was attempted. 
No publication on the functional benefits of miR-92a inhibitor transfection into EPCs 
using NPs as vectors was found in the literature. Moreover, it is the first time that 
pluronic facilitated transfection of NP:miRNAs into vessel walls is reported. Further 
optimization is warranted, hence the data is preliminary yet and hence discussion takes 
place in an appendix format only. 
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miR-92a inhibitor enhances arterial angiogenesis ex 
vivo 
 
Given that endothelial sprouting from aortic rings requires combined endothelial cell 
(EC) proliferation, migration, survival and tube formation (Iaconetti et al., 2012), this 
was considered a complete assay to extrapolate the effect of miR-92a inhibitor ex vivo. 
Therefore, endothelial-lineage cell sprouting from aortic rings embedded in a collagen 
matrix was quantified 7 days after transfection with miR-92a inhibitor (Figure IV.2). 
Compared with the scrambled control, functional inhibition of miR-92a significantly 
increased the outgrowth area of aortic rings (1.43x106 vs. 0.67x106, p<0.001, coverage 
area in pixels2). Ideally outgrowth cells should have been co-stained with CD34, but 
unfortunately, this would not distinguish endothelial precursor cells (EPCs) from 
resident proangiogenic cells (PACs), as there is no specific surface marker for EPCs. Still, 
I was satisfied with the functional output of isolectin B4 (IBL4) staining endothelial 
committed cells (which comprehend EPCs (Mieno et al., 2010; Mieno et al., 2008)) 
following antagomiR-92a, therefore I considered useful to go through with miR-92a 
inhibition in vivo with no further ex vivo characterization. 
Figure IV.2| miR-92a inhibitor enhances mouse aortic angiogenesis. Mouse aortic rings were treated 
with 30 nM of miR scrambled, miR-92a (5p) or miR-92a (5p) inhibitor,  embedded in a collagen matrix and 
cultured in supplemented medium before IF analysis. (A) Representation of a miR-92a inhibitor 
transfected ring after 7 days in culture, captured at 5x. The picture reveals peripheral angiogenic aortic 
sprouts composed of endothelial lineage ILB4+ cells, supported by a stalk of SMA actin positive cells. (B) 
Before fixation treated rings were photographed at 4x magnification, and representative brightfield 
images are shown, where one can observe apparently diminished and enhanced ex vivo aortic ring 
angiogenesis in miR-92a, and miR-92a inhibitor transfected samples, respectively, compared to miR-
scrambled. (C) Quantification of the peripheral IBL4+ angiogenesis network area in square pixels 
(subtracted digitally by the ring area itself) was performed at 2.5x IF. Results of that quantification after 3 
independent experiments (3 replicates each) are plotted as means, with errors bars representing ± SEM. 
**P<0.01 and ***P<0.001 compared with miR scrambled (1-way ANOVA, Bonferroni’s test for multiple 
comparisons). DAPI - 4',6-diamidino-2-phenylindole; IB4 – isolectin B4; IF - immunofluorescent; miR – 
microRNA; Si – short interfering; SEM – standard error of mean; SMA – smooth muscle actin.





 References - 277 
 
Peri-adventitial gel-delivered miR-92a inhibitor is 
capable of arterial wall transfection in vivo 
 
The in vivo strategy consisted in using the pluronic gel as a transfection vector for 
localised delivery of miR-92a inhibitor around the rat carotid artery to avoid possible 
systemic off-target effects, instead of delivering the microRNA (miR) via rat tail vein 
injection as previously attempted (Bonauer et al., 2009). Data from 
immunohistochemistry (IHC) and immunofluorescence (IF) demonstrated an efficient 
uptake of the FITC-tagged miR across the 3 arterial layers just 24h after periadventitial 
delivery (Figure IV.3). 
 
Figure IV.3 | Pluronic gel periadventitial delivery is efficient at promoting rat carotid artery miR-92a 
inhibitor-FITC transfection. 
An uninjured rat left common carotid artery was surgically exposed so that pluronic gel containing 1 µM 
miR-92a (5p) inhibitor-FITC conjugated could be applied peri-adventitially onto the whole length of the 
vessel.  The animals were sacrificed 24h postoperatively, and the artery samples were processed either 
by IHC or IF (anti-FITC). (A) Representative IHC image at 40x of a rat carotid artery treated in vivo with 
miR-92a inhibitor. (B) Representative IHC image at 40x of a treated artery where primary antibody staining 
was omitted (IHC negative control). (C) Representative IHC image at 40x of a non-treated artery 
(experimental negative control). (D) Representative IF image at 20x of a rat carotid artery treated in vivo 
with miR-92a inhibitor. (E) Representative IF image at 20x of a treated artery where primary antibody 
staining was omitted (IF negative control). (F) Representative IF image at 20x of a non-treated exposed 
artery (experimental negative control). DAPI -  4',6-diamidino-2-phenylindole; FITC - Fluorescein 
isothiocyanate; IHC – immunohistochemistry; miR – microRNA. 
 




The immunostaining results were complemented by protein expression (Figure IV.4), 
with a pilot western blot (WB) revealing a possible relative upregulation of ITGA5 
following miR-92a inhibitor treatment after 48h compared to miR scrambled (124% vs. 
100%, n=1). On the opposite direction, preliminary results seemed to indicate that miR-
92a determined an ITGA5 downregulation just after 24h (49 % vs. 100%, n=1). 
Unfortunately, for time restraints related to my PhD leave coming to an end and having 
to return mandatorily to my clinical work as per contract, I was unable to reach the “n” 
numbers necessary to reach statistical significance. 
 
Figure IV.4 | In vivo peri-adventitial pluronic gel delivery miR-92a inhibitor seems to enhance local 
ITGA5 levels. 
The uninjured rat left carotid artery was surgically exposed, so that Pluronic gel containing 1µM mirR 
scrambled, miR-92a (5p) or miR-92a (5p) inhibitor could be applied externally. After a 24-48h post-
operative period, the artery was harvested. Protein extraction involved bead-beating homogenization and 
retrieval of the protein lysate. Following normalisation, proteins were separated by SDS-PAGE, and (A) 
immunoblotted with the antibodies indicated. (B) Levels of ITGA5, were quantified during a time course 
by scanning densitometry and expressed as relative units compared to ACTB. Results in this figure are 
preliminary and reflective of one experiment. ACTB – actin beta; ITGA5 – integrin alpha 5 subunit; miR – 
microRNA; RU – relative units. 
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miR-92a inhibitor localised delivery seems to mitigate 
post-angioplasty neointima formation 
 
One of my original research purposes, when I started my PhD, was to demonstrate that 
miR-92a inhibition could prevent neointima formation following vascular injury (an 
effect that had never been reported), with particular contribution from EPCs, which, 
hypothetically, would show enhanced engraftment and re-endothelialisation activity. 
After inducing a balloon angioplasty injury, I investigated whether periadventitial 
delivery of miR-92a inhibitor caused a reduction of neointima formation. The analysis of 
injured arteries seemed to indicate that miR-92a antagonism could mitigate neointimal 
formation 7 days following the balloon injury compared to miR scrambled controls (0.3 
vs. 0.63, n=1) (Figure IV.5). The post-angioplasty survival was rated at 100%, with the 
rats demonstrating normal behaviour and welfare after returning to their environment 
both in control and in interventional arms. There were no local or systemic 
complications to report. During the entire experimental period, the animals tolerated 
procedures well as assessed by activity level and food and water intake, which were 
normal. Body weights did not differ between three groups at the end of the experiment 
 
I was planning to reach statistical significance to demonstrate proof-of-principle, 
however, Iaconetti and colleagues confirmed one year into my PhD that, indeed, that in 
vivo administration of antagomiR-92a significantly enhances re-endothelialisation of 
injured carotid arteries and reduces neointimal formation after arterial balloon injury or 
stenting (Iaconetti et al., 2012). This was done via systemic administration of miR-92a 
inhibitor, which can potentially have undesirable off-site effects. Therefore, my focus 
changed from proof-of-principle to introducing specific modifications to the localised 
delivery of miR-92a inhibitor that could be translatable into man use and result in a safer 
more efficient delivery of the miRNA. 
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Figure IV.5 | Pluronic gel-delivered miR-92a (5p) inhibitor treatment seems to reduce post-angioplasty 
stenosis. 
Following carotid balloon angioplasty, 300 µl of 1 µM miRNA were applied peri-adventitially using  
pluronic gel. Animals were sacrificed after 7 days, and processed arteries stained with hematoxylin and 
eosin in order to quantify the intima/media ratios. (A) Representative cross-section images of miR-
scrambled treated artery (left picture) and miR-92a inhibitor (middle picture) taken at 5x and 40x 
magnification, compared to an uninjured rat carotid artery (right image). Dashed lines (arrowed) indicate 
the internal elastic lamina. (B) Neointima/media ratios were determined by morphometric analysis, with 




The goal became developing a NP-based transfection method which would serve as a 
future stent coating capable of presenting the miRNA inhibitor on the luminal surface to 
rolling EPCs. 
 References - 282 
 
Nanoparticles for CD34+-derived EPC labelling 
 
Previously, the Portuguese group where I conducted one year of PhD had demonstrated 
that HUVECs could rapidly internalise protamine sulphate(PS)-coated Poly(lactic-co-
glycolic acid (PLGA) nanoparticles (NPs) (Gomes et al., 2013). The optimal transfection 
strategy had been defined as requiring incubation with 500 µg/mL NPs for 4 hours, 
although in concentrations up to 1 mg/mL no substantial cytotoxicity was reported 
(Gomes et al., 2013). Since EPCs share many common features with ECs, I tested the 
same strategy with the precursor cells. To quantify labelling efficiency in EPCs, FACS was 
performed on cells transfected with NP-fluoresceinamine for the same period. Trypan 
blue was used after fixation to differentiate between the signal from membrane-
associated (external) and internalised fluorochromes (internal)(McNeer et al., 2011). 
After quenching treatment, 99% of EPCs were fluorescein-positive, which establishes a 
very high transfection efficiency (Figure IV.6). 
 
After vascular injury, the vessel wall is typically a deprived milieu. One hour after balloon 
angioplasty, there are very few intact adventitial microvessels (Pels, Labinaz, Hoffert, & 
O'Brien, 1999) due to the barotrauma associated disruption, conditioning an 
environment poor in nutrients. Therefore, I wanted to mimic to some degree the same 
environment in vitro. However, my plans to subject EPCs in culture to deprivation 
conditions for longer term studies could jeopardise the feasibility of 500 µg/mL as the 
selected NP concentration. Therefore, I used a lower concentration (250 µg/mL) in the 
following experiments.  
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Figure IV.6| NPs are efficiently internalised by human CD34+-derived late -outgrowth EPCs. 
EPCs were transfected for 4 hours with 500 µg/mL NP-FITC labelled, after which cells were analysed by 
flow cytometry. External refers to Trypan blue quenched fluorescent signal, presumably membrane 
outbound NPs.  (A) Representative FSC-SSC dot plots and histograms of non-quenched samples are 
presented. (B) Labelled cells exceeding an autofluorescence threshold were quantified and considered 
positive for the internalisation of NP-FITC. Results are expressed in mean values ± SEM following 3 
individual experiments (each condition measured in duplicate), *** p<0.001 vs no transfection control (t-
Student test). EPC – endothelial precursor cell; FITC - Fluorescein isothiocyanate; FSC – forward scatter; 
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NPs can efficiently deliver miRNAs into EPCs 
 
Incubating NPs with miRNA produced electrostatic complexes with a mean diameter of 
219 ± 14.2 nm and a zeta potential of +1.95 ± 0.99, at intracellular pH (Table IV.1).  
 
Table IV.1 | Characterization of NPs. 
Diameter, PDI and zeta potential are properties of NPs which facilitate its internalisation. NPs were 
reconstituted at 500 µg/mL and complexed with miRNA at 800nM, before being diluted 1:4 for dynamic 
light scattering analysis in 10 mM KCl, pH 5.5. Results for the before mentioned properties are presented 
as means ± standard deviation, after 3 independent measurements from 3 different NP batches. NP – 
nanoparticle, PFCE -perfluoro-1,5-crown ether, PDI – polydispersion; PLGA – polylactic(glycol)acid, PS – 
protamine sulphate. 
 
Diameter (nm) PDI Zeta potential 
NP-PFCE 212.9 ± 14.3 0.244 -9.7 ± 0.7 
NP-PFCE-PS 218.0 ± 9.3 0.381 +7 ± 1.7 
NP-PFCE-PS-miR 219 ± 14.2 nm 0.267 +1.95 ± 0.99 
 
Compared to non-coated NPs, the miRNA overlayer did not significantly influence the 
diameter (218.0 ± 9.3 nm vs. 212.0 ± 14.3 nm, p=0.91), and so was unlikely to 
compromise the transfection strategy. As expected, the NP:miRNA complexes’ net 
charge was inferior to NPs not coated with miRNAs (+1.95 ± 0.99 vs. 7± 1.7, p=0.01), as 
a result of the conjugation with negatively charged oligonucleotides.  
 
PLGA NPs are known to be internalised by endocytosis (Gomes et al., 2013), therefore 
the fact that the NP: miRNA conjugates remained positively charged after complexation 
is essential for the transfection efficiency, which was next demonstrated by IF. EPCs 
were transfected with NPs complexed with a FITC-labelled miRNA (hsa-miR-92a-1 
inhibitor) for 4h under normoxia, and 24h after that using an anti-FITC antibody we 
documented intracellular miRNA-associated fluorescent signal only in the condition 
where miRNA delivery was facilitated with NPs (Figure IV.7) 
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Figure IV.7 | Internalisation of NP: miR complexes by human CD34+-derived EPCs. 
Cellular transfection with NP:miR-92a-FITC conjugated complexes was confirmed by IF at 60x. 24h after 
transfection with 2) NP at 250 µg/mL; 3) miR-92a inhibitor-FITC 100 nM; 4) NP-FITC 250 µg/mL; 5) NP:miR-
92a inhibitor-FITC 250 µg/mL and 100 nM respectively, cells were processed for IF. 1) No treatment and 
6) transfection with NP:miR-92a inhibitor-FITC 250 µg/mL and 100 nM but omitting primary antibody 
staining were the experimental and IF negative controls, respectively. The nuclei of the cells were counter-
stained with DAPI. DAPI - 4',6-diamidino-2-phenylindole, FITC - Fluorescein isothiocyanate, miRNA or miR– 
microRNA, NP – nanoparticle. 
 
 
NP facilitated miRNA internalisation efficiency was quantified using FACS. When EPCs 
were incubated for 4h with miRNA-fluorescein labelled complexed to NPs, 81 ± 7% of 
the cells were labelled, and virtually no miRNA was found at the external surface (Figure 




Figure IV.8 | Internalisation of NP: miR complexes by human CD34+-derived EPCs. 
Transfection with NP:miR-92a-FITC complexes was confirmed by flow cytometry.  Trypan blue is used to 
quench externally attached particles/miRNA to differentiate between the signal from membrane-
associated (external) and internalised fluorochromes (internal). Treatment with miR-92a-FITC only, non-
fluorescent NPs or NP:miR-92a-FITC without quenching, and omission of treatment were used as negative 
controls. Results are plotted as mean values ± SEM of 3 independent experiments, each condition 
measured in duplicate. ***P<0.001 compared with negative transfection controls (1-way ANOVA, 
Bonferroni's test for multiple comparisons). FITC - Fluorescein isothiocyanate, miR– microRNA, NP – 
nanoparticle. 
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miR-92a is released from NPs and mediates EPC 
post-transcriptional modulation 
 
Previous co-localization studies in HUVECs had shown that this specific PLGA NP 
formulation could present miRNAs to AGO2 and GW182 RISC proteins, which are in close 
interaction with the endosome membrane, thus likely promoting microRNA-RISC strand 
invasion (Gomes et al., 2013). Therefore, to confirm that internalised NP:miR-92a 
inhibitor complexes interact with the RISC machinery in EPCs, and that released miR-92a 
inhibitor had become readily available for processing, I conducted gene expression 
analysis on a miR-92a validated target, in particular, ITGA5. EPCs were incubated for 4 
hours with NP:miR-92a (and its inhibitor) or NP: miR scrambled treatment, followed by 
48h in serum-free culture, before evaluating mRNA levels by qRT-PCR (Figure IV.9). This 
timing, adopted by others (Bonauer et al., 2009), presumably allows for exogenously 
delivered miRNAs to reach peak biological activity. The pilot results from a single 
experiment hint that EPCs that were transfected with NP:miR-92a had a down-
regulation in the expression of ITGA5 compared to controls, whereas the inhibitor had 
the opposite effect on ITGA5 levels. 
 
Figure IV.9 | miR-92a is released from NPs complexes intracellularly. 
The gene expression profile of ITGA5 was evaluated in EPCs transfected with NP: miR complexes at 250 
µg/mL and 200 nM respectively, following a 48h knockdown incubation period under starvation 
conditions. EPCs transfected with NP: Dy547 served as negative transfection controls. (A) Representative 
amplification plots and dissociation curves of the different transfection samples are presented for the 
target (ITGA5) and housekeeping (ACTB) genes. The mean minimal Ct were calculated from triplicate 
reactions. Blue line – experimental sample; green line – no template control sample (B) The target gene 
signal was first normalised to the housekeeping gene and then expressed about the value obtained with 
control transfection EPCs by using the formula 2-Δ Δ Ct. Results shown in the bar graphic are derived from 
1 individual experiment and are therefore preliminary (C) Representative gel used to test primers. ACTB 
– actin beta; EPC – endothelial precursor cell; FITC - Fluorescein isothiocyanate; ITGA5 – integrin alpha 5 
subunit; miRNA or miR– microRNA; NP – nanoparticles.  
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Some cellular death was still seen with 250 µg/mL compared with untreated cells. 
Therefore I tried an alternative transfection concentration (125 µg/mL) before leaving 
EPCs in serum-free medium for 48h and conducting an ATP quantitation-based survival 
assay (Figure IV.10). The latter concentration was not detrimental (127 % ± 4 vs 100%, 
p<0.01), whereas EPCs transfected with the former concentration showed decreased 
survival (68 % ± 7 vs 100%, p<0.001). 
 
Figure IV.10 | A transfection NP concentration of 125 µg/mL is not detrimental for human CD34+-
derived EPCs. EPC survival after transfection with NPs (125 or 250 µg/mL) for 4h, followed by 48h in 
starvation medium (under normoxia or hypoxia), as measured by an ATP based assay. Results represent 
mean values ± SEM after 5 independent experiments, ** p< 0.01, *** p<0.001 vs control transfection, t-
student test).  ATP – adenosine triphosphate; NP – nanoparticle; RLU - Relative light unit. 
 
 
To track intracellular dynamics, EPCs were incubated 4 hours at 37ºC with serum-free 
medium containing NPs labelled with fluorescein amine or NPs complexed with a 
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fluorochrome-tagged miRNAs (Figure IV.11). Dy547-labeled miRNA, a transfection 
control miRNA without any known human targets, was readily internalised complexed 
to the NPs after just 4h of incubation, whereas no intracellular miRNA signal was seen 
when the vector was omitted. The NPs and miRNA seemed to co-localize in complexes 
aggregated inside cytoplasmic vesicles distributed towards the periphery of the cell.  
 
Figure IV.11| Internalisation of NP: miR complexes by human CD34+-derived EPCs. 
The intracellular distribution of NP-FITC: miR scrambled-Dy547 complexes immediately after transfection 
of EPCs was analysed via confocal microscopy. Representative images at 60x of the intracellular 
distribution of the complexes after 4h of incubation at 125 µg/mL and 100 nM respectively (top panel) 
versus incubation with individual components alone (bottom left - NP-FITC, bottom right - miR-Dy547), 
revealed that Dy547-labeled miR was readily internalized complexed to the NPs, whereas no intracellular 
miRNA signal was seen when the vector was omitted. Cells were stained with anti-CD31 plasmatic marker 
and DAPI, further evidencing that the NPs and miRNA were in close association towards the periphery of 
the cell. DAPI - 4',6-diamidino-2-phenylindole; CD – cluster differentiation; FITC - Fluorescein 
isothiocyanate; miR– microRNA; NP – nanoparticle. 
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According to the confocal microscopy data, 24 h after transfection, intracellular vesicles 
loaded with NP:miRNAs complexes seemed to have increased in number and size, 
revealing a more perinuclear distribution, presumably corresponding to the early 
endosomal compartment, as reported previously for HUVECs (Gomes et al., 2013). 
Moreover, there was a lower degree of association between NPs and miRNA signal 
overall, thus evidencing that a good portion of the miRNA had already been released by 
the NPs (Figure IV.12). 
 
Figure IV.12 | Intracellular miRNA release from NPs after 24h. 
The intracellular distribution of NP-FITC: miR scrambled-Dy547 complexes 24h after transfection of 
human late-outgrowth EPCs (125ug/mL and 100nM respectively) was analysed via confocal microscopy. 
The images at 60x revealed intracellular vesicles loaded with NP:miRNAs complexes which seemed to 
have increased in number and size, revealing a more perinuclear distribution, and with a lower degree of 
association between NPs and miRNA signal overall compared to immediately after transfection. CD – 
cluster of differentiation, DAPI - 4',6-diamidino-2-phenylindole; FITC - Fluorescein isothiocyanate; miR– 
microRNA; NP – nanoparticles.  
 
 
miR-92a inhibitor containing NPs have pro-survival 
and –migratory effects in EPCs cultured under 
ischemic conditions 
 
To demonstrate the pro-survival activity of miR-92a inhibitor, EPCs were incubated for 
4 h with NP:miR-92a inhibitor and cultured under starvation for 48 h (Figure IV.13). 
NP:miR-92a inhibitor formulation significantly increased cell survival compared to 
controls (128.33 ± 3.23 vs. 100%, p < 0.001, % of controls). 
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Figure IV.13 | NP:miR-92a inhibitor exerts a pro-survival effect in human CD34+-derived EPCs. 
Cells were transfected with 200nM miR-92a (5p) inhibitor complexed to NPs at 125 µg/mL. Survival in the 
serum-deprived medium after 48h was assessed using a Luminescent cell viability ATP-based assay. 
Results are plotted as means, with errors bars representing ± SEM, after 5 independent experiments 
(replicates of 5 were used for each experimental condition). ***P<0.001 compared with transfection 
control (t Student test). ATP - Adenosine triphosphate; EPC – endothelial precursor cells; miR- microRNA; 




The scratch assay of cell migration was used to assess the effects of NP-miR delivery on 
the migration of EPCs. After a scratch had been made on a confluent cell monolayer, 
cells were incubated for 48h in serum free medium (Figure IV.14). NP:miR-92a inhibitor 
transfected EPCs managed to narrow the gap area more than controls by 48h and re-
establish new cell–cell contacts significantly faster than controls (3.16 ± 3 % vs. 33.5 ± 
7.48 %, p<0,05, % of baseline wound area). 
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Figure IV.14 | Pro-migratory effects of NP:miR-92a inhibitor in human CD34+-derived EPCs 
Cells were transfected with NP:miR-92a (5p) inhibitor complexes at 125 µg/mL and 200 nM respectively. 
After overnight incubation in complete medium, the monolayer of cells was manually scratched, and cells 
left in serum-free medium for 48h. At the end of the follow-up, cells were photographed at 5x and the 
denuded area (µm2) was quantified digitally. (A) Representative brightfield images of EPCs transfected 
with either NP (transfection control) or NP:miR-92a inhibitor after 48h. (B) Wound area after 48h 
quantification results after 6 independent experiments are plotted as means (conditions in duplicates), 
with errors bars representing ± SEM. *P<0.05 compared with NP (Student t-test). EPC- endothelial 
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Peri-adventitial gel delivery of NP:miR-92a inhibitor  
complexes results in efficient arterial wall 
transfection 
 
A peri-adventitial route to deliver the NP and corresponding NP:miRNA complexes was 
pursued. Ex vivo transfection of rat carotid rings with NP-FITC (5 mg/mL) using serum 
free media (SFM), pluronic gel or PLGA gel, evidenced superior internalisation efficiency 
for medium, followed by pluronic gel, and lastly PLGA, as evaluated by a direct 
fluorescence assay (Figure IV.15). Accordingly, we chose to pursue the in vivo NP 
delivery to the rat carotid adventitial wall using the pluronic gel, since medium would 
produce heavy leaking jeopardising the localised delivery method.  
 
Figure IV.15 | NP internalisation by the rat carotid artery via peri-adventitial gel delivery. 
Rat carotid artery segments were transfected ex vivo during 24h with FITC-labelled NPs resuspended at 
5mg/mL either in Optimem medium, PLGA or Pluronic gel. The samples were then photographed under a 




Using IF and IHC analysis, we were successful in showing NP-FITC (5mg/mL) 
internalisation throughout the entire vascular wall (from adventitia to intima) after just 
24h following gel deposition (Figure IV.16). 
 
Figure IV.16 | Rat carotid artery NP-FITC internalisation is efficient by pluronic gel periadventitial 
delivery. Pluronic solution containing NP-FITC (5mg/mL) was applied externally to the outer surface of 
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the exposed LCA. The animal was allowed a 24h post-operative recovery before the LCA was harvested 
and processed for IF and IHC. (A) 20x IF pictures: 1 represents a cross-section image of an LCA treated 
with NP-FITC (5mg/mL in pluronic gel) via periadventitial delivery. 2-4 are representative images of 
controls. 2- positive control ex-vivo treated rat carotid ring segment (NP-FITC 5mg/ml in the medium for 
4h); 3- negative controls non-treated rat LCA; 4- staining control ex-vivo treated rat carotid ring segment 
(NP-FITC 5mg/ml in the medium for 4h) where primary antibody incubation was omitted. (B) 10x and 40x 
magnification IHC pictures: 1-4 images represent the same conditions as in A). DAPI - 4',6-diamidino-2-
phenylindole; FITC - Fluorescein isothiocyanate; IF – immunofluorescence; LCA – left carotid artery; miR 
– microRNA; NP – nanoparticles. 
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Transfecting the arterial wall with miR-92a inhibitor-FITC -labelled complexed to NPs 
(5mg/mL, 200nM) was also successful as indicated by IHC (Figure IV.17).  
 
Figure IV.17 | Rat carotid artery NP:miR-92a inhibitor-FITC internalisation via peri-adventitial gel 
delivery. 
A periadventitial delivery of NP:miR92a inhibitor-FITC was carried out. The animal was allowed a 24h post-
operative recovery before the LCA was harvested and processed for IHC. These are representative images 
of NP:miR-92a-FITC treated arteries via peri-adventitial pluronic gel delivery at 20x and 40x magnification. 
On the right the negative control is presented, where the primary antibody incubation was omitted.  FITC 





Once inside the cells, miRNA-92a inhibitor is progressively released from the NPs as 
hinted by miR-92a target gene regulation in a 24h post-transfection time course (Figure 
IV.18). ITGA5, an established miR-92a target gene should be upregulated upon miR-92a 
inhibitor transfection (Bonauer et al., 2009). Indeed, at 24h there was an upregulation 
of ITGA5 levels following miR-92a inhibitor pluronic gel delivery compared to control. 
Also, ITGA5 levels at 24h rose higher with transfection miRNA alone than with an NP-
mediated strategy, which could suggest an advantageous slow release mechanism by 
the NPs. 
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Figure IV.18 | Pluronic gel delivery of NP:miR-92a inhibitor may be efficient at upregulating arterial 
ITGA5 levels after just 24h. 
Representative western blot analysis of uninjured rat carotid arteries treated with NP:miR-92a inhibitor 
(5mg/mL, 1µM) or miR92a inhibitor (1µM) delivered by 30% pluronic gel, against no treatment control. 
The animals were sacrificed 24h after surgery. This blot represents a single set of 3 paired mice. Therefore 
results are preliminary only. eNOS- endothelial nitric oxide synthase; ITGA5 – integrin alpha 5 subunits; 




Intra-luminal delivered NP:miR-92a inhibitor 
complexes are capable of arterial wall transfection 
 
 
Next, the feasibility of delivering miRNA conjugated to NPs to the inner side of the 
arterial wall, via intraluminal infusion, was investigated. Rat carotid ring segments were  
used for tissue culture transfection optimisation with NP-FITC or NP:miR-92a inhibitor-
FITC resuspended in medium at different concentrations (Figure IV.19). The ex vivo 
titration strategy demonstrated that NPs in solution at 5 mg/mL were able to transfect 
the carotid segments efficiently and facilitated fluorescent miRNA delivery (1uM). 
 
Figure IV.19 | NP and NP:miR-92a inhibitor in suspension are internalised by the rat carotid artery. 
Rat carotid artery segments were transfected ex vivo during 4h in 96 well plates with increasing 
concentrations of (A) FITC-labelled NPs or (B) miR-92a inhibitor-FITC labelled complexed to NPs in 
Optimem. The samples were then photographed under a fluorescent macroscope in the green channel. 
FITC -Fluorescein isothiocyanate; miR – microRNA; NP – nanoparticle. 





Next, intravascular delivery of the NPs to the rat carotid artery was carried out by 
infusing an NP-FITC labelled solution (5 mg/mL) through the arteriotomy hole at an 
infusion rate of 10 µl/min for a total of 20 min of occlusion time. This strategy resulted 
in efficient vascular wall internalisation of NPs, with a discernible pan-layer distribution 
pattern, as assessed 24h after infusion by IF and IHC staining (Figure IV.20).  
 
 
Figure IV.20 | Rat carotid artery NP-FITC internalisation is efficient by intraluminal infusion. 
An intravascular delivery of FITC labelled NPs was carried out. The animal was allowed a 24h post-
operative recovery before the LCA were harvested and processed for IF and IHC. (A) IF 20x pictures: 1 
represents a cross-section image of an LCA treated with NP-FITC (5mg/mL in PBS) via intraluminal infusion. 
2-4 are representative images of controls. 2- positive control ex vivo treated rat carotid ring segment (NP-
FITC 5 mg/ml in the medium for 4h); 3- negative controls non-treated rat LCA; 4- staining control ex vivo 
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treated rat carotid ring segment (NP-FITC 5mg/ml in the medium for 4h) where primary antibody 
incubation was omitted. (B) IHC 10x and 40x pictures: 1-4 images represent the same conditions as in A). 
DAPI - 4',6-diamidino-2-phenylindole; FITC - Fluorescein isothiocyanate; IF – immunofluorescence; LCA – 
left carotid artery; miR – microRNA; NP – nanoparticles. 
 
 References - 300 
 
Internalisation of NPs:miR-92a inhibitor complexes (NP 5 mg/mL and miR 1 µM) was also 
feasible for intravascular delivery using the same interventional procedure, as 
demonstrated by IHC staining of treated arteries 24h post-infusion (Figure IV.21). The 
future plans will be discussed in the global discussion chapter. 
 
Figure IV.21 | Rat carotid artery NP:miR-92a inhibitor internalisation via intraluminal gel delivery. 
An intraluminal delivery of NP:miR-92a inhibitor-FITC (NP 5 mg/mL and miR 1 µM) was carried out. The 
animal was allowed a 24h post-operative recovery before the LCA were harvested and processed for IHC. 
These are representative images of NP:miR-92a-FITC treated arteries via intraluminal infusion at 20x and 
40x magnification. On the right the negative control is presented, where the primary antibody incubation 
was omitted. Given the positive FITC signal present in all layers of the artery, the intraluminal delivery 
strategy seemed efficient at promoting rat carotid artery NP:miR-92a-FITC internalisation.  FITC - 








Restenosis prevention by miR-92a inhibitor 
Isolated aortic rings transfected with miR-92a inhibitor and cultured on Matrigel with 
endothelial growth medium showed significantly improved outgrowth of aortic ring cells 
compared with the control, as expected according to the literature (Iaconetti et al., 
2012). This result pushed us to search for the effect of miR-92a inhibitor in the injured 
artery. One year within the PhD works, Iaconetti et al. published a seminal paper 
reporting that systemic administration of miR-92a inhibitor significantly enhanced re-
endothelialisation in injured carotid arteries and reduced neointimal formation after 
balloon injury or stenting (Iaconetti et al., 2012). Later, Daniel et al. confirmed that 
systemic inhibition of miR-92a expression with LNA-modified antisense molecules 
resulted in a significant acceleration of re-endothelialisation and reduced neointima this 
time after wire-induced injury of the femoral artery in mice (Daniel et al., 2014). Our 
preliminary results regarding the reduction of neointima following the delivery of miR-
92a inhibitor after experimental balloon injury seem to agree with the findings by 
Iaconetti et al. Endothelial denudation after vascular injury, and the subsequent loss of 
local NO synthesis could be a critical factor in the pathogenesis of restenosis. The results 
from Iaconetti and colleagues suggested that miR-92a inhibitor induced an increase in 
NO bioavailability (Gareri et al., 2016), which causes a selective increase in the EC 
proliferation/migration and the inhibition of VSMC proliferation (Iaconetti et al., 2012; 
Indolfi et al., 2002). Interestingly, our in vitro results seem to hint that another vascular 
player could contribute to the reduction of neointima, i.e., engrafting/vascular wall EPCs 
that show enhanced activity upon miR-92a inhibition. Cui et al. transplanted GFP-labeled 
EPCs overexpressing eNOS gene into balloon-denuded carotid arteries and found that 
these cells engrafted at the denuded parts of the artery, which resulted in a significantly 
inhibited neointimal hyperplasia (B. Cui et al., 2011). One can speculate that the NO 
overexpressed and released at an early stage from the regenerating endothelium and 
EPCs incorporating into the injured site might participate in inhibiting VSMC 
proliferation and migration(B. Cui et al., 2011). We too have shown a possible increase 
in engraftment of (miR-92a inhibitor -primed) EPCs at the injury site after 
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transplantation. Although, we could not show enhanced endogenous EPC engraftment 
following treatment of target tissue with miR-92a inhibitor (the planned experiments 
would surpass the remaining PhD duration), we did observe a trend towards increase in 
T-eNOS expression in miR-92a inhibitor treated arteries, therefore, it is conceivable that 
the enhanced EPC activity results obtained in vitro can translate into an enhanced re-
endothelialisation response in vivo following in-situ transfection. We postulate that the 
ability of the engrafted EPCs to rapidly restore endothelial integrity at the injury site may 
restore endothelium-dependent NO bioavailability and suppress more efficiently the 
activation of VSMC proliferation and migration from the underlying media, thus 
resulting in attenuation of neointimal proliferation. Besides ITGA5-eNOS pathway, miR-
92a has also been found to target KLF2 and KLF4 (Y. Fang & Davies, 2012) (genes that 
were not unfortunately included in my WB experiments since for the time of the PhD I 
could not find antibodies that would have good resolution in CD34+-derived EPCs). 
These transcription factors can also enhance eNOS activity which inhibits VSMC 
proliferation (Boon & Horrevoets, 2009; Y. Fang & Davies, 2012; Hamik et al., 2007; 
Iaconetti et al., 2012; Parmar et al., 2006). Moreover, KLF2 and KLF4 typically exert an 
anti-inflammatory and atheroprotective effect in ECs after injury (Y. Fang & Davies, 
2012). This was elegantly shown by Hinkel and colleagues who tested leukocyte 
adhesion on an EC monolayer underflow after TNF-alpha activation and verified that 
pretreatment of either the ECs or the THP-1 cells with miR-92a inhibitor reduced 
leucocyte adhesion (Hinkel et al., 2013). miR-92a inhibition, by acting to de-repress KLF2 
and 4, may result in the downregulation of leucocyte adhesion molecules on ECs, 
therefore limiting inflammatory cell infiltration.  
 
Systemic vs. localised miR-92a inhibitor delivery to the target 
tissue 
 
The delivery approaches per se may vary according to the end application. In diffuse 
conditions, such as atherosclerosis, or for tissue targets which are not easily accessible 
by direct injection, systemic antagomiR delivery may be optimal (Salmena, Poliseno, Tay, 
Kats, & Pandolfi, 2011). Yet, one should try to minimise off-target effects by using 
localised deliveries, as information about tissue distribution and pharmacokinetics of 
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miRNAs are presently scarce and their promiscuous nature makes the side effects of 
long-term inhibition difficult to predict. Even though miR-92a knockout mice are viable 
and fertile, there are reports of increased embryonic lethality as well as growth and 
skeletal defects (Penzkofer et al., 2014). Moreover, the systemic administration also 
requires a large quantity of biomolecules.  
For local regenerative applications, incorporating the miR-92a inhibitor into biomaterial 
scaffolds or other depots for in situ sustained delivery may, therefore, be preferred. An 
added benefit is that anti-miR approaches may be integrated with conventional 
regenerative biomaterial scaffolds that can simultaneously create tissue templates and 
provide platforms for sustained/controlled release, enabling greater spatiotemporal 
control over miRNA activity. One possibility to achieve the latter is to use material 
surface immobilizing agents, such as a stent coating that simultaneously serves as a 
template for the healing template and allows for local and sustained anti-miR release.  
 
Cell-cell miR-92a inhibitor shuttle 
 
miRNAs have been found outside the cells in a surprisingly stable form (Polimeni et al., 
2013), and it has been recently demonstrated that they can exert their regulatory 
function as extracellular messengers on protein expression also in recipient cells after 
transfer (Gareri et al., 2016). Transfer of miRNAs from cell to cell occurs mostly by means 
of membrane vesicles, which can be of different type and size. Exosomes (30–100 nm), 
shedding microvesicles (≤1000 nm) or even apoptotic bodies (50–5000 nm) are the most 
common. In addition to being packed into membrane vesicles, extracellular miRNAs can 
be loaded into high-density lipoprotein (HDL), or bound by AGO2 protein outside of 
vesicles (J. Zhang et al., 2015). miRNA secretion from releasing cell and subsequent 
uptake by a recipient cell provides a mechanism for cell-to-cell communication and 
exchange of material between cells (J. Zhang et al., 2015). There are 3 mechanisms of 
interaction between exosomes and their recipient cells described. First, the 
transmembrane proteins of exosomes directly interact with the signalling receptors of 
target cells (Munich, Sobo-Vujanovic, Buchser, Beer-Stolz, & Vujanovic, 2012). Second, 
the exosomes fuse with the plasma membrane of recipient cells and deliver their 
content into the cytoplasm (Mulcahy, Pink, & Carter, 2014). Third, the exosomes are 
 References - 304 
 
internalised into the recipient cells and have two fates. In one case, some engulfed 
exosomes may merge into endosomes and undergo transcytosis, which will move 
exosomes across the recipient cells and release them into neighbouring cells. In the 
other case, endosomes fused from engulfed exosomes will mature into lysosomes and 
undergo degradation (Mulcahy et al., 2014). Examples of miRNA exchange among cells 
involved in neointima formation are emerging in the literature.  Zhou et al. recently 
showed that miR-126 is secreted by ECs in Ago2 protein complexes on atheroprone 
stimuli (Zhou et al., 2013). This miRNA is then internalised by VSMCs, where it inhibits 
the expression of proteins that normally keep the cells in a contractile and quiescent 
state.  Additional reports uncovered miR-143/145 transfer between ECs and VSMCs 
through different trafficking networks (Climent et al., 2015). It was recently reported 
that ECs could release and transfer miR-503 to pericytes via microparticle trafficking 
(Caporali et al., 2015). These data are in keeping with the hypothesis that miR-92a 
inhibitor and NP:miR-92a inhibitor actions could be propagated across the different cell 
players involved in restenosis, to exert a combined anti-proliferative effect. Iaconetti 
and colleagues had demonstrated that miR- 92a was not expressed in VSMCs at 
comparable levels to other VSMC miRNAs in carotid media and adventitia. In fact, they 
found that the expression levels of miR-92a were significantly higher in RAO-ECs than in 
RAOSMCs (Iaconetti et al., 2012).  MVBs, where miR-92a inhibitor and NP:miR-92a 
inhibitor presumably accumulate, are generated at endosomes by the inward budding 
of their delimiting membrane followed by the release of  100 nm vesicles into the 
endosomal lumen. These endosomal vesicles have a cytosolic-side inward orientation. 
Numerous MVB serve as a sorting station for endocytosed membrane cargo that need 
to be transferred to and degraded in lysosomes. As explained, other MVBs may instead 
fuse with the plasma membrane, resulting in secretion of their intraluminal vesicles as 
exosomes.  
 
The use of nanotechnology for interventional miR-92a inhibitor 
vascular delivery 
 
The therapeutic targeting of various cardiovascular conditions using miRNA has been 
emerging as a novel approach in biomedicine, but the difficulty of introducing epigenetic 
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material into cells is a serious bottleneck in the development of this method. Limited 
cell penetration, unfavourable pharmacokinetics, toxicity, stability, as well as insertional 
mutagenesis represent some of the potential obstacles to the current in vivo miRNA 
delivery vehicles, including chemical modification, liposomes, adeno-associated virus or 
lentivirus (M. A. Shi & Shi, 2010). As an example, commercial liposomal transfection 
agents are not approved by the regulatory agencies for human use, and  the viral carrier 
systems also have drawbacks, such as the risk of immunogenicity, random integration 
of oligonucleotide sequence into host chromosome, specific tissue tropism, their 
recombination with wild-type viruses, limited payload capacity, related toxicity, and 
large scale production issues (Pathak, Patnaik, & Gupta, 2009).  
 
The enhancement of EPC functions combined with advances in tissue-engineered carrier 
matrices that permit embedding of EPCs and provide optimal conditions for EPC survival 
and endothelial outgrowth can contribute to therapeutic re-endothelialisation in wound 
healing. We have envisioned the use of biomaterials to (1) enhance cellular adhesion, 
survival, and function upon transplantation and (2) appropriately provide miRNAs with 
spatiotemporal control that enable enhanced recruitment/thriving of circulating 
progenitors.  The introduction of genetic materials using nanotechnology could provide 
a practical alternative to the other delivery systems. In this study, I have described the 
development and application of biocompatible and biodegradable copolymer NPs, 
composed of PLGA, with approximately 200nm of diameter, capable of carrying miR-92a 
inhibitor on their surface for delivery into EPCs or into the arterial luminal and adventitial 
surface. NP-facilitated delivery of miRNA in the angioplasty-injured vascular wall could 
be a promising option, with several undisputed advantages over traditional transfection 
agents (Cyrus, Wickline, & Lanza, 2012; Gvili, Benny, Danino, & Machluf, 2007; Jukema, 
Ahmed, Verschuren, & Quax, 2012): (a) High internalization efficiency - small vector size 
in the nanoscale range bestows quicker and increased cellular uptake; (b) 
Biocompatibility - depending on the synthetic material, NPs can be designed to have low 
toxicity and immunogenicity; (c) Biodegradability, achieved by some polymer-based 
formulations; (d) Sustained gene delivery, which is accomplished by entrapping the 
biomolecules in their core, through RNAse protection mechanisms, or endosomal 
release modulation; (e) Targeted delivery, since NPs can be designed to target specific 
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cells, epitopes or intracellular localizations preferentially and hence tailored to the 
desired effects; (f) possibility of vector immobilization to the stent, which allows 
increased local concentration of the therapeutic agent at the targeted vascular segment 
without distal spread to non-target tissue, thereby avoiding systemic toxicity and 
increasing the chance of effecient gene transfection to adjacent cells. Stent-tethered 
vectors can better persist in tissues as they are physically protected from the shearing 
effect of blood flow. 
 
Others have also sought innovative NP-mediated drug delivery for restenosis 
prevention. Cohen-Sacks and colleagues developed PLGA nanospheres encapsulating 
platelet-derived growth factor beta receptor antisense, which were successfully used in 
a balloon-injured rat carotid artery model (Cohen-Sacks et al., 2002). Controlled release 
of oligonucleotides following polymer biodegradation was achieved over a period of 1 
month, resulting in inhibition of neointima formation. Nevertheless, since PLGA 
formulations can take long to degrade and release their encapsulated content, our 
strategy to coat the NP with the miRNA on the surface, and not inside the core, offers 
the rationale of a more rapid biological effect following post-angioplasty injury, when 
EPCs are engrafting, and re-endothelialisation is triggered.  
 
NP engineering for EPC transfection 
 
The promise of NP systems that enable spatiotemporal control of miRNAs cues has 
fuelled further investigation into the kinetic delivery profile required for optimal EPC 
transfection in vitro, influencing future recruitment/re-endothelialisation at the site of 
vascular injury. The transfection efficiency of NPs results not only from how well these 
particles overcome the membrane barrier, but also the barriers outside and within the 
cell once they are internalised. My results indicate an EPC transfection efficiency of 
NP:miRNA complexes of about 80% after  short-term incubation, a result which is largely 
related to the physicochemical optimisation performed in the NP synthesis process. 
Based on diameter, particles can be categorised as small (≤100 nm), medium (100–200 
nm), large (201–1000 nm) or giant (≥1000 nm)(Donkuru et al., 2010).  The controlled 
size nanoformulation used was designed to yield medium-sized NPs, designed to confer 
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on them a faster cell internalisation profile than large-sized particles (Pathak et al., 
2009). These NP are internalised either ex vivo in just 4h and under 24h in vivo, making 
them useful for clinical translation. NPs were coated with specific miRNAs using a PS 
linker, a polycationic peptide that has been shown to condense plasmid DNA efficiently 
(D. Luo & Saltzman, 2000). The electrostatic interactions between the NPs and miR-92a 
inhibitor result in the self-folding of the oligonucleotide against the linker surface, 
theoretically preventing extracellular RNases from degrading the miRNA before 
internalisation. Optimisation of the surface charge of the NP also plays an equally 
important role in internalisation. A cationic substrate, PS, was coated on the NP’s surface 
to electrostatically bind the negatively charged oligonucleotides, rendering an overall 
zeta potential around +2. The physicochemical properties of the resulting complex were 
determined by the optimisation of relative cation/anion amounts, preparation 
parameters (mixing speed, time, the temperature of mixing, the concentration of 
reactants) and material properties, such as hydrophobicity, charge density and 
molecular weight. The complexation masks the negative charge of the RNA molecule, 
thus enabling the miRNA complexes uptake by the cells. Additionally, the coating 
properties also dictate the electrostatic miRNA dissociation kinetics occurring at 
physiological pH, which will influence the concentration and duration of miR-92a 
inhibitor release, thereby potentially enhancing the therapeutic time window of these 
short-lived biomolecules. According to Gomes et al., about 50% of the miRNA is still 
bound to the PLGA NPs inside the endosome compartment 24 h after EC transfection 
(Gomes et al., 2013), which correlates with my qualitative confocal microscopy results 
in EPCs. 
 
NP:miR-92a inhibitor and starvation 
 
Several reasons underlay the fact that medium deprived of serum and VEGF was used 
at the different stages of the ex vivo assays. During the transfection period (4 h), by 
removing anionic proteins from the medium, we reduced the likelihood of positively 
charged NPs:miR-92a inhibitor complexes being sequestered, thus maximising cellular 
internalisation (although this might not happen in vivo). VEGF downregulates 
endogenous mir-92a expression (Iaconetti et al., 2012), which would make 
 References - 308 
 
interpretation of the effects of exogenous miR-92a inhibitor more complicated. The 
incubation period (48h) to allow time for miR-92a inhibitor processing after transfection, 
was performed under starvation also so to mimic the post-injury milieu better.  
 
NP:miRNA intracellular compartmentalization and biological activity 
 
Studies on miRNA delivery using nanoformulations have explored NPs that accumulate 
in the membrane free intra-cytosolic compartment (S. J. Shi et al., 2012), as it was 
believed that mRNA regulation occurred largely there. However, recent data reveals 
that many RNA processes may be spatially restricted to the endolysosomal 
compartment to promote specificity and kinetic efficiency, namely miRNA maturation 
and mRNA regulation (D. Gibbings & Voinnet, 2010). Curiously, another NP engineering 
property that influenced NP:miR-92a inhibitor intracellular delivery was the composition 
of the biomaterial used in the NP formulation. PLGA NPs are internalised partly through 
ﬂuid phase pinocytosis or clathrin-mediated endocytosis and accumulate in the 
endosomal compartment (Danhier et al., 2012). The intracellular pathways of 
internalised PLGA NPs have been characterised previously, and appear to be conserved 
across different epithelia (Cartiera, Johnson, Rajendran, Caplan, & Saltzman, 2009). 
Cartiera and colleagues demonstrated by electron microscopy that PLGA NPs colocalize 
with early endosomes shortly after exposure (approximately 2 hours), later to be found, 
over a period of 4-24 h, in other compartments within the cytoplasm, notably Golgi and 
endoplasmic reticulum. Interestingly, the in-house PS-coated PLGA nanoformulation 
also was shown to be incorporated into endocytic vesicles that fuse with early 
endosome within the first 24h following transfection (Gomes et al., 2013). Gomes and 
colleagues were able to coat these NPs with miRNAs, which are rapidly internalized and 
target the endolysosomal compartment, interacting with higher frequency with AGO2 
and GW182 (proteins which are involved in the biological action of miRNAs), than 
liposome complexes formed by commercial reagents and miRNA, which in turn 
accumulate in the cell cytoplasm (Gomes et al., 2013). Interpreting the confocal 
microscopy internalisation data collected so far in the light of these considerations, one 
could speculate that PLGA copolymers also target the endosome compartment in CD34+-
derived EPCs, although the represented images are in mitosis which hampers the 
 References - 309 
 
analysis of the cytoplasmic distribution of the NPs. This may result in enhanced miRNA 
biological effect since RISC assembly and turnover also occurs at endosomes (D. 
Gibbings & Voinnet, 2010). The close relationship between RISC machinery and the 
endomembrane system seems to promote more frequent encounters between AGO2, 
one of the RISC incorporating proteins, and the exogenous oligonucleotides released 
from NPs localised in the endosome. This was demonstrated previously by Gomes et al., 
by quantifying NP:miRNA/AGO2 cluster association in NP:miRNA transfected cells, and 
comparing it to the number of AGO2/miRNA foci following liposomic delivery (Gomes et 
al., 2013). The latter seemed to be reduced, probably, due to the diffusion and dilution 
of the oligonucleotides in the cytoplasm, resulting in fewer encounters. The controlled 
release of the proangiogenic miR-132 from the NPs exerted described in their research 
had significant pro-survival and pro-angiogenic effects compared to liposomal delivery 
in HUVECs, raising the possibility that delivery within the endolysosomal compartment 
offers an excellent opportunity to enhance the biological effect of miRNAs. 
More than just promoting the localised concentration of miRNA closer to the RISC 
machinery, NPs may in fact help in bridging the contact between both. Since AGO2 
proteins are located on the cytosolic face of the endolysosomal membrane (D. Gibbings 
& Voinnet, 2010), the miRNA released from the NPs still has to cross the membrane. 
PLGA NPs are able to mediate endosome escape in a sustained manner, sometimes for 
days or weeks (Moynihan, Jones, Farrar, & Howard, 2001). This process is thought to be 
facilitated by the cationic properties of the NPs, through what is titled the “proton 
sponge effect”(J. G. L. Huang, T.; Gu, F. X, 2011). This effect is a temporary and localised 
destabilisation of the membrane resulting in the escape of NPs and/or miRNA 
translocation into the cytosol via transient holes. Alternatively, the miRNA release from 
the endolysosomal compartment may be mediated by AGO-chaperone heat shock 
proteins, such as HSP90. This HSPs are reported to interact with acidic phospholipid 
membranes to create functionally stable ATP-dependent cationic pores which could 
mediate the miRNA translocation from the endolysosomal compartment (Gomes et al., 
2013) to the cytosolic surface of its membrane, where AGO2 and the RISC machinery is 
located. Immunoprecipitation studies suggest that the NPs are able to serve as a scaffold 
or to bridge the assembly of more Ago2-HSP90 complexes resulting in increased miRNA 
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translocation, especially under hypoxia, a condition that upregulates HSP90 (J. X. Chen 
& Meyrick, 2004). 
The slow electrostatic release from the NP surface and the sustained endosome escape 
of the miRNA molecules, probably result in the depot release profile evidenced by the 
milder upregulation of ITGA5 following perivascular delivery of the inhibitor of miR-92a 
complexed to NPs, when compared to delivery without NP facilitation, an observation 
that obviously warrants a more expanded time course analysis. 
 
 
NP:miR-92a inhibitor localised delivery routes 
 
Pluronic gel periadventitial administration has been attempted before for miRNA 
transfection with success (Choe et al., 2013), but to the best of our knowledge it was the 
first time it was used to mediate the transfection of NP:miR complexes. Pluronic F-127 
is a nonionic, surfactant polyol, which consists of hydrophilic ethylene oxide (EO) and 
hydrophobic propylene oxide (PO) blocks that are polymerised in a basic A-B-A structure 
(EOx-POy-EOx) and have amphiphilic properties. The pluronic gel has been reported to 
enhance cell interactions, DNA transport, and transgene expression, since pluronics 
possess the unique ability to incorporate themselves into cell membranes in the 
presence of the hydrophobic poly(propylene oxide) chain (W. Fan et al., 2012). But, even 
when locally delivered, non-targeted drugs often do not accumulate in quantities high 
enough to achieve the desired effects at the cellular compartment where they could be 
more efficient. Accordingly, combining the transfection properties of polycationic NPs 
embedded within a surface-active gel seemed a logical way of enhancing internalisation 
and compartmentalization efficiency. In the present study, pluronic gel NP delivery 
demonstrated similar ex vivo transfection efficiency compared to incubation with NP 
solution, as assessed by macroscopic fluorescence intensity analysis, encouraging me to 
advance to in vivo delivery. There, the NP-facilitated delivery of miRNA within the 
surfactant gel to the adventitia proved to be efficient, with NP and miRNA penetration 
going deep into the intima after just 24h. Several trafficking combinations could account 
for the highly efficient miRNA tissue dissemination I have observed in such a short 
period. Either the peri-adventitial NP:miR-92a inhibitor or recently unbound miRNA use 
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a paracellular pluronic gel-facilitated route towards the intima, or they are actually 
internalised by adventitial and medial cells. MiR-92a inhibitor further makes their 
transcellular way to the innermost layer by microvesicle-mediated cell-cell 
communication after being released from the NPs, or NP:miR-92a inhibitor complexes 
travel through a typical “endocytosis–exocytosis” route. Concerning intercellular NP 
trafficking, there is microscopy evidence that PLGA NPs are actually prone to 
escape/avoid endolysosomal degradation and subsequently interact with the exocytic 
organelles of the cell over time: the ER, the Golgi apparatus, and secretory vesicles 
(Cartiera et al., 2009). In the future, a localised stent delivery could make use of an 
eluting matrix combining both PLGA NPs and pluronic polymer, as both biomaterials 
have been used in this type of platform (S. I. Jang et al., 2012; Pan, Tang, Weng, Wang, 
& Huang, 2007). The delivery of a miRNA with angiogenic activity conjugated to a PLGA 
NP delivery system which has been used in stents with good drug eluting kinetics 
(Luderer et al., 2011), provided the rationale to attempt NP:miR-92a inhibitor 
intravascular provision in the rat carotid balloon angioplasty model. No miRNA 
epigenetic stent has ever been described, but Blindt in 2006 deployed a stent 
impregnated with an integrin-binding cyclic Arg-Gly-Asp (cRGD) peptide in in vivo 
porcine models for its potential to recruit and bind EPCs to limit coronary neointimal 
formation (Blindt et al., 2006). EPCs express integrins with integrin-binding cRGD 
peptide-binding motifs on their surface. It was hypothesised that the homing and 
differentiation of EPCs depend largely on their adhesion to integrins and the resulting 
signalling cascade that occurs on cell binding. At 12 weeks, both mean neointimal area 
and mean percent area stenosis were significantly reduced in cRGD peptide-loaded 
polymer stents compared with unloaded or bare metal stents, in part by accelerating 
stent endothelialisation. One can speculate that if using integrin-binding peptides 
represents a promising target to accelerate healing after vascular injury, stents capable 
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miR-92a inhibitor and oncogenic potential 
 
A non-estimated quantity of miR-92a inhibitor, even if locally delivered, could leak into 
circulation and target multiple organs and cell types, which could alter miR-92a activity 
also in non-EPCs which at the time being could pose a risk mostly regarding 
tumorigenesis. Volinia et al. identified that miR-92a was markedly overexpressed in 
tumour tissues from a large-scale miRnome analysis (Volinia et al., 2006), while several 
experiments have already implicated miR-92a in tumorigenesis, namely by promoting 
tumour proliferation, inhibiting tumour apoptosis, and promoting tumour invasion and 
metastasis (M. Li et al., 2014). However, despite the need to gain further insights into 
the mechanisms of the miR-92a and their target genes in tumours before going into 
man, reassuringly, all experiments point towards an expected beneficial effect in tumour 
proliferation, apoptosis, and invasion/metastasis by inhibiting miR-92a. Upregulation of 
miR-92a could activate the PI3K/Akt/mTOR pathway, and inhibit cell apoptosis induced 
by chemotherapy in mantle cell lymphoma (MCL) cells; while downregulation of miR-
92a could inhibit the growth of tumours in a xenograft MCL mouse model (M. Li et al., 
2014). Tsuchida et al. demonstrated that the expression of miR-92a was increased in 
colon adenomas and carcinoma, and it could target Bim directly and inhibit colon 
carcinoma cell apoptosis, whereas miR-92a inhibitor-induced colon carcinoma cell 
apoptosism (Tsuchida et al., 2011). Transfection of miR-92a precursor reduced ITGA5 
expression in ovarian cancer cells, which was associated with inhibition of cancer cell 
adhesion, and potentiation of invasion since integrins mainly mediate cell–cell and cell–
ECM interactions (Missan & DiPersio, 2012). Furthermore, it was reported that miR-92a 
could directly target E-cadherin (CDH1), which results in lymphatic metastasis and 
invasion of oesophagal squamous cell carcinoma (Z. L. Chen et al., 2011). Altogether, 
miR-92a inhibition might be a cancer therapy strategy in the future, which is reassuring 
for those studying the strategy in the field of therapeutic angiogenesis, and not a risk. 
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